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ABSTRACT
There is a lack of longitudinal studies of infertile patients with oligo/ainenorrhoea examining changes in 
hormone concentrations and ovarian morphology. In this prospective longitudinal study, women witli 
oligo/amenorrhoea (n = 42) were studied in detail and compared with a weight-matched group of 
regularly menstruating females (n = 20). Women with oligo/amenorrhoea exlribited an insignificant 
increase in body weight (BMI) but truncal-abdominal fat (WHR) was significantly Mgher than tliat of the 
control group. The mean basal FSH concentrations were similar in both tire groups; E2 and SHBG 
concentrations were lower, and LH, T and F AI were significantly higher in patients than in controls. 
The comparison of tire mean follicular phase endocrine profile dining tire 5-week window of 
observations, showed tliat tire ovary was in a dynamic state, even in the absence of follicular growth and 
ovulation, and tliat E^ , LH, T and consequently FAI were variable, both between and witliin patients. 
The mean follicular phase SHBG concentration was the most stable endocrine variable, and SHBG was 
also the only endocrine parameter able to distinguish between ovulatory and anovulatory cycles. 
Significantly liigher concentrations of SHBG were found in spontaneously occurring ovulatory cycles of 
patients in comparison to tliose in patients who were anovulatory dming the period of observation; the 
former group SHBG levels were compatible witli tire levels of controls measured in the follicular phase. 
The dynanric test for measmement of insulin resistance (IR), the SITT, was canied out twice in patients 
with oligo/arnenoiThoea (n = 34) and in corrtrols (n = 20). The SITT yielded similar KITT-values in 
patients and controls, tlrere was considerable witlrin patient variation and no relationship with 
antliroponretric variables. Fasting I, GLU/INS ratio and FIRI (logio FIRI) appeared to be better markers 
of IR than the KITT-value in patients with oligo/arrrenoiThoea, as tlrey showed the significant expected 
relationships with anthropometric variables, especially WHR. The differences in IR between the groups 
appeared to be related to body mass differences as they disappeared after controlling for antliropometric 
variables. The longitudinal window of observations showed that the occurrence of follicular growth and 
spontaneous ovulation was common in patients with oligo/amenorrhoea (n = 18). However, inadequate 
luteal phase function (assessed by PI) was demonstrable in most of cases. It was apparent tliat LH, 
androgens and IR had no direct influence on the occurrence/absence of follicular' growth and spontaneous 
ovulation. The follicular IGF-1 concentrations were significantly lower in patients tlian in controls, 
despite similar follicular GH concentrations. The IGF-1 did not correlate with follicular FSH but it did 
correlate with FAI. The IGF-1 was significantly liigher in patients who ovulated than in tliose who did 
not ovulate. Body fat distribution (WHR), rather than body weight (BMI), had a significant negative
impact on the incidence of spontaneous ovulation. Leptin concentrations were strongly correlated witli 
antluopometiic variables, FI and FIRI (logio FIRI). However, there was no significant relationship 
between leptin and tlie occurrence of spontaneous oWation. Longitudinal US observations confirmed 
tliat the ovary is not a static organ in such patients and that TOV, the nmnber and distribution of follicles 
all showed considerable intra- and inter-patient variability. The most sensitive US criterion for the 
diagnosis of PCOs was the thickened stroma, wliile TOV was the least sensitive and most variable 
parameter. Ultrasound diagnosis of unilateral PCD was observed in a number of patients (n = 8). The 
mean TOV of the study patients was significantly larger tlian reported normal values. The US indices, 
TOV, follicle number and distribution and stromal thickness, did not correlate with endocrine, metabolic 
or antliropometric variables during the period of observation. Asymmetry of the ovarian volume was 
noticeable in 64.4% of cases and about half of the patients showed more than 100% increase in TOV 
during monitoring, regardless of tire presence of follicular growtli. Almost half of tire patients showed a 
mixed picture of peripheral and central follicular distribution and a change from peripheral to central 
distribution or the reverse, was observed in > 60% of cases. It was foimd that the larger TOV favoured 
peripheral distribution of follicles, was associated with significantly higher follicle numbers and tire 
occurrence of bilaterally thickened stroma compared with the smaller ovary. Women with PCOD (n = 
11) demonstrated higher WHR, fasting TG and lower HDL-C concentrations than did a group of healthy 
females. Post-heparin hepatic lipase assays showed that the concentrations, in women with PCOD, were 
significantly higher than those in nomial females and approached tire male range.
These studies showed tliat women nitli oligo/amenorrhoea, showed dynamic changes in ovarian and 
biochemical / endocrine parameters when examined serially. These changes were independent of 
o\mlation and did not appear to be directly related to any of the metabolic parameters. The only 
parameter wMch was significantly linked to ovulation was SHBG.
The results of these studies improve our insight into oligo/amenorrhoea and tlie associated PCOD and 
mean that in futme any investigations performed on such patients should involve serial rather than single 
observations.
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CHAPTER ONE - INTRODUCTION
1.1 GENERAL INTRODUCTION
In Britain it is believed that about 14% of couples experience difficulty eitlier achieving pregnancy or 
having a liveborn cliild (Hull, 1992), although rates as high as 25% have been reported when shorter 
durations of infertility are used (Greenhall & Vessey, 1990). At least half of tliese couples will present 
with secondary infertility, and the infertility will remain muesolved in a fiirther half of each group (Hull, 
1992).
In general, the main categories of infertility appear to be ; ovulatoiy disorder (mainly amenorrhoea or 
oligomenorrhoea) about 30%; sperm defects and unexplained infertility each about 25%; and pelvic 
and/or tubal damage about 20%. Much less frequent causes are endometriosis (5%), cervical mucus 
defect (4%) and coital impairment (6%) (Hidl, 1992).
Anovulation is a very common problem which presents itself in a variety of clinical manifestations 
including amenorrhoea, irregular" menses and liirsutism. Serious consequences of clnonic anovulation 
are infertility and a greater risk of developing endometrial carcinoma.
Normal ovulation requires coordination of tire menstrual system at all levels, tlie central hypotlralamus - 
pituitary axis, tlie feedback signals and local responses within the ovary. The loss of ovulation may be 
due to any one of a variety of factors operating at each of these levels. The end result is a dysfunctional 
state ; anovulation (Insler & Lunenfeld, 1990).
Anovulation is a key feature of PCOD. Polycystic ovarian disease represents a heterogeneous gr oup of 
conditions ranging from a mere ultrasonic ovarian finding to tlie full clinical syndrome described by 
Stein & Leventhal in 1935 (Shaw, 1991). The symptoms may be the consequence of the loss of ovulation 
: dysfunctional bleeding, oligo/amenorrhoea, hirsutism and infertility. Each presentation requires a 
specific diagnostic and tlierapeutic approach (Insler & Lunenfeld, 1990).
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1.2 BACKGROUND
L2.1 HISTORICAL BACKGROUND
Insler & Lunenfeld (1990) reported that Antonio Vallisneri in 1721 described the classical clinical and 
anatomical featmes of what is now called "Polycystic Ovarian Disease". Chereau (1844) was tlie first to 
describe the "sclerocystic" disease of the ovaries, which was described as thick, pearly white ovarian 
capsule. Removal of botli ovaries was a popular procedure in Europe tliereafter, particularly in cystic 
degeneration or sclerocystic disease. Pozzi (1894) and Waldo (1895) then advocated a less radical 
procedure, the wedge resection (Futtem'eit, 1984).
"Microcystic degeneration" was described by Forgue and Massabuau in 1910 as a condition ivith many 
pea-sized folliculai" cysts scattered over tlie ovarian cortex. living F. Stein and Michael L, Leventlial 
(1935) were the first to relate polycystic ovaries in some of their patients witli amenorrhoea and 
infeitility; prior to that amenorrhoea had been related only to small atiopliic ovaries.
Based on diagnostic studies of wedge resection biopsies, Stein and Leventlial (1935) gave their 
description of a syndrome, named after tliem, consisting of clinical features of amenorrhoea, infeitility, 
obesity and hirsutism associated with bilaterally enlarged cystic ovaries (Stein & Leventhal, 1935). 
These were S-L ovaries: enlarged ovaiies witli tliickened tunica. There has been much interest in the 
condition since then.
1.2,2 DEFINITION
In the presence of a diversity of clinical manifestations and biochemical variabilities, tliere is no one 
miiversally accepted definition of PCOD. It has become clear" tliat the criteria of anovulation, infertility, 
obesity, hirsutism and the presence of bilaterally enlarged polycystic ovaries are restrictive as witli time, 
an increasing number of patients with PCOD and divergent clinical findings have been obseived. The 
classical picture was also found to be associated with a nmnber of endocrine disorders of diverse 
aetiology. Therefore, the so called "S-L syndrome" is now only applied to those patients with the criteria 
described above whereas tlie term PCOD is now adopted to describe a broad heterogeneous spectrum of 
abnormalities, characterized by "poly-follicidai" rather tlian "polycystic" ovaries (Futtenveit, 1984).
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The most clear cut definition of PCOD consists of an association of clnonic anovulation, multifollicular 
ovaries, tliick stroma, hyperandrogenism and IGS (an increased plasma concentiation of LH relative to 
that of FSH - increased LH;FSH ratio) (Futtenveit, 1984).
Multifollicular ovaries, obseived in women witli weight-loss related amenorrhoea, are considered to 
represent a normal ovarian response to a hypothalamic disturbance of Gn control (Adams et al 1985). 
Such ovaries are usually normal in size or slightly enlarged and filled by > 6 cysts 4-10 mm in diameter; 
in contrast to women with PCOD, stroma is not increased. Such women are not Inrsute and serum 
concentrations of LH and FSH are normal and decreased respectively. Ovarian morphology reverted to 
normal in ovulatory cycles, whereas in PCOD tlie polycystic pattern persisted.
PCOD is categorized as WHO Group II ovarian insufficiency with hypothalamic-pituitary dysfunction 
(Breckwoldt et al 1986). The classic SL-PCOD (type I PCOD) is described by the association of (a) 
bilateral polyfollicular ovaries, (b) anovulatory infertility, (c) menstrual dysfunction, and (d) liirsutism.
This disease is commonly associated wth obesity, hyperandrogenism, increased peripheral conversion of 
androgens to oestrogens, and an elevated LH to FSH ratio (Stein & Leventhal, 1935). This may result 
from an aberrant puberty caused by an abnormal neural development in the brain with a resulting 
hypothalamic-pituitaiy-ovarlan axis alteration (Mechanick & Futterweit, 1984; Mechanick & Futtenveit, 
1986).
While type II non classical PCOD includes tliose rvithout one or two of those classical clinical signs, they 
do have PCO and an abnormal adrenal androgen secretion (Wu & Mikhail, 1979; Mechanick & 
Futterweit, 1984).
The term PCOD, or polyfollicular ovarian disease, is applied to a wide clinical ar ray of ovarian, adrenal, 
and mixed ovarian and adrenal disorders wliich eventually culminate in polyfollicular ovaries in various 
stages of growth and atresia (Mechanick & Futterweit, 1986). It is considered as a spectnmi of disorders 
witli hypertliecosis at one end and asymptomatic fertile women with polycystic ovaries at the other end, 
involving complex inter-relationships between hypothalamus-pituitary, adrenals and ovaries; this may 
result in oligomenorrhoea or anovulation and excess androgenicity (Berger et al 1975).
There can be clinical, biochemical, histopathological or ultrasonic definitions of PCOD. Some would 
consider PCOD to include more tlian one entity or it could represent different degrees of tire same 
disorder.
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LZS PREVALENCE OF PCOD
Polycystic ovarian disease is probably the most common endocrinological disorder resulting in chronic 
anoWation among women during their reproductive lives including adolescence (Vaitukaitis, 1983; 
Franks et al 1988; Dunaif, 1992b). Little is known of the true incidence of polycystic ovaries and it 
appears quite variable. Tliis is to be expected since neither clinical manifestations, biochemical changes 
characterizing the disorder, nor the patliophysiological mechanism(s) underlying the disease have been 
well defined and generally understood,
In a series of 12,160 unselected gynaecological laparotomies, the prevalence of polycystic ovaries was 
1.4% (Insler & Lunenfeld, 1990). Ginsburg & Havard (1976) had reported a much liigher incidence of 
PCOD - about 17% in tlieir experience. Poison et a l (1986b; 1988) performed pehic ultrasonographic 
examination in 158 normal women of reproductive age. Polycystic ovaries were defined ultrasonically by 
the presence of > 10 cysts 2 - 8  nun in diameter, associated with an increase in tlie ovarian stroma 
(Adams et al 1986b). They reported tliat 22% of tlie ovaries examined were polycystic, altliough when 
tlrey reviewed their menstrual histories they found PCO in oidy 9% of the women with regular cycles (vs. 
75% of tliose witli menstrual irregularities). They concluded that tlie prevalence of polycystic ovary in 
women with regular cycles was very low. The incidence is quite different if menstrual disorders or 
hirsutism are present. PCOD, diagnosed by US, was reported in 26% of amenoiTlioeic women, 53- 86% 
of oligomenorrhoeie women (Adams et al 1986a; Eden & Place, 1989) and ranging between 75 and 92% 
of hirsute patients after exclusion of adult onset CAH (Adams et al 1986a; Baron, 1991). This shows 
that PCOD diagnosed by US is very common in anovulatoiy women (57%) (Adams et al 1986a) and this 
incidence might be increased by the presence of obesity (Eden & Place, 1989). Tulppala and his group 
(1993) assessed the occurrence of PCO in 50 patients with liistoiy^  of recurrent miscarriage and found 
44% of their patients had PCO detectable by vaginal US. This frequency was liigher than tliat in a 
control group but it was not predictive of tlie outcome of a subsequent pregnancy. It can therefore be 
concluded tliat although more definitive diagnostic criteria are needed, PCOD is more prevalent in 
women with menstrual irregularities (oligo/amenorrhoea).
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1.3 IMPLICATIONS ON GENERAL HEALTH
Insulin is a pofi'peptide hormone wlüch is secreted by tire p-cells of the pancreas and affects 
carbohydrates, protein and lipid metabolism. Under normal circimistances, I regulates glucose 
metabolism mainly in liver, muscle and adipose tissues. In the liver, I inliibits the production of glucose 
by inhibiting gluconeogenesis and glycogenolysis and promoting glycogen storage. In muscle and 
adipose tissue, I stimulates tlie uptake, storage, and use of glucose. Insulin also has a major role in the 
systemic regulation of protein and lipid metabolism. Otlier actions of I which are less known include 
stimulation of potassium transport in muscle, cellular differentiation in adipocytes and its effect on 
ovarian androgen production.
Women with PCOD may have major metabolic complications. Hyperinsulinaemia and IR may be 
involved in the pathogenesis of PCOD. Insulin resistance is defined as a subnonnal biologic response to 
a given concentration of I. The clinical consequences of IR results from either deficient or excessive I 
action.
Insulin resistance has a major role in the pathogenesis of many health disorders which include :
1. Type A syndrome of severe IR is an inherited disorder due to defects in I-receptor locus. It is 
characterized by marked endogenous hyperinsulinaemia with or without glucose intolerance, 
acantliosis nigricans and ovarian hyperandrogenization. The presentation is usually of amenorrhoea, 
hirsutism and virilization in a lean patient.
Variants of type A syndrome include leprochamiism and lipodystrophy. Leprochaunism is a rare 
congenital syndrome characterized by intrauterine growth retardation, dysmorphic features, lipoatrophy, 
acanthosis nigricans and IR. This disorder affects newborn females who present with cystic ovaries, 
hirsutism and cliteromegaly. Lipodystrophy, where patients may have no adipose tissue, is characterized 
by acromegaly, dysmorphic features, genital hypertrophy and cardiomyopathy.
2. Type B syndrome where IR is caused by the presence of autoantibodies to tlie I receptor. The patients 
present witli uncontrolled diabetes, acanthosis nigricans and ovarian hyperandrogenization.
3. Non-insulin dependent diabetes rnellitus caused by a defect in tlie functional capacity of the 
pancreatic P-cells to secrete I or by IR. The ability of I to stimulate glucose uptake in muscles and fat 
is impaired. Obesity alone may be associated with a similar but less severe defect.
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4. Severe IR is associated udth ovarian tliecal hyperplasia, hyperandrogenism and obesity. 
Hyperinsulinaemia resulting from IR may contribute to the patliogenesis of tire PCOD.
5. Hyperinsulinaemia is implicated in the pathogenesis of cardiovascular disease, essential hypertension 
and hypertriglyceridemia. The clinical association of IR, hypertension, increased VLDL and 
decreased HDL-C concentrations in plasma is termed “ syndrome X ”.
The association between hyperinsulinaemia and tliese significant health disorders requires intensive 
investigation for a better understanding of the pathogenesis of disorders characterized by IR.
1.4 OBJECTIVES OF STUDY
Polycystic ovarian disease is a fairly common cause of female infertility presented witli menstrual 
dysfunction (mainly oligomenorrhoea). The pathophysiology of PCOD is far from clear and is still the 
subject of many hypotlieses and speculations.
Women with PCOD have been shown to have significant peripheral IR similar to individuals with 
NIDDM (Dunarf, 1992a). These women are at increased risk of developing NIDDM at a very early age. 
The effect is exacerbated by the presence of obesity, a common finding in PCOD patients. The 
association of hyperinsulinaemia and hyperandrogenism has led to a better understanding of PCOD 
patliogenesis and to tlie recognition of its subsequent metabolic as well as reproductive complications. It 
should be appreciated tliat as a consequence to PCOD, women may have major metabolic complications.
Hyperinsulinaemia may be tlie trigger mechanism of the pathogenesis of PCOD. Insulin resistance is 
generated peripherally. Fasting hyperinsulinaemia may be used as a guide to the existence of IR and tlie 
SITT might be a suitable metliod for assessing IR (Akinmokun et al 1992; Hirst et al 1993). The 
changed sensitivity of peripheral tissue to I activity may constitute a primary event in the genesis of IR. 
The literature shows conflicting reports regarding the correlation between hyperinsulinaemia and ovarian 
hyperandrogenism in PCOD.
Some growth factors may have important roles in modulating ovarian responses to Gn. Among them, 
IGF-I seems to be an important stimulatory factor of granulosa cell differentiation. The physiological 
activity of IGF's is modulated by a number of specific binding proteins (IGF-BP's). IGF-I is stimulatory 
to FSH action (i.e. potentiates ovarian steroidogenesis), whereas I inhibits binding of IGF-I to its
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receptors. IGF-I may also potentiate the ability of LH to stimulate androgen production. It is postulated 
that I, directly or via IGF-I, may modify ovarian steroidogenesis or the action of androgens at target 
tissue levels. Obese PCOD patients, who also tended to have Mgher androgen levels, have been reported 
to have more pronounced IR tlian non-obese women which may influence IGF-I concentiation 
(Slowinska-Srzednika et al 1992).
Among hormones known to cause or predispose to IR are GH, cortisol and PRL. Increased feedback of 
IGF-I at the level of the pituitary gland could lead to a reduction in GH secretion.
Leptin, a recently discovered hormonal product of tlie obesity gene expressed in adipocytes, is tliought to 
play a role in tlie regulation of food intake and metabolism (Barash et al 1996; Caro et al 1996). In 
mice, leptin receptors were identified in the ovary and leptin was foimd to stimulate gonadal function 
(Chehab et al 1997). Little is known about the physiologic action of leptin in humans, although it is 
clear that circulating leptin concentrations are linked with total adiposity, and it may show abnormal 
secretions in women witli PCOD.
T h e  m a i n  o b j e c t i v e s  o f  t h i s  s t u d y  w e r e  :
1. To study the relationships between I levels and tliose of glucose, A, T, FT (FAI), DHEA-S, cortisol, 
SHBG, Ez, PRL and GH.
2. To compare the efficacy of tlie “SITT” method as a measme of IR, to that of the FI and other 
estimates of IR or IS - FIRI, GLU/ÎNS ratio.
3. To investigate the role of obesity and hyperandrogenization in influencing I hypersecretion; the 
following groups of patients were studied :
a) obese PCOD vs non obese PCOD patients,
b) obese PCOD vs obese normal controls,
c) hyperandrogénie PCOD vs PCOD patients witli normal androgen levels.
4. To study the impact of aiitliropometric parameters on the endocrine and metabolic variables.
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5. To investigate tlie discrepancy that exists in the literature with regard to the GH status of PCOD 
patients. Fasting GH and tlie change in its levels duiing the SÎTT were compared between PCOD 
patients and normally ovulating volunteers.
6. To study the relationsliip between tlie changes in ovarian activity (including ultrasound and E?) and 
LH levels, and the values of IR, GH and IGF-I activity.
7. Insulin sensitivity in ovulatoiy and anovulatory cycles were compared.
8. To compare leptin concentrations in women with oligo/amenoirhoea with those of weight-matched 
contr ols, in relation to anthropometric variables and whetlier leptin may be involved in the blockade 
of follicular maturation and ovulation often seen in patients witli oligo/amenon hoea.
9. To compare fasting concentrations of plasma free fatty acids and serum lipoprotein lipids in women 
with PCOD with those of weight-matched controls, and in relation to antliropometiic, endocrine and 
metabolic variables.
31
CHAPTER TWO - REVIEW OF THE LITERATURE
2.1 CLINICAL MANIFESTATIONS
The existence of bilateral PCOD has been known for a long period of time. However, a broad interest 
was stimulated in 1935 when S-L described an associated syndrome consisting of menstrual irregularity 
and presenting mainly as amenorrhoea, a history of sterility, hirsutism and to a lesser degree, presence 
of retarded breast development and obesity (Stein & Leventlial, 1935). With time, atypical clinical 
presentations were noticed in a significant number of cases. Analysis of histories of 100 documented 
PCO cases showed common findings, which may enable PCO syndrome to be distinguished from otlier 
causes of chr onic anovulation (Yen, 1980) ;
1. Mean age at menarche (12.3 years) was close to the mean of 12.9 years found in the normal 
population. Primary amenorrhoea does occm-, but rarely.
2. Post menarcheal menstrual irregularity persists in most cases.
3. Onset of clinically discernible excessive hair growth (hirsutism) eitlier before or around the time of 
menarche (a reliable history can be obtained fiom the parents).
4. Obesity is common prior to the onset of the menarche.
Therefore these abnormalities suggest an early onset, occurring before and during puberty, prior to 
complete cyclic development of the hypothalaniic-pituitaiy-ovarian system. The clinical syndrome has 
come to be known as PCOD because of the presence of multiple subcapsular follicular cysts ( 2 - 8  mm in 
diameter) and a thickened ovarian capsule. PCOD classical group (S-L syndrome) is composed of 
oligo/amenorrhoea, hirsutism, obesity, infertility and bilaterally enlarged ovaries, wliile the non-classical 
PCOD includes tliose patients witliout one or two of the classic clinical signs but who do have PCO (Wu 
& Mikliail, 1979). The clinical expression of endocrinological conditions such as hirsutism, 
hyperinsulinism, acantliosis are not so important to define tlie syndrome since tliey may or may not be 
present; with ivide individual variations in the number and severity of symptoms (Venturoli et al 1989). 
In patients witli ultrasonic demonstration of PCOD, it was found that 50% had the classic signs and 
symptoms associated with S-L syndrome, 25% had variants of tlie syndrome and in 25% no abnormal 
clinical signs and symptoms were evident (Swanson et al 1981). The major presentations of patients
32
with PCOD are menstrual disturbance, infertility and liirsutism and they represent the main reasons for 
such patients seeking medical advice (Futtenveit, 1984).
2,1,1 MENSTRUAL DISTURBANCE
Most women have nomial onset of menarche, although oligomenorrhoea may be significant and 
persistent from the beginning of menses (Futterweit, 1984). A considerable number of patients show 
menstrual abnormalities from tlie time of menarche or shortly tliereafter (Goldzieher & Green, 1962; 
Ibraliim et al 1966; Yen, 1980; Vaitukaitis, 1983; Mechanick & Futterweit, 1984; Mechanick & 
Futterweit, 1986). Neitlier the duration nor tlie severity of tlie symptoms was correlated with tlie criteria 
of tlie syndrome (Goldzieher & Green, 1962). In a study carried out on Thai women (Rojanasakul et al
1989), it was interesting to note tliat tlie Mstoiy of menstrual irregularity, androgenic symptoms and 
being overweight began about the perimenarcheal period in most patients. Tins finding may support the 
hypothesis that tlie disorder starts around the period of pubeily and persists tliereafter. Clironic 
anovulation refers to menstrual arrhythmia that results from repeated ovulatory failure and is manifested 
clinically as amenorrhoea or menstrual acyclicity (Yen, 1986). A spectrum of amenorrhoea, 
oligomenorrhoea, polymenorrhoea, obesity, dysmenorrhoea and occasionally even regular cycles is 
encountered (Coney, 1984). PCOD is a common cause of oligomenorrhoea in women without classical 
signs of PCOD (Eden et al 1988b). An miselected series of 73 women with amenorrhoea and 75 women 
witli oligomenonhoea were analyzed (Franks et al 1988); PCO were found in 26% of women presented 
with amenorrhoea and in 87% of tliose who complained of irregular periods. Similar results were 
presented by Adams et a l (1986b). Goldzieher & Axelrod (1963) reviewed a total of 187 references 
containing 1097 cases. Amenorrhoea was obseived in only about half of the patients. It really varied 
from 15 - 77% and regular cycles were noted in 12% of the patients. PCOD was diagnosed in 22% of 
women who volimteered for pelvic ultrasonic examination with normal cycles and normal Gn levels, 
whereas 75% of women with iiTegular cycles or amenorrhoea had PCO by US (Adams et al 1986b). 
Prolonged acyclic oestrogen stimulation of the endometrium resulted in dysfunctional uterine bleeding 
(Gindoff & Jewelewicz, 1987). The incidence of anovulatory cycles in eimienorrhoea has been estimated 
to be 11% while plasma hormones are within normal ranges. Tliis may be a transient phenomenon 
possibly resulting from mild hypotlialamic dysfunction and is reversible to ovulatoiy cycles (Wu & 
Mikliail, 1979). Altliough PCOD in emnenorrhoeic patients is rare it has been reported (Goldzieher & 
Axelrod, 1963; Adams eta l 1986b).
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2A.2 INFERTILITY
Infertility is one of the major reasons why these patients consult a physician. The incidence of infertility 
varied between 35 and 94% (Goldzieher & Green, 1962; Goldzieher & Axelrod, 1963) and in one series 
was 76% (Goldzieher & Axelrod, 1963). Failure of ovulation or oligo-ovulation are the main causes of 
infertility (Gindoff & Jewelewicz, 1987) altliough ovulation was observed in 12-40% of PCOD patients 
(Goldzieher & Axelrod, 1963).
2 A . J  HIRSUTISM
Hirsutism is an increased hair groivth of the masculine pattern in women as a reflection of androgen 
stimulation of hair follicles. The degree of hirsutism in PCOD does not always correlate \rith the 
magnitude of the androgen excess (Yen, 1986). This apparent dissociation between androgen le^ e^ls and 
the degree of Mrsutism reflects different degrees of sensitivity of the target tissues to androgen. 
Hirsutism is a manifestation of androgenicity, whetlier it is due to androgen excess, to an increased 
sensitivity to androgen, or to botli. It may or may not be progressive. The time course of development of 
the androgenic signs is of gr eat importance; a recent rapid onset of androgenization requires urgent and 
special diagnostic methods for distinguishing PCOD from otlier causes of androgen excess. It generally 
implies excessive hair that is coarser, longer, darker or more intense than in normal females of tlie same 
age and race. Principally, the sexual or hormone-dependent hair follicles are involved, such as tliat of 
tlie pubic, axillary, abdominal, chest and facial hair. Hirsutism may develop in women as a result of two 
mechanisms: (i) elevated androgen levels witli abnormal androgen production and/or metabolism 
(Coney, 1984; Schriock et al 1985; Gindoff & Jewelewicz, 1987); (ii) increased 5oc-R.
In PCO patients, 30 - 40% are not hirsute despite tlie presence of elevated androgen levels. The presence 
of hirsutism is determined not only by a modest increase in circulating androgens but also by the 
sensitivity of the hair follicles to androgens. It would appear tliat utilization of androgens by the skin and 
hair follicles is greater in PCOD patients who develop Mrsutism (Yen, 1986). Decreased hair follicle 
sensitivity to androgens probably explains the failure of Mrsutism to occm in some patients. Circulating 
levels of SHBG play a complex role that contributes to tlie concentration of FT (McKemia et al 1984). It 
is possible tliat local oestrogen formation by tlie hair follicles may play a modulating role in determining 
the degree of Mrsutism. Hair follicle is a sex steroid target but the mechamsm of hair groivth regulation 
is poorly understood (Yen, 1980). Hirsutism has been reported to occm in around 50% of PCOD patients
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(Stein & Leventlial, 1935; Ibrahim et al 1966; Chang et al 1983; Adams et al 1986a; Wajchenberg et al 
1986). In one review tlie incidence was reported to range between 17 - 83%, with an average of 69% 
(Goldzieher & Axelrod, 1963). The onset of liirsutism was noticed in 4 patients before tlie age of 15 
years giving an incidence of 62% (Goldzieher & Green, 1962). Hirsutism is graded according to the 
Ferriman and Gallwey scoring system (1961) where a score of 8 is considered the limit for normal 
feminine hair growth as the 95*^ ' centile of normal menstruating women falls in this range. The 
diagnosis is possible among 75% of all Idrsute patients after exclusion of late-onset CAH (Baron, 1991).
1 1 .4  OBESITY
Body mass index is calculated as weight in Kg/(height in metres)  ^(Eden et al 1989c). Obesity is defined 
as BMI > 25 Kg/nf (Bates & Wliitwortli, 1982; Conway et al 1989; Eden et al 1989c) or BM3 > 29 
kg/nf (Kazer et al 1990; Slowinska-Srzednika et al 1992). Others define obesity as body weight 
exceeding ideal body weight by 20% or more (Bates & Wliitwortli, 1982). Women with PCOD tend to 
be obese (altliough this may reflect a genetic tendency, (Poison et al 1988)). Most of tlie researchers 
agreed that changes in body weight in PCOD lead to variations in clinical and biochemical presentations 
of the syndrome. In patients attending infertility clinics, 15% were found to be obese, liirsute and 
oligomenoiThoeic (Eden et al 1989c). Altliough obesity has been reported to be infrequent in PCOD in 
some series (Goldzieher & Green, 1962; Ginsburg & Havaid, 1976) in others up to 50% of PCOD 
patients had some degree of obesity (Bates & Whitworth, 1982; Yen, 1986). Marked obesity and signs of 
masculinization tended to be conelated (Goldzieher & Green, 1962). Hirsutism and oligomenorrhoea 
were strongly associated with obesity and increase in FAI in PCOD patients (Gindoff & Jewelewicz, 
1987; Conway et al 1989; Eden et al 1989c). Free androgen index is correlated with BMI. The 
patliophysiology of tliis increase in fat disposition, usually apparent at tlie time of puberty, is unknown. 
However, recent research has shown that I is a tiopldc agent. Fat cells are oestrogen targets and the 
increased adipose tissue in PCOD patients may be causally related to the exposure of fat cells to 
clnonically elevated and unopposed extra-ovarian oestrogen production, probably beginning at the time 
of puberty (Yen, 1986). Obesity at puberty or later in reproductive years is one mechanism for onset of 
PCOD by increased production of E] (Bates & Whitwortli, 1982). Sex hormone binding globulin- 
binding capacity is also decreased in obesity (Kim et al 1979; Laatikainen et al 1983). Obesity is often 
associated with IR (Poison et al 1988; Rebuffé-Scrive et al 1989). It was found that obese PCOD patients 
had higher plasma I values tlian non-obese, but lean body mass, glucose tolerance, plasma TG, blood 
pressure were not different in spite of almost a two times increase in body fat mass in obese PCO females.
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There is a preferential abdominal accumulation of adipose tissue (Ibrahim et al 1966) with a liigh WHR 
in both PCO groups (Rebuffé-Scrive et al 1989), Wliile comparing tlie non-obese PCOD control women, 
with equal body fat mass, tlie PCOD women had liigher blood pressure, plasma TG and I, as well as a 
tendency to increased lean body mass. It might be tliat hyperandrogenicity plays a part in body 
composition in tliis disease but it has not been proved if metabolic abnormalities are a consequence of 
tliese endocrine disturbances. Body fat distribution is more closely related to hypertension and metabolic 
derangement than total fat mass in PCOD. Whether tliese metabolic abnormalities are due to obesity is 
not clear.
Simple weight reduction reduced plasma androgen excess and restored cyclic ovulation in 85% of women 
who lost more tliat 15% of body weight (Bates & Whitworth, 1982; Scluiock et al 1985). It was reported 
tliat 77% of infertile females conceived spontaneously after weight reduction (Bates & Whitworth, 1982) 
suggesting that the increased extraglandular aromatization found in association witli obesity was 
reversible and that a reduction of extraglandular E, production facilitated restoration of cyclic ovulation 
in women with chronic anovulation. Androstenedione and T are decreased following weight reduction. 
Simple weight reduction is recommended as a first method of treatment (Bates & Wliitwortli, 1982) and 
otlier modalities of tlierapy should be used as adjuvants if the patient fails to respond to weight reduction 
alone. Obesity is associated with a lower success rate and spontaneous abortion remains a prominent 
complication even after GnRH-A suppression (Filicori et al 1990). It has been reported tliat obese 
patients required larger doses of Gn in PCOD for induction of ovulation. The difference between obese 
and non-obese PCOD patients was independent of tlie baseline and/or mid-follicidar LH concentration 
either before or during therapy and it was also independent of maternal age (Hamilton-Fairley et al 
1992). Treatment of obesity in tlie hope of restoring normal SHBG levels and decreasing androgen 
production is generally fmstrating but it should be encouraged before considering ovulation induction 
(Scliriock et al 1985; Hamilton-Fairley et al 1992).
2.L5 ENDOMETRIAL CARCINOMA
Endometrial hyperplasia can develop in PCOD patients at a relatively yoimg age because of prolonged 
unopposed oestrogen stimulation of tlie endometrium (Yen, 1980; Gindoff & Jewelewicz, 1987). An 
excessive rate of oestrogen production compared to that of oWatoiy women, (mainly Ei, from A; 
extraglandular, with little from the ovary directly) would lead to various degrees of endometrial 
hyperplasia in a number of patients and in some tliis hyperplasia progresses to carcinoma (Aiman et al
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1978; Yen, 1980; Yen, 1986; Gindoff & Jewelewicz, 1987; Schwartz et al 1987). Reliable estimates of 
the incidence of endometrial carcinoma in PCOD are not available. Goldzieher & Green (1962) in their 
review of 466 cases of surgically proven PCO, collected 46 cases of endometrial carcinoma in association 
witli PCOD. Endometrial hyperplasia was diagnosed in 5 patients and endometrial carcinoma in 3 
patients out of 17 patients studied in one series (Aiman et al 1978). In the great majority of cases, the 
carcinoma is well differentiated and with high survival rate (Schwartz et al 1987). To prevent the 
endometrial changes, periodic treatment ivith progestational agents is indicated; medroxyprogesterone 
acetate is used in a dose of 10 mg for 5 days every 6 weeks (Schriock et al 1985). Induction of oWation 
is possible if endometrial biopsy indicates improvement. Tliis treatment carries minimal risk to the 
patient and if no improvement is observed during conservative therapy, hysterectomy can be performed. 
There is no evidence that tlie delay is harmful to the survival of the patient (Scluiock et al 1985). A high 
coincidence of ovarian timiours has been reported in these patients and this should be taken into account 
during their evaluation (Schwartz et al 1987).
2 ,h6  GALACTORRHOEA
Galactorrhoea may be a presenting symptom (Futterweit & Mechanick, 1988). Its exact incidence is as 
yet not defined, but it has been reported in 13% of patients witli PCOD in one series (Futtei'weit, 1984). 
Careful examination of breasts should be performed routinely to identify the presence or absence of 
galactorrhoea.
2.L 7 INSULIN RESISTANCE
H}peririsulinaemia resulting from IR is common among women with PCOD (Moller & Flier, 1991) and 
it is similar to that of individuals witli NIDDM. Patients with PCOD are among the youngest women at 
risk for NIDDM. About 20% of obese PCOD patients have impaired glucose tolerance or frank NIDDM 
by their tlmd or fourth decades (Dunaif, 1992a). The effect is exacerbated by the presence of obesity, a 
common finding in PCOD patients. Non-obese PCOD patients also have an increased risk of NIDDM, 
probably at a later stage of life. Hyperinsulinaemia has been associated with hyperandrogenism. Tliis 
association has been suggested to affect lipid profiles and therefore, places PCOD patients at increased 
risk of cardiovascular disease.
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2,1.8 OTHER PRESENTATIONS
Clitoral enlargement and virilism could be identified in 21% of PCOD patients with ranges between 0 - 
28% (Goldzieher & Green, 1962). An adequate degree of oestrogenic acthdty as deteimined by breast 
and vaginal mucosal development is invariably present. In the majority of cases, bilaterally enlarged 
cystic ovaries can be detected on examination (Goldzieher & Green, 1962) although unilateral enlarged 
or even normal sized ovaries are also encomitered (Ibraliim et al 1966). Normal ovaries were diagnosed 
in 30 - 40% (Futterweit & Mechanick, 1988).
Cystic acne, or difilise scalp hair loss may be a presenting Qmptom (Futterweit & Mechanick, 1988). 
Polycystic ovarian disease may also be associated with acanthosis nigricans (Schriock et al 1985). 
Acantliosis nigricans, described as a brown velvety, sometimes as verrucous, discoloration of the skin 
frequently noted around tlie nape of the neck and axillae was reported in 5-10% of PCOD patients and 
witli skin tags in 20% of cases (Schriock et al 1985; Futterweit & Mechanick, 1988), Acanthosis 
nigricans is present in a nmnber of endocrine disturbances including PCOD, hjpeithecosis and pituitaiy 
tumoms. Its significance may be its correlation witli IR (Futterweit, 1984). Virilization (cliteromegaly, 
deep voice and temporal baldness) is uncommon in PCOD, so if present otlier disorders of androgen 
abnormality must be excluded (Insler & Lmienfeld, 1990). It was noticed that the incidence of extensive 
virilization and endometrial carcinoma increased with advanced age (Goldzieher & Green, 1962).
Conway et a l (1989) studied 556 PCOD patients. They divided tlie patients into high and normal LH 
groups. Infertility was more prevalent in the liigh LH group, but not liirsutism. Amenorrhoea was less 
in tlie liigh LH group. Infertility was diagnosed in 21% witli higher significant mean T and LH and FSH 
concentrations. Hirsutism was diagnosed in 61% of cases with significantly greater mean BMI, liigher T 
and lower mean FSH, Hyperprolactinaemic patients had significantly lower mean T concentrations and 
smaller ovarian volumes than normoprolactinaemic patients. There was no difference in infertility, 
hirsutism, menstrual irregularity, uterine size and endometrial thickness between tlie hyper and normal 
prolactinaemic groups. It can be concluded that the range of incidence of each symptom reported by 
different authors is dramatically large. These clinical variations have been claimed to be simply different 
stages in the evolution of tlie disease process. However, tliis explanation is unsupported by evidence and 
no detectable association between tlie duration of the disease and the completeness of the syndrome 
(Goldzieher & Green, 1962) has been demonstrated. The wide range observed in tlie incidence of each 
of tlie used symptoms probably indicates differences in the diagnostic criteria or in tlie sources from 
which tlie patients were obtained (Goldzieher & Green, 1962; Venturoli et al 1989). It is well 
recognized tliat the combination of ovulatoiy faihne (and infeitility), liirsutism, obesity and bilaterally
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enlarged cystic ovaries is not unique to tlie PCO syndrome. It is also associated ivitli Cusliing's 
syndrome, CAH, virilizing ovarian and adrenal tumours, liypeiprolactinaemia and lijper/hypotliyroidism 
(Yen, 1980). Therefore formation of rigid clinical criteria ivill not fit many patients who subsequently 
are shown to have PCOD (Goldzieher & Green, 1962; Gindoff & Jewelewicz, 1987). PCOD probably 
represents a whole array of different distiubances leading to a similar stiirctural change in the ovaries 
and clinical diagnosis is tlierefore presumptive in the majority of cases. Despite tlie high prevalence of 
PCOD in the normal population (22%) it carmot be considered as a normal ovarian variation but is a 
definite morphological entity (Poison et al 1988). Frequent follow up and laboratory testing are required 
because clinical features may vary at different times, witli episodes of anovulation alternating with 
ovulatory cycles or oligomenorrhoea (Futterweit & Mechanick, 1988).
The prevalence of PCOD detected by transvaginal ultrasoimd scan in women with a history of recurrent 
spontaneous miscarriage was reported to be liigh (Sagle et al 1988; Tulppala et al 1993). It ranged 
between 44-82% wliile the prevalence of PCOD was 18-20% in tlie control population. 
Hyperandrogenism associated witli PCOD appeared to be a significant factor (Tulppala et a I 1993). 
About 1/5* of women with recurrent miscarriage are hyperandrogénie and 83% of them miscarried 
again. Otlier researchers tried to relate tlie weight of tire patient to the poor outcome. Miscarr iage rate 
was found more firequent in the obese group (60%) than the lean group (27%) treated witli Gn and was 
independent of mid-follicular LH concentration and tlie maternal age (Hamilton-Fairley et al 1992). 
Bohrer & Kemmaim (1987) found that obesity does contribute to the high miscarriage rate.
2.2 CONCEPTS OF PATHOPHYSIOLOGY
The patliophysiology of PCOD is still uncertain and is tlie subject of hypotheses and speculations. This is 
true, in particular, of the possible mechanisms in tlie initiation and the maintenance of the syndrome.
Excessive FSH stimulation was postulated as tlie cause of ovarian changes when Ingersoll and 
McDermott (1950) were the first to suggest that PCOD might be due to excess LH secretion but this was 
not documented by hormonal assays at that time. McArtliur et al. (1958) were tlie first to docimient 
increased urinary excretion of LH in PCOD women (Givens, 1982). Some studies have incriminated the 
ovary as tlie main site of androgen hypersecretion, but tlie possible role of the adrenal gland in the 
aetiology of PCOD is still a question. Pituitary dysfunction does not appear to be the source of tlie defect. 
The role of tlie hypotlialanius has been also explored and is still open to more detailed investigations.
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It is uncertain whetlier the clinical abnormalities are due primaiily to abnonnal steroidogenesis by the 
ovary or tlie adrenal cortex which produces elevated levels of circulating androgens witli secondary 
changes in Gn secretion or whetlier Mgher centres like the hypothalamus initiate abnormal Gn release 
which in turn causes polycystic changes in the ovary and abnormal steroidogenesis (Duignan et al 1975; 
Mahesh et al 1978).
The climcal and biochemical derangements associated witli PCOD result in a classic picture of acyclic 
Gn secretion, androgen hypersecretion, increased peripheral conversion of androgens to oestrogen, 
deficient Ea production compared to tliat expected at mid-cycle, anovulation and infertility.
2,2.1 INAPPROPRIATE GONADOTROPHIN SECRETION (IG S }
Follicle stimulating hormone and LH must act in harmony to ensure the proper interaction between 
oestrogens and androgens at the ovarian level to modulate normal follicular function. The optimal 
conditions for follicidai maturation depend on LH:FSH ratio (Heineman et al 1984). It appeared that 
successful maturation of small antral follicles dming the early follicular phase was enlianced when there 
was a relatively Mgh FSH concentration, thus a low LH:FSH ratio. It is well established that tMs normal 
sequence of events does not occur in PCOD (Coney, 1984) and as a result of a chronic persistent increase 
in tlie LH.FSH ratio, hyperandrogenism and relative liyperoestrogenism result with different ratio of 
Ei:E2 (Venturoli et al 1989). The presence of numerous follicles in different stages of development and 
atresia are compatible with inappropriate Gn secretion and inadequate folliculogenesis in PCOD (Yen et 
al 1970b). Abnormal Gn secretion is a characteristic feature of PCOD. Inappropriate gonadotropMc 
secretion , that is, increased LH:FSH ratio, occurs in approximately 70% of PCOD patients (Hylka & 
diZerega, 1990). Repeated sampling of serum LH and FSH for several cycles in patients suspected to 
have the disease may furtlier increase the frequency of IGS wMch is an important featme of PCOD 
(Mechanick & Futterweit, 1986). Therefore different LH levels do not necessarily mean different 
subgroups but rather a reflection of different hormonal statuses from time to time.
Abnormal Gn secretion could be due to tlie central nervous system, hypothalamic-pituitary, ovarian and 
adrenal derangements. Combinations of causes have also been described.
PCOD may be represented by two distinct stages : a causative central nervous system generator stage and 
a resultant effector stage, manifested by a series of events involving die ovaries and die brain (Futterweit, 
1984; Mechamck & Futtenveit, 1984; Mechamck & Futterweit, 1986). The events wliich create an
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initial state of IGS aie referred to as the "generator" stage. Abnormal neural development in the brain 
decreases the pituitary set-point for negative and positive ovarian hormone feedback. Tliis results in 
inappropriately elevated LH levels compared to those of FSH thus termed IGS. It is maintained by 
ovarian hyperandrogenaemia, increased peripheral aromatization of androgens, yielding elevated free E; 
and unbound Eg levels. Oestrone suppresses release of FSH wliile Ez exerts a positive feedback on LH 
release by increasing pituitary sensitivity to GnRH. Therefore, a vicious cycle is created in this effector 
stage causing polyfollicular ovaries and increased ovarian androgen production (Mechanick & 
Futteiweit, 1984; Mechanick & Futterweit, 1986).
The origin of the primary defect of PCOD is not settled. There is a general agreement on tlie pubertal 
onset of PCOD (Mechanick & Futterweit, 1984; Mechanick & Futteiweit, 1986; Lobo, 1988; Ventmoli et 
al 1989) tliat establishes a persistent faulty hypothalamic-pituitaiy-ovarian axis (Mechanick & 
Futterweit, 1984). Anovulation is one of tlie most conmion featmes of the developing reproductive 
system and it is physiological during adolescence (Schaison, 1988; Venturoli et al 1989). Children in 
early puberly have a surge in LH secretion once a day tliat is approximately synchronous with tlie 
nocturnal sleep period. Yomiger children and girls of late puberty or adulthood have no special surge 
period; they have episodic LH secretion of an essentially constant magnitude tliroughout tlie 24-hom 
cycle (Zumoff et al 1983). It has been reported that tlie normal mid-cycle surge in LH tliat initiates 
ovulation usually begins dming sleep and high noctmnal levels do not seem to be necessaiy for ovulation 
(Venturoli et al 1988; Mauvais-Jarvis & Bricaire, 1989). Desynchronization of the "LH clock" from the 
sleep period may result in failure of the mid-cycle LH singe to occm and miovulation. This is followed 
by an endless positive feedback cycle in which excessive androgen production leads to excessive Ei 
formation, excessive LH secretion and excessive ovarian androgens (Zumoff et al 1983). Tliirty percent 
of anovulatoiy adolescents showed LH mean values similar to those of PCOD patients, and similar 
pulsatile patterns with increased pulse amplitudes which were significantly higher than those of normal 
adolescents but had a similar pulse frequency (Venturoli et al 1989). Low pulse frequency in adolescents 
could be due to nemo-endocrine immaturity. Polycystic ovarian disease patients and adolescents botli 
have similar LH circadian secretion (peak in the afiemoon) (Venturoli et al 1989). As many of the girls 
are adolescents, tliey cannot be called PCOD but rather PCOD-like. Some individuals show 
improvement of both LH patteiii and tlie ovarian aspect in late adolescence while persistence of PCOD 
featmes beyond adolescence, probably indicates an establishment of deranged endocrinological patliways. 
However, no obvious discriminative marker(s) is yet known.
Kandeel et al. (1980) observed tliat tlie mean height of tlieir PCOD patients was less tlian tliat of 
controls, which led tliem to postulate tlie presence of an early adrenal androgen release resulting in a
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premature epiphyseal closure. Onset of menarche is delayed in many PCOD patients and in the majority, 
menstruation has never been regular (Ibrahim et a! 1966; Falsetti et al 1989),
2.2.2 HYPOTHALAMIC/PITUITARYDYSFUNCTION
Abnormal LH circadian control could upset tire follicular matmation and steroidogenesis. This woidd 
prordde evidence for a primary central nervous system defect in PCOD. TMs might also support the 
hypotliesis of the presence of a low dopaminergic inhibitory tone responsible for enhanced pulsatile LH 
secretion in PCOD (Venturoli et al 1988). p-endorphins have been proposed as the most important 
opioids involved in pathophysiology of disturbed Gn secretion in PCOD (Lobo & Goebelsrnami, 1982; 
Laatikainen et al 1987; Petraglia et al 1990). The central opioid activity does not seem to be increased in 
PCOD patients despite tire fact that circulating endorphins levels are increased (Laatikainen et al 1987). 
Dopamine, serotonin and noradrenaline are neurotransmitters contributing to LH regulation (Segos et al 
1989; Hylka & diZerega, 1990). It has been suggested tliat dopamine may play a physiological role in 
the genesis of LH pulses, therefore an alteration of hypotlialamic-dopaminergic regulation of LH 
secretion has been implicated in abnormal LH secretion in PCOD (Lightrnan et al 1981; Lobo & 
Goebelsniann, 1982; Murdoch et al 1984; Lobo, 1988; McKeima, 1988; Paradisi et al 1988; Berga & 
Yen, 1989; Ferriani eta l 1989; Segos et al 1989; Hylka & diZerega, 1990; Petraglia et al 1990; Yosliino 
et al 1990; Lanzone et al 1993). However, dopamine receptor blockade was foimd not to block LH 
pulses; therefore it does not alter LH response to GnRH, possibly having its effect at the hypothalamic 
level rather than due to changes in pituitary sensitivity to GnRH. It has been reported tliat dopamine was 
a major factor causing a decrease in secretion of immunoactive LH but it did not conelate ivith the ratio 
of BLH : ILH (Lobo et al 1984). The aetiology of cMomcally acyclic Gn secretion in PCOD is thought to 
remain in the domain of inappropriate feedback by ovarian and androgen factors rather than being a 
primary hypotlialamic defect (Berga & Yen, 1989; Lobo, 1988). The role of opioids in modulating 
reproductive fiinction is diffuse from brain to gonads but it is thought that each works independently 
(Petraglia et al 1990). Hypothalamic opioids act on release of GnRH/LH axis wliile gonadal opioids 
modulate the release of steroid hormones. Ovulation is the key event wliich is characterized by the most 
relevant changes in hypothalamic, plasma and follicular fluid opioids. At present, it may be suggested 
that opioids play a major role in regulation of reproductive events. The efficacy of naltrexone (long- 
acting opioid antagomst) in normalizing LH levels after a GnRH bolus may represent a useful tool for 
PCOD management (Lanzone et al 1993).
42
It has been suggested tliat the mechanisni of dopaminergic control of PRL is disturbed (Alger et al 1980; 
Milewicz, 1984; Ferrari et al 1988; Minakami et al 1988b) with hyperprolactinaemia. 
Hyperprolactinaemia has been reported in PCOD patients witli variable prevalence (20-50%). Fenaii et 
al. (1988) in tlieir series found liigh plasma PRL levels in about 12% of their PCOD patients witli great 
day-to-day variability, that is, persistent physiological circadian rhytlimicity. The role of increased PRL 
in association with PCOD is tliought to be tlirough eitlier an abnomial hormone status acting on 
hypotlialamic regulation, directly on Gn secreting cells or indirectly by decreasing dopaminergic tone 
(McKemia, 1988). Alternatively hyperprolactinaemia may induce disorders of ovarian steroidogenesis 
leading to morphological ovarian changes. It was suggested tliat a significant portion of PCOD patients 
have abnormal PRL secretion and that tlie oestrogen pool is augmented by increased syntliesis from 
androgen conversion and enhanced sensitivity of lactotroph cells can be assumed despite not all PCOD 
patients having hyperprolactinaemia (Milewicz, 1984). The data of persistent circadian rhythm of PRL 
secretion, the normal response to TRH and dopamine antagonist (dompeiidone) and tlie lack of effect of 
dopaminergic dmgs such as bromocriptine and L-dopa, on plasma LH in PCOD, do not support the 
hypothesis of a central dopamine impairment in PCOD at least as far as regulation of PRL secretion 
(Ferrari et al 1988; Minakami et al 1988b; Feniani et al 1989; Segos et al 1989). However, involvement 
of central dopaminergic changes in the patliogenesis of IGS in PCOD camiot be excluded. It is thought 
that as tlie prevalence of hypeiprolactinaemia in PCOD may be low rather than high; tlie association of 
hyperprolactinaemia witli PCOD may be coincidental rather tlian a pathogenically related phenomenon 
(Minakami et al 1988b).
The role of PRL in tlie pathophysiology of PCOD is therefore unknown but its receptors are present in 
both ovarian and adrenal glands (Vaitukaitis, 1983). The data argued tliat dopamine is not tlie sole 
regulator of release and secretion of LH. Despite tlie high secretion of LH, an adequate pituitary store 
may be present in PCOD and LH is being syntliesized. This is indicated by an augmented LH response 
following cloniiphene or LHRH (Yen et al 1970c; Duignan et al 1975). Hence, the hyperdynamic state 
of Gn secretion in PCOD could be due to an increased sensitivity of tlie pituitaiy gland to GnRH (Bates 
& Wliitworth, 1982; Givens, 1982; Lobo et al 1984; Levin et al 1991; Dunaif, 1992b). The discrepancy 
between LH and FSH levels in PCOD suggests an increased responsiveness of tlie positive feedback 
mechanism in tlie liigh LH group (Givens et al 1976). This is supported by increased responsiveness of 
LH secretion to LHRH. There is considerable variation in response to LHRH in PCOD patients (Givens, 
1982). It is postulated tliat there is an increase in endogenous GnRH (Givens, 1982; Waldstreicher et al 
1988). Increased LH pulse amplitude may result from a combination of hypothalamic and pituitary 
effects whereas pulse frequency clearly reflects hypothalamic events - tliat is an accurate reflection of
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GnRH secretion (Waldstreicher et al 1988). Whether PCOD is due to a central (neurotransmitter) or to a 
hypothalaraic-pituitaiy (neurohormone) abnormality remains unsolved. It is ratlier difficult to resolve 
because of the lack of non-invasive measures for assessing tlie neurotransmitters and multiple inputs 
regulating the neurohormones (central neivous sj s^tem, positive and negative feedback).
2.2.3 THE ROLE OF ABNORMAL STEROIDOGENESIS IN  THE 
PATHOPHYSIOLOGY
It is assumed that optimal folliculogenesis is dependent upon relative changes in FSH and LH secretion 
during tlie first half of the cycle and tliat tlie cyclic pattern is lost in PCOD (Yen et al 1970b; Chang et al 
1982; Givens, 1982). In the absence of noimal variations in the levels of Gn, increased LH:FSH ratio, 
tliere will be arrested follicular development, tlieca cell hypeiplasia, multiple cysts of various sizes, 
impaired Ez production and hyperandrogenaemia.
It was once believed that ovulatoiy failure in PCO patients was due to tlie mechanical barrier of the 
tliickened ovarian capsule. However, this could not be confirmed by restoration of cyclic ovulatory 
menses following unilateral oopherectomy or successful induction of ovulation with clomiphene (Maliesh 
et al 1978; Schwartz et al 1987; McKenna, 1988). There is accumulating evidence that excess androgen 
plays a role in the patliogenesis of PCOD (Yen, 1980; Lobo & Goebelsniann, 1982; Francis et al 1990; 
Nakamura, 1990; Pache et al 1992a). Hyperandrogenaemia seems to originate from tlie abnormally lügh 
mmiber of cystic atretic follicles seen in PCOD and not from an augmented androgen production per 
follicle (Pache et al 1992a). Hyperandrogenaemia is mainly regulated by 5oc-R activity and SHBG 
wliich is an important modulating factor of androgen action (Lobo & Goebelsniami, 1982). Androgens 
by some mechanism in some cases can distort Gn secretion (Devesa et al 1987; Dunaif, 1992b) to 
produce tlie typical Gn secretion abnormality of PCOD. There are three mechanisms for their action; (i) 
androgen can be converted by aromatization both in peripheral tissues (adipose tissue and muscles) and 
in the hypotlialamus into oestrogen, (ii) oestrogens that can be made are Ei and Ez. Oestrone is 
primaiily derived from A and T can be converted into Ez, (iii) E? continues to be secreted by tlie ovary in 
PCÙD (Dunaif, 1992b). There is no evidence for an androgen effect on the pituitaiy gland as there were 
no changes in sensitivity to GnRH while oestrogens appear to act at the pituitaiy (Dunaif, 1992b) by 
selectively increasing resen^es of LH causing an enliancement of LH release in response to GnRH. 
Reduction of circulating steroid levels appears to be a more important factor in the resumption of 
ovulation than is disturbance in hypothalamic regulation (Gambrell et al 1973). Studies to determine
44
ovarian and adrenal contributions to androgen excess yielded conflicting results because of limitations of 
the metliods for assessing glandular- somces of androgen production by selective venous catheterization 
and DXM suppression tests (Dunarf, 1992b). Hyperandrogenism may be adrenal, ovar ian or combined in 
origin. It was demonstrated that piuely ovarian or adrenal androgen overproduction is not very frequent 
(< 39%) (Fulghesu et al 1991). Several dynamic tests for suppression or stimulation (DXM suppression 
test, ACTH stimulation test) to differentiate between ovarian and adrenal contributions have been 
attempted Mtli controversial resrdts. Dynamic tests can also detect the presence of genetic enzyme 
defects which affect adrenal steroid production in 9% of hyperandrogenaemrc women (Fulghesu et al 
1991). It is now appreciated that there are tliree compartments for androgens : ovarian, adrenal and 
peripheral conversion (Lobo, 1988). Combined suppression of ovarian (with long acting GnRH) and 
adrenal (DXM) provided evidence that the adrenal contributes to androgen excretion (Devesa et al 1987; 
Lanzone et al 1990b; Dunaif, 1992b). The ovary is tliought to be the main source of androgen and 
peripheral T and A excess (Aiman et al 1978; Kim et al 1979; Chang et al 1983; Fleming et al 1985; 
Puzigaca et al 1991). The majority of tire serum T originated from the ovary and tlie correlation between 
T and DHEA-S suggested the possibility tliat DHEA-S may serve as an important precursor for ovarian 
steroidogenesis. It is suggested that tlie primary defect in some forms of PCOD is in the ovary rather 
than in the hypothalamus or pituitary (Berger et al 1975; Ginsburg & Havard, 1976; Vaitukaitis, 1983; 
Adams et al 1986a; Berga & Yen, 1989; Francis et al 1990; Rittmaster & Thompson, 1990). It is 
tliought that the decline in sex steroids of ovarian origin would eliminate a persistent positive feedback 
wliich allows LH back to normal levels while not affecting FSH, therefore normalizing tlie ratio and 
causing ovulation (Katz et al 1978). Exogenous oestrogen administration resulted in a slow decline in 
both Gn in normal patients while in PCOD patients LH decreased but FSH did not (Yen et al 1970b) and 
with an erdianced LH responsiveness to GnRH (Chang et al 1982). This suggests an intact oestrogen 
negative feedback mechanism (Yen et al 1970b). The effect could be due to E^  or mildly increased Ez
levels. The disparity between Gn levels may reflect tire preferentially inhibitory feedback action of 
oestrogen on FSH compared to LH (Chang et al 1982). It was reported that tlie positive and negative 
feedback mechanisms for LH secretion are qualitatively intact but may differ quantitatively among 
individuals (Givens, 1982). Synthesis and secretion of FSH are suppressed by excess circulating 
oestrogens (Vaitukaitis, 1983).
Despite all of this data, tissue culture studies showed the ability of isolated granulosa and theca cells from 
mid-antral follicles to secrete C21 and C l9 steroids in tlie absence of Gn stimulation and tlieir intact 
steroidogenic capacity (Wilson et al 1979) seems to exclude a primary ovarian steroidogenic dysfunction.
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No causative abnormality of adrenal function or ACTH secretion has been established (Kandeel et al 
1980). The mechanism of increased androgen production by the adrenal cortex is miknown. In one 
series tlris was found to occm’ in 60% of cases (9/15 patients) (Kandeel et al 1980). It could be due to 
high LH stimulating adrenal androgenesis (Yen et al 1970b). The conüibution from tlie adrenal gland 
camiot be excluded (as the somce of peripheral excess) (Berger et al 1975; Aiman et al 1978; Rittmaster 
& Thompson, 1990). There is actually mild hypersecretion of adrenal androgens associated with PCOD 
without apparent specific dysfimction (McKeima, 1988). Elevated adrenal androgen levels have 
remained unexplained (Lobo et al 1983). In PCOD, tlie adrenal related androgen production is positively 
related to baseline values. The liigher tlie baseline, tlie more important is tlie amount of secretion of 
these andr ogens. In PCOD 1/3'^ '^  of tlie patients have adrenal-derived excess androgens based upon high 
DHEA-S levels (Fulghesu et al 1991). The adrenal gland may trigger PCOD in some females. 
Alternatively, it is also possible that ovarian T and A could start it. A certain degree of a clironic state is 
dictated by tlie LH stimulating effect, leading to an increase in unbound T and A, an increase in Eg, 
exaggerated LH secretion with IGS and chronic anovulation and subsequently increased andr ogen (Lobo 
& Goebelsmann, 1982).
There is some abnormality in the regulation of adrenal steroidogenesis in many PCOD patients (Devesa 
et al 1987; McKenna, 1988; Fulghesu et al 1991; Dmiaif, 1992b) characterized by elevated levels of 17a- 
OHP and DHEA-S and exaggerated 17a-0HP, A and cortisol responses to exogenous ACTH (Devesa et 
al 1987).
Ovarian hyperandrogenism may induce adrenal enzymatic defects (Vermesh et al 1988). It was proposed 
that ovarian 17KSR deficiency, transmitted as AR trait or X-linked R, may result in hirsutism duiing 
puberty, along with menstrual dysfunction and PCOD (Pang et al 1987; Toscano et al 1990). There is no 
clear cut evidence for a deficiency in 3p-OHSD activity in PCOD patients (Hague et al 1989). 
Congenital adrenal hyperplasia and PCOD have been interrelated. It was found in one series that only 
6.4% of PCOD patients had evidence of 210H deficiency (Hague et al 1989), so it is unlikely that PCOD 
is due to an adrenal defect.
Follicular matmation is FSH dependent, tlierefore it seems more logical to consider that tlie central 
defect is a failme of FSH action wliich may be exacerbated by liigh levels of androgens witliiri tlie 
follicles. If no ovulation occurs, tliere is no subsequent P rise and so the normal negative feedback 
control of Gn secretion is disturbed. The expected inter-cycle rise of FSH fails to occur (Franks ei al
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1988). Although P is essential for a normal Gn surge, it operates by synergizing the obligatory action of 
E., (Liu & Yen, 1983).2
Polypeptide growth factors are paiacrine modidators of FSH action and the most important of these are: 
(i) stimulatory : IGF-I and II,TGF-p ; (ii) irdiibitory; TGF-a, EGF and inliibin. Other paracrine 
modulators of FSH are oestrogens and androgens. These paracrine grmvth factors are of potential 
importance in controlling tlie action of FSH (Franks et al 1988).
Inhibin is produced exclusively by granulosa cells and has been proposed as a non-steroidal marker of 
granulosa cell function and follicle liability. The relative FSH decrease to GnRH may primarily reflect 
pituitary desensitization (Waldstreicher et al 1988) and bioactive inhibin was reported to be elevated in 
PCOD and could play a role in granulosa cell dysfunction (Tanabe et al 1990; Pache et al 1992a). 
Inhibin activity in tlie ovaiy depends on follicular viability and not on follicular size. Since PCOD 
follicles contain fewer gianulosa cells per follicle in comparison with normal follicles, yet contain 
comparable levels of inliibin, it is possible that the inhibin secretion per granulosa cell is greater in 
PCOD tlian in the normal ovary (Tanabe et al 1990). Nevertlieless, there was no evidence for a defect in 
ovaiian inliibin production (Waldstreicher et al 1988; Pache et al 1992a).
In summary, the hyperplastic ovarian tlieca is tliought to be secondaiy to LH stimulation, immature 
ovarian follicles are secondary to relative suppression of FSH release and subcapsular follicles are 
secondaiy to chronic anovulation due to disordered Gn secretion, while increase in follicular atresia and 
cortical tliickening are due to high androgen levels (Dimaif, 1992b). Possible causes of PCOD include a 
vicious cycle of increased serum T levels, leading to increased serum LH levels, leading to furtlier 
increases in serum T levels. This remains a functional disorder while morphological changes in tlie 
ovaries are not fomid, but a second vicious cycle becomes involved (Idgh serum T levels leading to 
LH/FSH separation, leading to fiirther increases in serum T levels), then morphological changes in the 
ovaries, i.e. PCO ivill come about (Takahashi et al 1991). In females with high T, the presence of a 
morphological abnormality' on tlie ovaries has an effect on Gn production and so the incidence of 
menstmal irregularity and liirsutism. If PCOD is moiphologically identified and clinical symptoms 
appear, the interactions of the hypothalaniic-pituitary-ovarian system are disturbed. Even if no 
morphological indications of PCOD ai e present but abnonnalities of semm androgen and Gn are evident, 
tlie possibility of PCOD developing should be considered. If PCOD is fomid, but androgens and Gn are 
normal; then the possibility of fliture hormonal abnormalities should be suspected (Takaliaslii et al 
1991). Regular hormonal assays are therefore required for diagnosis.
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2.2,4 THE ROLE OF OBESITY IN THE PATHOPHYSIOLOGY
There is little doubt that obesity and anovulation are interrelated phenomena (Friedman & Kim, 1985). 
Over half of the patients with PCOD have some degree of obesity (Aiilgren et al 1976; Yen, 1986; Lobo, 
1988; Dale et al 1992b). The role of increase adiposity in PCOD was suggested by findings of increased 
body weight and BMl in PCOD patients when compared with idiopathic liirsutism and control patients 
(Byrne et al 1991). The pathophysiology of this increase in fat disposition, usually appar ent at the time 
of puberty, is unknown. However, it is postulated that oestrogen regulates adipocyte replication and 
differentiation. Fat cells aie oestrogen taigets and tlie increased adipose tissue in PCOD patients may be 
casually related to tlie exposure of fat cells to chronically elevated and unopposed extra-ovarian oestrogen 
production, probably begimiing at tlie time of puberty. Obesity may play a role in the patliogenesis of 
PCOD (Fisher et al 1974; Bates & Whitworth, 1982; Pasquali et al 1983; Falsetti et al 1989). Obesity at 
puberty or later in reproductive life could be an initiating factor by increasing Ej production and 
consequently altering pituitary Gn secretion. Obesity has been found to cause changes in steroid 
hormone metabolism (Lobo et al 1981; Laatikainen et al 1983) tlirough a decrease in SHBG 
concentrations with resultant increase in unbound, biologically active, steroids (E^ , T), therefore 
contributing to tlie increase in Gn secretion. Obesity was associated witli liigh free androgen indices, low 
LH:FSH, low concentration of LH, A and SHBG (Paradisi et al 1986; Anttila et al 1991; Invitti et al 
1991; Anttila et al 1992). The mechanism by which body weight could induce lower LH secretion in 
PCOD patients is not clear. It could be due to sex steroid imbalance, p-endorpliins are thought to be 
more elevated in obese PCOD patients and by an inliibitory mechanism may suppress tlie LHRH-LH 
system to a greater extent than in non-obese PCOD patients (Paradisi et al 1986). The apparent success 
of weight reduction in suppressing the hyperandrogenaemia (Friedman & Kim, 1985; Eden et al 1989c), 
causing a decrease in Ej, normalizing Gn secretion and restoring ovulation suggest a common link 
(McKenna, 1988). Inappropriate Gn secretion and ovarian changes are consequences of obesity wliich 
could be due to tlie presence of hyperoestronaemia and hyperinsulinaemia (Friedman & Kim, 1985; 
Pasquali et al 1986; McKenna, 1988; Invitti et al 1991; Lanzone et al 1991; Carmina et al 1992). The 
increased aromatase activity and hyperinsulinaemia observed in obese subjects probably plays a major 
role in causing the hyperandrogenaemia, eitlier by stimulating LH secretion or by directly stimulating tlie 
ovary, as in the case of I (Friedman & Kim, 1985). In addition to ovarian hyperandrogenaemia, pituitary 
hypotlialamic dysfunction has been obseived in response to obesity. Inadequate central serotonin 
stimulation, excessive dopamine stimulation, and insensitirdty to endorphins may all be involved in the 
pituitary hypotlialamic dysfunction, as well as resistance to weight reduction (Lobo & Goebelsmann, 
1982; Friedman & Kim, 1985).
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There are several mechanisms by which obesity could be involved in tlie patliogenesis of PCOD: (i) 
increased body weight is associated with increased extraglandular aromatization of androgens into 
oestrogens, primarily Ej and decreased plasma SHBG levels, (ii) obesity is associated with increased 
circulating levels of I wliich may be involved in the patliogenesis of PCOD by directly stimulating 
ovarian androgen production and/or altering Gn release, (iii) it is possible that obesity in PCOD is either 
centi ally mediated (via changes in hypothalamus, control of food intake or endogenous opiate secretion) 
or is secondary to an androgen mediated increase in body weight and thus may be associated with a 
unique form of PCOD (Dunaif et al 1988).
2.2.5 INSULIN RESISTANCE
Hyperinsulinaemia may be tlie trigger mechanism of tlie pathogenesis of PCOD (Urdl et al 1991). 
Insulin resistance is defined as normal glucose levels in the presence of hyperinsulinaemia (Burghen et al 
1980). Insulin resistance has been linked to hyperandrogenaemia (Shoiipe & Lobo, 1984). Fasting 
hyperinsulinaemia may be used as a guide to the existence of IR (Shoupe et al 1983) and the SITT is 
another method for assessing IR (Akinmokun et al 1992) (Chapter 5-Insulin Sensitivity). In women 
with PCOD, independent of the degree of obesity, IR was demonstrated in terms of increased basal I 
levels and I responses to oral GTT (Burghen et al 1980; Bates & Whitworth, 1982; Pasquali et al 1982; 
Chang et al 1983; Dunaif et al 1987; Givens et al 1987; Schwartz et al 1987; Coiro et al 1989; Duriaif et 
al 1989; Dimaif et al 1990; Falcone et al 1990). Chang and liis colleagues (1983) demonstrated raised 
serum I concentrations in lean women witli PCOD compared with lean controls, and observed an 
association between serum I and androgen concentrations. An apparent association between 
hyperandrogenaemia and hyperirrsulinaemia in the human female has been widely appreciated since 
1921 (Adashi, 1990).
The primary role of I is to facilitate the supply of glucose to cells. If insufficient glucose is made 
available, because of resistance to die action of I, tlie pancreas produces more I. In cases of adequate 
pancreatic resen^e, normal circulating glucose levels are maintained at higher semm I concentrations. If 
the pancreatic reserve is not adequate, impaired glucose tolerance and diabetes rnellitus ensue (Shaw, 
1991).
There are several processes which are known to resirlt in resistance to the action of I and therefore 
hyperinsulinaemia : raised concentrations of "anti-I" hormones (acromegaly, Cushing's syndrome.
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phaechromocytoma), structural defects of the I receptor (type A syndrome of IR) and the presence of 
antibodies against the I receptor (type B syndrome of IR). More conmion tlian any of these phenomena is 
obesity. The mechanism by wliich obesity causes IR is a complex series of events whereby reduced 
receptor numbers and post-receptor defects cause resistance to tlie action of I  The resulting 
hyperinsulinaemia in turn maintains the reduction in tlie number of receptors "down-regulation" (Shaw, 
1991). Interestingly, PCOs are associated with several of the above conditions and obesity is a common 
finding.
The primary disturbance is apparently IR, which produces a compensatory hyperinsulinaemia to 
maintain euglycaemia. IR, therefore, may be due to any of the following :
1. Decreased number or abnormal function of I receptors.
2. I receptor antibodies.
3. Post-receptor defects in I expression. (Ahlgren et al 1976; Burghen et al 1980; Pasquali et al 1982; 
Shoupe et al 1983; Givens et al 1987; Jialal et al 1987; Falcone et al 1992).
Levels of I depend on the secretion rate of the p-cells of tlie pancreas, on the hepatic removal of I and on 
the type of stimulation (Pasquali et al 1982). There is some sort of p-cell parallel to the IR of peripheral 
tissue. IR is mainly generated peripherally; the changed sensitivity of peripheral tissue to I activity may 
constitute a primary event in the genesis of IR. This beha\dor has been demonstrated in obese, PCOD 
patients witli acanthosis nigricans. Therefore, a heterogeneous group of pathogenesis exists in wliich the 
common feature is reduced peripheral IS (Raiidazzo et al 1989).
Mechanisms underlying the association of hyperandrogenism and hyperinsulinism are complex and of 
considerable interest (Chang et al 1983; Dunaif et al 1987; Laatikainen et al 1989). Obese patients were 
reported to have a significant correlation between I and FT levels while non-obese had significant 
correlations between I and FSH, DHEA-S and SHBG levels (Dmiaif et al 1987). 
Dehydi'oepiandrosterone sulphate suppression by I is impaired in IR PCOD patients (Falcone et al 1990; 
Farah et al 1990). Tliis may contribute to androgen excess. Hyperinsulinism is a heterogeneous feature 
of PCOD patients where 80% of obese PCOD patients showed hyperinsulinaemic pattern while only 30% 
of obese controls and of non-obese PCOD patients showed this hyperinsulinaemia (Lanzone et al 1989).
Many studies have shown a positive correlation between I and androgen levels (Burghen et al 1980; 
Pasquali et al 1982; Chang et al 1983; Pasquali et al 1983; Poretsky et al 1984; Shoupe & Lobo, 1984;
50
Jialal et aî 1987; Dimaif & Graf, 1989; Lanzone et al 1989; Adaslii, 1990; Taketani & Mizimo, 1990; 
Elkind-Hisch et al 1991; Nestler et al 1991; Buyalos et al 1992) with significant correlation in obese and 
non-obese patients while other researchers foiuid tliat hyperinsulinaemia did not play a major role in 
ovarian hyperandrogenism in PCOD (Geffner et al 1986; Dunaif et al 1987; Lanzone et al 1989; 
Lanzone et al 1990c; AbdelGadir et al 1991; Anttila et al 1991; Dale et al 1992a; Dale et al 1992b; 
Toscano et al 1992) since hyperinsulinaemia persisted even after ovarian inhibition with a long acting 
GnRH-A. Hirsute patients were found not to have higher serum I levels tlian non hirsute patients 
(AbdelGadir et al 1991). Theoretically hyperandrogenaemia, per se, may promote hyperinsulinaemia but 
despite tlie relatively high circirlating androgen in men, only a minority of them display IR. Exogenous 
T has no eftect on fasting glucose in normal men. Lowering of circulating androgen levels in 
hyperandrogénie hyperinsulinaemic patients by medical or surgical means does not appear to exert a 
measurable effect on the IR state as assessed by GTT, and I requirement (Shoupe & Lobo, 1984; Adaslii,
1990). The argument that I may stimulate ovarian androgen biosynthesis has received increasing support 
from botli in-vitro and in-vivo studies witli ovarian tlieca-interstitial cells the possible site of I receptors 
and action. The theca-interna cells' surface exliibits specific I receptors (Adaslii, 1990; Nagamani & 
Stuart, 1990; Anttila et al 1991). Supraphysiologic as well as physiologic concentration of I, acting 
alone or witli pituitary Gn, enliance ovarian androgen production by theca-interstitial cells (Dunaif & 
Graf, 1989; Adashi, 1990; Lanzone et al 1990c).
Peripheral resistance to I occurs in PCOD and the resultant hypersecretion of I may modulate 
ovarian/adrenal function and produce abnormal steroid secretion (Pasquali et al 1983; Poretsky et al 
1984; Gefiher et al 1986; Dimaif & Graf, 1989; Lanzone et al 1990c; Nestler et al 1991; Sharp et al
1991). Patients witli PCOD and elevated androgens had higher IR than those witli chronic anovulation 
and normal androgens of similar body weight (Shoupe & Lobo, 1984). The I response to oral glucose 
correlated positively with serum A and T concentrations, independent of the effect of LH (Shaw, 1991). 
It is hypothesized tliat many lean women with PCOD have fasting hyperinsulinaemia and tliat I 
stimulates the ovarian prodirction of androgens which contributes to menstrual disturbances. Therefore 
high I could be involved in the patliogenesis rather tlian being a result of the primary disorder (Geffner et 
al 1986; Taketani & Mizuno, 1990).
Acute elevation of LH does not appear to cause IR in PCOD (Shoupe & Lobo, 1984; Geffner et al 1986). 
The fact tliat BLH but not ILH was found related to I raised the possibility that I or altered glucose 
metabolism in IR subjects may change the bioactivity of BLH. This is supported by the fact that BLH is 
lower in obese patients and correlated negatively to BMI (Anttila et al 1991). Since endogenous opiates 
aie involved in modulating pancreatic islet function and increases in I secretion, hyperinsulinaemia may
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be opiate dependent (Givens et aï 1987; Laatikainen et aï 1989; Laatikainen et ai 1990; Lanzone et aî
1991) but it was found that opioid blockade (by naloxone) did not affect IR response to glucose or IGF-I 
whereas IGF-binding protein (IGFBP-1) decreased (Laatikainen et al 1990). Therefore the role of 
opiates in the patliogenesis of PCOD is unclear (Givens et al 1987) and whether tliis may result in a 
reduction of hyperandrogenaemia is not known. Glucagon is not implicated in peripheral IR in PCOD 
(Golland eta l 1990).
Insulin is positively correlated with BMI (Pasquali et al 1983; Shoupe & Lobo, 1984; Anttila et al 1991; 
Carmina et al 1992). Hyperandrogenaemia, obesity and acantliosis nigricans can be independently 
associated witli IR (Jialal et al 1987; Lanzone et al 1989; Taketani & Mizuno, 1990). Acanthosis 
nigricans is a conmion finding in obese hyperandrogénie females (29%) and was fomid to be associated 
witli significantly liigher I levels when it occurred in obese PCOD women. The PCOD women with 
acanthosis nigricans had sex hormones and Gn levels similar to tliose in women witliout acanthosis 
nigricans, wliich suggests tliat they formed a subgroup of PCOD rather than a distinct endocrine disorder 
(Dunaif et al 1987). In acanthosis nigricans anti-receptor antibodies and I antibodies have been 
demonstrated (Pasquali et al 1982; Shoupe et al 1983) with normal receptors. It was fomid that only 
women with PCOD have hyperinsulinaemia independent of obesity (Dunaif et al 1987). The negative 
impact of PCOD and obesity on I action is additive (Dunaif et al 1989; Anttila et al 1991).
Insulin growtli factors are peptides witli stmctmal similarities to pro-I and I, and have been shown to be 
intra-ovarian modulators of steroid syntliesis (Urdl et al 1991; Shaw, 1991). The IGFs have growth- 
promoting and I-like metabolic effects. The liver seems to contribute to most of tlie circulating IGFs in 
adults. Granulosa cells contain and secrete IGFs. The IGF-I potentiates the stimulating effect of FSH on 
ovarian aromatase activity, and P secretion and expression of tlie LH receptor. Insulin-like growtli 
factor-I also stimulates accumulation of androgens in tlie ovary (Shaw, 1991). The semm IGF-I level is 
regulated by GH. Growtli hormone deficiency is associated witli low semm IGF-I levels. The IGF-I 
levels decline dming fasting. The IGFs are bound to specific binding proteins in serum. There have now 
been at least six IGFBPs identified. The circulating level of IGFBP-1 is regulated by I, whereas tliat of 
IGFBP-3 is regulated by GH. The IGFBP-1 has been found to inliibit FSH-induced granulosa cell 
proliferation and its seiimi concentration is inversely correlated to the I concentration. Obese women 
with PCOD and hyperinsulinaemia have subnormal semm IGFBP-1 levels. The levels of IGFBP-1 have 
a positive correlation witli those of SHBG, wliich also are low in PCOD (Shaw, 1991).
The mechanism by wliich I stimulates androgen production by the ovary may be complex. Fasting I 
concentrations correlated positively witli semm IGF-I and negatively witli IGFBP-1 concentrations in
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lean women witli PCOD. The IGFBP-1 is thought to play a role in regulating tlie bioavailability of IGF-I 
and is known to be regulated by I (Shaw, 1991). Micromolar concentrations of I have been found to 
inhibit IGF-I binding to its receptors in multiple cells and tissues. Insulin, by causing a reduction in the 
circulating IGFBP-1 levels may increase tlie potential for IGF-I to stimulate tlie ovaiy for androgen 
production. The demonstration of tlieca-intema cells IGF receptors and their apparent coupling to tlie 
stimulation of androgen production may accomit for the phaimacological action of I (Adaslii, 1990; 
Nagamani & Stuart, 1990; Anttila et al 1991; Buyalos et al 1992). Frequently, tlie onset of liirsutism is 
accompanied by weight gain in women with PCOD (Shaw, 1991). Obese patients have been found to 
have low IGFBP-1 levels (Anttila et al 1991). It is speculated that elevated BLH in lean PCOD patients 
stimulates tlieca androgen production whereas in obese patients high I concentration may act through 
IGF-I receptors and potentiate Gii-induced androgen production. The effect of obesity is to exacerbate 
tlie endocrine abnormalities of PCOD. Weight gain is associated witli a rise in semm I and a consequent 
fall in SHBG concentrations (Shaw, 1991). It is possible that the IR of obesity is not only quantitatively 
greater tlian that related to PCOD but also qualitatively distinct, resulting in tlie need for liigher semm I 
concentrations before significant stimulation of androgen synthesis occurs. It is therefore possible that 
obesity is both a result of, and a contributing factor to, tlie endocrine imbalance in PCOD (Shaw, 1991).
It would appear that acute elevation of circulating I levels during the euglycaemic clamp teclmique may 
not be sufficient to promote ovarian androgen production (Adaslii, 1990). Women witli PCOD and 
hyperthecosis have hyperinsulinaemia and IR. It is possible tliat I in supraphysiological concentrations 
exerts its steroidogenic action on ovarian stromal cells tlirough IGF-I receptors. Insulin and IGF-I levels 
were found positively correlated. Elevated (Damajanovic et al 1990; Urdl et al 1991) or normal (Kazer 
et al 1990; Slowinska-Srzednika et al 1992) serum IGF-I and decreased HGH were found in PCOD. 
Among homiones known to cause or predispose to IR are GH, cortisol and PRL (Chang et al 1983). 
Concentrations of growth factors were examined in 28 patients witli clinical and endocrinological signs 
of PCOD. The HGHTGF-I ratio reflects the functional dynamics of tliese substances. The IGF-I 
concentrations were increased, therefore, HGHTGF-I ratios were significantly decreased in PCOD 
patients than controls (Urdl et al 1991). The iimnber of 1 receptors, receptor affinity and I receptor 
complexes were significantly liigher in PCOD tlian controls (Urdl & Desoye, 1991; Urdl et al 1991). 
Elevated I and IGF-I levels seem to play a patliogenic role in PCOD by influencing synthesis and/or 
secretion of this growth factor and its binding protein (IGF-BPl) by liver cells and other IGF-I producing 
organs. Growth hormone has also been shoivn to produce relative IR (Burghen et al 1980).
Obese PCOD patients showed higher IR with hyperinsulinaemia, which is tliought not to be entirely due 
to obesity because IR levels were lower in patients ivith simple obesity than in obese PCOD patients.
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Hyperinsulinaemia in simple obesity could be due to impaired I removal in the liver (Pasquali et al 
1982). Therefore, IR is probably the most important factor in determining tlie hyperinsulinaemia in 
obese PCOD patients.
Falcone et al. (1991) reported an absence of association between the degree of IR and inliibin 
concentrations. In addition, the same authors found that tlie women witli PCOD had inhibin levels 
compar able to those of the control group during the ear ly follicular phase but significantly lower than late 
follicular phase or luteal phase. They postulated tliat inliibin concentration in women with PCOD most 
likely reflects ovulatory state witli lack of a dominant follicle and subsequent ovulation; therefore, inhibin 
may reflect impaired follicular maturation and that Inhibin and are both markers of follicular 
maturation. Several hormones tliat are known to stimulate granulosa cell differentiation appear to 
enhance inhibin production in-vitro. During a nonnal menstrual cycle, inhibin levels change very little 
from tlie early to mid-follicidar phase. In late follicular phase, inhibin levels rise witli tlie LH surge; 
peak inliibin levels occur in the mid-luteal phase. Inliibin secretion is not acutely affected by I seeretion 
in normal or hyperandrogénie females (Falcone et al 1991). In-vitiv experiments with PCOD granulosa 
cells indicated tlie following : (i) physiological concentrations of IGF-I are as effective as FSH in 
stimulating E^  production; (ii) IGF-I and FSH act synergistically to control tlie level of E^  production and 
(iii) this synergy was not observed with I or IGF-II therapy (Holly et al 1990). The mechanisni(s) 
responsible for arrest of folliculogenesis have to be established.
Insulin-like growth factor-I has been shown to potentiate tlie ability of LH to stimulate interstitial theca 
cell androgen production and an increase in local IGF-I activity could contribute to the ovarian 
hyperandrogenism characteristic of PCOD. Also, increased feedback of IGF-I at tlie level of the pituitary 
could lead to a reduction in GH secretion (Kazer et al 1990). There is considerable evidence tliat IGF-I 
plays an important role in the human ovary and that physiological activity of IGF's is undulated by a 
number of IGFBP's. There are at least 4 discrete types of IGFBP's in ovarian follicular fluid and it is 
suggested that each may be produced independently witliin tlie ovary (Holly et al 1990). The possibility 
that I, directly or via IGF-I may modify the par acrine control of ovarian steroidogenesis or tlie action of 
androgens at target tissue levels remains the subject of investigation (Toscano et al 1992). 
Hyperandrogenized patients can be subdivided into (i) tliose witli IR, normal or minimal increase in LH 
and markedly elevated I levels (obesity is associated with tliis type); (ii) tliose with elevated LH levels, 
no IR and normal I concentration (liigh BLH is associated witli tliis type) (Anttila et al 1991; Dale et al 
1992b).
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Fasting I concentrations are raised in 1/3 of lean and 3/4 of obese women with PCOD (Shaw, 1991). 
Insulin, and perhaps IGF-I, has a gonadotrophic type action promoting ovarian androgen synthesis and 
contributing to menstrual disturbance.
In conclusion, although there may be a threshold level of free androgens in women above which IR may 
be affected, androgens are only one of the multiple factors influencing the development of IR. Peripheral 
androgen production and LH may not correlate with hyperinsulinaemia in PCOD (Shoupe & Lobo,
1984). Polycystic ovarian disease represents a distinct subphenotype of IR with a different genetic basis 
from IR associated witli typical NIDDM (Ahlgren et aî 1976).
2 .16  THE ROLE OF LEPTIN
Leptin, the so called the “ fat-melting hormone ”, is a newly discovered hormonal product of tlie obese 
gene. It is derived from tlie Greek word “ leptos ” which means tlün (Caro et al 1996). Leptin is 
expressed by adipocytes and thought to play a role in tlie regulation of food intake and metabolism 
(Barash et al 1996; Caro et al 1996). Adipose tissue produces leptin that is then secreted into the 
systemic circulation (Klein et al 1996). Leptin receptors are widely distributed in the brain (including 
the hypotlialamus and tlie choroid plexus), liver, lungs, heart, kidney, testes, adipose tissue and spleen 
(Caro et al 1996). The reported plasma leptin half life is 25 minutes (Klein et al 1996). Plasma leptin 
concentrations are gender specific, being higher in women than in men (Haffuer et al 1996; Segal et al 
1996). There is a circadian rhythm for leptin concentration (Pijl et al 1996), witli liighest levels between 
midnight and ear ly morning hours and lowest around noon to mid-afiemoon. It was postulated tliat tlie 
nocturnal rise in leptin could have an effect in suppressing appetite during tlie night while sleeping 
(HaSher eta l 1996).
There is a strong positive correlation between senun leptin concentration and body fat, tlierefore, serum 
leptin concentrations reflect the amount of adipose tissue in tlie body (Caro et al 1996). Wlien energ>^  
intake and energy output are in balance, leptin reflects the amount of TG stored in the body as adipose 
tissue. When a disturbance causes an increase in fat deposition and BMI (positive energy balance), an 
increase in energy expenditme and a decrease in energy intake due to a reduction in appetite will occur. 
These compensatory changes are necessary to restore the steady-state energy balance with no addition to 
tire adipose tissue. The reverse would occur if the distmbance causes fat loss (Caro et al 1996). The 
same authors also found a large decrease in serum leptin concentration in the presence of a relatively
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small change in body weight suggesting tliat leptin is regulated by otlier factors tlian the size of the 
adipose tissue depot, such as caloric intake and lasting.
Caro et aî. (1996) proposed that most obese humans are resistant to their endogenous production of 
leptin since tlie majority of hiunan obesity is characterized by hyperleptinaemia. This increase in leptin 
production may be caused by leptin antibodies, leptin antagonists, or increased production of leptin 
binding proteins resulting in a decrease of tlie free leptin reaching the brain. It is not known yet where 
the site(s) of leptin action is located in tlie hypothalamic-pituitary-gonadal axis.
It is known that hormones, such as I, glucocorticoid and adrenergic agents, regulate leptin secretion. 
Acute I does not stimulate leptin secretion in humans, while chronic I plays an important role in 
stimulating leptin secretion (Caro et al 1996).
Studies have revealed an association between nutritional status, adiposity and reproductive maturity in 
female animals. Chehab et al. (1997) reported tliat normal pre-pubertal female mice injected ivitli leptin 
reproduced earlier than controls and showed accelerated maturation of the reproductive tract. In 
addition, leptin-treated female mice were found to have significantly elevated serum levels of LH and 
increased ovarian and uterine weights (Barash et al 1996). Therefore, it was suggested tliat leptin may 
be a metabolic signal triggering puberty (Chehab et al 1997), and stimulating the reproductive endocrine 
system of nonnal female mice (Barash et al 1996; Chehab et al 1997).
2.3 LABORATORY DIAGNOSIS
Biochemical studies historically were confined to analyses of urinary steroid metabolites. Elevated 
excretion of urinary 17-ketosteroids had been obseived by many investigators. Altliough it is known that 
ovarian androgen production as T will produce less elevation of urinary 17-ketosteroids than an 
equivalent level of androgen production as A or DHEA from the adrenal gland (Goldzieher & Green, 
1962) it was evident tliat tliere was a spread of values which precluded categorization of these patients 
into well defined subgroups. In addition, measurement of urinaiy 17-ketosteroids is of little value since 
botli adrenal and ovarian ketosteroids are metabolized to tlie same excretory products (androsterone and 
etiocholanolone) (Goldzieher & Axelrod, 1963). As a consequence, dynamic studies of steroid 
metabolism were developed in an attempt to distinguish the ovarian contribution from that of the adrenal. 
More recently tlie advent of radioimmunoassays opened up new approaches to the understanding of botli 
the disease processes and the diagnosis of PCOD.
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Polycystic ovarian disease is characterized by abnormalities in plasma levels of LH, oestrogens, 
androgens, PRL and glucose metabolism. The clinical features of women witli PCOD may vaiy at 
different times, witli episodes of ano^mlation alternating with regular’ menstrual cycles. Therefore 
frequent laboratory testing of tliese women is essential (Gindoff & Jewelewicz, 1987; Futterweit & 
Mechanick, 1988).
2.3.1 GONADOTROPHINS
Luteinizing hormone is a heterogeneous molecule with the possibility of 2 or more molecular forms of 
LH being secreted with different biological actmties (Lobo et al 1984). Variation in LH levels in PCOD 
can be large. There are three groups of investigators with tliree types of results concerning tlie levels of 
LH. The first group believe tliat LH values are persistently elevated compared to tlie levels obsewed in 
the follicular phase of tlie normal cycle (Duignan et aî 1975; Rajaniemi et al 1980; Lobo et al 1981; 
Chang et al 1983; Laatikainen et al 1983; Heineman et al 1984; McKemia et al 1984; Abdulwahid et al 
1985; Dimaif, 1986; Messina et al 1986; Eden et al 1988a; Homburg et al 1988; McKeima, 1988; 
Minakami et al 1988a; Venturoli et al 1988; Waldstreicher et al 1988; Eden et al 1989a; Murdoch et al 
1989; Rojanasakul et al 1989), the second group divided the PCOD into two types, tliose witli 
persistently elevated serum LH levels and tliose with levels in the normal range (up to 10 - 20% of tlieir 
patients) (Goldzieher & Green, 1962; Givens et al 1976; Yen, 1980; Givens, 1982; Vaitukaitis, 1983; 
Schriock et al 1985; Mason et al 1986; Wajchenberg et al 1986; Gindoff & Jewelewicz, 1987; Franks et 
al 1988; Conway et al 1989), and tlie tliird group considered LH levels to be high, normal or low 
(Gambrel! et al 1973). Different LH levels do not necessarily mean different subgroups, but may reflect 
different hormonal statuses of individuals from time to time (Givens, 1982). The daily concentrations of 
LH in individual patients were highly variable (Gambrell et al 1973; Gindoff & Jewelewicz, 1987). The 
discrepancies between different reports regarding LH levels might result from the conflict between the 
nature of the LH secretion and the methods used for measuring tlie levels of this hormone in tlie blood. 
Measuring tlie hormone levels in plasma once daily can lead to conftising results, depending on the 
timing of blood sampling in relation to fluctuations of the hormone (Yen, 1980; Schwartz et al 1987; 
Dolyan et al 1989; Insler & Lunenfeld, 1990).
Follicle stimulating hormone was found to be in the low-normal range by almost all investigators 
(Duignan et al 1975; Katz et al 1978; Rajaniemi et al 1980; Bates & Whitwortli, 1982; Chang et al 
1983; Lobo et al 1983; Heineman et al 1984; Abdulwaliid et al 1985; Messina et al 1986; Wajchenberg
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et al 1986; Mavroudis et al 1988; Minakami et al 1988a; Venturoli et al 1988; Waldstreicher et al 1988; 
Murdoch et al 1989; Rojanasakul et al 1989).
Abnormal Gn secretion pattern is expressed by high LH:FSH ratio even if LH is normal (Givens, 1982). 
This abnormal ratio is of diagnostic value in tlie disease (Lobo et al 1981; Chang et al 1983 ; Lobo et al 
1983; Heineman et al 1984; Schriock et al 1985). Abnormal ratios of more that 2.5 can be found in 60 - 
70% of PCO patients (Futterweit, 1984; Futterweit & Mechanick, 1988). The ratio varies depending on 
tlie assay metliods used; tliis is expected since different criteria are used in tlie different assays (Lynch et 
al 1989). An abnormally high ratio of LH;FSH is not unique to PCOD patients but is also observed in 
chronic liver disease, hypertliyroidism and simple obesity (Givens, 1982) and can occur ivith other 
hyperandrogénie disorders such as adult onset 210H deficiency and androgen secreting tumorus (Dmiaif,
1986). Therefore, it is important that tlie reference ranges for each hormone be assessed for each rnetliod 
and tliat the upper normal limits of LH:FSH should not be quoted without stating tlie metliods employed. 
The LH:FSH ratio may change if follicular development and the occasional ovulation occur (Lynch et al
1989) indicating tliat the best timing for assessment of tlie Gn status is the eaily follicular phase. The 
disparity between FSH and LH may be explained by tlie negative feedback effect of oestrogen wliich is 
greater for FSH tlian for LH. Follicle stimulating hormone is relatively insensitive to GnRH and tlie 
multicystic ovaries may secrete increasing amounts of follicular inhibin which selectively decreases FSH 
(Yen, 1980). Normally tlie disappearance rates of FSH like that of LH can be resolved into at least 2 
components : the initial (fast) fraction with ti/2  of 3.9 hours and the second (slow) component with ti/2  of 
7.04 hours. The metabolic clearance rate of FSH is about half that of LH (Yen et al 1970a). In studying 
tlie LH receptors in ovarian follicles from PCOD patients, tlie number present was lower than in normal 
pre-ovulatory follicles but was similar to tliat of early normal follicular* phase follicles suggesting that the 
deranged follicular development may be due to tonic elevation of LH producing down regulation of its 
own receptors, resulting in a decrease in the number of available receptor sites ratlier tlian a lack of LH 
receptors (Rajaniemi et al 1980). Due to wide fluctuations of Gn levels, urinary Gn measurements were 
suggested (Kulin et al 1975; Givens et al 1976) and 3 hourly mine samples assessing Gn were well 
correlated with the levels in 24 hour Gn excretions of urine. Urinary LH was high in most patients. 
There may be qualitative differences in LH. Metliods using monoclonal antibodies are specific for 
detecting only tlie intact molecule. Values obtained using such methods were found to be lower than 
those obtained with methods employing polyclonal antibodies. Monoclonal methods possess good 
specificity towards tlie molecule enabling better detection of conditions ivitli qualitative variations in tlie 
LH molecule (Ventmini et al 1989). Patients ivith PCOD have elevated mean BLH levels and a 
significantly higher BLH : ILH ratio (Lobo et al 1983; Lobo et al 1984; Gindoff & Jewelewicz, 1987;
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Schwartz et al 1987; Mavroudis et al 1988) than at any stage of the normal cycle indicating that LH 
secretion is both qualitatively and quantitatively different from that of the normal female. The ILH may 
not be increased. The sensitwty of the pituitary gland and the hyperdynamic state of Gn secretion may 
result in the increased release of BLH (Gindoff & Jewelewicz, 1987). The increased ratio leads to the 
suggestion that a more biologically active form of LH may be secreted in these patients. Bioactive LH 
may be an important hormonal marker in the clinical diagnosis of PCOD (Lobo et al 1983). Increased 
ILH has been reported in a few studies (Vaitukaitis, 1983; Lobo et al 1984). Elevated ILH and LH:FSH 
ratio may be contributed to by liigher oestrogen circulation, a relative deficiency in central dopamine and 
elevated levels of GnRH. It is not known if these factors also raise BLH (Lobo et al 1984). There was no 
correlation found between BLH, ILH and androgen levels (Mavroudis et al 1988). Treatment with 
oestrogen and P resulted in a decrease in ILH, BLH and tlie ratio. The decreased ratio may be due to 
eitlier a direct effect of oestrogen and/or P on the biological quality of LH or to a direct effect through the 
negative feedback.
Endocrine glands usually secrete hormones in an intermittent or pulsatile pattern including all 
hypophyseal honnones. Pulsatile secretion as well as amplitude may transmit information to the target 
cells thus inducing tlie activation or inliibition of tlieir activity. Direct sampling for GnRH is not possible 
in humans; the best way to study neuro-endocrine acti\dty of tlie hypothalamus on the Gn is to study tlie 
Gn secretory pattern. It is important to have a precise and sensitive assay metliod for pulse detection 
(Genazzani et al 1989). In normal menstruation episodic pulsatile secretion of LH changes tliroughout 
tlie cycle. Luteinizing hormone pulse frequency remained constant dining the follicular phase. Changes 
in pulse frequency and duration are explained by the secretion of gonadal steroids and tlieir feedback 
effects on tlie hypotlialamic-pituitary axis. Other substances may affect LH pulse release, e.g. opiate 
receptor antagonist, naloxone, which increases LH pulsatile frequency dming the luteal phase 
(Genazzani et al 1989). The detailed Gn pulse patterns are not well defined. Luteinizing hormone is 
secreted in a pulsatile pattern. In any study of honnonal pulsatility, two problems have to be solved : (1) 
duration of the study and (2) frequency of sampling. Reduction in sampling frequency and/or tlie 
duration of the study ivill result in a significant reduction in the number of pulses detected. The basal 
serum LH level is the result of GnRH pulses wliich are released at relatively regular inteivals into the 
portal vessels. Most researchers describe an LH pulse interval of 1 - 2 hours during the follicular phase 
of the normal cycle. The LH pulse frequency observed in PCOD is similar to that seen in secondary 
amenorrhoea. Therefore increased LH pulse frequency is not unique for PCOD wliile pulse amplitude is 
liigher in patients witli PCOD and lower in patients witli non-PCO secondary amenorrhoea compared to 
that of the normal follicular phase (Burger et al 1985). There is a marked degree of variability in LH
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pulses but not in FSH pulses (Laatikainen et al 1983; Gindoff & Jewelewicz, 1987; Schwartz et al 1987; 
Venturoli et al 1988). Enlianced pulse amplitude seems the main factor responsible for the high LH 
levels. Circadian pulsatilit)' together with episodic LH pulsatility could promote a rhytlimic ovarian 
activity. Anovulation would result from a distmbance of tlris pulsatility (Venturoli et al 1988), The 
frequency of LH pulses can vary from 1 to 5 in a 6-hour period wliile tire amplitude can range from 5.5 - 
31.0 rnlU/niL (Gindoff & Jewelewicz, 1987; Schwartz et al 1987). The increased pulsatile release of LH 
is probably related to the increased sensitivity of tlie pituitary gland to endogenous GnRH, released at 
higher frequency (Genazzani et al 1989; Mmdoch et al 1989). Most studies agree tliat an increased 
pulse amplitude occurred in PCOD (Laatikainen et al 1983; Bmger et al 1985; Mason et al 1986; 
Gindoff & Jewelewicz, 1987; Ventmoli et al 1988; Waldstreicher et al 1988; Genazzani et al 1989; 
Murdoch et al 1989) while conflicting results on pulse frequency were reported; with no change in some 
series (Bmger et al 1985; Mason et al 1986; Ventmoli et al 1988; Genazzani et al 1989; Mmdoch et al
1989) and a significant rise in others (Yen, 1980; Laatikainen et al 1983; Gindoff & Jewelewicz, 1987; 
Waldstreicher et al 1988). This discrepancy could result because, even in normal subjects, LH is 
secreted in a complicated pattern of superimposed pulses of different frequencies. Pulses were detected at 
frequencies of 1 hour and 2 - 3  minutes (Mmdoch et al 1989). In addition to pituitary responsiveness, 
there may be qualitative differences in LH, tliat is tlie BLH (Schwartz et al 1987). Therefore, there is a 
heterogeneous pattern of LH pulsatility in PCOD. Frequent measurements are recommended to define 
patterns of LH. There is no clear conelation between the clinical picmre and the LH pulse pattern 
(Mason et al 1986) but in severe cases of obesity and hirsutism, lower pulse amplitude LH peaks were 
detected than those of women of normal weight (Laatikainen et al 1983; Mason et al 1986). It is 
suggested that in obese PCOD patients, a greatly elevated level of biologically active T suppresses the LH 
secretion. Plasma LH responses to GnRH were significantly liigher in PCOD than in normal patients. 
This is probably related to E, concentrations. Gonadotrophin releasing hormone stimulation of FSH 
levels was normal or low (Mortimer et al 1978; Chang et al 1983; Vaitukaitis, 1983; McKerma et al 
1984; Gindoff & Jewelewicz, 1987; Minakami et al 1988a; Rossmanith et al 1989), GonadotropMn 
releasing hormone stimulation was found to result in increased BLH:1LH ratio (Lobo et al 1983; 
Schwartz et al 1987). This response may reflect several factors: (i) increased pituitary cell sensitivity to 
GnRH induced by chronically elevated oestrogen levels, (ii) altered dopaminergic modulation of 
hypotlialamic nemons that secrete GnRH and (iii) other nemotransmitter defects (Vaitukaitis, 1983). 
Despite these differences a marked degree of overlap existed between PCOD patients and controls.
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CONCLUSION
Most authors agreed on the significance of tlie increased LH pulse amplitudes in PCOD patients over the 
controls while tlie increase in LH pulse frequency was not unique for PCOD patients. Therefore, it is 
important to have precise and sensitive assay methods for pulse detection.
2.3.2 ANDROGENS
The nonnal ovary, in addition to the adrenal gland, secretes tliree major C l9 steroid androgens; T, A 
and DHEA synthesized by stroma and thecal internal cells. The relative contributions of the adrenals 
and the ovaries may vary during tlie coinse of the nienstmal cycle (Yen, 1986). Andiostenedione is 
secreted by the ovary and the adrenal with a variable ratio exlubiting a diurnal variation. Thus, in the 
morning, the adrenal contribution may be 80 % of the total A production and decreases by evening in a 
similar way to tliat of cortisol. Daily adrenal secretion of A exceeds that of both ovaries in the early 
follicular phase. The mature follicle secretes increasing amounts of A. Therefore, tlie time of sampling 
is important. Testosterone is considered the most potent androgen. Its action is exerted either directly or 
indirectly depending on tlie target tissue. The expression of andiogenicity in sexual target cells requires 
the formation of DHT and androstenediol by the enzyme 5<x-R, mainly in hair follicles and external 
genitalia. Testosterone and A are precursor hormones (prehormones) of plasma DHT. Circulating T is 
derived from the adrenals (25%), tlie ovaries (25%) and from peripheral conversion of prehormones 
(precursors) at sites like liver, fat and skin tissues (50%). At least 2/3"^  of plasma DHT is formed by 
peripheral conversion of A, and to a lesser extent T, wliile little is derived from direct ovarian secretion. 
It is suggested, therefore, that the plasma DHT concentration in normal women may reflect the activity in 
peripheral target tissues for androgen. The metabolic clearance rate of DHT is slow due to its high 
binding afiinity to SHBG. The physiological role of DHEA in humans is unclear (Yen, 1986). 
Androgens produced in increased amounts from tlie ovary are often reflected by increased T and A levels 
in tlie circulation. Prolonged exposure to elevated LH levels may lead to hyperplasia of tlieca cells and 
increased production of the ovarian androgens, A and T. In spite of an increased androgen production, 
PCOs have a decreased aromatization actixdty of androgens to oestrogens which is mainly due to the 
relative deficiency of FSH coupled with tlie absence of large follicles (Schriock et al 1985). 
Dehydroepiandrosterone and DHEA-S are less potent than other androgens (Yen, 1986). They represent 
tlie major androgens secreted by the adrenal gland witli less than 10% of tlie daily DHEA secretion being 
of ovarian origin. There is neitlier intraglandular nor peripheral conversion from delta 4 steroids (T and
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A) to delta 5 steroids (DHEA and DHEA-S). Normally there is conversion from delta 5 to delta 4 and 
from delta 5 to Ei at extraglandular sites but this conversion is insignificant in amount. 
Dehydroepiandrosterone-sulphate appears to be hydrolyzed continuously to DHEA and secretion of 
DHEA by the adrenal cortex is ACTH dependent with diinnal variation as for coitisol. 
Dehydroepiandrosterone-sulphate induces both androgenic and oestrogenic effects in humans. There are 
no short term variations in DHEA-S levels, therefore its measmement is an easy and reliable metliod for 
evaluation of adrenal androgen secretion,
Hyperandrogenaemia is a characteristic feature of PCOD but not all patients display tlie manifestations 
of androgen excess. Elevation of almost all androgens has been found to occur in PCOD patients and the 
principal androgens secreted by the ovary are T and A (Gambrell et al 1973; Duignan et al 1975; 
Ginsburg & Havard, 1976; Givens et al 1976; Aiman et al 1978; Kim et al 1979; Quagliarello & Weiss, 
1979; Kandeel et al 1980; Bates & Wliitworth, 1982; Chang et al 1983; Laatikainen el al 1983; 
Milewicz et al 1983; Pittaway et al 1983; Heineman et al 1984; McKenna et al 1984; Murdoch et al 
1984; Cunningham et al 1985; Fleming et al 1985; Haning et al 1985; Gross et al 1986; Poison et al 
1986; Wajchenberg et al 1986; Carlstrbm et al 1987; Schwartz et al 1987; Eden et al 1988a; Venturoli et 
al 1988; Conway et al 1989; Eden et al 1989a; Eden et al 1989c; Matteri et al 1989; Murdoch et al 
1989; Lynch et al 1989; Rossmanith et al 1989).
Altliough tliere is almost miiversal agreement regarding the elevations of T and A, other androgens like 
DHEA and DHEA-S have been reported as elevated in some patients (Cumming et al 1982; Chang et al 
1983; Horrocks et al 1983; Pittaway et al 1983; Carmina et al 1986; Wajchenberg et al 1986; Schwartz 
et al 1987; Rojanasakul et al 1989).
Dehydroepiandrosterone-sulphate was found raised in 30 - 47% of PCOD patients with mild clinical 
presentation (Carmina et al 1986; CarlstrOm et al 1987) and more than 90% was of adrenal original 
(Carlstrom et al 1987). The explanation for the raised DHEA-S levels is not known. The rise could be 
explained by increased PRL and Ei levels (Carmina et al 1986; Schwartz et al 1987) but DHEA-S was 
found higher than normal with normal PRL level (Rojanasakul et al 1989). It was suggested that tlie 
elevation was not due to adrenal enzyme deficiency but to a tonic hjperstimulation of the adrenals. The 
possibility of an exaggerated secretion of some pituitary homiones with adrenal androgen stimulating 
activity must be considered. It was suggested that some cases of PCOD with Iiigh DHEA-S might be due 
to a mild form of CAH which only manifested in the adult but this was disproved by an ACTH test. 
Dehydroepiandrosterone-sulphate is mainly of adrenal origin. Other alternative hypotlieses for DHEA-S 
sources aie ; (i) due to high Ei concentration, oestrogen may inhibit tlie enzyme 3(3-0HSD and increase
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the DHEA response to ACTH in patients witli PCOD, so adrenal abnomiality may be a secondary effect 
arising because of a relative deficiency in 3p-OHSD, (ii) an abnormality of factors which control adrenal 
androgen secretion, possibly ACTH (Honocks et al 1983). Bioactive LH is found positively correlated 
Avith DHEA-S (Lobo et al 1983) wliich might explain adrenal androgenization.
Androgen status was evaluated by measming plasma TT although T is elevated in < 50% of cases of 
"benign androgen excess conditions" including PCOD (Pittaway et al 1983). About 97 - 99% of T is 
protein bound mainly to SHBG. The biologically active fraction of T is the free portion (FT) which 
should be measmed because even a small increase in T can reduce its own SHBG resulting in an increase 
in FT (Quagliarello & Weiss, 1979; Milewicz et al 1983; Carlstrom et al 1987; Eden et al 1989a). It is 
reported that FT is found elevated even when TT is normal or decreased (Milewicz et al 1983). Total T 
is suitable for detecting androgen producing tumours. Free androgen index which is defined as T/SHBG 
X 100 (T:SHBG ratio) (Cunningham et al 1985) is a better predictor of androgenic status (Quagliarello & 
Weiss, 1979; Cunningham et al 1985; Carlstrom et al 1987; Eden, 1988; Eden et al 1988a; Eden et al 
1988b; Eden et al 1989a; Eden et al 1989c) than is TT. In comparison, raised T was fomid in 53% of 
patients, raised FT in 53% only while FAl was high in 90% of patients witli better prediction (Carlstrom 
et al 1987) altliough having a few false positive results in conditions like CAH and androgen secreting 
tumours wliich are rare (Eden, 1988). An FAI > 4.5 is suspicious of PCOD (Eden, 1988; Eden et al 
1988a; Eden et al 1989c) and FAl is affected by BMI (Eden, 1988; Eden et al 1989a), age and the phase 
of the menstrual cycle (Eden et al 1988a) and should be calculated in the early follicular phase. There 
are conflicting data regarding the correlation between androgens and Gn, with positive (Conway & 
Jacobs, 1987), negative (Duignan et al 1975) and no correlation (Heineman et al 1984; Dunaif, 1986; 
Messina et al 1986) all reported wliile 17oc-OHP showed a significant inverse correlation. Tliis could be 
seen as e\ddence for a negative feedback directly or indirectly exerted by 17qc-OHP on LH and FSH. 
Therefore the importance of 17oc-OHP was stressed in determining the hormonal status of tlie syndrome 
(Messina et al 1986).
Although tliere is general agreement that androgens rise in PCOD the source of excess androgens 
secretion is questionable. All tlie previously described tests are helpful but not useful to determine the 
source of the androgens. Selective simultaneous catlieterization of adrenal and ovarian veins is suggested 
to be the only certain ivay of determining the source of androgen production and the contribution of each 
gland (Ginsbmg & Havard, 1976; Mileivicz et al 1983; Wajchenberg et al 1986). This showed ovaries to 
be the source of the excess androgen secretion, but the teclmique has limitations. Treatment with GnRH- 
A resulted in a decrease in LH and subsequently E2 , Ej, A and T. Oestrogens Avere reduced to
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low/noimal values and androgens although reduced remained eleAUted. Tliis may indicate tliat a 
considerable amomit of the androgen is derived from the ovaiy (Fleming et al 1985). It has been 
established tliat the adrenal glands contribute to the androgen secretion in patients with PCOD but the 
significance is as yet unclear (Aiman et al 1978; Gross et al 1986; Wajchenberg et al 1986).
The commoidy used adrenal djmamic tests (DXM suppression test, and ACTH stimulation test) do not 
provide an accurate localization of androgen production (Berger et al 1975; Ginsburg & Havard, 1976; 
Kim et al 1979; Milewicz et al 1983; Wajchenberg et al 1986). The five day DXM test may suppress 
both ovarian and adrenal secretion and tlie ACTH test may give heterogeneous results.
2 .3J  OESTROGENS AND EXTRAGLANDULAR HORMONE CONTRIBUTION
Anovulatoiy cycles in women with PCOD are characterized by a failure of normal follicular maturation. 
Levels of E2 in PCOD patients are similar to the levels seen in the early follicular phase of a normal cycle 
(Gindoff & Jewelewicz, 1987; Schwartz et al 1987). In a normal cycle, E] production is 100 ug per day, 
and of this 40 ug arises from peripheral conversion (Yen, 1980; Gindoff & Jewelewicz, 1987; Schwartz 
et al 1987). Peripheral conversion of the elevated A is probably the reason for the liigh Ei levels 
observed in PCOD patients (Aiman et al 1978; Yen, 1980; Gindoff & Jewelewicz, 1987; Schwartz et al 
1987).
Typically E2 concentrations are witliin normal ranges wliile Ei is usually lügh (Katz et al 1978; Kandeel 
et al 1980; Rajaniemi et al 1980; Bates & Wliitworth, 1982; Chang et al 1983; McKenna et al 1984; 
Cunningham et al 1985; Scluiock et al 1985; Wajchenberg et al 1986) with an increased Ei:E2  ratio. 
The high Ei provides inhibitoiy feedback on the hypotlialamic-pituitaiy system and is tliought to be tlie 
key factor in maintaining clironic anovulation (Yen, 1980).
Persistent endogenous production of oestrogen is of limited diagnostic value in identifying and 
classifying patients with PCOD (Insler & Lunenfeld, 1990). It has been found that many women with 
oligo-ovulatioii or anovulation show persistent oestrogen production altliough their gonads do not exhibit 
tlie characteristic structural changes associated witli PCOD. It is also important to realize that absolute 
values of oestrogen in plasma do not identify the som ces of tlieir secretion.
Oestrone and E2  may be produced by tlie ovary, by the adrenal or by peripheral conversion 
(extraglandular aromatization) of A (Aiman et al 1978; Insler & Limenfeld, 1990). Even in women with
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presumably ovulatory cycles, a considerable variability of honnonal levels from cycle to cycle in the same 
subject has been recorded. The increased LH levels acts upon tire ovarian stroma to stimulate A secretion 
and to a lesser extent T secretion. In females, A is converted to E]. Women witli PCOD are found to 
have an increased concentration of Ei relative to E^  when compared to normal women because of tlie 
increased A (Bates & WMtvi'orth, 1982). Administration of GnRH-A resulted in a marked decrease of A, 
T, El and Eg to the levels of the oophorectornized female (Chang et al 1983; Gindoff & Jewelewicz, 
1987; Musacchio, 1988).
It has been suggested that elevated Ei causes a chr onic feedback on Gn secretion leading to increased LH 
secretion and FSH suppression altliough it is also possible that elevated LH levels lead to ovarian 
hyperproduction of E]. Most of the circulating oestrogen does not originate from direct ovarian secretion 
but from peripheral conversion of androgens (Heineman et al 1984). Plasma Ei is mainly derived from 
peripheral conversion of A. It was hypothesized that those patients witli the hyperandrogénie state and 
with lowest aromatase actiAdty demonstrated idiopatliic hirsutism, wliile hjiierandrogeriic subjects ivith 
mean or elevated aromatase activity developed PCOD (McKerma et al 1984). Since PCOD patients are 
fr equently obese, tliere is increased extraglandular tissue residing in adipose tissue capable of converting 
androgen precursors into oestrogens, mainly Ei. In a study, Ei was found elevated to three times tlie 
normal value but with no demonstrable correlation with obesity (Laatikainen et al 1983).
It is thought tliat oestrogens, rather than androgens contribute to the distortion of Gn release seen in 
hyperandrogénie females as chronic exposure to androgenic gonadal steroid regulation of hypothalamic- 
pituitary axis in PCOD is different from that seen in men and acute androgenic administration did not 
result in distortion of Gn release in androgenized women (Dunaif, 1986).
2 3 .4  SEX HORMONE BINDING GLOBULIN (SH BG )
The transport of hormones from their sources to the designated "target" or sites of action requires that the 
binding affinit}' of tlie cellular receptors be greater than tliat of tlie canier protein to permit dissociation 
from the latter and association witli tlie former.
In comparison to the binding affinity for T, SHBG has tiuee times the affinity for DHT but about 
tliat for Ez. The SHBG-bound steroids are not readily available for target-tissue binding and action. The 
free fraction and the albumin-bound fraction are biologically active. The production of SHBG is 
promoted by oestrogens and inliibited by androgens. The relationship between SHBG and the balance
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between androgens and oestrogens is important in interpreting levels of circulating hormones and tlieir 
biologic action at target tissues. Alterations in SHBG levels could be due to physiological conditions; 
decreasing during puberty which is normal and does not depend on increased androgen levels and 
increasing dming pregnancy wliile pathologically, low SHBG concentrations may result from progestins 
(except medroxyprogesterone acetate), glucocorticoid excess as in Cushing's syndrome, GH excess as in 
acromegaly and from thyroid hoimone deficiency. Thyroid hormone is the only hormone other tlian 
oestrogen that stimulates SHBG production (Yen, 1986). Elevated plasma androgen on the other hand 
lowers tlie circulating levels of SHBG. Thus in PCOD patients with increased androgens, the SHBG 
level is loivered witli a subsequent increase in tlie free biologically active portion of the hormones 
(Ginsbmg & Havard, 1976; Kim et aî 1979; Carter et al 1983; Laatikainen et al 1983; Schwartz et al 
1987; Eden et al 1988a; Eden et al 1989c; Rojanasakul et al 1989). The level of SHBG ivas found 
decreased in 60% of PCOD patients (Carlstrom et al 1987). Decreased SHBG could explain the 
manifestation of liirsutism in PCOD patients with normal TT levels (Ginsbmg & Havard, 1976; 
Cunningham et al 1985). Obesity causes a further decrease in SHBG (Kim et al 1979; Laatikainen et al 
1983; Cunningham et al 1985). Free T concentrations may contribute to suppression of SHBG in 
obesity. Reduced SHBG levels in obese subjects may be secondary to increased FT levels. A fall in 
SHBG levels, in addition to that caused by androgens, will amplify' changes in sex steroids by increasing 
tlie circulating iion-protein-bomid fractions, the biologically active moieties (Cminingliam et al 1985). It 
would appear that obese PCOD patients have no excessive androgen production but ratlier higher 
biologically active free and albumin-bound T (Laatikainen et al 1983). Factors otlier than androgens 
may be responsible for SHBG suppression in obesity (Cumiingliam et al 1985).
Dehydroepiandrosterone-sulphate is not a significant modulator of plasma SHBG (Cimningham et al
1985). Small doses of DXM could result in an increase of SHBG level, Tliis increase is independent of 
changes in androgen and oestrogen and may be due to a direct effect of glucocorticoid on syntliesis and 
degradation of SHBG. Sex-hormone binding globulin is found lowest in tlie late follicular phase (Eden 
et al 1988a) and it decreases with advanced age (Cunningham et al 1985). Treatment with clomiphene 
citrate resulted in an increase in SHBG similar to levels seen in spontaneous ovulatory cycles. It is likely 
tliat loss of the usual rise in Ez in both the follicular and luteal phases of an ovulatory cycle is the main 
reason for the low SHBG concentration found in PCOD (Eden et al 1989b).
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2 3 .5  PROLACTIN
Hyperprolactinaemia is frequently found in association with infertility and hypogonadism, and may 
occm in 1/3’’^  of PCOD patients (Vaitukaitis, 1983; Futtemeit, 1984). Hyperprolactinaemia in PCOD 
may result from the effects of the abnormal serum oestrogen concentrations on pituitary lactotrophs 
(Futterweit, 1984; Schriock et al 1985) but tlie presence of normal PRL ftmction in norrnoprolactinaemic 
PCOD patients excludes a specific impairment of lactotioph function. The hyperoestrogenic state in 
PCOD or the milder elevations of oestrogen, predominantly E], is due mainly to peripheral conversion of 
androgens (mainly A) and decreased SHBG which result in exaggerated oestrogen concentrations 
(Scluiock et al 1985). Hyperresponsiveness to TRH is frequently noted probably because of Ei excess 
(McKenna et al 1984).
It is thought that PRL may exert a direct effect on DHEA-S secretion because tlie production rate was 
decreased in PCOD women treated with bromocriptine and was related to a similar decline in serum PRL 
(Gindoff & Jewelewicz, 1987; Schwartz et al 1987). Hyperprolactinaemia may be a reflection of a 
central abnormality such as altered dopaminergic activity, affecting Gn and PRL secretion (Goldzieher & 
Green, 1962; Scluiock et al 1985). All study patients with PCOD in one series who had elevated PRL 
levels, showed an excessive response to dopamine receptor antagonist (metoclopramide) (Goldzieher & 
Green, 1962). Senun PRL was found negatively correlated witli T, LH and ovarian volume (Conway & 
Jacobs, 1987). Administration of GnRH has been shown to stimulate PRL release (Shoupe & Lobo,
1985).
23 .6  INSULIN AND SHORT INSULIN TOLERANCE TEST (S IT T )
Since the description by Himsworth in 1936 tliat human disease could be associated ivith reduced 
sensitivity to 1 (IR), several methods have been developed for detection and quantification of IR (Caro, 
1991). Insulin resistance is diagnosed when nomial glucose levels exist in the presence of 
hyperinsulinaemia (Burghen et al 1980). The GTT, euglycaemic I-clamp teclmique, the minimal model 
technique, and the SITT are all provocation methods wliich have been used to quantify IS. Other tests 
include measmement of IS in-vitro in cell cultures and tissue samples. HoAvever, most of these tests are 
complicated to perform on a large series of patients and there has been much debate about tlie relative 
merits and limitations of each of tliem.
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Total body IS can be assessed via the intravenous GTT, or minimal model. Although the euglycaemic I- 
clamp teclmique is the most widely accepted standard method for estimating IR against wliich other 
methods are compared, it is expensive, time-consmning, requires specialized equipment and highly 
trained staffing and tlie feedback control of glucose levels is complex; all of which make it a laboratoiy 
investigative procedure rather than suitable for use in a clinical setting (Caro, 1991). These 
disadvantages demonstrate the need for an acceptable method to measme IS that could be used in large 
scale studies or even clinically.
An alternative to tlie euglycaemic clamp, the SITT is a short useful altemative(Akinmokim et aî 1992; 
Hirst et a! 1993). A close correlation was found between the glucose disappearance rate (KITT) and the 
M/1 ratio derived from the SITT and the euglycaemic hyperinsulinaemic clamp in botli normal and 
diabetic subjects. Results suggest that tlie SITT is a suitable metliod of assessing IS and particularly 
useful for large-scale studies, although tlie requirement for arterial blood adds a measme of complexity 
(Matthews et aï 1985; Akimnokun et aî 1992; Holte et al 1994a). The SITT is simple and rapid to 
perform. The SITT method uses the ratio of decline in blood glucose after tlie intravenous 
administration of I as an index of IR. The metliod is used increasingly in clinical research because 
studies have shown that tlie rate of fall of blood glucose during the SITT, the KITT-value, significantly 
correlated with tlie euglycaemic clamp (Akinmokun et al 1992). Anotlier advantage of the SITT is that 
tlie test is safe, reproducible and could be used to measme IR in large-scale epidemiological studies 
(Akinmokun et al 1992; Hirst et al 1993). The degree of IR and deficient j3-cell ftmction can be assessed 
from a patient's FI and glucose concentrations (Mattliews et al 1985). The fasting plasma glucose 
concentration depends primarily on the rate of hepatic glucose release, which in turn is regulated by 1 
concentration. Fasting plasma GLU/INS concentration ratio may provide the simplest estimate of IR. It 
has been observed that the GLU/INS ratio calculated from a single fasting plasma sample correlated ivith 
the measmement of IS determined by the euglycaemic clamp, tlie minimal model teclmique, and the oral 
GTT (Caro, 1991), The higher tlie plasma FI concentration for a given fasting plasma glucose, the more 
IR an individual is. Fasting insulin and FIRI are simple and reproducible measures of IS. Cleland et al. 
( 1996) reported that fasting hyperinsulinaemia may be used as a guide to the existence of IR and that 
log,Q FIRI was iiiglily correlated with tlie euglycaemic hyperinsulinaemic clamp (r = 0.67, P < 0.001).
Tlierefore, simpler estimates of IR such as FI, GLU/INS ratio and FIRI may ob\date the need for more 
complex procedures to obtain a useful index of IR in large-scale studies.
It is now well established that hyperinsulinaemia is involved in, and may be a trigger phenomenon in the 
pathogenesis of PCO (Urdl et al 1991). Basal and glucose-stimulated hyperinsulinaemia are recognized 
features of PCOD (Dunaif & Graf, 1989).
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CONCLUSION
Laboratoiy tests may include estimation of LH, FSH, E] and Ez witli elevation of LH:FSH and E] :Ez 
ratios. These are compatible with PCOD but tliese can be seen in any type of cluonic anovulation or 
other conditions like testicular feminization syndrome (Yen, 1986). It can be concluded that no single 
biochemical test can diagnose PCOD (Ginsburg & Havard, 1976; Schriock et aî 1985) because the 
biochemical spectra include minimally to markedly elevated plasma androgen levels and normal to 
extremely high LH levels (Givens et al 1976). It is important to note tliat Gn, androgen and oestrogen 
production depend on the stage of follicular phase which is of great importance for sampling and 
interpreting results. It is suggested tliat the initial laboratory evaluation of patients suspected to have 
PCOD should include the following tests : plasma LH:FSH, T, DHEA-S, PRL, A and 17oc-OHP. 
Additional studies of: plasma SHBG, FT, % FT, Ez, Ei, DHT, I (IR), ACTH test, GnRH test and TRH 
test (if hj'perprolactinaemic), are not always essential but give a clearer picture of the associated 
endocrine dyshuiction (Futteiweit, 1984).
2.4 THE ROLE OF ULTRASONOGRAPHIC SCANNING IN THE 
DIAGNOSIS OF PCOD
Ultrasonography can aid in the non-invasive diagnosis of gynaecological abnormalities. It is an accurate 
and reliable method that can help in determining ovarian morphology and size (Campbell et al 1982; 
Orsini et al 1985; MacDougall et al 1992).
In post-pubertal females, the ovaries enlarge rapidly mider hormonal stimulation involving mainly the 
width and thickness where tlie enlargement is attributed to an increase in the number of follicular cysts 
(Sample et al 1977).
Ch'arian volume is calculated using tlie formula : [4/3 x ?t x dl/2 x d2/2 x d3/2] ;
where dl = widest transverse diameter; d2 = longest diameter oitliogonal to tliis in tlie A-P axis; d3 = 
maximum vertex diameter]; (Campbell et al 1982). It normally ranges between 1.8 - 5.7 cnf; while tlie 
average ovarian volume of polycystic ovaries is 12.5 cm  ^ (range is 6 - 30 cnf) - 2-5 times nonnal size 
(Swanson et al 1981). Polycystic ovaries as defined by US scanning are veiy conmion in anovulatory 
women (57%). Polycystic ovaries were found in 26% of patients with amenorrhoea, 87% of patients with
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oligomenorrlioea and 92% of tliose with idiopatliic liirsutism (Adams et al 1986a). Enlarged polycystic 
ovaries could be fomid in ovulating and fertile patients (Feniman & Pmdie, 1965) where a corpus 
luteum could be detected in 16/23 US-diagnosed PCOD patients (Adams et al 1986a). Bilateral 
enlarged globular shaped ovaries are rare and usually asymmetrical in size (Conway et al 1989). A 
unilaterally enlarged PCO was reported by Rojanasakul et al. (1989) who studied 54 Thai women with 
PCOD using a liigh resolution real-time US scanner - two patients had unilateral polycystic ovaiies.
Measurement of ovarian volume should be more accurate tlian determination of any one dimension 
(Sample et al 1977) and should be helpful in assessing inappropriate hormonal stimulation. Wliile 
ovarian volmne, expressed as the mean of both ovaries (Hague et al 1990), has been suggested as an 
indication of abnormal ovarian size, tliis may not be practical (Ginsburg & Havard, 1976; Yeli et al 
1987; Rojanasakul et al 1989) as nonnal ovarian volume does not exclude tlie diagnosis of PCOD (Harm 
et al 1984; Orsini et al 1985; Taketani, 1990; Puzigaca et al 1991). It was fomid tliat tlie average size of 
ovaries in PCOD patients was much larger than tliat of healthy females (Hann et al 1984; Yeh et al
1987) but tliat 29.7% of ovaries in patients Avith PCOD Avere nonnal in size. Enlarged ovaiian volume is 
therefore not a necessary criterion for tlie diagnosis of PCOD (Ginsburg & Havard, 1976; Puzigaca et al 
1991).
Sonographic findings recorded by Adams et al. (1986a) and Comvay et al. (1989) for diagnosing PCOD 
Avere as folloAvs : multiple cysts (> 10) 2 - 8 mm in diameter, arranged either peripherally around a dense 
core of stroma or scattered throughout an increased amount of stroma (or both). The ovaries are usually 
enlarged. This should be distinguished from multicystic ovaries normally seen during puberty and also 
associated Avith hypothalamic amenorrhoea due to weight loss. Those ovaries have larger cysts than PCO 
and nonnal stroma (Abdulwaliid et al 1985; Adams et al 1985; MacDougall et al 1992). Conway et al.
(1989) studied 556 PCOD patients and tried to correlate trans-abdominal ultrasonographic featmes to 
clinical and endocrinological manifestations. They found that subjects in a high LH group had 
significantly higher mean serum FSH and T concentrations and larger ovaries compared to tliose in tlie 
nonnal LH group while Givens (1982) argued that tlie division of US versus raised LH levels 
concentrations, does not necessarily mean different subgroups but may reflect a different hormonal status 
of each individual from time to time.
Takai et al. (1991) studied ultrasonically and endocrinologically 69 euprolactinaemic patients with 
anovulation and liigh LH secretion. They divided PCOD patients into three groups: (i) patients with 
neither hirsutism nor increased A and/or T concentrations; (ii) patients without liirsutism but Avith 
increased A and/or T concentiations; (iii) patients Avith hirsutism and increased A and/or T
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concentrations. Polycystic OA'aries were diagnosed ultrasonographically in 88, 84 and 100% of patients 
in types i, ii and iii respectively. These authors postulated that each type may represent a subset of tlie 
whole spectrum of PCOD from SL syndrome to simple ano\mlation with increased LH secretion, and, 
tliat type (i) precedes type (ii) PCOD.
Hyperproiactinaemic PCOD patients had significantly lower mean T concentrations and smaller ovarian 
volumes tlian nornioprolactinaemic subjects, wliile no difference in ovarian volume was found between 
obese and nonnal weight subjects (Conway et al 1989).
Eden & Place (1989) found a high correlation between an elevated FAl and ultrasonic and laparoscopic 
diagnosis of PCOD. Free androgen index is an index of FT activity (Carter et al 1983). Clinical history 
and ultrasonographic data were analyzed and tlieir possible interrelationships in a group of 72 PCOD 
patients, were evaluated (Puzigaca et al 1991). Twenty three point six percent of PCOD women were 
found to have an ovarian volume ivithin tlie normal range, while 72.2% had enlarged ovaries. Serum 
androgen levels (especially A) were higher in PCOD patients ivitli enlarged ovaries although liirsutism 
was found in equal amounts in patients witli nomial and enlarged ovaries. Patients witli tlie most 
enlarged ovaries, who also have the highest serum A and E^  concentrations, had the most frequent 
occurrence of amenorrhoea.
Ovarian morphology was classified according to the presence or absence of echo-jfree cystic fimctional 
structures into (1) predominantly solid if fewer than 4 small (^ 9.0 nmi) cystic structures were detected in 
tlie ovaiy; (2) predominantly cystic if multiple small cystic structuies or at least one large (> 10.0 nmi) 
cyst was present (Conway et al 1989; Rojanasakul et al 1989). Orsini et al. (1985) could demonstrate 
the classical ultrasonic picture of PCOD (i.e. symmetrically enlarged ovaries with numerous tiny cysts) in 
only 36.3% of tlieir cases while Rojanasakul et al. (1989) found the typical ultrasound appearance in 2/3 
of tlieir patients and 1/4 of them had bilaterally solid ovaries.
In correlating ultrasonic evaluation with clinical and hormonal data (Parisi et al 1984) the criteria 
included ovarian size, shape, margins, structure of the ovaiy and uterineiovarian ratio. Uterine:ovarian 
ratio was calculated as the maximum A-P diameter of tlie uterine fundus in relation to the longitudinal 
diameter of the ovaiy. The degree of ovaiian enlargement had a significant conelation witli both tlie age 
and the duration of symptoms. Furthermore, tlie ovaries tended to have a more roimded shape in older 
patients and in those who had had PCOD the longest. This might indicate that botli ovaiian size and 
shape are fimctions of the disease duration and that PCOD, once established, causes progressive 
enlargement of the ovaries, which tend to become completely round in shape. Identification of large
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ovaries with a rounded appearance may therefore be an indication of advanced stages of the disease, 
which once established, is tlie cause of progressive enlargement of tliese organs. Other researchers found 
a striking conelation between cycle Mstory and ovarian appearance and tliey considered calculating the 
ovarian volume (Poison et al 1988). Some authors (Parisi et al 1984; Futterweit & Mechanick, 1988; 
Puzigaca et al 1991) stressed the value of the uteriiie:0 A'arian ratio and it was always < 1 in PCOD cases; 
Orsini et al. (1988) found this in 11.3% of tlieir patients. In contrast, ovarian volume measured by 
ultrasound, was not considered essential for diagnosis and difficulties were encountered in finding the 
reference plane for measmement (Rojanasakul et al 1989). Ovarian volmne did not show a significant 
correlation witli endocrine hormones (Gn, T, Eg, I) or with echogenicity (AbdelGadir et al 1991). These 
authors also reported that bigger ovaries were not produced in response to prolonged dmation of 
symptoms, higher LH levels or to any specific Gn pulse pattern. These ovaries did not produce more T 
tlian smaller ones and this confirms tliat normal sized ovaries may have tlie same histological and 
biochemical abnormality as do enlarged ovaries in PCOD patients. AbdelGadir and his colleagues 
(1992a) concluded that ovarian size did not indicate tlie severity of the condition and that more elaborate 
treatment regimens are not indicated on tlie sole criterion of enlarged ovaries .
Roundness index is defined as tlie ratio between tlie width (tlie second laigest ovarian diameter) and tlie 
length (the maximum ovarian diameter) (Yeh et al 1987). The shape of tlie ovaiy in PCOD, expressed 
as the RI, was fomid to be not different from tliat of healtliy females and tliere was no significant 
correlation between the size mid tlie shape of the ovaries. There was also no correlation between RJ and 
ovarian volume and the ranges and average of the RI of the ovaries in PCOD patients were tlie same as 
those of normal healthy ovaries. This indicates tliat enlargement of the ovaries in PCOD is due to a 
diffiise process and that the ovaries maintain tlieir shape as tliey enlarge. The shape of tlie ovaiy or RI is 
therefore of no value in diagnosing PCOD. A considerable number of PCOD patients (25.5 - 40%) have 
normal sized ovaries so the size of the ovaiy is neitlier a specific nor sensitive criterion for ultrasonic 
diagnosis of PCOD (Yeh et al 1987; Puzigaca et al 1991). Yeh et al. (1987) described ovarian cysts in 
general and divided tliem into: (1) developing follicles (0.4 - 1.4 cm in size) wliich is characteristic of 
PCOD; (2) maturing follicles (1.5 - 2.9 cm) wliich were much rarer in PCOD patients than in normal 
patients (13.5% vs 36%); mid (3) folliculm cysts (> 3.0 cm) wliich had the same frequency in PCOD and 
normal subjects. Ovmian cysts range in diameter from 2 - 8  nun and may be arranged in the peripheiy of 
an ovary or through the parenchyma ivitli more variability in size. High-resolution, real-time sector 
scanning improves the accmacy of ultrasonic texture evaluation of the ovary, differentiating from bowel 
loops, and enabling the detection of much smaller echo-ffee cystic functional structures (Swanson et al
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1981; Campbell et al 1982; Paris! et al 1984; Orsini et al 1985; Yeh et al 1987; Rojanasakul et al 1989; 
AbdelGadir et al 1991) than w tli the static B-scanner.
The precise diagnosis of PCOD depends on liistologic findings of follicular cysts and increased stroma of 
the ovaries that are usually but not always enlarged. These are features tliat can be identified, using high 
resolution US of the ovaries (Adams et al 1986a; Fame et al 1989; Rojanasakul et al 1989) as numerous 
small cystic structures surrounding an echogenic area at tlie middle representing tlie dense stroma. 
Various otlier ultrasonic patterns could be due to patient selection, stages of the disease, different US 
machines and examiners (Rojanasakul et al 1989). The most important morphological feature is an 
increased number of developing follicles, usually > 5 in each ovary wMch was found to be 82.4% 
sensitive and 100% specific v^ith an overall diagnostic accuracy of 85.9% for PCOD (Yeh et al 1987). 
In general, it can be concluded tliat tlie presence of multiple small cysts of the ovaries in women witli 
menstrual irregularities should lead to tlie suspicion of PCOD wliile tlie presence of a solid structure does 
not exclude tliis condition. Difficulties could be fomid in identifying tlie ovaries in extremely obese 
patients or if there has been previous pelvic surgery.
Methods wliich have been suggested for better diagnosis of PCOD include (i) scanning ovaries from 
valions angles by placing the transducer on eveiy part of the lower abdomen; (ii) scanning ovaries 
tlioroughly and caiefidly by sweeping from one edge of ovary to the otlier edge slowly; (iii) adjusting the 
gain setting for each patient to optimize follicular visualization; (iv) appropriately distending tlie bladder 
and (v) using a small part scanner when ovaiies are superficially located (Yeh et al 1987), It is well 
knoivn that the ovaiian location, the uterine position, the degree of bladder distension and bowel fiillness 
are more coimiion limiting factors tlian ovarian size itself in ultrasonic visualization (Orsini et al 1985).
Earlier studies of PCOD focused on ovaiian morphological findings wliich were considered to be an 
important criteria. It was then found tliat PCOD changes of ovaries were often associated witli otlier 
well-defined diseases such as Cushing's Syndrome and other endocrine disorders (Ardaens et al 1991) or 
adrenal or ovai ian tumoius capable of producing androgens (Paiisi et al 1984; Taketani, 1990). Women 
with weight-ioss and hypothalamic amenorrhoea, usually have a multifollicular ovarian appearance with 
normal stioma on ultrasonic examination. Ovaries are noniial or slightly enlarged filled with > 6 , 4 - 1 0  
mm follicles but unlike PCOD patients, they are not liirsute and tlieir Gn are normal (Adams et al 1985). 
It was therefore generally agreed to consider ovarian imaging as complementaiy to endocrine evaluation 
(Paris! et al 1984; Tucker et al 1984; Dolyan et al 1989; AbdelGadir et al 1992b) and it also helps to 
predict the response to therapy. About 22% of females with other endocrinopathies would have been 
mistakenly diagnosed as PCOD if US diagnosis had been used as the sole diagnostic criterion (Insler &
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Lunenfeld, 1990; AbdelGadir et al 1992a; AbdelGadir et al 1992b; Aiittila et al 1992). Uterine scanning 
for evidence of endometiial masses was emphasized (Swanson et al 1981) to exclude endometrial 
carcinoma. Some autliors suggested MRI as a better contrast-resolution is obtained which enables 
visualization of organ structures not seen witli other techniques. Magnetic resonance imaging showed 
superiority in detecting PCOD moiphology over US (Fame et al 1989). As typical findings are often 
seen in US or MRI, there is still heterogeneity (Fame et al 1989; Quartero et al 1989). However, recent 
technological advances in US and specifically the advent of high fi-equency trans-vaginal US is of 
particular value in the study of PCOD.
Recently many authors have favoured tlie vaginal ultrasonograpliic approach over the transabdominal 
approach for increased facility in establisliing tlie diagnosis (Gindolf & Jewelewicz, 1987; Ardaens et al 
1991). The typical appearance of PCO by vaginal US shows the subcapsular follicular cysts in a "pearl 
necklace" pattern aromid tlie periphery of tlie somewhat enlarged ovaries (Dunaif, 1992b). Vaginal US 
was found helpful to diagnose PCOD in 44% of a study population with a history of recurrent 
miscarriage (Tulppala et al 1993). Ardaens et al. (1991) conducted a study tluough which tliey 
evaluated the superiority of vaginal over abdominal US for PCOD diagnosis. Vaginal US allowed a 
better analysis of tlie ovarian stroma as it improved tlie ultrasonic study of internal PCO criteria. 
Increased ovarian stroma seems to be the most sensitive and specific sign of PCOD (incidence 64.5% in 
vaginal US vs. 15.1% abdominal US). Wliile abdominal US allows correct measurement of ovarian 
sizes, wliich is less accurate with vaginal US, not all PCOD ovaries are enlarged. Abdominal US is 
diftrcult to perform in obese patients especially to visualize the stroma and to detect the microcysts but 
this is more feasible with vaginal US. The criteria used to diagnose PCO by vaginal ultrasound were : 
(i) cross section > 10 cm  ^(increased ovarian area); (ii) Uterine volume/ovarian length < 1; (iii) RI > 0.7 
(excessive roundness index); (iv) number of follicles > 5 (PCO appearance); and (v) increased amount of 
hyperechoic stroma. Stroma was considered abnormal when it was mainly central with an area 
exceeding tliat of microcysts that were pushed together towards the ovarian periphery and/or when it was 
dense witli enhanced microcysts whose walls appeared tliickened. Although vaginal US is superior in 
detecting the stromal density and especially helpful in obese patients, it has its limitations in 
measurement of longer ovarian axes and in visualization of superficially located ovaries. Hence tlie 
autliors emphasized the need for abdominal US before scaiuiing the patients vaginally but they did not 
recommend a scanning system because the various parameters were not equal in terms of specificity and 
sensitivity. In conclusion, a wide spectrum of US ovarian findings can be demonstiated in PCOD 
extending from apparently normal to markedly enlarged cystic ovaries, but only a limited part of this
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spectium is covered by the classic sonograpliic picture of ovaries, and uterine volume and the uterine 
volume/ovarian lengtli ratio should be included to improve the diagnostic accuracy of US.
2.5 HISTOPATHOLOGICAL FINDINGS
Diagnosis need not depend on ovarian size or specific clinical presentation but tlie final analysis can be 
made histologically following microscopic examination of tlie tissue. Polycystic ovaries may occur in 
normal sized or enlarged ovaiies witli common macro and microscopic findings (Ginsburg & Havard, 
1976; Schwartz et al 1987; McKenna, 1988; Insler & Lunenfeld, 1990). The patliological spectrum 
extends fi-oni normal sized to massively enlarged ovaries.
The typical PCO has been traditionally described as being grossly enlarged, pearly white and witli a thick 
capsule and numerous subcapsular cysts (Insler & Lmienfeld, 1990).
Stein and Leventhal (1935) described tlie ovaiies of tlieir patients (n = 7) as enlarged witli thickened 
tunica albuginea, where the only consistent pathological findings in all their biopsies were the presence 
of follicular cysts lined by tlieca cells and a tliickened tunica. Goldzieher & Green (1962) examined in 
detail tlie histological features of ovaries jftom 18 PCOD patients and a thickened tunica albuginea was 
the most noticeable feature and was almost invariably present. The thickening resulted from an increase 
in the number of collagen fibres which resulted in a thickened capsule surrounding the ovary (normal 
ovarian capsule was found to be approximately 100 u wide while in PCO the thickness was 2-6 times 
that). There were numerous gr aafian follicles in all stages of development and atresia except for the pre- 
ovirlatory stage. Corpora lutea were seen in only 2 ovaries (11%). There were no consistent stromal 
changes. A tliickened tunica was tliought to be unlikely to cause a hormonal disturbance in PCOD but 
excess androgens in the circulation might cause capsular fibrosis.
There were variations in the histological pictures of 9 wedge resection biopsies examined (Ibrahim et al 
1966) but tlie main featmes included: (i) thickened tunical albuginea (up to 10 times the normal) while 
increased fibrosis was not prominent; (ii) tlie presence of nmnerous small follicles and a thin layer of 
granulosa cells situated all around and under tlie ovmian capsule; (iii) other less characteristic features 
included hyperplasia and luteinization of the theca interna cells.
Berger et al. (1975) divided tlie patients into two groups according to ovarian pathology : (I) typical - 
“Type 1” markedly enlarged ovaries (2-4 times tlie normal size) witli multiple follicular cysts \4sualized
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underneath the fibrotic ovarian cortex ivith tliickened capsule and usually luteinized follicular cells with 
stromal hypeiplasia; (II) atypical - “Type II” small to slightly enlarged ovaries witli sub-cortical cysts and 
thickened capsules. Histologically, stromal hyperplasia and tliecal luteinization were occasionally 
observed in type II PCO. Morphologically, tlie ovaiies may be small and sclerocystic or enlarged. 
Capsular tliickening is variable but was not always present. Subcapsular fibrosis and cyst formation (4 - 
10 nmi in diameter) were always present and were characteristic of tlie syndrome, in botli large or small 
ovaries (Ginsburg & Havard, 1976; Parker et al 1980; Schwartz et al 1987; McKemia, 1988; Insler & 
Lunenfeld, 1990); even a unilaterally enlarged ovary was reported (Parker et al 1980). Typically, no 
corpora lutea and/or corpora albicantia were seen (Schwartz et al 1987), although corpora lutea were 
reported in 11% of tlie series of Goldzieher & Green (1962).
The steroidogenic capacities of isolated granulosa and theca cells from mid-antral follicles ( 4 - 7  mm in 
diameter) of PCOs were studied and compared to those of nomial ovaries (Wilson et al 1979). The 
findings strongly suggested that the mid-antral follicles of PCOs were normal and tlie authors concluded 
tliat chronic anovulation in PCOD patients may not be causally connected witli an inlierent endocrine 
abnoimality in tlie theca and granulosa cells of the developing follicles. Chronic anovulation is not due 
to deficiency in tlie steroidogenic potential of the follicles or to a deficiency of Gn receptors on PCO 
follicular cells but tonic elevation of serum LH may cause doivn regulation of its own receptors leading to 
atresia of granulosa cells, luteinization of thecal cells and accumulation of small cystic follicles in tlie 
ovaries (Rajaniemi et al 1980). The pathogenesis of development of enlarged ovaries in PCOs is 
unknown and little information is available to correlate biochemical and liistological parameters. This 
task has gained the special interest of some investigators. Goldzieher & Green (1962) failed to find a 
correlation between tlie thickness of the capsule and tlie clinical findings, severity of symptoms and the 
advancement of the disease. Ovarian hyperandrogenism can be associated with histologically normal 
ovaries (Kim et al 1979). Some investigators have proposed that tlie initiation of ovarian enlargement 
(involving theca cell hyperplasia and tlieca luteinization) in PCOD is caused by excessive Gn, especially 
excess LH, (Gambrell et al 1973; Givens et al 1976; Kim et al 1979; Rajaniemi et al 1980; Yen, 1980; 
Conway et al 1989) and the associated excessive androgen production, where the amount of ovarian 
androgen production may parallel tlie degree of liistologic change (Kim et al 1979). Histologic changes 
under the effect of long-term androgen (T) treatment were studied in 10 patients who underwent sex 
reassignment surgery. The findings were compared to those among PCOD patients and a normal 
control group (Amirikia et al 1986). It was concluded that exogenous androgen can Üiicken the tunica 
albuginea and basal membrane giving similar histological changes to tliose seen in PCOD ovaries under 
excess endogenous androgen production.
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A direct action of excessive androgen on tlie ovaries may account for capsulai’ fibrosis (Yen et al 1970b). 
As enlargement occurs, tlie increased steroid production may lower LH secretion to noraial. There may 
be also a concomitant increase in sensitivity of the ovaiy to LH as hyperplasia progresses (Givens et al 
1976). Otlier investigators (Schwartz et al 1987) fomid no conelation between LH and ovaiian size and 
suggested that tlie gross enlargement of the ovaries was a manifestation of a prolonged period of 
anovulation and was of no diagnostic value in classifying patients into subgroups of the syndrome. Some 
autliors considered hyperthecosis as one of die liistological manifestations of PCOs (Insler & Lunenfeld,
1990). Polycystic ovaiies classified as Group 1 hypeithecosis or called thecosis interna consisted of 
bilateral multiple follicular cysts and superficial collagenization with persistence and predominance of 
normal or altered theca interna but witli no stromal theca cells (Fienberg, 1981), i.e. tlieca interna 
hyperplasia of the ovary (Futterweit, 1984). On tlie otlier hand other autliors questioned whetlier 
hyperthecosis is one of the inherent morphological featmes of PCOD (Insler & Lunenfeld, 1990; Speroff 
et al 1983) or represents a completely separate entity (Insler & Lmienfeld, 1990) with diffuse 
hyperplastic ovarian stroma rather tlian limited to tlieca interna as in PCOD (Ainian et al 1978). Some 
or all morphological characteristics of PCO can appear in individuals who certainly do not have PCOD.
Polycystic changes of tlie ovaries are also fomid in association with Cushing's Syndrome, CAH, adrenal 
and ovarian tumours (Insler & Lunenfeld, 1990) and in women with morbid obesity except for tlie lack of 
cystic appearance (Fisher et al 1974). It should be emphasized tliat liistological changes in the ovary are 
not present in all PCOD patients. Variations do occur and may be related to tlie variable clinical and 
laboratory manifestations of the syndrome (Yen, 1980).
2.6 GENETIC INHERITANCE
Polycystic ovarian disease is thought to be due to genetic rather tlian environmental causes. It has been 
shown in cytogenic studies that: (i) androgen binding protein is present in the cyst fluid of patients with 
PCOD; (ii) defects in aromatization mechanisms that interfere with conversion of C-19 oxygenated 
steroids into oestrogens occur , (iii) chi'omosomal abnormalities exist, and (iv) tliere are occmTence of 
familial cases (Parker et al 1980).
Most women with PCOD have a normal 46, XX karyotype (Yen, 1980). It is possible that in some cases 
an autosomal anomaly can lead to PCOD (Schwartz et al 1987) although a typical and consistent 
chromosomal abnormality is not associated with PCOD. Parker et al. (1980) carried out cytogenetic
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studies in 15 PCOD patients; 5 of them showed trisomy 14 in 2 - 4% of their cells, which was considered 
to be significant as such an occurrence is rare in tlie general population.
The relationship to HLA has aided in understanding the genetic transmission of an inherited disorder. 
Congenital adrenal hyperplasia (210H deficiency) has close genetic linkage with HLA on chromosome 
no. 6 (Hague et aï 1989). Several authors have described tlie association of CAH and PCOD. Broster et 
al (1938) was tlie first to suggest tlie association of CAH and PCOD. Hague et al (1989) reported a 
6.4% incidence of PCOD patients ivith evidence of 210H deficiency. The same autlior (Hague et at
1990) showed a similar association in post-pubertal females (76%). Cystic ovarian changes were 
diagnosed in the majority of CAH patients (Eden et al 1989c; Levin et o / 1991; AbdelGadir et aï 1992b) 
and tlie last authors also found that the PCO appearance persisted even after normalization of androgens 
with corticosteroids. Yen (1980) proposed tliat PCOD could be inherited as an x-linked disorder and the 
incidence was liigher if inherited from the father (Ginsburg & Havard, 1976). As 17 ketosteroid 
deficiency could be transmitted as AR and could be an x-linked R, the discovery of its deficiency in some 
families of PCOD patients might explain tlie occurrence of menstrual dysfimction and PCOD (Pang et al 
1987; Toscano et al 1990).
In studying the prevalence in families, Mahesh et a l (1978) diagnosed PCOD in 3 sisters, and it has also 
been diagnosed in identical twins (Goldzieher & Green, 1962). Mandel et a l (1983) studied 4 families 
in whom at least 2 siblings had clinical evidence of PCOD. Futterweit (1984) had reconunended 
investigating all women with a family liistory of menstrual irregularity for PCOD. In addition, Poison et 
a l (1988) foimd tliat 44% of women with irregular periods, diagnosed to have PCO by ultrasound, had a 
sister or a motlier with irregular periods (compared to 4% in tliose with regular periods). As Hague et al
(1990) studied relatives of tlieir PCOD patients, they fomid tliat 67% of pre-menopausal mothers and 
86% of sisters of PCOD patients were found to have PCO as well. Although the sample of families 
studied was small (4), Mandel et a l  (1983) foimd tliat PCOD does not exhibit linkage to the HLA 
system. A study of the prevalence of ultrasonically detected PCO in family female members of 59 
patients suggested a dominant inheritance of PCOD with variable phenotypic expression, but tire 
prevalence was higher than expected for either an x-linked or AD inlreritance (Hague et al 1986).
The occmTence of hypertension, hyperlipidaemia, hypennicaemia, IDDM, obesity and acanthosis 
nigricans in families with PCOD is of special interest (Yen, 1980). Although there is some evidence of a 
genetic factor of inheritance, larger studies are needed to ascertain tire mode of inheritance.
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2.7 DIFFERENTIAL DIAGNOSIS
The so-called “PCO-like Syndrome” (Yen, 1980)
Any condition causing anovulation willi LH-dependent androgen excess secretion and increased 
extraglandular production of oestrogen may result in a gross appearance of tire ovaiies similar to tiiat 
seen in PCOD (Yen, 1980; Futterweit, 1984). Appropriate oestrogen secretion occurs only when FSH- 
dependent orderly follicular maturation takes place. Thus, when tire LH:FSH ratio is increased, often due 
to acyclical peripheral oestrogen feedback, chronic anovulation witli increased ovarian androgen 
production ensues resulting in a gross appearance of the ovary similar to that seen in the PCO syndrome.
Cushing’s Syndrome
Oligo/amenoniioea or menstrual irregularity, obesity and hyperandrogenism occur in the majority of pre­
menopausal women with Cushing's Syndrome (Yen, 1980; Yen, 1986) simulating PCOD. Clironic 
anovulation and menstrual irregularity may be due to disturbed cyclical Gn release secondary to central 
nervous system defence and/or increased peripheral production of oestrogens (Yen, 1980). Although 
cortisol release is in excess with loss of normal circadian rhytlmi, some degree of sex steroid increase 
from tlie adrenal gland may also be present (Yen, 1980; Yen, 1986). An oveiproduction of ovarian 
androgens due to clironic anovulation may occur leading to tlie formation of PCO-like ovaiies.
Congenita! Adrenal Hyperplasia (CAH)
Congenital adienal hyperplasia is a variety of disorders of adrenal steroidogenesis which result from an 
inherited deficiency of one of several enzymes necessary for normal adrenal steroid synthesis (Futterweit, 
1984). The most common defect is tliat of adrenal 210H or 3 j3-0HSD isomerase enzymes. Severe 
hirsutism, menstrual dysfunction and infertility with vaiying degrees of androgen excess, mainly 
reflecting adrenal androgens, are present. The differential featme from PCOD is the maiked elevation of 
17 a-OHP and P botii basally and in response to ACTH stimulation (Yen, 1980; Futterweit, 1984; Yen, 
1986; Levin et al 1991). The elevated androgens are readily suppressed by DXM and stimulated by
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ACTH. The deficiency of 3 p-OHSD can be manifested with elevated LH:FSH ratio, decreased SHBG 
and androgen excess (mainly delta 5 andi'ogens - DHEA, DHEA-S and androstenediol) (Yen, 1986). 
The diagnosis is made by elevation of plasma pregnenolone, 17 a-hydroxypregnenolone, DHEA, DHEA- 
S witli relatively low levels of delta 4 compounds such as P, 17 a-OHP and A (Fiitteiweit, 1984).
Androgen-producing Tumours
"Virilizing ovaiian and adrenal tumours". Several types of ovarian and adrenal tumours produce 
androgens and cause clironic anovulation and often virilization. These tmiiours include "liilai cell 
tumours", "arrhenoblastoma" (Sertoli-Leydig cell tumours), "benign cystic teratomas", "luteinized 
thecoma", "adrenal nest tumoms of tlie ovary", and "adrenal adenoma" and "carcinoma" (Yen, 1980; 
Yen, 1986). Any rapidly progressing hirsutism in association with amenorrhoea and cliteromegaly is 
liighly suggestive of a virilizing tumour. Markedly elevated plasma T values may be diagnostic 
(Futterweit, 1984). Therefore adrenal and ovarian ultrasonography and adrenal CT scanning will be of 
great help in localizing tlie tumour.
Oestrogen-producing Tumours
Granulosa-tlieca cell tumoms are the most common hormone-producing neoplasms of the ovary, 
accounting for 15 - 20% of all solid ovarian tumoms (Yen, 1986). These usually produce mainly 
oestrogen but frequently also produce androgens.
Ovarian hyperthecosis
The term "hypertliecosis" is a non-neoplastic pathologic lesion of the human ovary, characterized by a 
diffuse hyperplastic process in tlie hmnan ovary resulting in diffusely distributed islands of luteinized 
tliecal cells tliroughout tlie ovarian stroma (Yen, 1980; Fienberg, 1981; Yen, 1986). The clinical picture 
is usually composed of severe hirsutism, mild cliteromegaly, obesity, temporal balding, oligomenorrhoea 
and resistance to clomiphene tlierapy (Futterweit, 1984). They may respond to ovarian wedge resection. 
Obesity, diabetes rnellitus and hypertension occur with greater frequency in hyperthecosis.
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Hyperthecosis and PCOD may differ from one another histologically. Islets of luteinized tlieca cells in 
tlie ovarian stioma aie not present in ovaries of PCOD patients (Yen, 1980; Futterweit, 1984; Yen, 
1986). Therefore, in the absence of a specific clinical or biochemical difference between the two, 
hypertliecosis should be included witliin tlie spectiiun of PCOD (Futteiweit, 1984),
Hyperprolactinaemia
Altliough the clinical picture (liirsutism, seborrhoea, \rith or witliout amenonhoea and galactorrhoea) 
may resemble PCOD, tlie presence of hypeiprolactinaemia, normal or low Gn levels, and selective 
increase of DHEA and DHEA-S distinguishes those patients from tliose with PCOD (Yen, 1980; Yen,
1986).
PCOD-like syndrome due to hypersecretion of LH and PRL is relatively rare (Yen, 1980). Clinically, the 
patients present with liirsutism, infrequent menses and galactorrhoea. Laboratoiy studies showed 
hyperprolactinaemia, witli inappropriate elevation of LH and low FSH levels. The aetiology is unknown. 
Luteinizing hormone and PRL levels showed a marked decline following dopamine infiision, a response 
similar to tliat found in hyperprolactinaemic and PCOD patients. Treatment with bromocriptine results 
ill normalization of PRL but not LH (Yen, 1980).
Hyper/Hypothyroidism
Marked changes in SHBG and sex steroid metabolism and secretion could result from an excess or 
deficiency of tliyroid hormones resembling PCOD. Plasma T concentrations are elevated in 
hypertliyi'oidism and a significant increase in the conversion of T to A occurs (Yen, 1980). There is an 
increase in circulating oestrogen levels in hyperthyioidism resulting from peripheral conversion rallier 
than from direct glandular secretion. Clnonic oestrogen elevation results in anovulatory cycles tlnough 
inappropriate feedback and elevated LH.
In hypothyroidism, the MCR for T is increased due to the reduced SHBG while tlie MCR for A is 
normal. The conversion of A to T is increased and, consequently, an increase in the conversion of T to 
Ej occurs. However, the metabolism of E^  appears to be altered as well, since preferential 16- 
hydroxylation takes place witli tlie formation of Eg instead of E^  (Yen, 1980). Oestiiol is less potent than
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Es in feedback regulation of Gn secretion resulting in clnonic anoWation and/or menstrual disturbance 
(Yen, 1980). Exclusion of tliyroid dysfimction in suspected cases is relatively appaient.
Idiopathic hirsutism
This is defined as hirsutism in women with relatively normal T levels and regular menstrual cycles (Yen,
1986). Hirsute women with normal seium T levels may have hypersensitivity of tlie target cell to 
androgens, due to increased 5a-reduction of T to DHT or may be due to a primary increase in tlie 
concentration of androgen receptors. The andiogen receptor is not regulated by androgens in the skin in 
contrast to the 5a-R activity wliich increases andiogen action in androgen stimulated areas such as pubic 
skin (Futteiweit, 1984; Yen, 1986). The degree of liirsutism correlates with the relative rate of 
conversion of T to DHT (5a-R activity). The mechanism, which accounts for tlie increased 5a-R activity 
remains to be clarified. Altliough tlie majority of PCOD patients have elevated circulating androgen 
levels, up to 30% are not liirsute (Futterweit, 1984). Tliis sensitivity may be determined by the target 
tissue.
82
CHAPTER THREE - CLINICAL AND LABORATORY 
PROCEDURES
3.1 PATIENTS
3.L1 INCLUSION CRITERIA
Patients were selected according to tlie following criteria ;
1. Age less than or equal to 38 years
2. Menstrual cycle >41 days (oligomenorrhoeic)
3. Infertile (primaiy or secondary infeitility)
4. Laparoscopy or hystrosalpingogiam, carried out wtliiii the last tliree yeais, indicating normal pelvic 
organs and patent fallopian tubes
3,1.2 SOURCES OF RECRUITMENT
The patients in this study were recruited from the specialized Infertility and Reproductive Endocrinology 
clinics at :
Glasgow Royal Infirmaiy (GRI), Glasgow Western Infirmaiy, and Royal Alexandra Hospital, Paisley. 
All cases were managed at GRI.
A number of obese patients was included to allow for the analysis of the role of obesity in tlie 
pathophysiology of PCOD.
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3 A J  PATIENTS CLINICAL DATA
For all patients selected, tlie folloiving data were collected and recorded in the “Patient Infertility Sheet” 
(Appendix I) :
Name of the patient and her partner, residency and telephone number 
Age at menarche 
Menstrual and obstetric liistoiy 
Duration of infertility 
History of medication and response
Onset of symptoms in relation to menarche, marriage, childbirth, use of contraceptives ... etc. 
Progression of symptoms 
Detailed family liistoiy.
All of tlie patients had a general examination with special emphasis on :
BMI
Thyroid enlargement 
Galactoirhoea 
Abdominal masses 
Hair distribution 
Signs of otlier endocrinopathies 
Pelvic examination.
Androgeiiization was assessed using tlie Ferriman & Gallwey scoring system and hirsutism was 
diagnosed when the score was > 7. Virilism was diagnosed if one or more of the following clinical 
features was present :
• Clitoral hypertrophy
• Breast atrophy
• Male-type baldness
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Deepening of the voice.
3.1.4 PATIENT INFORMATION SHEET
Once a suitable patient was found, a “Patient Information Sheet” was given to her. This information 
sheet contained simple descriptions of the procedmes and the tests to be earned out (Appendix II).
3.1.5 THE CONSENT FORM
The study protocol was approved by the Elliical Conunittee of tlie Greater Glasgow Health Board. An 
informed written consent was obtained in each case before proceeding to the investigations. It was 
clearly stated in the consent tliat the patient could witlidraw from tlie study at any time witliout 
jeopardizing her future follow up or treatment (Appendix III).
3.1.6 CATEGORIES OF PATIENTS
Patients recruited according to tlie above mentioned criteria were defined to have polycystic ovarian 
disease by the presence of at least 2 of tlie following diagnostic criteria :
1. Clinical diagnosis.
The patient showed some or all of the symptoms and signs of PCOD. These include :
i- menstrual irregularity
ii- hyperandrogenization
iii- primary or secondary infertility
iv- obesity.
2. Ultrasound diagnosis.
Ultrasonographic examination of ovaries showed at least two of the following :
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i" ovarian volume > 9.0 en /
ii-> 10 follicles of 2-8 mm, peripherally or centrally distributed in the ovarian stroma, at any cut 
section, in one ovaiy^
iii- tliickened ovarian stroma.
3. Biochemical diagnosis.
The patient showed some or all of the following biochemical criteria ;
i- LH ; FSH ratio >2:1 during the early follicular phase (between day 5-8) of the menstmal 
cycle
ii- T or A levels above the upper limit of normal values of the biochemistiy laboratory at GRI 
iii~FAI>4.5.
3.1.7 PATIENTS RECRUITED TO THE STUDY
The aim of tlie study was to recruit about 150 patients in order to achieve hopeflilly significant answers to 
the objectives of the study (Section 1.4). During the study workshop time scale, 1993-1995, about 150 
patients were inteiviewed in the 3 hospitals allocated for recniitment of patients tlirough their specialized 
“ Infertility and Reproductive Endocrinology Clinics ”. In spite of huge effort and time spent and 
persistence, and due to problems of recruitment, only 42 patients who agreed to participate in tlie study 
were found to satisfy the inclusion criteria.
All patients gave blood samples and undenvent US scans (Section 3.3.3 and 3.3.5). However, only 34 
patients had 2 SITTs performed (Section 3.3.8.1). The rest of the patients did not undergo the test 
because of either patient’s refusal to undergo this invasive test or for logistic reasons as tlie patient 
presented late, in the last few months of the study time-scale.
All data represent all of the patients for all hormones except IGF-I which was carried out for only 18 
patients. Tliis was due to laboratory tlirough-put problems vdthin the time scale of the study for IGF-I 
assay. The remainder will be assayed and analysed for future publication purposes.
One patient had failed to continue the 5-week longitudinal obsen^ations, therefore, she was excluded 
from the relevant analyses (Chapter Six).
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Eleven out of 34 patients, who were chosen randomly, underwent the post-heparin HL test (Chapter 
Seven). The sample was small due to logistic reasons.
3.2 CONTROLS
3.2.1 INCLUSION CRITERIA
The “volunteers control gioup” were recruited according to tlie folloiving inclusion criteria :
1. Age matched to tlie patients
2. Menstrual cycles regular (i.e. between 24 and 35 days)
3. Preferably parous (i.e. no difficulty in getting pregnant)
4. No contraceptive pills for at least the last 2 montlis
5. Physically and mentally noniial
6. Included a group of lean and a group of obese (BMI > 29) volunteers.
All “control group” subjects had régulai' menstrual cycles and were studied during the midfollicular and 
midluteal phases of tlieir menstrual cycle. None was liirsute, or had diabetes mellitus. None had 
received any horaional medication witliin the last 2 months before being studied.
3.2.2 SOURCES OF RECRUITMENT
The control group consisted of regularly menstruating volunteers who were students, hospital staff or 
were recruited from local Healtli Centi'es.
3.2.3 CONFIRMATION OF OVULATION
The mean plasma concentrations of E^ , LH, FSH, T, SHBG and FAIs of the control group in samples 
collected during the early follicular phase are shown below. Ovulation was documented in the same
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group by a typical rise in and a rise in plasma P values during the midluteal phase. One of the 
controls (n = 20) was excluded because she did not ovulate dming tlie monitoring period as indicated by 
the midluteal plasma P (1.6 ng/niL) (Table 3-1).
Table 3-1 : Follicular & Luteal Phase Endocrine Data in the Control group
Follicular Phase Luteal Phase
Ej ( pg/niL) 65.00 ±  34.2 ( 25 - 145 ) 91.15 ±39 .35  (47 .5 -215)
L H (IU /L ) 5.253 +  4 .390(1 .60-19 .8)
FSH (IU /L ) 5.150 ± 1 .730  (2 .9 5 -9 .8 5 )
LH /FSH  ratio 1.070 ±  0.799 (0.281 -3.47)
T { miiol/L ) 1.529 ± 0 .928  (0 .3 0 -3 .2 0 )
SHBG ( nniol/L ) 62.53 ±  2 5 .7 7 (2 8 -1 2 0 )
F AI C TT/SHBG x 100 ) 2 .904 ± 2 .1 2 5 (0 .3 6 1  -8.00)
P { ng /  niL ) 12.20 ± 7 .1 6  (4 -2 6 .0 )
3.Z4 CONTROLS RECRUITED TO THE STUDY
There was difficulty in recniiting weight-matched controls witli normal and regular menstmal cycles. 
Only 20 controls agreed to participate in tlie study. However, one control was excluded after 
investigation; retrospectively she was foimd to have iiregulai menstrual rhythm ratlier than normal 
cycles.
All tlie controls agreed to imdergo the blood tests and to have 2 SITTs but unfortunately, were reluctant 
to have US scans. Therefore, the literature data for normal US observations were used for reference for 
tliis study.
3.3 PROCEDURE OF INVESTIGATIONS
3.3.1 ANTHROPOMETRIC MEASURES
Body mass index was calculated as weight (kg) divided by height (m) squared (BMI = wt/(height)fy. 
Obesity was defined as BMI > 29 Kg / m^ .
Waist/llip ratio was calculated from tlie circumferences measured in duplicate in tlie supine position 
(waist : midway between tlie lower rib margin and the iliac crest; hip ; widest circmnference over tlie 
great trochanters).
3.3.2 ENDOCJftlNE INVESTIGATIONS
Blood for tlie endocrine measurements was obtained in a standardized manner between 08:00 - 10:30 h. 
Oestradiol was measured using a competitive fluoroimmunoassay (Delfia Estradiol; Wallac Ltd, Turku, 
Finland). Luteinizing hormone, FSH, SHBG and PRL were assayed using noncompetitive sandwich 
fluoroimmunoassays (Delfia hLH, Delfia liFSH, Delfia SHBG, Delfia PRL; Wallac Ltd, Turku, Finland). 
Testosterone, A, P, cortisol, 17a-OHP, I, GH and C-peplide were measured using competitive 
radioimmunoassay (Coat-A-Count TT Kit, Coat-A-Coimt A, Coat-A-Coimt P, Coat-A-Coimt cortisol, 
Coat-A-Count 17a-0HP, Immulite I, Double Antibody Human Growth Hormone, Double Antibody C- 
Peptide Kits; Diagnostic Products Corporation, Los Angeles, CA, USA). The FAI or the FTI was 
calculated as T concentration (nmol/L) x 100, divided by SHBG concentration (nmol/L). 
Dehydroepiandrosterone sulphate (DHEA-S) was measured using competitive radioimmunoassay 
(InmiuChem™ DHEA-S Coated Tube Kit; ICN Biomedicals, Inc., Costa Mesa, CA, USA). The IGF-I 
was assayed using competitive radioinmiunoassay (IGF-I/Somatoniedin-C Coated Tube RIA Kit; Euro- 
Diagnostica B.V., Health Care Biotechnology). Plasma glucose was measured using the glucose oxidase 
method (Glucose Reagent Kit - Olympus AU5200, Olympus Optical Co Ltd ). Triidothyronine, T4 and 
FT4 were measured using chemiluminescent enzyme immunoassays (Immulite Total T3 and Immulite 
Total T4 Kits; Diagnostic Products Corporation, Los Angeles, CA, USA). Plasma leptin concentrations 
were measured in duplicate using solid-phase '^I-radioimmmioassays (Linco Research, St. Charles, Mo).
Oestiadiol values were expressed in pg/mL. The standard values for LH and FSH were expressed in lU/L 
calibrated against the WHO 2nd International Standard (IS) for pituitary LH for immunoassay (80/552), 
and the 2nd International Reference Preparation (IRP) of pituitary FSH/LH (ICSH), human, for bioassay 
(78/549), respectively. The values for PRL (mlU/L) and hGH (ng/mL) used the 3rd IS for PRL (84/500) 
and 1st IRP of human GH for inummoassay (66/217 and 80/505), respectively.
Hepatic lipase was assayed in post-heparin plasma. In tliis assay, gum aiabic stabilized TG emulsion 
containing glycerol tii [I-’‘’C] oleate at a specific activity of 30 uCi/mmol TG fatty acid was use as 
substrate. The fatty acid products of lipolysis were captured by bo\ane serum albumin, extracted from the
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glycerides and counted by liquid scintillation. The activity of HL was assayed in the presence of LO M 
NaCl to inactivate lipoprotein lipase. Enzyme activities are expressed in mnol of fatty acids released per 
hour per mL of plasma (umolFA/mL/li).
The between- and within-assay coefficients of variation for the hormones are listed in Appendix IV.
3.3.3 TIMING OF INVESTIGATIONS
• The investigations were star ted at least 14 days after tlie last menstrual period in oligomenorrhoeic
cases
• For those cases who had prolonged periods of amenorrhoea, a blood estimation of E^  and a pelvic 
ultrasound scan were carried out randomly. The investigations usually started once E^  concentrations 
were found to be < 100 pg/niL and the ultrasound scan showed no follicles > 10.0 mm in diameter.
• Controls with regular menstrual cycles were started in the follicular phase (i.e. between days 5-8).
3.3.4 FIRST VISIT TO THE CLINIC
During the first visit tlie following were carried out :
1. Recruitment of cases according to inclusion criteria
2. Simple introduction to tlie study
3. The “ Patient Infertility Sheet ” was completed
4. Blood investigations and ultrasomid scans were airanged
5. Semen analysis was checked
6. The “ Patient Information Sheet ” was handed over
7. The patient was consented when appropriate (i.e. if inclusion criteria were fulfilled).
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3.3.5 LONGITUDINAL INVESTIGATIONS
The basic duration of tlie investigations was 5 weeks for oligo/amenorrhoeic cases.
3.3.5.1 Day One
An endocrine profile was perfonned to establish the circulating levels of :
1. FSH, LH, Ey TT, SHBG, FAI, A, I7a-0HP, DHEA-S, cortisol, PRL and thyroid function tests
2. First SITT was performed (as described in 3.3.8.1)
3. A basic pelvic ultrasound examination (transvaginal ultrasound) was performed, identifying 
specifically the ovarian volume, echogenicity, stromal tliickness and tlie presence of microcysts.
3.3.5.2 Weeks (1-5)
All patients were monitored for any ovarian activity twice weekly by measuring plasma E^  levels and 
once a week by an ultrasound examination. The monitoring was carried out for 5 weeks.
If Ej concentrations and/or the ultrasound scan indicated no ovaiian activity, the E^  sampling was 
teiininated and the SITT was repeated during the 5*^ ' week.
If Ej concentrations and/or idtiasomid scans indicated any ovarian activity at any stage dming the 5 week 
period, then E^  was shifted to daily estimations and the ultrasound examination for follicular maturation 
and ovulation was performed as required over tlie following 2 weeks. At the midluteal phase serum P 
concentrations were estimated and the SITT was repeated.
3.3.6 ASSESSMENT OF LUTEAL FUNCTION
Ovarian activity was monitored twice weekly by measuring plasma E^  levels. The monitoring was 
carried out for a maximum of 5 weeks.
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If levels indicated ovarian acthdty at any stage during the 5-week period, E^  was sliifted to daily 
measurements. Ovulation was defined by the occurrence of an "LH smge” followed by a significant rise 
in P (à 4.0 ng/mL ). The “LH surge” was diagnosed by the presence of at least doubling of the preceding 
LH values from one sample to tlie next to a concentration > 10.0 lU/L. Evidence of adequate 
luteinization was confirmed if a single P concentration of > 4.0 ng/mL was detected, 48 hours after the 
“LH surge”. At midluteal phase semm P concentration was estimated to assess luteal function. Tliis 
required a sample to be taken between days LH peak +4 and LH peak +9 inclusive. The mean of tlie 
samples at tlie foUiculai’ phase represent the mean of all the samples of the obseivation period for those 
who did not ovulate, and tlie mean of all samples of the follicular phase calculated at least 2 days before 
the LH smge for tliose who ovulated.
3.3.7 ULTRASOUND SCANNING
3.3.7,1 Ultrasound Scanner
Ovarian ultrasonography was performed using a Siemens P/C, Sonoline SL-1 machine. Serial No. NM 
80460 using sector real-time transvaginal transducers of frequencies of 5,0 and 7.5 MHz. The macliine 
was equipped witli a Polaroid Camera, 35 nun SLR - Camera adapter. All ultiasound examinations were 
perfonned by one operator (HA).
Vaginal US allows a much more precise analysis of internal ovaiian morphology to be performed. As the 
probe can be brought closer to the ovaries, than by abdominal ultrasound, higher ultrasound frequencies 
(5.0 to 7.5 MHz) can be used, yielding high resolution ovarian pictures.
3.3.7.2 Technique of Ovarian Ultrasonography
Pelvic scans were cairied out vaginally. Tliis technique does not require tlie full bladder which is 
necessary using tlie abdominal ultrasound technique to displace the gas-containing bowel out of the 
pelvis. A special vaginal probe was used, covered by a clean condom, changed after each patient, and 
smeared with a jelly at its apex.
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The utems was identified, and the more transonic structures, the ovaries, were identified on either side of 
the uterus. The right and the left ovary were both examined. The following sonographic findings were 
recorded :
1. Ovaiian volume = length(dj )/2 x widtli(d2)/2 x tliickness(dg)/2
2. The greatest number of echo free, roimd, or ovoid translucent stmctmes known as follicles, <10 mm 
in size, in one US plane was recorded, regardless of their distribution
3. Presence or absence of hyperechogenic ovarian stroma.
Because tlie ovaiy is mobile and not spherical, tlie measurements of the tliree diameters vaiy with 
position. However, the ovarian volume remains constant. In order to calculate the ovarian volume, the 
following procedure was performed :
When the largest available section of the ovaiy in the transverse plane had been displayed, the widest 
transverse diameter (d|) and the longest diameter ortliogonal to tliis in tlie A-P axis (d2 ) were measured. 
The transducer was then rotated through 90° and when tlie ovary was identified in the longitudinal plane 
the maximum vertical diameter (dg) was measured. The procedure took from 10-15 minutes per patient.
In order to increase tlie reproducibility of scanning, the basal US measurements of ovarian volume were 
repeated on 2 occasions for each patient. The details of tlie patient’s mean and coefficient of variation 
are listed in Appendix V.
High-resolution, real-time US, enables the detection of small cysts (2 to 8 mm) witliin an ovary. These 
microcysts looked translucent on the US screen and may be arranged in the periplieiy of the ovary or 
tliroughout tlie parenchyma.
Follicle size was deteimined from two dimensions, longitudinal and A-P. The mean of tliese two 
measurements was taken to be tlie follicle diameter.
As the evaluation of the ovarian stroma is purely visual, inter-observer bias was prevented since all scans 
were done by one operator. The stroma was considered abnormal when it was mainly central witli an 
area exceeding that of the microcysts that were pushed together toward the ovarian periphery, and/or 
when it was hyperechogenic and dense witli enhanced contrast between tlie microcysts and the stroma, 
and/or when it infiltrated the microcysts whose walls appeared tliickened.
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3.3.7.3 Ultrasound Information Collected
All patients had a basal pelvic US examination performed on the first day of investigations. Ovarian 
volume, echogenicity, stromal tliickness and the presence of microcysts were assessed. All cases were 
monitored for any ovarian activity once a week by an US examination. The monitoring was carried out 
for 5 weeks. Whenever concentrations and/or US scans indicated any ovarian activity during the 5 
weeks' period, US examination for follicular maturation and ovulation was performed as required over 
the following 2 weeks.
3,3.8 DYNAMIC PROCEDURES
3.3.8.1 Short Insulin Tolerance Test ( SITT )
All subjects were instructed to remain on their usual diet prior to study. None was known to have 
diabetes or impaired glucose tolerance, and no subject was on any medication affecting glucose tolerance. 
Each subject was studied on two separate occasions with an interval of at least 2 weeks for controls and 3 
weeks for patients. Human actrapid I ( Novo Laboratories, Nordisk, UK ) was used.
The test was conducted after an overnight fast, between 08:30 - 11:00 horns. The fasting periods ranged 
from 8-12 horn s, and the duration of each test was 1 horn" and 15 minute. The weight of tlie patient was
recorded in kilograms. The patient was tlien asked to lie on a couch, and a teflon camiula (Biovalve
venflon, G:22, Ecouen France, made in Belgium) was inserted into a large antecubital vein. The 
following, pre-I injection, blood samples were collected :
1. The basal, “-15” time blood sample, 15 mL, for glucose. I, and E^
2. “-5” time sample, 2 mL, for glucose
3. “0” time sample, 17mL, for glucose, GH, FSH, LH, E^ , TT, A, cortisol, 17a-0HP, DHEA-S, PRL and 
thyroid function tests.
• To arterialize the venous blood, the hand was placed in a water bath at a constant temperature of 
43°C, for 10 minute prior to the start of I infiision and kept tliere imtil tlie end of tlie test. To ensure 
that only blood from tlie hand was sampled, the vein was retrogradely caimulated ivith a butterfly 
needle. Total I dose was calculated as 0.1 lU/Kg body weight and diluted in a bag of 100 niL normal
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saline. The total calculated dose of I was then withdrawn from the dilution bag. Insulin was 
administered, by constant infusion, intravenously into the teflon cannula. Timing was calculated in 
relation to 1 infusion time. Blood was sampled as follows :
• For glucose at 1, 3, 5, 7, 9, 11, 13 and 15 minute (2 mL each), as a standard procedure. Sampling for 
glucose was continued at 20, 25 and 30 minute if no symptomatic hypoglycaemia developed.
• For 1 at 9 and 15 minute.
• For GH at 15, 30 and 60 minute (5 mL for each sample).
• Samples at 30 and 60 minute for Gn, frill androgen profiles, PRL and tliyroid fimction tests. Ten mL
was required for each of these samples.
Blood for glucose estimation was sampled tlirough tlie butterfly needle while tliat for the hormones was 
sampled tlirough the venflon. Needles were flushed between sampling with nonnal saline. The fast was 
terminated at +15 minute if tlie patient felt liypoglycaemic; otlierwise tlie test was continued until +30 
minute. A 10-20 mL sample of 50% glucose was injected intravenously to terminate the effect of the I 
injection and tlie patient was given a snack. All glucose blood samples were placed immediately on ice 
until analyses.
3.3.S.2 Post-Heparin Hepatic Lipase Activities and LDL Subfraction Distribution
The aim of the heparin test was to conelate the LDL subfraction distribution and concentration with 
anthropometric indices, plasma lipid and lipoprotein concentrations, the activities of post-heparin 
lipoprotein and hepatic lipase status in PCOD patients.
Eleven patients from the whole study group who presented witli oligomenorhoea and witli biochemical 
evidence of hyperandrogenism agreed to undergo the plasma lipids study.
Inclusion Criteria :
1. Normal FBC
2. Patients who have given tlieir informed consent to participate in this study.
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Exclusion Criteria :
As described earlier in Chapter Three plus in addition ;
1. Contraindications to intravenous heparin such as : sensitivity to heparin, history of any bleeding 
disorder (e.g. haemophilia), recent injmy or tramna. Rheumatic fever or stroke.
2. Patients taking any medication known to interfere witli lipoprotein concentrations such as non­
steroidal anti-inflanmiatoiy drugs.
The selected oligomenorrhoeic patients were advised to fast overnight and requested to report to the 
clinic on the following morning during their 5-week monitoring period, bringing with them a 24-hour 
collection of urine. Fasting blood (total of 30 mL in EDTA) was collected for ;
• Plasma concentrations of cholesterol, TG and HDL
• Determination of VLDL, LDL and HDL subfraction distributions
• Cholesterylester transfer protein activity.
The patients were then heparinized witli 70 U/Kg body weight and a blood sample (10 mL in heparin) 
was collected for lipoprotein and HL. All blood samples were placed immediately on ice. The patients 
blood pressure was also recorded on the day of sampling.
3.3,9 STATISTICAL ANALYSES
Results were analyzed using Student's two-tailed Mest ( for paired and impaired data as indicated ) and 
for comparison of means between two groups; Mami-Wliitney f/-test was used for variables not normally 
distributed. Group differences in category variables were tested with Fisher's exact test. Pearson 
correlation coefficients were used for simple linear correlations : P < 0.05 was taken as significant. 
Where such correlation coefficients are reported in any results section they were performed using tlie 
Pearson method. For evaluating the relationsliip between anthropometric, endocrine or metabolic 
variables, i. e. if there was a significant impact of BMI or WHR on the variables, the material was 
subgiouped according to BMI into < 29 and > 29 Kg/nE and/or WHR into < 0.8 and > 0.8. A number of 
analyses of covariance were used as an alternative metliod whenever appropriate. Results of all 
determinations shown in this thesis are expressed as mean values of the appropriate group of patients or
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controls ± SD. In all tables where figures aie shoivn as “ x ± y y represents the standard deviation of 
the mean x.
All statistical analyses were performed using " Prism ", version 2, GrapliPad Software, Inc.
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CHAPTER FOUR - BASELINE CHARACTERISTICS OF 
PATIENTS & CONTROLS
4.1 INTRODUCTION
Tills chapter comprises tluee main subsections of investigations : clinical characteristics and endocrine 
characteristics in botli patient and control groups and ultrasonographic observations in tlie patient group 
only. Clinical characteristics include age, clinical presentation of patients and antliropometric 
obseivations as well as the inter-relationsliips between anthropometric and clinical obser\'ations. The 
subsection of endocrine characteristics includes data from study group patients and controls, the 
relationships between endocrine characteristics and clinical presentations. Ultrasonographic 
observations include basal ovarian scan findings and tlieir relationships ivith clinical presentations 
including anthropometric variables and endocrine variables.
4.2 CLINICAL CHARACTERISTICS
4.2.1 AGE
The characteristics of the study and control populations witli respect to age and smoking habits are 
presented in Table 4-1 . It shows that the mean age for tire patients witlr oligo/amenorrhoea (mean =
29.1 years) was lower tlian that of the control group (mean = 34.0 years). Tliis reflected the difficulties 
in recruiting weight-matched control subjects. There was no difference in the incidence or degree of 
smoking between tlie 2 groups.
Tabic 4-1 : Characteristics of the Patients and the Controls
Patients Controls P value
n 42 19
Age 29.07 + 4.23(21-37) 34.00 ±6.57 (18-41) 0.0008
Smoking 7.14 ±10.77 (5 -40) 3.68 ±6.63 (5-20) 0.2021
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4.Z2 CLINICAL PRESENTATION
Table 4-II summarizes the clinical features of the study group, and shows tliat 35 (83.3%) of the women 
had oligomenorrhoea, and seven (16.7%) had ameiiorrhoea. The patients with oligomeiiorrhoea, showed 
different clinical histories in tliat 18 patients (51.4%) had had die problem since the menarche, seven 
patients (20.0%) dated the problem following the use of oral contraceptive pills wliile 3 of the whole 
group (8.6%) started to notice the change in their menstrual pattern after deliveiy. The rest of die 
patients (n = 7, 20.0%) were unable to date when their menstrual disturbance started. Primary infertility 
was a complaint in 61.9% of die women widi oligo/amenorrhoea; the mean duration of the infertility 
was 4.31 years (range 1-14 years).
Dysfunctional uterine bleeding was a complaint in only 5 (11.9%) of diose patients who presented with 
oligo/amenorrhoea (Table 4-II).
Hirsutism was diagnosed in 26 patients (61.9%) witii Ferriman and Gallwey scores of > 7 points, and 14 
(33.3%) of them had more than mild hirsutism and virilization. Almost all of the patients had noticed 
progression of die symptoms - oligomenorrhoea and hirsutism in particular - with advance in their age, 
commonly coincident with significant weight gain. None of the patients showed acanthosis nigricans. 
Galactorrhoea was an infrequent observation (4 patients, 9.5%).
None of the patients or the controls had diabetes mellitus or cardiovascular problems. A positive famdy 
liistory of menstiual irregularity was reported in 9 cases (21.4%).
Table 4-H : Clinical Features of the Patients
Presenting features (n) Total (%)
Oligomenorrhoea 35 83.3
Ameiiorrhoea ( Primary/Secondary ) 7 16.7
Primary infertility 26 61.9
Secondary infertility 16 38.1
Dysftinctional bleeding 5 11.9
Androgenization 26 61.9
Virilization 14 33.3
Galactorrhoea 4 9.5
Overvveiglit ( BMI > 25 Kg/iu ) 24 57.1
Obesity ( BMI > 29 Kg/m ) 17 40.5
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4.2.3 ANTHROPOMETRIC OBSERVATIONS
The BMI for the patients was not significantly higher than tliat of tlie control group. However, tlie mean 
value of the patients' WHR was significantly higher than that of tlie contiol group, indicating different 
weight (fat) distribution between the patients and the controls (Table 4-111).
Table 4 -in  ; Anthropometric Observations
Patients Controls P
n 42 19
BMI 28.09 ±  7.06 ( 15 .6 3 -4 5 .3 1 ) 25.98 + 6 .6 4 (1 9 .6 -4 0 .6 5 ) 0.2756
WHR 0.87 ± 0 .09  (0 .7 4 -1 .1 5 ) 0.79 ±0.076 (0 .6 9 -0 .9 4 ) 0.0017
Seventeen patients (40.5%) and 7 contiols (36.8%) were obese (BMI > 29 Kg/m ). Twenty seven 
(64.3%) patients admitted a significant increase in tiieir weight coinciding with the start or worsening of 
their symptomatology, witli an average increase of 18.3% in tlieir weight (range 8.8% - 39.5%).
A liighly significant correlation was found between BMI and WHR in tlie patients as well as in the 
control group, irrespective of the difference in weight distribution wliich was indicated by the difference 
in WHR (Figure 4.1).
Figure 4.1 :
Correlation : WHR and BMI in Patients and 
Controls
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4.2,4 RELATIONSHIP BETWEEN CLINICAL PRESENTATION AND 
ANTHROPOMETRIC VARIABLES
There was no significant relationship between BMI or WHR and menstinal pattern, androgenization or 
virilization.
4.3 ENDOCRINE CHARACTERISTICS
4.3.1 COMPARISON OF ENDOCRINE DATA  -  PATIENTS AND CONTROLS
Women with oligo/amenorrhoea were found to have liigher plasma concentrations of LH, and T, and 
lower levels of FSH and SHBG than tlieir weight-matched controls (Table 4-1V) who were sampled 
between days 5 and 8 of their menstrual cycle. This resulted in increases in LH;FSH ratios and in FAI 
respectively. Basal plasma concentrations of 17oc-OHP, DHEA-S, E^ , P, PRL and thyroid fimction tests
were similar in tlie patients and the contiols (Table 4-ÎV).
In the patient group a liighLH (>I0.0 lU/L; mean ± ISD of control group) was found in 47.6%, LHiFSH 
ratio was >2 in 48.8%, T was >2.5 nmol/L (mean ± ISD of control group) in only 24.4 %, while 53.7% 
had a high FAI (> 4.5; mean ± ISD of control group). In comparison, 2 controls (10.5%) had a high LH 
and LHrFSH ratio while 15.8% (3) had T >2.5 nmol/L and 26.3 % (5) had FAI > 4.5.
The results suggested that the patients had lower FSH levels than those obtained in the early follicular 
phase of normally ovulating women (Table 4-IV), but tlie difference was not statistically significant.
Although 4 patients had clinically demonstrated galactorrhoea, only one had a liigh PRL level 
(I645mIU/L).
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Table 4-IV : Endocrine Results for the Patients and the Controls
Patients Control P
E^(pg^niL) 59.09 ± 31 .54 65.00 ±34.20 NS
LH (1U /L) 10.02 ± 5 .30 5.25 ± 4.39 0.0012
FSH (IU /L ) 4.95 ±  1.29 5.15 ±1.73 NS
LH : FSH ratio 2.05 ± 1 .05 1.07 ± 0.80 0.0007
T ( luuol/L ) 2 .2 7 ± 1 .1 0 1.53 ±0.93 0.0132
SHBG ( nmol/I. ) 47.57 ± 24 .28 62.53 ±25.77 0.0336
FAI* 5.57 ± 4 .16 2.62 ±  1.78 0.0061
P ( ng/niL ) Follicular. 0.719 ± 0 .48 1 .1 4 ± i.6 7 NS
P ( iig/mL ) Luteal 6.89 ± 6.23 12.20 ±7.16 0.0067
A ( lunol/L )* 8.09 ± 4 .36 6.13 ±2.85 0.0795
I7«:-OHP ( luuol/L ) 1.44 ± 0 .76 1 .48±1.14 NS
DHEA-S ( umol/L ) 1971.2 ±1306.6 2126.0 ±  1788.0 NS
PR L(m U /L) 291.12 ±240.03 424.30 ±519.60 NS
T4 ( muol/L ) 114.92 ±25.035 109.70 ± 19.29 NS
T3 ( nmol/L ) 144.15 ±26.976 140.10 ± 29.59 NS
FT4 14.36 ±3 .55 14.42 ± 2 .32 NS
Groups were compared using Student's t-test, except for values witli (*) where Mann-Wliitney 
nonparanietric test was used for comparison. Piogesterone was estimated only for tliose patients 
(n=17) and controls (ii=19) who ovulated at follicular and luteal phases. NS means P ^ 0.05.
The correlations of the basal endocrine profiles in all subjects are shown in Figures 4.2 - 4.4. In the 
patients, the LH was not correlated to T or FAI, but there was a weak correlation witli FSH (Figure 4.3). 
There was a tendency for FSH to rise with increased severity of high LH. There was also a weak 
negative correlation between the patients' T concentrations and FSH levels in both study groups (Figure 
4.4), wliich could be related to some follicular activity contributed by those individuals who ovulated.
Figure 4.2 :
Correlation : % and Testosterone in Patients 
and Controls
200-1 1-= 0.11, P = 0.48 (PI) 
r = 0.50, P -  0.0284 (CTRL)
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Figure 4.3
Figure 4.4
CoiTelation : LH and FSH in Patients and 
Controls
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There were no differences in the mean basal values of T and FAI between the group of patients who had 
liigh LH (> 10.0 lU/L) and those wdtli normal basal LH concentrations 10.0 lU/L) (Table 4-V).
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Table 4-V : Mean Basal T and FAI in Patients with Normal/High Basal LH 
Concentrations
N o n n a l LH H igh LH P
T (nmol/L) (n = 20) 2,08 +  0.64 (n — 22) 2,46 ±  1.36 NS
FAI (n = 2I) 5.71 ± 4 .7 6 (11 = 21) 5,42 ±3.45 NS
4,3.2 RELATIONSHIP WITH CLINICAL PRESENTATION
The relationship between the presenting clinical symptoms and the endocrine profiles are showm in 
Tables 4-Vïa and 4-VIb. Patients who presented witli prolonged histoiy of menstrual disturbance, 
oligomenonhoea since menarche, were found to have lower levels of FSH than those whose menstrual 
irregularity started later (P = 0.0325). Women with DUB were found to have lower basal levels of
tlian otlier study subjects (P = 0.0228).
Table 4-Vla shows that patients presenting with amenorrhoea had significantly lower plasma
concentrations than tliose with oligomenonhoea (P = 0.0458) but LH, FSH, LHiFSH, T, SHBG and FAI 
were not statistically different.
Androgenized and virilized patients showed higher mean concentrations of LH, FSH, T, LH:FSH and 
FAIs, and lower levels of E^  and SHBG compaied with the rest of tlie study group, but tliese differences
were not statistically significant.
Patients with primary infertility had significantly higher SHBG (P = 0.0313), and significantly lower 
FAIs (P = 0.0267), than those witli secondaiy infertility. This finding could be due to weight changes 
although their BMI and WHR were similar.
Table 4-VIa : The Relationship beriveen the Presenting Symptoms and the Endocrine Profiles
Presenting symptom Prevalence Hormone concentrations in Patients
n & ( % ) ^2 (pg/niL) LH(IU/L) FSH(IU/L) LH : FSH
Oligo.since menarche 18(42.9) 55.29±26,13 9.73+3.42 4.60+0.86* 2.17+0,82
Otlier Oligo/amenonh. 24 (57.1) 63.80±35.52 10.65+6.15 5.35+1.33* 2.04+1,17
Hirsutism 27 (64,3) 57,87±31.36 10,13+5.11 4.99+1.29 2,06+0,95
No hirsutism 15 (35.7) 62,14±33.81 9.79+5.84 4.89+1,32 2,02+1.27
Virilized 13(31.0) 57.69±35.68 10.96+4.17 5,43+1.32 2.07+0,80
No virilization 29(69.1) 60,09+30.59 9,57+5.76 4.73+1.23 2,04+1,17
DUB 5(11.9) 45,00+38.66* 9.20+2,95 5.07+1.23 1,85+0,62
No DUB 37 (88.1) 61.32±33,44* 10.13+5.57 4,94+1,31 2.07+1.10
Oligomenorrhoea 35 (83.3) 62.72+32,57* 10.54+5.32 4.90+1.16 2.19+1.05
Amenorrhoea 7(16,7) 42,86+23,47* 7.44+4.75 5.21+1,88 1.33+0.76
1° infertility 28 (66,7) 61.20+31.10 9.94+5.05 5,05+1.34 2.01+1.04
2iid ijifertility 14 (33.3) 55.71+34.17 10.15+5.94 4.77+1.21 2.12+1.12
Tlie groups were compared usiiig Student's t-test, where (*) indicates significant P< 0.05.
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Table 4-VIb : The Relationship between the Presenting Symptoms and the Endocrine 
Profiles
Presenting symptom Prevalence Hormone concentrations in Patients
n & ( % ) T (mnol/L) SHBG (nmol/L) FAI
Oligo.since menarche 18(42.9) 2.30+0.97 42.47+21.89 5.94+2.70
Other Oligo. 24(57.1) 2.30+1.20 51.41+26.23 5.43+5.05
Hirsutism 27(64.3) 2.44+1.23 44.57+23,62 5,66+3.43
No hirsutism 15 (35.7) 1.95+0.73 53.36+25.39 5.40+5.45
Virilized 13(31.0) 2.32+1.11 47.69+24.57 5,69+3,29
No virilization 29(69.1) 2.25+1.11 47.52+24,60 5.51+4.56
DUB 5(11.9) 1.53+0.58 45.80+33.93 4.43+2.61
No DUB 37 (88.1) 2.38+1.12 47.82+23.28 5.73+4.33
Oligomenorrhoea 35 (83.3) 2.36+1.15 49.23+23.33 5.70+4.38
Attieuorrhoea 7(16.7) 1.83+0.67 39.50+29,09 4,95+3.04
H infertility 28 (66.7) 2.22+0.70 52.61+26.47* 4.56+2.99*
2"^ infertility 14 (33.3) 2.56+1.61 37,86+16.09* 7.52+5.39*
The groups were compared using Student's t-test, where (*) indicates significant P< 0.05.
4.3.3 RELATIONSHIP BETWEEN ENDOCRINE AND ANTHROPOMETRIC 
VARIABLES
4.3.3.I. BMI
The subgrouping for BMI is arbitrary, therefore the results may be highly dependent on tlie limits 
applied. Accordingly, to examine the effect of excess weight, results were analyzed with a cut-off point
of BMI equals 25 Kg/m  ^ indicating oveiweighl (subgroups < 25, > 25 Kg/m),  and the same analyses
2were repeated with BMI equals 29 Kg/m to indicate the obese patients and controls (subgroups < 29, > 
29 K g/n i\
The major endocrine impact of obesity is shown in Tables 4-VIIa and 4-VIIb.
Patients :
Plasma levels of E^ , LH, LH:FSH ratio, tlie levels of 17oc-OHP, and DHEA-S were similai’ in lean and
obese patients (Table 4-VIIa). Plasma concentrations of FSH, SHBG, and PRL were significantly lower, 
and those of T and the FAI were both significantly liigher in obese than in lean patients. The differences 
were less significant when the higher BMI cut-off point was applied.
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Table 4-VIIa ; The Impact of BMI on the Endocrine Profiles of the Patients
<25 ^25 P <29 ^ 9 P
11 18 24 25 17
(pg/niL) 58.89 59.67 NS 60.10 58.13 NS
LH(IU/L) 10.24 9.84 NS 9.94 10.13 NS
FSH(IU/L) 5.64 4.42 0.003 5.28 4.45 0.024
LH:FSFI ratio 1,78 2,26 NS 1.86 2.34 NS
T (nmol/L) 1,86 2,60 0.0189 1.97 2.75 0,049
A (nmol/L) 7,38 9.15 NS
SHBG (lunol/L) 59.78 38,02 0.0028 54.82 36.25 0,013
FAI 3.57 7.13 0.0026 3.60 8,65 0,0004
17oc-OHP (nmol/L) 1.42 1.46 NS 1.44 1,45 NS
DHEA-S (umol/L) 836.14 2297.83 0.004 1886.80 2103,1 NS
PRL (niU/L) 381.94 220.04 0.059 343.76 208,88 0.034
Tlie groups were compared using Student's t-test. P < 0.05 is significant
Controls :
BMI showed a significantly negative impact on SHBG (Table 4-VIIb), and consequently a higher FAI in 
obese compared to lean controls. Otlier honnones showed no significant association witli obesity.
Table 4-VlIb : The Impact of BMI on the Endocrine Profiles of the Controls
<25 ^ 5 P <29 ^ 9 P
11 10 9 12 7
Ej (pg/mL) 62,25 65.00 NS 67,50 57.81 NS
LH(IU/L) 4.60 6.04 NS 4.83 6.04 NS
FSH (lU/L) 4.78 5.51 NS 4.82 5.63 NS
LH:FSH ratio 0.95 1.22 NS 1,00 1.20 NS
T (mnoI/L) 1.24 1.92 0.099 1.39 1.86 NS
A (nmol/L) 6.24 5.87 NS
SHBG (nmoLL) 75.60 45.20 0,0072 73.58 40.63 0.0037
FAI 2.06 4.71 0,0483 2.26 5,07 0.0765
17oc-OHP (nmol/L) 1.54 1,34 NS 1.59 1,21 NS
DHEA-S (umol/L) 1620.0 2570.0 NS 1841.67 2475.0 NS
PRL(mU/L) 462.30 362.40 NS 414.42 409,25 NS
Tlie groups were compared using Student's t-test, P < 0.05 is significant
4.3.3.2 WHR
Similarly, the impact of WHR on tlie endocrine profiles is shown in Tables 4-VIIIa and 4-VIIIb.
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Patients :
Basal LH, FSH, LH:FSH ratio, T, A, 17oc-OHP and PRL levels were similar for patients witli WHR
< 0.8 and tliose witli WHR > 0.8 (Table 4-VIIIa). The levels of SHBG, were related to WHR. The 
difference between the mean values of SHBG for patients with WHR <0.8 compared to tliose ivith WHR 
> 0.8 was highly significant (P = 0.0014). Consequently, similar findings were obseived for FAI (P = 
0.0006) and the levels of DHEA-S (P = 0.0212).
Table 4-Vnia : The Impact of WHR on the Endocrine Profiles of the 
Patients
< 0 . 8 > 0 . 8 P
n 8 34
Ej (pg/mL) 60,94 + 27.74 58.94 + 33.16 NS
LH (lU/L) 7.96+ 5,74 10,51+5.15 NS
FSH (iU/L) 5,51+1.41 4.82+ 1,24 NS
LH;FSH ratio 1.48+0.87 2.19+1,06 0,0876
T (mnol/L) 1.78+0,67 2,39+1,15 NS
A (nmol/L) 7.90+5,48 8.13+4,14 NS
SHBG (nmol/L) 71.0+25,98 41.89+20.47 0,0014
FAI 2.72+ 1,61 6.26+ 4,30 0.0006
17«-OHP (nniol/l.) 1.05+0,31 1,54+0.81 NS
DHEA-S (umoI/L) 1293,8 +  689,95 2135.5 +1373.77 0.0212
PRL(mU/L) 453.75+493.74 251.69 + 102.37 NS
The groups were compared using Student's t-test. P < 0.05 is significant
Controls :
There was no statistically significant difference in E^ , LH, FSH, LHiFSH ratio, 17oc-OHP, DHEA-S and
PRL between controls with WHR < 0,8 and tliose with WHR > 0.8 (Table 4-VHIb), Testosterone levels 
and FAI were significantly liigher, and SHBG levels were significantly lower in controls with larger 
WHR tlian in those with smaller WHR.
Table 4-VlHb : The Impact of WHR on the Endocrine Profiles of the 
Controls
< 0 . 8 S 0 . 8 P
n 11 8
Ej (pg/mL) 57,73+23.60 70,83+43.80 NS
LH(IU/L) 4.97+5,18 5.74+3.12 NS
FSH (lU/L) 5.52+ 1.93 4.68+ 1,29 NS
LH:FSH ratio 0.93+0.89 1,27+0,62 NS
T(nmol/L) 1.02+0.51 2.26+0.88 0.001
A (mnol/L) 5.40+2.34 7.07+3.18 NS
SHBG (nmol/L) 72.73+27.54 45.33+ 17.23 0.0184
FAI 1.62+ 1.17 5.54+3.14 0.0061
17oc-OHP (nmol/L) 1.26+1,24 1.66+0.99 NS
DHEA-S (umol/L) 1718.2+ 1098,9 2555,6+ 2301.7 NS
PRL(mU/L) 427,46+ 649,9 393.89+ 292.5 NS
The groups were compared using Student's t-test. P < 0.05 is significant
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4.3.3.3 Comparison of Patients and Controls with Respect to the Influence of 
Obesity
BM I:
Basal plasma levels of E^ , FSH, 17oc-OHP, DHEA-S and PRL did not show any statistically significant
difference when patients were compared to the control group of similar BMI (Tables 4-IXa and 4-IXb). 
However, the levels of LH and the LH:FSH ratio were significantly higher when comparing the patients 
to tlie controls for all BMI subgroupings. Testosterone and FAI mean values were increased, and SHBG
values were decreased for both the overweight (^ 25 Kg/m^) and the obese (> 29 Kg/m^) individuals 
compared to the lean patients and controls. However, the differences in T and SHBG concentrations
reached statistical significance only when comparing the lean patients to the lean controls for both the
2cut-off points of BMI < 25, as well as < 29 Kg/m (data in table). The differences did not reach statistical
significance comparing the patients to the controls for the higher BMI of ^  25 and > 29 Kgjm,  (Tables 
4-IXa and 4-IXb).
Luteinizing hormone levels were found to be equivalent in obese and lean patients as well as in the 
control group. However, when comparing patients to controls of matched BMI, the differences were 
significant for all BMI ranges (Tables 4-IXa and 4-IXb ).
Table 4-IXa : The Impact of Ovei*weight on the Endocrine Profiles of the Patients in Comparison 
to the Controls
PT(<25) CTRL (< 25) P PT (> 25) CTRL (>r 25) P
n 18 10 24 9
E^(pg/mL) 58.89 62,25 NS 59.67 65.00 NS
LH (lU/L) 10.24 4.60 0.022 9.84 6.04 0,024
FSH (lU/L) 5.64 4.78 NS 4,42 5.51 NS
LHrFSH ratio 1.78 0.95 0.044 2.26 1.22 0,006
T (nmol/L) 1.86 1.24 0,021 2.60 1,92 NS
SHBG (nmol/L) 59.78 75.60 NS 38.02 45,20 NS
FAI 3.57 2.06 0.094 7.13 4.71 NS
17oc-OHP (nmol/L) 1.42 1.54 NS 1.46 1,34 NS
DHEA-S (umol/L) 836.14 1620.0 NS 2297.83 2570.0 NS
PRL(mU/L) 381.94 462.30 NS 220.04 362.40 NS
Tlie groups were compared using Student's t-test. P < 0.05 is significant
108
Table 4-IXb : The Impact of Obesity on the Endocrine Profiles of the Patients in Comparison to 
the Controls
PT «  29) CTRL (< 29) P PT (> 29) CTRL (>29) P
u 25 12 17 7
Ej (pg/nïL) 60.10 67.50 NS 58.13 57.81 NS
LH (lU/L) 9.94 4.83 0.017 10.13 6.04 0.014
FSH (HJ/L) 5.28 4.82 NS 4.45 5.63 NS
LH:FSH ratio 1.86 1.00 0.026 2.34 1.20 0.004
T (umol/L) 1.97 1.39 0.033 2.75 1.86 NS
A (nmol/L) 7.38 6.24 NS 9.15 5.87 NS
SHBG (nmol/L) 54.82 73.58 0.036 36.25 40.63 NS
FAI 3.60 2.26 0.082 8.65 5.07 0.068
I7c3c-OHP (nmol/L) 1.44 1.59 NS 1.45 1.21 NS
DHEA-S (umol/L) 1886.8 1841.7 NS 2103.13 2475.0 NS
PRL (niU/L) 343.76 414.41 NS 208.88 409.25 NS
Tlie groups were compared using Student's t-test. P < 0.05 is significant
The correlations between BMI and T, SHBG and FAI in botli groups of patients and controls are 
demonstrated in Figures 4.5 - 4.7. There was no significant correlation between BMI and T in either 
patients or controls. A significant negative conelation was obseived between BMI and SHBG in botli 
groups wliich was reflected in the FAI.
Tlie two regression lines for patients and controls comparing T and BMI (Figme 4.5), were not 
statistically different (95 % confidence interval for the slope of patients was -0.0155 to 0.1192 and for the 
controls -0.003931 to 0.09174). Therefore, for a imit increase in BMI, SHBG and T responded similarly 
in the patients and in the controls.
Figure 4.5 :
Correlation : T and BMI in Patients and 
Controls
r = 0.29, P = 0.0635 (PI) 
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Figure 4.6
Correlation : SHBG and BMI in Patients and
Controls
1 = - 0.36, P = 0.0203 (PT) 
r = - 0.57, P = 0.0106 (CTRL)
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W HR:
Plasma concentrations of E^ , FSH, , SHBG, FAI, A, 17oc-OHP, DHEA-S and PRL were similar in both
patient and control subgroups of similar WHR (Table 4-X).
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The levels of LH and FAI were liigher in patients than controls with WHR < 0.8 as well as WHR ^ 0.8. 
But tliese levels reached statistical significance only witli tlie higher WHR (Table 4-X ). The LH levels 
and LHiFSH ratio were significantly liigher in the patients than the controls at WHR ^ 0.8 (Table 4-X).
Testosterone levels were not significantly higher in patients than controls witli higher WHR (P = 0.15), 
but were significantly higher in controls with larger WHR than in controls witli smaller WHR (P = 
0.001). When comparing tlie mean value of tlie patients to that of tlie contiols witli similar WHR, the 
difference in T levels reached statistical significance with smaller WHR women only (P = 0.0132 for 
WHR < 0.8 and 0.7403 for WHR > 0.8).
The SHBG levels were influenced by the WHR. The mean values of SHBG for botli patients and controls 
with WHR< 0.8 were significantly higher tlian tliose with WHR > 0.8 (P = 0.0014 and 0.0184, 
respectively). The findings were tlie same for FAI (P = 0.0006, and 0.0061); very significantly higher 
indices being found for both patients and controls witli WHR >0.8.
Table 4-X : The impact of WHR on the Endocrine Profiles of the Patients in Comparison to 
Controls
PT (< 0.8) CTRL(< 0.8) P PT (> 0.8) CTRL(£ 0.8) P
11 8 11 34 8
(pg/mL) 60.94+27.74 57.73+23.60 NS 58.94+33.16 70.83+43.80 NS
LH (lU/L) 7.96L5.74 4.97+5.74 NS 10.51+5.15 5.74+3.12 0.0118
FSH(IU/L) 5.51+1.41 5.52+1,93 NS 4.82+1.24 4.68+1.29 NS
LH:FSH ratio 1.48±0.87 0.93+0.89 NS 2.19+1.06 1.27+0.62 0.0177
T (nmoI/L) 1.78+0.67 1.02+0,51 0.0132 2.39+1.15 2.26+0.88 NS
A (muol/L) 7.90+5.48 5.40+2.34 NS 8.13+4.14 7.07+3.18 NS
SHBG (nnioFL) 71.0+25.98 72.73+27.54 NS 41.89+20.47 45.33+17.23 NS
FAI 2.72+1.61 1.62+1.17 NS 6.26+4.30 5.54+3.14 NS
17oc-OHP (nmol/L) 1.05+0.31 1.26+1.24 NS 1.54+0.81 1.66+0.99 NS
DHEA-S (umol/L) 1293.8+690.0 718.2+1098.9 NS 2135.5+1373.8 555.6+2301.69 NS
PRL(mU/L) 453.75+493.7 427.46+649.9 NS 251.697+102.4 393.89+292.5 NS
The groups were compared using Shident's t-test. P < 0.05 is significant
Weak but significant correlations were obseived between SHBG, and PRL and WHR of tlie patients (r = - 
0.36, P = 0.0179; r = -0.31, P = 0.0484, respectively) (Figures 4.9 and 4.11). The significant correlation 
between PRL and WHR was due to one veiy high PRL value in a patient with a low WHR, which was 
lost when tins patient was excluded (P = NS).
For the contiol group, the negative correlation between WHR and SHBG was tighter and more 
significant (r = -0.61, P = 0.0052) as shown in Figure 4.9, and significant positive correlations between
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T, and FAI and WHR (r = 0.64, P = 0,003; r = 0.78, P < 0.0001, respectively; Figures 4.8 and 4.10) were 
also obseived.
Figure 4.8
Figure 4.9
Correlatiou : T and WHR in Patients and 
Controls
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Figure 4.10
Figure 4.11
Correlation : FAI and WHR in Patients and
Controls
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4.4 ULTRASONOGRAPHIC OBSERVATIONS
4.4.1 BASAL OVARIAN SCAN OBSERVATIONS
C o n t r o l  D a t a  :
Unfortunately, there was no US examination for tlie control group because of their reluctance to 
volunteer for the examination. The mean (± SD) ovarian volmne for normal subjects was taken from
published reference ranges as 5.2 ± 1.9 cm (Yeh et al 1987) and 5.4 ± 1.6 cm (Poison et al 1988; 
Franks, 1989). The cut-off point of normal ovarian volume, in this study, was considered to be 2 SD
above the mean normal ovarian volume, tliat is 9.0 cm .^ Therefore, the ovary was considered enlarged in
patients when the volume was greater than 9.0 cm .^
P a t i e n t  D a t a  :
The US scanning was always effected > 14 days after the first day of the last menstrual period. The mean
ovarian volimie for oligo/amenorrhoeic patients was 9.36 cm ,^ while tlie mean of TOV was 18.73 cm  ^
(Table 4-XI).
Table 4-XI ; The Ovarian Volume in Patients
3mean ±  SD ( cm ) range (cm  )
No. o f Patients 42
Rt. ovary 9.58 ± 6.33 1.09 - 31.54
Lt. ovarj' 9 .13+  5.55 1.83 - 27.30
TOV 18.73+ 8.88 2.92 - 40.50
Ovarian Volume (mean Rt./Lt.) 9.36 ±  4.44 1.09 - 29.42
Two out of 42 patients showed normal US ovarian picture, while the rest (n = 40) satisfied the criteria of 
"PCO" US (Chapter Three). Therefore, the following analyses included those patients with "PCO" US 
diagnosis only (40 patients).
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Table 4-XII : The Ovarian Volume in "PCO" Patients
mean ±  SD ( cm ) range ( cm )
No. o f Patients 40
Rt. ovary 9.79 ±  6.26 1.48 - 31.54
Lt. ovary 9.34 ±  5.46 2,13 - 27.30
TOV 19.15+ 8.57 4.60 - 40.50
Ovarian volume (mean Rt./Lt.) 9.57 ±  4.29 2.32 - 20.24
There was heterogeneity within subjects, as 10 patients (24.4%) showed one ovaiy less than 50% of tlie 
size of the other, and this general finding resulted in there being no relationship between Rt. and Lt. 
ovaiian volumes (Figure 4.12). This is a remarkable observation showing the dynamic nature of the 
organ, even in tlie relatively stable conditions of oligo and amenorrhoea.
Figure 4.12 ;
Corixilation : Rt :md Lt Ovarian Volume in 
Patients
40-1
r =  0.11, P =0.48
•  • •
0 5 IS10 20 25 30 35 40
Rt Ovarian Volume ( cm )
Twenty two (55%) of patients had at least one ovaiy of a volume >9. 0 cnf, and only 40% had botli 
ovaries > 9.0 cn f. The basal US ovarian characteristics of tlie patients are shown in Table 4-XIII. The 
mean number of ovarian follicles ( 2 - 8  mm) was 11.68 ± 2.55 (range 5 - 2 0  follicles) on the right ovaiy,
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and 12.61 ± 3.81 (range 6 - 3 0  follicles) on the left ovaiy (Table 4-XIII). Ovarian follicles were 
peripherally distiibnted in only 46 ovaiies (56.1 %), while tlie rest showed central distribution.
Table 4-X in ; Ultrasonographic Ovarian Characteristics
Rt. Ovary Lt. Ovary P
No. o f Patients 40 40
Ovarian Volume (cm ) 9.58 + 6 .33 (1 .09 -31 .54 ) 9,13 + 5 .55 (0 .83 -27 .30 ) NS
No. o f Follicles (2-8 mm) 1 1 .6 8 + 2 .5 5 (5 -2 0 ) 12.61± 3.81 ( 6 - 3 0 ) NS
The groups were compared using Student's t-test. P > 0.05 is NS
All 40 PCO patients (95.2 %) had at least 10 follicles ( 2 - 8  mm in diameter) in one section on one ovai>^ , 
and bilaterally in 36 patients (85.7%). Also 40 patients (95.2 %) showed tliick (dense) stroma in at least 
one ovary, wliile 32 patients (80.0 %) had an increased amount of stroma in both ovaries.
The US ovarian characteristics and a comparison between "unilateral PCO" with "bilateral PCO" are 
shown in Table 4-XIVa and 4-XIVb. The mean ovarian volume and TOV was significantly larger in the 
patients with bilateral PCO than those witli miilateral PCO diagnosis. The number of follicles was 
higher with bilateral PCO than unilateral PCO (P = 0,0127) but the distribution of the follicles was 
similar (Table 4-XIVb). However, this observation could be masked by the small size of the imilateral 
PCO sample.
Table 4-XIVa : Ultrasonographic Ovarian Characteristics 
in Patients
One Ovaiy Botli Ovaries
n ( % ) n ( % )
PCO Diagnosis 8 ( 2 0 ) 3 2( 80 .0)
Follicles >10 40( 95 .2) 3 6( 85 .7)
Tliick Stroma 40 ( 95.2 ) 3 2( 80 .0)
Table 4-XIVb : Comparison between**Unilateral PCO”and“BI[atcral PCO”
Unilateral PCO Bilateral PCO P
No. o f Patients 8 32
Rt. Ovarian Volume 8.09 ± 9 .74 9.94 ± 5 .35 NS
Lt. Ovarian Volume 5.06 ±2.41 10.12 ± 5 .67 0.019
Mean Ovaiian Volume 6.58 ±5.38 10.03 ± 3 .99 0.048
TOV 13.17± 10.75 20.07 ± 7 .98 0.048
Mean No. o f Follicles 9.25 ±2.38 12.67 ± 2 .61 0,0127
Peripheral Follicular Distribution 2 15
Central Follicular Distribution 3 8
Mixed Follicular Distribution 3 9
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4,4,2 CORRELATION 
PRESENTATION
OF OVARIAN VOLUME WITH CLINICAL
Women witli large ovarian volumes (>9.0 cm ) were more commonly presented witli oligomenorrhoea 
tlian with amenorrhoea but tlie difference was not statistically significant (P = 0.0931). The duration of 
menstrual irregularity, the presence of DUB, androgenization and/or virilization were not associated with 
ovarian volume.
There was no significant correlation between TOV, tlie presence of a tliick ovarian stroma and the 
duration of infertility, androgenization or virilization. There was no correlation between tlie clinical 
presentation and the presence of unilateral or bilateral polycystic ovaries diagnosed by US scaiming. 
However, patients witli unilateral tliick stroma were found to have longer periods of amenorrhoea than 
those witli bilateral changes (ranges 14-18 vs 5-12 weeks, respectively; P = 0.0395).
4,4,3 CORRELATION OF OVARIAN VOLUME WITH ANTHROPOMETRIC 
VARIABLES
For the purpose of comparisons between patients with different BMI and WHR, the mean ovarian 
volumes were used. There was no relationship between the mean ovarian volume, and the BMI and 
WHR as shown in Table 4-XV and Figures 4.13 and 4.14.
Table 4-XV 
Patients
The Correlation betiveen BMI, WHR & Ovarian Volumes in the
OV.VOLUME < 9.0 cni^ OV.VOLUME > 9.0 cm^ Total
11 (%) mean ±  SD n (%) mcan± SD
BMI < 25 10 (23.8) 5.58 ± 2 .58 7(16.7) 12.64±3.79 17
BMI > 25 12 (28.6) 6.69 ± 2 .09 13(30.9) 12.94±3.21 25
BMI < 29 13(31.0) 6.04 ± 2.43 9(21.4) 1I.46±3.38 22
BMI S:29 8 (19.0) 6.05 ± 2 .20 12(28.6) 13.10±3.33 20
WHR < 0.8 6 (14.3) 6.10 ± 2 .42 2 (4.8) 9.78 ± 0 .17 8
WHR > 0.8 15(35.7) 6.02 ± 2 .32 19(45.2) 13.18±0.79 34
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Figure 4.13 :
Figure 4.14 :
Correlation : Basal TOV and BMI in Patients
r = 0.26, P -  0.1
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4,4,4 CORmLATION OF OVARIAN VOLUME WITH ENDOCRINE RESULTS
The endocrine variables were also correlated with tlie TOV. There was no correlation between tlie TOV 
and the endocrine profiles (Table 4-XVI). Although tlie basal levels of E^ , LH, LH:FSH, T, and SHBG
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were higher in patients witli larger ovarian volumes (> 9.0 cm ), tlie differences were not significant. 
Patients with larger ovarian volume (> 9.0 cm ) showed lower levels of FSH, FAI, 17qc-0HP, PRL and 
DHEA-S but the differences were not statistically significant.
Peripheral distiibution of tlie ovaiian follicles was shown to be associated with higher ovarian volume, 
BMI, WHR, E^ , LH, FSH, LH:FSH, T, FA 
concentrations but no difference was significant.
I, 17oc-OHP, DHEA-S, and lower SHBG and PRL
Patients with imilateral PCO had higher levels of basal E^ , LH, FSH,T, SHBG and FAI tlian tliose with 
bilateral PCO but none of tliese differences was significant.
The coiTelations between the endocrine, anthropometric parameters and the TOV are also shown in 
Table 4-XVI.
Table 4-XVI : Correlations between Endocrine and Anthropometric Parameters 
and TOV
r SLOPE P
TO V/BM I 0.257 -0.05460 to 0.5237 NS
TOV/W HR 0.112 -0.2030 to 0.4055 NS
TOV / E2 0.125 -0.2076 to 0.4315 NS
TO V / LH 0.161 -0,1717 to 0.4614 NS
TO V/FSH 0.083 -0.2478 to 0.3964 NS
TOV/LH:FSH 0.179 -0.1536 to 0.4758 NS
T O V /T 0.075 -0.2935 to 0.4237 NS
TO V/SH BG 0.030 -0.3620 to 0.4123 NS
TOV/FAI 0.095 -0.3032 to 0.4657 NS
TOV/IMF) 0.309 -0.0171 to 0.5752 NS
TOV / I70C-OHP 0.264 -0.1374 to 0.5911 NS
TOV/PRL 0.267 -0.5634 to 0.09005 NS
TOV/DHEA-S 0.097 -0.4981 to 0.3388 NS
4.5 DISCUSSION
Polycystic ovarian disease is characterized by heterogeneous clinical and endocrine features. The 
controversy and uncertainty about its aetiology, has attiacted nmnerous publications. It has been shown 
that most women diagnosed as PCOD had menstrual disorders and/or hirsutism, but there were patients 
who were non-hirsute and others who showed evidence of ovulation (Goldzieher & Green, 1962; 
Goldzieher & Axelrod, 1963; Yen, 1980).
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Clinical Findings
None of the study patients had evidence of an androgen-secreting tumour, Cushing's syndrome, CAH or 
thyroid disease. All tlie women of the control group considered themselves to be normal witli regular 
menstrual rhytlun, and had not found it necessaiy to consult a doctor for menstrual disturbance, 
infertility or liirsutism.
M e n s t r u a l  D i s o r d e r s  a n d  E n d o c r i n o l o g y
In this study, only 42.9 % of women with oligo/amenonhoea (PCOD) had all tlie classical signs of the 
disorder as described by Stein & Leventlial (1935), namely oligomenorrhoea, liirsutism and obesity. 
Hirsutism prevalence was comparable to the findings reported in the literature for patients with PCO 
(Franks, 1989; Holte et al 1994c). However, the presence of oligomenorrhoea and DUB were more, and 
amenonhoea was less prevalent in the patient group probably due to the inclusion criteria.
In tlie present study, the mean basal plasma Ez concentration was similai* in the patients and tlie controls, 
but significantly lower in patients with DUB than those without DUB (P = 0.0228). The effects of 
“imopposed” oestrogen (tliat is, without the “protective” effect of progesterone) on the uterus are thought 
to account for endometrial hyperplasia and DUB in anovulatory women with PCO. However, the uterus 
is larger and die endometrium is thicker tiian normal even in oWating women wiüi PCO (Adams el al
1988). Therefore, it is difficult to explain these findings on die basis of unopposed oestrogen (Franks,
1989). It has been reported diat die concentrations of free, non-bomid E^  is elevated in women with PCO
despite normal total E^  concentrations (Lobo et al 1981; Lobo, 1988) because of either the androgen- 
induced decrease in SHBG and/or the inhibition of binding by die excess androgens (Lobo & 
Goebelsmami, 1982). However, Poison et a l (1987) were unable to find any significant increase in die 
absolute concentration of free E_ in serum.
H i r s u t i s m  a n d  E n d o c r i n o l o g y
There were no differences in endocrine profiles between women with hirsutism and those without, 
coinciding with findings of other observers (Franks, 1989). Both gioups had raised seimn concentrations
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of T and the mean concentrations were slightly higher in tlie hirsute than in the non-liirsiite women; 
however, tliese differences did not reach statistical significance (hirsute : 2.44 ± 1.23 nmol/L; non-hirsute 
: 1.95 ± 0.73 imiol/L). In hirsute patients the conelation of the serum T with the degree of liirsutism is 
poor, a mmiber of hirsute patients having normal levels of senim T (Franks, 1989). Some hirsute women 
with a normal serum T concentration have an increased T production rate and therefore an increased 
MCR. The higher incidence of liirsutism in tlie obese women may be explained by reduced SHBG 
causing increased free androgen in peripheral tissues in obese subjects (Franks, 1989).
G a l a c t o r r h o e a  a n d  H y p e r p r o l a c t i n a e m i a
Although galactorrhoea was observed in 9.5% of the patients, hyperprolactinaemia was an infrequent 
observation (2.4%), compared to the 7% reported by Franks (1989). An interrelationship between 
hyperprolactinaemia and PCOD is complex. Some patients with PRL-secreting pituitary tumours have 
liirsutism as well as amenoiThoea (Franks, 1989). Women with hyperprolactinaemic amenorrhoea are 
known to be associated ivith the findings of PCOD (Yen, 1980). Elevation of PRL could be due to 
increased serum concentrations of Ei or the unopposed action of oestrogen on the pituitary (McKenna,
1988) as well as increased free oestrogen (i.e. normal oestrogen ivith decreased SHBG). The 
insignificant observation of hyperprolactinaemia in this study could be due to the selection criteria but 
whatever the association between elevated PRL and PCO, PRL is not a major contributing factor in the 
patients investigated in tliis study.
Endocrine Findings
When radioiimnunoassay became widely available in the early 1970's, a great reliance was put on the use 
of biochemical markers of "the syndrome" rather than tlie liistological appearance. The major problem is 
that tliere is no universal agreement on the biochemical definition of PCOD (Franks, 1989).
L H
In this study, significantly liigher LH concentrations were observed in tlie patients with 
oligo/amenorrhoea than in tlie contiol group (P = 0.0012). Twenty patients (47.6%) were found to have 
high basal LH levels greater tlian 1 SD above the mean of the normal control gioup (> 10.0 lU/L). Yen
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(1980) reported that about 10% of women with PCOD had normal LH concentrations. An LH level of >
10.0 lU/L was acceptably specific to diagnose PCOD (Yen, 1980; Eden, 1988; Eden et al 1989c) witli a 
sensitivity of 53% (Eden & Place, 1989). However, a higher cut-off point has been described in the 
literature - > 11.1 lU/L (Franks, 1989). If this was applied here, only 29.3% would satisfy this criterion 
which might question the exclusion of PCOD diagnosis based on a single LH concentration. The cut-off 
normal value applied depends very much on tlie assay used. Modern assays (monoclonal antibody 
assays) are more specific and give lower levels than those obtained witli previous (polyclonal antibody 
assays) assays.
It has been reported that some women with all the other clinical and biochemical features of PCOD had 
normal senun LH concentrations (Givens et al 1976) at tlie time of sampling. It is therefore, important 
to sample patients in the early follicular phase to avoid the confusion of the LH surge (Eden et al 1989c). 
Furtliermore, a high concentrations of LH during the follicular phase was found to have a dramatic effect 
on the success rate of induction of ovulation and the conception outcome and it may cause early 
pregnancy loss (Homburg et al 1988).
A weak but significant correlation (r = 0.33, P = 0.036) was found between LH and FSH. A similar 
observation was reported by Eden et a l (1988; 1989c). The LH:FSH ratio > 2 was foimd in less tlian half 
of tlie patients. TWs supports tlie statement that the LH:FSH ratio has a relatively poor ability to 
diagnose the PCOD.
FSH
The results in tliis study, showed that basal FSH concentrations were similar in patients and controls. 
This observation does not agree with those reported by Yen et a l (1970b) which showed higher values in 
normally ovulating women than in anovulatory women with PCOD during tlie first eight days of the 
follicular phase. Although it was suggested that subnoimal FSH levels might contribute to anovulation 
in the PCOD, given the high effectiveness of exogenous FSH in inducing oWation in these women (Yen, 
1980; Franks, 1989), most studies liave failed to confirm lower levels of FSH in women with PCOD than 
in controls (Duignan et al 1975; Dunaif et al 1988; Conway et al 1989; Franks, 1989). The presence of 
similar E^  and FSH concentrations in patients and controls could mean that there is no impairment of
FSH release and therefore FSH probably is not the main cause of anovulation in PCOD as suggested by 
Chang et a l (1982). The relationsliip between FSH concentration and the occurrence of spontaneous
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ovulation in tlie group of patients rvitli oligo/amenonlioea, will be discussed in Chapter Six. Patients 
witli oligomenorrhoea since menarclie had lower FSH concentrations (P = 0.0451) tlian other 
oligomenorrhoea patients which could be related to the degree of chronicitj' of the disorder. However, 
tire results in some studies may be affected by small samples or because the timing of the blood sampling 
in controls was not restricted to tire early follicular phase.
A n d r o g e n s  a n d  S H B G
The mean concentrations of T were significantly higher in the patients than the controls (P = 0.0132). 
Although the T concentration was higher in hirsute patients than those without hirsutism, this difference 
was not significant. Tliis may emphasize the importance of measuring FT, expressed by FAX.
Testosterone concentrations of > 2.5 imiol/L (mean + ISD of the study control subjects) were considered 
abnormal which agreed with other observers (Eden, 1988; Eden et al 1989c). Despite tire raised mean 
serum T concentrations in women with PCO, 75.6% had values winch were in the normal range (< 2.5 
nmol/L) in comparison to half the patients reported by Franks (1989). If the patients were subdivided 
according to whether serum T concentrations were raised or nonnal, LH concentrations were higher in 
tire hyperandrogénie group, although the difference was not statistically significant. On the contrary, 
slightly lower LH values in the hyperandrogénie group were reported (Franks, 1989), but these were still 
nearly twice as high as tire mean LH levels in the controls. On the otlier hand, basal T concentrations 
were similar in the patients with high LH to those patients rvith normal LH concentrations (< 10.0 lU/L). 
In addition, serum T concentrations in tire subgroup with normal LH levels were still sigirificantly 
greater (P = 0.047) than in normal subjects. It seems tirat patients with PCOD show a disorder of 
androgen wlrich is independent of elevated LH concentrations (Fleirring et al 1985).
As is tire case with LH measurements, a random sample of T is not necessarily an accurate reflection of 
androgen secretion but, in contrast to LH, this has less to do with episodic secretion of androgen than the 
fact tlrat a random serum T measurement is an inadequate index of either androgen production by the 
ovary (or adrenal) or of the bioavailability of circrrlating arrdrogen to target tissues (Franks, 1989).
In tiris study no significant correlation was found between T and SHBG; although the reverse has been 
reported (r = - 0.43) (Franks, 1989). Basal concentrations of SHBG were significantly lower in the 
patients tlian the controls (P = 0.0336) which agrees with other reports (Yen, 1980). However, in the 
population of women with PCO reported by Franks in 1989, tire mean and median concentrations of
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SHBG were not significantly different from tliose in normal women in tlie early to mid-follicular phase of 
tire cycle. Sex hormone binding globulin is made by the liver and serum levels fall in tire presence of 
excess androgen, especially T (Anderson, 1974; Carter et al 1983; Cunningham et al 1985). If levels of 
SHBG fall, T will be released and FT will increase. It has been suggested that low SHBG concentrations 
in the serum are a reflection of increased transport of the “biologically active” SHBG-androgen complex 
into the tissues but as yet tliere is no evidence to support this view.
The basal SHBG concentrations showed the most significant and consistent relatioirships with the 
antliropometric parameters in patients and controls, compared with other endocrine variables. Similar 
observations were found with the mean follicular SHBG concentrations (Chapter Six).
The activity of androgen in target tissues is determined by two main factors. The first is tire androgen 
binding capacity in serum of SHBG (Anderson, 1974) and albumin. The second is further metabolism 
of T or A to more potent 5a-reduced products.
In tliis study, F AI was the most serrsitive biochemical criterion for tire diagnosis of PCOD. An abnormal 
F AI was considered if FAI was > 4.5 (mearr + ISD of the control data). A Irigh follicirlar level of FAI > 
4.5 was observed in 53.7% of tire patients. The FAI is useful for detecting the PCOD in 
oligomenorrhoeic women as there appear to be few false positives. A follicular phase FAI > 4.5 shoirld 
be considered as Itiglily suspicious of PCOD (Eden, 1988; Eden et al 1988a; Eden et al 1988b). 
Altlrough an early follicular phase estimation of T and SHBG, to allow tire calculation of FAI, has been 
recommended in the biochemical investigation of the oligomenorrhoeic woman (Eden, 1988) this is 
difircult to apply in clinical practice for patients witlr oligo/amenorrhoea. Adding SHBG and FAI to LH, 
FSH and T gives a better chance of detecting PCOD.
Here, similar basal DHEA-S concentrations were observed in tire patients and the controls. There has 
been a debate over the years as to whether tire source of excess androgen secretion in women mth PCOD 
is tire ovary or tire adrenal. A proportion of subjects with PCOD was found to have elevated 
concentrations of DHEA-S (Yen, 1980), and the high prevalence of PCOs in subjects with CAH due to 
21 OH deficiency (Hague et al 1990) together witlr the occurrence of “PCO-like” features in women with 
Cushing's syndrome suggests tlrat there is a liirk between hypersecretion of adrenal airdrogens and 
PCOD. However, studies of tire family data suggested tlrat the adrenal production defect coirld be 
umelated to tire causes producing PCO changes in tire majorit}^  of cases (Hague et al 1989; Hague et al
1990).
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Ultrasonographic Findings
The availability of the liigh-resolution US scanning, especially with a transvaginal transducer, offered a 
non-invasive method of defining tire typical polycystic morphology of ovaries in women witlr 
reproductive disturbances (Swanson et al 1981; Parisi et al 1984; Adams et al 1985; Adams et al 1986b).
In this study, PCOs were identified in all the patients witlr oligomenorrhoea and 71% of patients witlr 
amenorrhoea. Adams et a l (1986b) were able to identify PCO in 85% of women uith oligomenorrhoea 
aird in 26% of the women with amenorrhoea.
The mearr ovarian volume of patients diagrrosed to have PCO was 9.57 cm ;^ small compared to the 11.6
3 3cm reported by Franks (1989) and tire 15.1 cm reported by Holte et al. (1994c). This could be 
explained by tire difficulty in identifying the follicular phase, hence, variations in timirrg of the scarming 
in oligo/amenorrhoeic patients. The ovaries can be normal in volmne and still polycystic (Givens et al 
1976).
There were no differences in US and biochemical indices between women with Irirsutism (androgerrized) 
and those without. Worrren witlr oligornerrorrhoea had a larger mean ovarian volmrre tlrarr those with 
amenorrhoea, however, this difference was not sigirificant. AbdelGadir et al. (1992b) concluded that 
ovarian size did not indicate the severity of the condition. On tire contrary, patients with the most 
enlarged ovaries were reported to have the most frequent occurTence of amenorrhoea (Puzigaca et al 
1991).
Altlrough US demonstration of bilateral, synmretrically errlarged, globular shaped ovaries has been 
described as a criterion for diagirosis of PCOD (Parisi et al 1984), such evidence was, practically, not 
possible to obtain in this study. A wide spectrum of ovarian sizes was seen in patients with PCOD. The 
TOV showed a wide variation within study patients (1.9 - 40.5 cm )^. Yeh et al. (1987) found normal 
sized ovaries present in PCOD patients. In a considerable nimrber of patients in the present study 
(82.9%), at least one ovary was irormal in size, and botlr ovaries were normal in size in 36.6% . This 
observation was higher tirait that reported by Harm et a l (1984) and by Yeh et a l (1987) - 29% . The
upper linrit of normal ovarian volume was reported to be 7.5 cm ,^ with a mean of 5.2 ±1. 9 cm  ^ , and 
gross asymmetry in size, that is one smaller than 50% of the other, was found in 20.9% in one series 
(Yeh et al 1987). A Irigher incidence was foimd in tire present study, (24.4%). This observation shows 
the dynamic nature of tire ovaries, even in relatively stable conditions such as oligo/amenorrhoea.
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However, the differences in observations may be due to differences in criteria for selection of patients 
and/or in tlie ultiasoimd technology. These obser\ntions will be discussed further in Chapter Six.
Enlargement of the ovaries in PCOD is due to a difluse process, and the ovaries maintain their original 
shape when they enlarge, indicating that tlie shape or tlie RI of the ovaries is of no value in diagnosing 
PCOD (Yeh et al 1987), Because of the considerable variations in the ovarian sizes, the large sized 
ovary is neitlier a sensitive nor a specific criterion for tlie US diagnosis of PCOD. However, the majority 
of ovaries (95.9%) can be seen by means of a real - time scanner (Yeh et al 1987).
The frequency of visualization of follicles ( 2 - 8  nmi) was high in PCOD patients using a real - time 
seamier with high frequency and a vaginal probe. In the present study, follicles (> 10) were seen in 
95.2% of PCOs, with almost equal distribution in the stroma of tlie ovaiy (peripheral or centr al). Yeh et 
al. (1987) reported that the presence of multiple small cysts 8 mm in size) is the most important US 
criterion for tlie diagnosis of PCOD - similar to the developing follicles of healthy individuals but 
increased in number. Transi^aginal US is prefened for visualization of tlie ovarian details, especially in 
obese patients. The study of Adams et al. (1986b) utilizing US had shown tliat PCOs are common in 
oligomenorrhoeic women rvithout hirsutism or obesity.
Tliick stroma was identified in all tlie patients witli oligomenoiriioea and in 71.4% of the patients with 
amenorrhoea. Therefore, tliick stroma was the most sensitive single US criterion to diagnose PCOs. An 
increase in tlie ovarian stroma was added to tlie US criteria. Increased ovarian stroma has been reported 
in the literature as the most sensitive and specific US sign of PCOD (Ardaens et al 1991).
The mean basal ovarian volume in the “high T” group was similar to that in the “normal T”group. Tliis 
finding is in contrast to previous observations tliat androgen production in women with PCO can be 
related to ovaiian volmne (Puzigaca et al\99V).
The prevalence of a unilateral PCO was higher (20%) than reported in the literature (3.7%, (Rojanasakul 
et al 1989)). The group of patients who had a unilateral PCO were observed to have a significantly 
smaller mean basal ovarian volume, TOV and a lesser number of small follicles but follicular distribution 
was not different from tliose witli bilateral PCO ovaries. The clinical presentation, age, BMI, WHR and 
tlie basal endocrine profiles were similar in both groups. It may be argued that bilateral US PCO change 
is not necessaiy to have tlie typical clinical and endocrine criteria of PCOD. These findings are 
confirmed with the longitudinal obseivations in Chapter Six. However, whether patients with a 
miilateral PCO would have a mild degree of tlie disease, have more prevalence of spontaneous ovulation 
and contribute to tlie present confusion of understanding PCOD remain to be studied. Long-term follow-
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up may be necessary to determine whether a patient with a unilateral PCO will develop bilateral disease 
in the futme.
Role of Obesity
Obesity is common in tire study patients (40.5%). A liigher mean BMI was recorded for both the patients 
and controls (28.09, 26.64 Kg/m  ^; respectively) compared to the means reported by Franks (1989) (24.2
Kg/m for patients and 22.0 Kg/m for controls) and by Holte et al. (1994c) (25.7 Kg/m  ^for patients and
225.1 Kg/m for controls). Body mass index had no significant influence on hirsutism, menstrual pattern 
or ovarian volume, similar to findings reported in the literature (Holte et al 1994c). Although there was 
no statistically sigrrificant difference in BMI between patients and controls, the difference in WHR was 
highly significant (P = 0.0023); this is in contrast to the observations of Holte et al. (1994c).
Patients with LH > 10.0 lU/L were foimd to be less obese, witli slightly larger ovarian volume but tlrese 
differences did not reach statistical significance, similar to the findings reported by Franks (1989). The 
differences in LH concentrations were significant when comparing patients to controls for all the BMI 
range (see Table 4 - IXa and IXb), although more noticeable if the cut-off point of BMI was taken as ^ 
29. Therefore, LH levels may be more related to PCOD tlian to BMI. Similar observations have been 
reported by others (Laatikainen et al 1983; Paradisi et al 1986; Anttila et al 1991; Dale et al 1992b). 
Holte et a l  (1994c) showed a negative association between LH and obesity in both patients and normal 
control groups; an effect of obesity, independent of PCOD. Follicle stimulating hormone was 
significantly lower in obese patients tlian in tlie non-obese (P = 0.024) but the correlation between FSH 
and BMI was weak (r = 0.27, P = NS). It is reported in the literature that although the mean serum FSH 
in obese women was not significantly lower tlian that in non-obese subjects there was a weak but 
significant inverse correlation between FSH and BMI in the obese but not in non-obese women (Franks,
1989). This may explain tlie higher incidence of anovulation in tlie obese subjects. A clinical implication 
of these findings is that the diagnostic value of LH levels or the LH:FSH ratio for PCOD could actually 
be liigher than has been recently proposed if obese women witli PCOD are carefiilly compared witli BMI- 
riiatched controls rather tlian with normal non-obese women.
Obesity is associated witli a rise in T and a fall in SHBG (Bates & Whitwortli, 1982; Cunningham et al 
1985), therefore; the presence of gross obesity may affect the interpretation of a liigh FAI (Eden, 1988; 
Eden et al 1988a; Eden et al 1988b). There was no significant conelation of T witlr SHBG; altlrough the
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reverse has been reported (r = - 0.43) (Franks, 1989), but the inverse correlation between SHBG and BMI 
was clear (r = -0.36) in the present study. Obese normal women had low levels of SHBG compared witlr 
lean individuals whereas the PCO women of nonnal BMI had normal SHBG concentrations despite 
significantly elevated serum T levels. Therefore, BMI is tire most important factor affecting SHBG 
concentrations. These results confimied the previously observed negative effects of obesity and PCOD on 
SHBG levels.
Obese women were reported to be more hirsute than tliose of nonnal weight (73% vs 56%), and more 
likely to have menstrual disturbances tlian lean subjects witli PCOD (Goldzieher & Green, 1962; 
Goldzieher & Axelrod, 1963; Dunaif et al 1988). Similar observations of hirsutism, witli BMI > 25, 
were found in tliis study (21% vs 43 %), as well as menstrual irregularity. However; these observations 
were absent when BMI S 29 is used. Despite the tendency for tire obese women to be more liirsute and 
have more cycle disturbance than non-obese PCO patients, tliere was no significant difference between 
the groups in Gn, Tor A concentrations. These observations confimied previous reports (Dunaif et al 
1988; Franks, 1989).
CONCLUSION
All patients recruited had menstrual irregularity (oligo/amenoiThoea witli or witliout DUB) and 
infertility. Patients' presentation was biased since their referral to tlie outpatient clinic was due to either 
a menstrual problem or infertility or both. About half of tlie patients were either obese or 
hyperandrogenized.
Women with PCOD had higher serum concentrations of LH (double the control value), LH:FSH, T and 
FAI, lower SHBG, and similar FSH, E^ , 17oc-OHP, DHEA-S, PRL and thyroid function tests to those of
tlie controls. The same findings were reported by Holte et al. (1994c), except for the lower FSH levels 
and the latter finding liigher values for DHEA-S.
Regarding the biochemical diagnosis - LH:FSH ratio > 2:1 was diagnosed in only 20 patients (48.8%). 
The presence of high LH concentration (> 10.0 lU/L) was found in < 50% of the study patients, and the 
presence of a correlation between LH and FSH weaken the sensitivity of LH:FSH as a diagnostic criterion 
of PCOD. Elevated T concentrations (> 2.5 rmiol/1) was a finding in less than 1/3^ *^  of tlie patients 
(24.4%) while FAI of > 4.5 was foimd in 53.7% of tlie patients. The accmacy of the diagnosis is
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increased when more tlian one criterion is applied. However, 26.2% of tlie whole group of patients were 
found to satisfy all of tlie biochemical diagnostic criteria.
Sex hormone binding globulin showed the most significant and consistent relationsliips with the 
anthropometric parameters in patients and controls, compared witli tlie other endocrine variables.
On US examination, a unilateral PCO was diagnosed in eight patients (20.0%). Tliick stroma, the most 
sensitive single criterion, was found in at least one ovary in 95.2% of tlie patients. However, ovarian
volume > 9.0 cm ,^ of either ovary, was found in only 55.0%, the least sensitive ultrasonographic 
parameter. Botli ovaries showed more tlian 10 follicles in one plane in 85.7% of patients. However, 
combination of more than one US criterion increases its diagnostic value. The TOV showed a wide 
vaiiation with patients and that tlie ovaiy is not static, even in tlie relatively stable conditions of 
oligo/amenorrhoea.
The intia-individual variation in biochemical markers (Franks, 1989) questions tlie selection of controls 
based entirely on the absence of PCO-like symptoms and biochemical markers. Tliis is particularly the 
case in obese women, as obesity is common in PCOD (40.5%) and tlie prevalence of PCOD in obese 
women can be expected to be high, given the high prevalence of PCO in the general female population 
(Poison et al 1988).
In the present study, subjects ivith PCOD, diagnosed on US scan, had significantly liigher BMI, LH 
concentiations, LH:FSH ratio, T concentrations and FAI and lower SHBG levels tlian did tlie controls. 
However, it has been reported that oligo/amenorrhoeic subjects with normal ovaries had significantly 
lower BMI, T and FAI than did those witli regular cycles (Eden, 1988; Eden et al 1988a; Eden et al 
1988b).
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CHAPTER FIVE ; INSULIN SENSITIVITY
5.1 INTRODUCTION
Insulin resistance is a metabolic state in wliich physiological concentrations of I produce a less than 
normal biological response. The fasting plasma glucose concentration depends primaiily on the rate of 
hepatic glucose release, which in turn is regulated by the I concentration (Caro, 1991; Dunaif, 1992a). 
The initial step in I action is binding of the hormone to cell surface receptors which causes activation of 
tyrosine-specific protein kinase activity. The receptor itself is phosphorylated. Subsequent events 
include generation of intracellular signals, modulation of enzyme activities, and importantly, stimulation 
of the ability of cells to take up and use glucose. Disturbance at any of tliese sites could result in IR 
(Harrison et al 1976; Ciaraldi et al 1992; Dunaif, 1992a). Therefore, IR may be due to : decreased 
number or defective fimction of I receptors (type-A), I receptor antibody (type-B), or post-receptor defects 
in I expression (type-C) (Moller & Flier, 1991; Dunaif, 1992a). Normal glucose concentration can be 
maintained if I-resistant persons are able to maintain a state of chronic hyperinsidinaemia (Dunaif et al 
1990; Moller & Flier, 1991). Insulin resistance will result in decreased I mediated glucose uptake into 
peripheral tissue and increased glucose release from liver, defects tliat are partially compensated by 
increased I secretion. Since a partial compensatory response to IR is hyperinsulinaemia and because IR 
may not be equally manifested in all I sensitive tissues, there may be a relative increase in I action in 
some tissues (Caro, 1991). The evidence has appeared to suggest that altliough hyperinsulinaemia may 
prevent NIDDM from developing, tlie cost of tliis is substantial. Specifically, it has been proposed tliat 
resistance to I-stimulated glucose uptake and hj-perinsidinaemia may play a central role in the cause and 
clinical comse of several diseases, including high blood pressme, abnormal lipoprotein metabolism and 
CHD.
Elevated I and/or C-peptide concentrations have been associated with increased risk of development of 
NIDDM in most populations. An increased fasting proinsulin/I ratio, wliich may be a marker for early 
p-cell dysfunction, has been associated witli increased development of NIDDM (Haffiier, 1996). The 
plasma FI concentration is largely determined by the glucose concentration and the basal hyperglycaemia 
in diabetes appears to arise from tlie feedback loop between the liver and p-cells, thereby maintaining an 
effective I action in the liver and at the periphery. The degree of basal hyperglycaemia is therefore 
determined by a combination of p-cell deficiency and IR (Matthews et al 1985).
130
Hyperinsulinaemia, secondaiy to a poorly characterized disorder of I action, is a feature of PCOD (Chang 
et al 1983; Pasquali et al 1983; Dmiaif et al 1989; Dunaif et al 1990; Rajkliowa et al 1994; Harrington 
& Balen, 1996) and patients with PCOD are at risk to develop NIDDM (Dunaif et al 1990). In the 
nonnal person there is a 14-minute cycle of plasma I secretion knmvn to occm". Altliough many factors 
have an influence on the basal concentrations of FI and glucose, tliere is a major role for the simple 
interaction of plasma glucose and I between tlie liver, p-cells and peripheiy (Mattliews et al 1985), The 
cellular mechanisms that account for target tissue IR in PCOD are miknown. Insulin resistance in PCOD 
involves a marked defect in glucose transport sensitivity without significant alterations in receptor 
dynamics. This miique feature distinguishes it from IR in obesity and NIDDM where both receptor and 
post-receptor defects are involved (Ciaraldi et al 1992). Obesity can also have an impact on I action 
(Ciaraldi et al 1992). It has also been suggested tliat androgens modulate IS in PCOD (Bruno et al 
1985). Studies have shown that chronic hyperinsulinaemia may be responsible for the hyperandrogenisni 
in PCO (Shoupe et al 1983; Buyalos et al 1993; Elkind-Hisch et al 1993; Rajkliowa et al 1994), although 
the niechanism(s) is unclear. Endogenous opiates are at least partially responsible for the 
hyperinsulinaemia and IR in PCOD (Givens et al 1987; Laatikainen et al 1990); although their role in 
the pathogenesis of PCOD is unclear.
This chapter sets out to explore tlie relationsliips between IS and disturbances of ovarian function seen in 
patients with oligo/amenorrhoea. After consultation, the method selected to estimate IS was the “ Short 
Insulin Tolerance Test ” (SITT), in which tlie sensitivity to I administration is estimated over a 15 
minute period by calculating the rate of decline in glucose concentrations. Fasting I (and glucose) 
measurements were taken as the initial part of the test, so simpler estimates (FI and FIRI) may also be 
used (Cleland et al 1996).
There are well established relationships between anthropometric variables and IS, so these can be used to 
compare the results of laboratory estimates of IS.
Basal metabolic variables of the study groups were recorded as were the changes which occurred during 
the SITT, i.e. over the 60 minutes following the administiation of I. The mean of 3 samples at 15 
minutes, 5 minutes and 0 minute prior to tlie I injection was calculated and used as the basal value for 
glucose (Chapter Tliree).
The SITT was carried out on two occasions in each subject. In the patients, tlie first was at least 15 days 
after the last menstrual period and in the controls the first was between cycle days 5-8. The test was 
repeated in the luteal phase in the controls and in those patients who oiulated, wliilst in patients who did
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not o\Tilate the test was repeated five weeks after the first test. The possible influence of the luteal phase 
was studied and the variations in tlie tests of IS were examined. Correlations between the SITT values 
(mean of 2 tests) and tlie antliropometric variables were effected. Failure to confirm tlie well-established 
relationships between IS and tlie antliropometric vaiiables as well as tlie practical problems of tlie SITT 
are discussed under 5.4.3. The alternative methods of estimating IS : - FI and FIRI- were examined, and 
the relationships between tliese and tlie aiithropometiic variables were compared. These estimates were 
used to examine the relationsliips between IS and ovarian activity, including follicular growth and 
luteinization, and hyperandrogenisni.
5.2 BASAL METABOLIC VARIABLES (PATIENTS AND 
CONTROLS)
The fasting basal serum levels of the metabolic variables measured before the first SITT test in the 
patients in comparison to the control group, are shown in Table 5-1.
Table 5-1 : Basal Metabolic Variables observed at the first SITT for
Patients Controls P
n 34 19
Fasting glucose ( mmo!/L) 5.13 ± 0 .49 5.09 ± 0 .58 NS
FI(m IU /L ) 12.47 ±9.93 7.53 ±  5.62 0.057
C-peptide ( iig/mL ) 1.21 ± 0.66 1.04 ±0.69 NS
IGF-I ( nmol/L ) 13.24 ±5.51 33.08 ± 14.24 < 0.0001
GH ( ng/niL )* 2.26 ± 4.45 2.48 ± 3 ,17 NS
Cortisol ( ug/dL ) 14.29 ± 6.56 15.50 ±4.53 NS
P R L (IU /L )* 291.1 ±240 .0 436.2 ±532 .0 NS
Groups were compared using Student's t-test, except for values witli (*) where Maim-Wliitney 
nonparametric test was used for comparison. NS means P k  0.05, Number o f patients was 34, 
except IGF-I was 18.
The fasting glucose and I estimations were taken at 08:00 hour after an overnight fast. The glucose 
concentration represented the mean of 3 values for each individual prior to the administration of I.
The cut-off accepted value for normal FI in tliis study, derived from the control group data, was 13 
nitU/L (mean ± ISD of own control group), wliich agrees witli tlie findings of otlier observers (Dunaif eî 
al 1989; Buyalos et aï 1991; Nestler et al 1991; Akinmokun et al 1992; Dale et al 1992b).
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All individuals had nonnal fasting blood glucose concentiations, with the liighest values of 6.6 minol/L 
for patients and 6.8 mmol/L for controls and the mean values were similar in both groups. Fourteen of 
the 34 patients (41.2%), and 5 out of 19 controls (26.3%) had FI concentrations significantly higher than 
tlie normal cut-off value. This distribution would explain tlie borderline significance seen when 
comparing tlie two groups (P = 0.057) (Table 5-1).
There was a significant difference in tlie lasting level of IGF-I between the two groups (Table 5-1). This 
agrees with observations from Barreca et al. (1996) who found lower IGF-I levels in follicular fluid of 
patients with PCOD than in normally ovulating women. Slownska-Srzednicka et al. (1992) reported a 
similar observation in serum, but tlie difference between their patients and controls was not significant.
The mean basal GH appeared to be slightly lower, and tire fasting C-peptide was slightly higher in tire 
patients than the control group but these differences were not significant. However, the actual GH levels 
were unclear in botli groups, since many (33.3%) of tire samples were below the lower limit of assay 
sensitivity (0.2 ng/mL). Fasting serum cortisol and PRL levels were similar in patients and controls.
C o r r e l a t i o n s  o f  t h e  B a s a l  C o n c e n t r a t i o n s  o f  t h e  M e t a b o l i c  V a r i a b l e s  a n d  t h e  
R e p r o d u c t i v e  H o r m o n e s
1 .  F a s t i n g  I n s u l i n
There was no significant correlation between tire basal FI and E^ , LH, FSH, LH;FSH, T, 17a-0HP, A or
DHEA-S in eitlier patients or the control group. However, basal FI was negatively and significantly 
correlated with SHBG in both patients and controls, (r = -0.45, P < 0.0001; r = -0.65, P = 0,0025; 
respectively) (Figine 5.1). Although there was no correlation with T, basal FI levels were positively 
correlated with FAI in both patients and controls, (r = 0.50, P < 0.0001; r = 0.47, P = 0.041; respectively) 
(Figine 5.2).
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Figure 5.1
Figure 5.2
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In the patient group, basal FI was significantly correlated with the basal fasting glucose concentration (r 
= 0.47, P = 0.0048), whereas for the controls there was no correlation (r = 0.35, P = 0.14) (Figure 5.3). 
There was no correlation between FI and IGF-I, GH, cortisol or PRL in eitlier group of women.
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Figure 5.3 :
Correlation : Fasting insuiin and Fasting 
glucose ( All subjects )
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2 .  F a s t i n g  G l u c o s e
Basal fasting glucose was not correlated ivith basal E^ , LH, FSH, LH:FSH, T, SHBG, FAI, 17a-0HP, 
DHEA-S, A, PRL, cortisol, GH, IGF-I or C-peptide in either group of the study.
3 ,  G r o w t h  H o r m o n e  a n d  I G F - I
No significant relationship was found between basal GH levels and these of any of the basal E^ , LH, FSH,
LH:FSH, T, SHBG, FAI, A, 17a-0HP, cortisol, fasting glucose, FI, IGF-I or C-peptide in eitlier tlie 
patients or the controls.
Basal IGF-I values in tlie patients were not correlated with E^ , LH, FSH, LH:FSH, T, SHBG, A, 17a-
OHP, cortisol, fasting glucose or C-peptide. However, FAI demonstrated a positive, altlrough weak, 
correlation with IGF-I values (r = 0.46, P = 0.0465). In the controls, there was no correlation between 
IGF-I values and any of the otlier variables measm ed.
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5.3 INSULIN SENSITIVITY : METHODS USED TO ASSESS 
INSULIN SENSITIVITY IN THIS STUDY
Since the description by Himsworth in 1936 that human disease could be associated with reduced 
sensitivity to I (IR), several methods have been developed for detection and quantification of IR (Caro,
1991). Insulin resistance is diagnosed when normal glucose levels exist in the presence of 
hyperinsulinaemia (Burghen et al 1980), and generally derives from abnoimal metabolic activity in 
peripheral tissues, while hyperinsulinaemia results not only from increased secretion of I by P-cells, but 
also from impainnent of receptor-mediated clearance of I by resistant peripheral target cells. The clinical 
consequences of IR result from eitlier deficient (due to reduced uptake) or excessive (due to high 
circulating levels) I action. An elevated FI is a coimnon feature of IR. The GTT, euglycaemic I-clamp 
teclmique, tlie minimal model technique and SITT are all provocation methods wliich have been used to 
quantify IS. Other tests include measurement of IS in-viiro in cell cultures and tissue samples. However, 
most of these tests are complicated to perform on a large series of patients and tliere has been much 
debate about the relative merits and limitations of each of them.
M E T H O D S  F O R  E S T I M A T I N G  I N S U L I N  S E N S I T I V I T Y
Total body IS can be assessed via the intravenous GTT, or minimal model, where an intravenous glucose 
injection is followed by frequent deteiminations of plasma glucose and I, and tlie results of this correlate 
well witli tlie euglycaemic clamp technique (Dunaif, 1992a). The test requires less staffing and could be 
used in a liighly specialized clinical setting (Caro, 1991). Although the euglycaemic insulin-clamp 
technique is the most widely accepted standard method for estimating IR. against wliich other methods 
are compared, it is expensive, time-consuming, requires specialized equipment and highly trained 
staffing, and the feedback control of glucose levels, all of which make it a laboratory investigative 
procedure rather than suitable for use in a clinical setting (Caro, 1991). These disadvantages 
demonstrate tlie need for an acceptable metliod to measure IS tliat could be used in large scale studies or 
even clinically.
One possible alternative is tlie glucose/I infiision test which correlates well witli the euglycaemic clamp 
but is costly in time (3 hours).
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Another alternative to the euglycaemic clamp, the SITT is a short useful alternative (Akimnokun et al 
1992; Hirst et al 1993). Results suggest that the SITT is a suitable method of assessing IS and 
particularly useful for large-scale studies, altliough the requirement for arterial blood adds a measure of 
complexity (Mattliews et al 1985; Akinmokun et al 1992; Holte et al 1994a). The SITT is simple and 
rapid to perform. The method is used increasingly in clinical research because studies have shown that 
the rate of fall of blood glucose during the SITT, the KITT-value, significantly correlated with tlie 
euglycaemic clamp (Akinmokun et al 1992). Another advantage of the SITT is that the test is safe, 
reproducible and could be used to measure IR in large-scale epidemiological studies (Akinmokun et al 
1992; Hirst et 1993).
The degree of IR and deficient p-cell function can be assessed from a patient's FI and glucose 
concentrations (Mattliews et al 1985). Fasting plasma GLU/INS ratio may provide tlie simplest estimate 
of IR. The higher tlie plasma FI concentration for a given fasting plasma glucose, the more IR an 
individual is. It is technically simple and inexpensive, and tlie availability of more accurate I assay 
methods has helped to overcome its limitations. Fasting I and FIRI are simple and reproducible 
nieasmes of IS (Cleland et al 1996).
The literature shows conflicting reports about the coirelation between hyperinsulinaemia and ovarian 
hyperandrogenisni in PCOD. Some groivtli factors, such as IGF-I, may have an important role in 
modulating tlie ovarian response. Among hormones known to cause or predispose to IR are GH, cortisol 
and PRL. The SITT test was the method used in this study to investigate such correlations.
The aim was to use the SITT to investigate IR in patients witli oligo/amenorrhoea (PCOD) and controls 
by reference to antliropometric criteria and also aspects of ovarian activity. Simpler methods of IR 
assessment were also available and used to compare with tlie results from the SITT.
5.4 THE SHORT INSULIN TOLERANCE TEST ( SITT )
S.4.1 CORRELATION OF “ SITT ” VALVES WITHIN SUBJECTS
The mean fasting hormonal and metabolic vaiiables at tlie first and the repeat SITT, of the patients and 
the controls are shown in Table 5-II.
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Mean fasting blood glucose concentrations were similar in the first and second SITT, and FI 
concenti ations were almost identical on the two occasions of testing for botli patients and tlie controls.
There was no significant difference in tlie GH, IGF-I or C-peptide in the t^  sample in tlie first and second 
SITTs in either gioup. It should be emphasized tliat IGF-I values, on both occasions were significantly 
higher in tlie control group than in the patients (P < 0.0001). Fasting GH values were almost half tlie 
levels of the controls (P< 0.0001), when the repeat SITT was effected few weeks later.
Table 5-ÏÏ : Metabolic Variables in the Basal State duting SITTs for the Patients and the Control
Patients Controls
1st SITT 2nd SITT P 1st SITT 2nd SITT P p**
F I(nü U /L ) I2.47±9.93 12.09±9.17 NS 7.53±5.62* 8.65±6.69* NS NS
Fasting glucose (ramol/L) 5.13±0.49 4.98±0.52 NS 5.09±0.58 5.11±0.44 NS NS
C-peptide(ng/mL) 1.21i0.66 1.21±0.88 NS 1.04±0.69 l.IO± 0.59 NS NS
GH ( ng/mL ) 2.26±4.45* 1.06±2.77* NS 2.48±3.17* 2.19±2.86* NS <0.0001
IGF -1 ( nmol/L ) 13.24±5.51 11.88±5.58 NS 33.08±14.24 29.83±11.17 NS <0.0001
Cortisol (ug/dL) 14.29± 6.56 12.67±6.53 NS 15.50±4.53 12.18±4.48 0.0365 NS
PRL(IU/L) 291.1±240* 294.6±277* NS 436.2± 532* 237.5±119.5 NS NS
KITT-value (%/min ) 4.14 ± 2.15 4.24 ± 2 .36 NS 4.91± 3.07 4.18± 1.46 NS NS
Groups were compared using Student's t-test, except for values with (*) where Maun-Whitney nonparametric test was used for 
comparison. (P**), comparing patients with controls, was calculated usmg analysis o f vaiiance where P £  0.05 is NS.
There was a close correlation between FI level at t^  before the first and the repeat SITT in both the 
patients and the control group (r = 0.86, P< 0.0001; r = 0.78, P = 0.0001; respectively) (Figure 5.4). 
Similarly, a significant correlation was foimd between the t^  GLU/INS ratio during the first and the 
repeal SITT in the patients, (r = 0.80; P < 0.0001). It was not significant, however, for tlie controls (r == 
0.33; P = 0.19) (Figure 5.5).
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Figure 5.4
Figure 5.5
Correlation : FI during SITTs in Patients and Controls
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The glucose and I responses during the SITTs are depicted in Figure 5.6. For the purposes of the graph, 
I concentration should start at t^ , i.e. assume ^ = t -  15. Following tlie intravenous injection of I, blood
glucose levels started to fall from tlie third minute in both groups.
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An index of IS, assessed using the rate constant KITT, was derived from a semilogarithmic plot of tlie 
decay in blood glucose values between t^  and t^  ^ (least squares analysis of concentration gradient) after
tlie injection of I (dose = 0.1 lU/Kg). The KITT-value, was therefore calculated from the slope of glucose 
disappearance between 3 - 1 5  min, using arterialised blood samples. The mean KITT-value of 4.55 ± 
2.27 in tlie control gioup appeared to be similar to those published for control populations by Hirst et al. 
(1993) and by Akinmokun et al, (1992). However, tlie liigh standard deviation (50%) may indicate an 
inherent weakness in the reliability of tlie test.
Figure 5.6 :
Glucose and Insulin Resiionse 
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Following intravenous injection of I, tlie mean blood glucose concentiation, fell from 5.08 (t^  - sample) to
2.91 mmol/L (t^  ^ - sample) for patients, and from 5.14 to 2.90 nmiol/L for controls, while the mean
plasma I concentiations rose to supraphysiological levels at 9-minutes and declined by 15-minutes (Table 
5-III). Circulating I levels at 9-minutes were similar in the two groups but showed wide variations (SD) 
(Table 5-III).
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Tabic 5 -in  : Mean glucose and I responses of patients and controls to injected I during the 
SITT
Glucose (mmol/L) I (mlU/L)
Time Patients Controls P Patients Controls P
0 - samples 5.08 + 0.45 5.09 +  0.46 NS 12.34+9.149 8.09 ± 5.53 0.071
1 min-samples 4.79 +  0.42 4.87 +  0.42 NS
3 miii-samples 4.78 + 0.41 4.84 +  0.44 NS
9 min-samples 3.87 +  0.53 4.01 +  0.45 NS 234.1+125.2 205.8+80.18 NS
15min-samples 2.91 +  0.72 2.90 +  0.68 NS 125.3+180.0 112.3+93.40 NS
The KITT-values (KITT-1 and KITT-2), for the individual patients as well as for the controls in both 
SITT tests are listed in Table 5-IV,
Table 5-IV : The KITT-Values in the duplicate tests in Patients and 
Controls
Patients Controls
KTIT-l KITT-2 KITT-1 KITT-2 KITT-1 KTTT-2
2.36 4.89 2.93 3.15 3.14 3.85
2.43 -2.42 1.58 1.58 4.33 4.33
4.24 1.18 8.99 7.97 3.00 4.39
5.07 5.30 4.82 1.63 1.21 3.71
3.42 3.34 2.39 2.48 2.85 2.65
4.21 4.36 4.07 3.92 5.21 5.28
4.91 5.41 6.35 5.64 14.89 5.33
2.27 4.20 6.52 4.92 3.86 4.05
7.02 8.99 5.93 3.35 2.68 3.60
3.89 2.94 4.64 4.96 6.52 6.25
6.24 9.60 4.58 2.90 5.34 2.94
2.84 5.09 6.23 6.23 3.99 3.99
2.20 4.04 6.96 4.53 3.22 3.76
2.76 2.76 7.26 4.67 3.74 3.66
3.07 2.51 2.47 5.79 6.37 4.74
4.87 5.43 3.66 3.66
0.40 0.40 6.13 4.86
5.93 6.34 3.98 4.91
3.46 2.79 5.56 8.22
In tlie patients, the mean KITT-value during the first SITT (KITT-1), and of the repeat SITT were 4.14 
% / min, and 4.24 % / min, respectively.
There was a significant correlation between the KITT-1 and the KITT-2 values in botli the patient gioup 
and tlie contiols, (r = 0.60, P = 0.0004; r = 0.66, P = 0.008; respectively) (Figui'e 5.7). This shows that 
tlie SITT yielded some level of reproducibility within patients when the analyses were effected few weeks
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apart in the patients and after 2 weeks in the controls. However, the correlations indicated that the test 
was less reproducible witlrin patients or controls than tire FI values shown above (KITT: r = 0.60 and 
0.66, FI: r = 0.86 and 0.78, in patients and corrtrols; respectively). This low level of correlation between 
KITT-1 and KITT-2 within patients is also lower tlian tlrat reported for SITT when compared to tire 
euglycaemic hyperirisulinaemic clamp (r = 0.86 in normal and 0.81 in diabetic subjects) (Akinmokun et 
al 1992).
Figure 5.7 :
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Wlien controls were assessed in follicular and luteal phases, no significant difference was observed in the 
metabolic variables, except for cortisol wliich was significantly higher in the follicular tlran the luteal 
phase (Table 5-V). The follicular phase mean KITT-1 was similar to tlie luteal phase mean KITT-2, 
(Figure 5.8).
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Table 5-V : Metabolic Variables in Follicular vs Luteal SITT in Controls
1st SITT 2nd SITT P
FI ( mlU/L ) 7.53 ±  5.62* 8.65 ± 6.69* NS
Fasting glucose (mmol/L) 5.09 ± 0 .58 5.11± 0.44 NS
C-peptide (ng/mL) 1.04 ±0 .69 1.10 ± 0.59 NS
GH ( ng/mL) 2.48 ±3.17* 2.19 ±2.86* NS
IGF-I ( nmol/L ) 33.08 ±  14.24 29.83 ± 11.17 NS
Cortisol (ug/dL) 15.50 ±4.53 12.18 ±4.48 0.0365
PRL (lU/L) 436.2 ±  532.0* 237.5 ±119.5 NS
KITT-value (%/min ) 4.91 ± 3 .07 4.18 ± 1.46 NS
Groups were compared using Student's t-test, except for values with (*) where Mann-Whitney 
nonparametric test was used for conipaiison. P > 0.05 is NS.
Figure 5.8 :
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The difference in IS between oWatoiy and anoWatoiy cycles in tlie patient group, measured by the 
mean KITT-values is demonstrated below, and it shows similar results in the two subgroups, (Figure 
5.9). This means tlrat the mean KITT-value is valid for both patients and controls, to be used in any 
further analysis.
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5.4,2 RELATIONSHIP BETWEEN ‘SIT T ” AND ANTHROPOMETRIC 
VARIABLES
Insulin sensitmly and antluopometiic criteria enjoy well established relationships (Sharp et al 1991; 
Rajkliowa et al 1994), such tliat any test for IR may be assessed relative to those criteria to confirm 
reliability. There is already some level of doubt with respect to tlie reliability of tlie SITT as assessed in 
these experiments because it showed poorer correlations tlian FI levels witliin individuals, and the mean 
KITT values in the patients and controls showed no difference. The SITT was tlierefore examined with 
respect to anthropometric criteria and compared to the other methods of assessing IR wliich were 
available.
5 . 4 . 2 . 1  R e l a t i o n s h i p  w i t h  B M I
Correlations between BMI and the basal metabolic variables aie demonstrated in Table 5-Vl, The mean 
KITT-values failed to show any relationship with BMI in either patients or controls (Figure 5,10), while 
the FI and fasting glucose (in the patient group) showed the expected relationship between obesity and 
IR.
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Table 5-VI : Correlations betiveen BMI and the Basal Metabolic Variables
Patients Controls
r P r P
FI ( mlU/L ) 0.55 0.0003 0.75 0.0001
Fasting glucose ( inniol/L ) 0.54 0.0011 0,27 0.271
C-peptide (ng/niL) 0.39 0.022 0.46 0.0381
GH ( ng/niL ) -0.22 0.2116 0.49 0.0296
IGF-I(mnol4.) 0.39 0.0975 0.33 0.194
mean KITT - values 0.25 0.15 0.06 0.80
P > 0.05 is not significant.
Figure 5.10 :
Correlation : Mean KITT-values and BMI
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Correlations between WHR and tlie basal metabolic valuables are shown in Table 5-VII.
Table 5-VH : Correlations between WHR and the Basal Metabolic Variables
Patients Controls
r P r P
FI ( inlU/L ) 0.40 0.0178 0.49 0.029
Fasting glucose ( nunol/L ) 0.55 0.0009 0.12 0.630
C-peptide (ng/mL) 0.16 0.368 0.38 0.1109
GH ( ng/mL ) -0.33 0.0573 0.46 0.0412
IGF-I ( nmol/L) 0.27 0.2697 0.36 0.1609
mean KITT-values 0.15 0.39 0.18 0.45
P ^ 0.05 is not significant.
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As with BMI, mean KITT-values did not show any relationsMp witli waist measurements or WHR 
(Figures 5.11 and 5.12), while the FI and fasting glucose (in the patient group) showed significant 
correlations witli tiuncal obesity.
Figure 5.11 :
Correlation : Mean KHT-values and WHR
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5.4,3 CRITICISM OF THE  "  SITT
Although the SITT has been evaluated and foimd to be a safe, simple and "reliable" test to assess IS 
(Akimnokun et al 1992; Hirst et al 1993), in tliis study the KITT failed to comply with the well 
established relationships between IR and tlie anthropometric variables BMI and WHR. This may be due 
to inherent problems with the endocrinology of the test, or to simple practical problems. Furthermore, 
the SITT gave disappointing poor consistency ivithin individual patients or controls.
5 . 4 . 3 . 1  P r a c t i c a l  P r o b l e m s
There were some practical problems. First, I-induced hypoglycaemia is unpleasant for the subject and 
potentially dangerous. Two of the patients (5.9%) (Figure 5.13), and one of tlie controls (5.0%), 
developed symptomatic hypoglycaemia and had a blood glucose level of < 2.0 mmol/L by 15 minutes. 
Their I concentrations at 15 minutes were 20 and 80 mlU/L for tlie patients and 32 mlU/L for tlie control 
subject. Second, difficulties were encountered in maintenance of the intravenous access used to collect 
an arterialised blood sample for glucose estimation over the period of test. Tliis problem was more 
pronounced in obese individuals and those who smoked.
5 , 4 . 3 , 2  V a r i a t i o n s  o f  I n s u l i n  P r o f i l e s
In spite of fairly consistent glucose responses (Figure 5.13), I concentrations showed variable patterns 
and inconsistent profiles following 1 injection during tlie SITT. These variable profiles were obseived in 
both patients and control groups and occurred despite dosage adjustment according to BMI (Figures 5.14 
and 5.15).
147
Figure 5.13
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5.5 ALTERNATIVE ESTIMATES OF INSULIN SENSITIVITY 
5 . 5 . /  F landF IR I
It has been reported that FIRI is a reproducible measure of IS (Matthews et a! 1985; Cleland et al 1996). 
The FIRI is calculated from the formula : fasting glucose x FI / 25 (Cleland et al 1996), such that 
individuals who show both raised glucose and I levels could be HL in contrast to the GLU/INS ratio 
which would tend to normalise the assessment. It may be a reasonable measure of IR in both non­
diabetic and diabetic individuals. Its use may obviate the need for more complex procedures to obtain a 
useful index of IR in large-scale studies. Cleland et al. (19%) reported a mean FIRI of 2.77 for normal 
non-diabetic individuals. A significant correlation was reported between log^  ^ FIRI and IS during 
euglycaemic hyperinsulinaemic clamp (r = 0. 67, P < 0.001) (Cleland et al 1996).
Weak, but significant correlations were found between the mean KJTT-values and FI and mean KITT- 
values and FIRI ( Figures 5.16 and 5.17).
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Figure 5.16
Figure 5.17
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Fasting I, FIRI and log^  ^FIRI were significantly reproducible, in patients and in controls, during the first
and repeat SITTs. These correlations are shown in Table 5-VIII and Figiues (5.18 - 5.20). The mean 
values of FIRI for patients and controls were lower than those reported for nonnal non-diabetic
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individuals (2.77) (Cleland et al 1996). The FIRI is dependent on sampling in the fasted state, and on 
the reproducibility of tlie I assay used.
Table 5-V in : Mean Values of FI and FIRI within Patients and Controls
Patients Controls
IstSITT 2nd SITT P 1st SITT 2nd SITT P P$
KITT(%/imn) 4.1412.15 4.24±Z.36 NS 4.9113.07 4.1811.46 NS NS
FI (nüU/L) 12.4719.93 12.0919.17 NS 7.5315.62 8.6516.69 NS NS
GLU/INS ratio 0.6710.50 0.6410.40 NS 0.9710.66 0.8110.53 NS NS
FIRI 2.5212.31 2.4411.98 NS 1.9411.89 2.1112.02 NS NS
Groups were compaied using Student's t-test. (P*), comparing patients wltli controls, was calculated using analysis o f variance where 
? > 0 .0 5  isNS.
Figure 5.18 :
Correlation : FI during SITTs in Patients and Controls
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r = 0.86; P <  0.0001 (M ) 
r = 0.62; P = 0.0079 (CTRL)5 0 -
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Table 5-IX shows tlie conelations between indices for measurement of IS between SITT-1 and SITT-2 in 
patients and controls. The KITT-value was the least consistent within patients and controls, while FI 
and FIRI showed equally good correlations. There was a smprisingly poor correlation between tlie two 
tests in tlie weight-matched control group, probably due to 2 exceptional values obseived. Although the 
SITT-2 was carried out in the luteal phase, cycle phase showed no effect (Table 5-V; Figure 5.8).
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Table 5-IX : Correlations betiveen SITT-1 and SITT-2 within Patients and Controls
Patients Controls
r ? r ?
KITr(Wrain) 0.60 0.0004 0.66 0.008
FI(inIU/L) 0.86 <0.0001 0.78 0.0001
GLU/INS ratio 0.80 < 0.0001 0.33 0.19
FIRI 0.83 <0.0001 0.85 <0.0001
p > 0.05 is not significant.
Figure 5.19 :
Correlation : FIRI during SITR in Patients 
and Controls
12.5-1
* r = 0.83, P <  0.0001 (PI) 
a r = 0.85, P < 0.0001 (CTRL)10.0 -
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FIRI-1
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Figure 5.20 :
Correlation : Logio FIRI -1 and Logio FIRI -2
in Patients and Controls
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r =  0.70, P <  0.0001 (PI) 
r = 0.77, P =  0.0002 (CTRL)1.0-
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5.5.2 CORRELATION OF FI AND FIRI WITH ANTHROPOMETRIC 
VARIABLES
As stated above, the expected correlations of antluopometiic variables ivith KITT-values was poor, so 
investigations were carried out to determine if tlie relationships of FI or FIRI with tliese variables were 
more reliable criteria reflecting IR, and showing the expected relationships.
5 . 5 . 2 . 1  R e l a t i o n s h i p  b e t w e e n  F I ,  G L U / E V S  r a t i o  a n d  F I R I  a n d  B M I
The relationsliips between BMI and FI, GLU/INS ratio and log^  ^ FIRI were all significant in botli 
patients and controls (Figures 5.21 - 5.23).
153
Figure 5.21 :
Figure 5.22 :
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Figure 5.23 :
Correlation : Logio FIRI and BMI in Patients
and Controls
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Willie tlie KITT-values did not show any difference between lean and obese patients and controls, otlier 
indices of measuring IR were significantly liigher in obese than lean individuals (patients and controls) 
(Table 5-X). Lean patients showed significantly higher FI, GLU/INS ratio and FIRI than their weight- 
matched controls but obese individuals (patients and controls) were similar.
Table 5-X : The Relationships between BMI and Indices of IR in Patients and Controls
Patients Controls
< 2 9 ^ 2 9 P <29 > 29 P p**
KITT(%/min) 4.54±2.17 3.4912.04 NS 4.2211.93 5.5914.04 NS NS NS
FI(niIU/L) 8.79±5.52 17.53111,1 0.0024 4.6711.90 16.3318.57 0.0002 0.0178 NS
GLU/INS ratio 0,7610.42 0.3910.17 0.0058 1.2410.54 0.4010.19 0.0006 0.0074 NS
FIRI 1.8311.21 3.7912.57 0.0049 0.9310.40 3.5512.15 0.0006 0.0194 NS
Groups were compared using Student's t-test. (P*) compares patients and controls of BMI < 29, while (?**) compares patients and 
controls of BMI ^ 29. P à  0.05 is NS.
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5 . S . 2 . 2  R e l a t i o n s h i p s  b e t w e e n  F I ,  G L U / I N S  r a t i o  a n d  F I R I  a n d  W H R  a n d  W a i s t  
M e a s u r e m e n t s
Similar relationships, altliough less significant, were found between WHR and FI, GLU/INS ratio and 
logj  ^FIRI. The WHR and waist measurements (cm) showed almost identical relationships witli FI and
logj  ^FIRI in the patients. In the control group, stronger correlations were observed between FI and log^ ^
FIRI and waist measinement tlian tliat of WHR (Figmes 5.24 - 5.29).
Figure 5.24 :
Correlation : FI and WHR in Patients and 
Controls
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Figure 5.25 :
Figure 5.26 :
Correlation : FI and Waist in Patients and
Controls
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Figure 5.27 :
Figure 5.28 :
Correlation : GLÜ/INS ratio and Waist in
Patients and Controls
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Figure 5.29 :
Correlation : Logio FIRI and Waist in Patients
and Controls
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KITT-values were similar in individuals with WHR < 0.8 and those with WHR > 0.8. However, tlie 
differences were significant when FI, GLU/INS ratio and FIRI were compared between subgroups of 
WHR (Table 5-XI). No significant difference was noticed between patients and tlieir WHR-matched 
controls.
Table 5-XI ; The relationships between WHR and Indices of IR in Patients and Controls
Patients Controls
<0.8 > 0 .8 P < 0.8 > 0 .8 P
KITT (%/min) 4.15±1.99 4.14+2.22 NS 3.89+1.99 5.84+3.63 NS NS NS
FI(mIU/L) 6.0+1.56 14.02+9.69 0.0266 6.05+5.95 13.34+8.57 0.0376 NS NS
GLU/INS ratio 0.87±0.24 0.56+0.40 0.0843 1.22+0.61 0.53+0.33 0.0071 NS NS
FIRI 1.23+0.37 2.87+2.16 0.0775 1.35+1.64 2.76+1.94 0.0945 NS NS
Groups were compared usiiig Student's t-test. (P*) compares patients and controls o f WHR < 0,8, while (P**) compares 
patients and controls o f WHR > 0.8. P > 0.05 is NS.
5 . 5.3 INFLUENCE OF CYCLE PHASE (  CONTROLS)
Values of FIRI determined in the follicular phase are compared witli those in the luteal phase of the 
controls (Figure 5.30). Cycle phase showed no significant influence on FIRI. The mean follicular phase
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FIRI (1.92 ± 1.89, range 0.37 - 7.56) was not different from the luteal phase FIRI (2.11 ± 2.02, range 
0.56-7.56).
Figure 5.30 ;
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5 . 5.4 HYPERANDROGENISMAND INSULIN SENSITIVITY
The relationships between tlie circulating androgen concentrations and tlie various estimates of IS were 
studied (Table 5-XIl). There was no significant correlation betiveen FI and T, A, or DHEA-S. Similar 
observations were noticed witli log^  ^FIRI and GLU/INS ratio.
Table 5-XII ; Correlations between Hormonal Indices of Hyperandrogenism and Estimates of IS
FI L o g ,„ FIRI
PT CTRL PT CTRL
r P r P r P r P
T (ninol/L) 0.13 0.47 0.05 0.85 0.22 0.22 0.15 0.53
A (muol/L) 0.14 0.42 0.26 0.29 0.10 0.56 O.Il 0.64
SHBG (ninoVL) -0.45 <0.0001 -0.65 0.0025 -0.54 <0.0001 -0.57 0.0004
FAI 0.50 <0.0001 0.47 0.041 0.55 <0.0001 0.57 0.0002
DHEA-S (iiinol/L) -0.16 0.36 0.05 0.84 0.18 0.31 0.10 0.58
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On the other hand, there were powerful coiTelations between the estimates of IR and SHBG (Figures 5.31 
-5.32) and FAI (Figures 5.33 - 5.34) in botli patients and controls. Fasting I and log^  ^ FIRI showed
almost identical patterns.
Figure 5.31 :
Figure 5.32
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Figure 5.33 :
Figure 5.34 :
Correlation : FAI and FI in Patients and
Controls
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Androgeiiized patients, with low SHBG (mean ± SD of that of the contiol group), as expressed by FAI > 
4.5 (mean ± ISD of study controls), showed significantly liigher values of FI, log^  ^FIRI and lower 
GLU/INS ratios tlian did those with normal FAIs (Table 5-XIII), (Figures 5,35 - 5.39).
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Table 5-Xin : Relationship between Hyperandrogenism and IS (Patients)
FAI < 4.5 FAI >4.5 P
No. o f Patients 16 18
FI (mlU/L) 7.23 ± 3 .4 4 16.79 ±10.38 0.0006
GLU/INS ratio 0.83 ±0.41 0.42 ±0.25 0.0014
FIRI 1.49 ± 0.75 3.55 ± 2 .37 0.0021
Figure 5.35 :
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Figure 5.37 ;
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Figure 5.39 :
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5.6 RESPONSES OF OTHER VARIABLES TO INSULIN 
ADMINISTRATION (PATIENTS AND CONTROLS)
The central, adrenal and ovarian endocrine responses to I administration, in patients and controls, are 
demonstrated in tlie following section.
5.6.1 CENTRAL RESPONSE
P a t i e n t s
Gonadotrophins, GH and PRL responses to I injection in patients are shown in Table 5-XIVa. Growth 
hormone, one of the regulatory hormones for I, showed a significant increase at 30-minutes which was 
sustained until 60-minutes. Gonadotrophins and PRL showed no change.
165
Table 5-XIVa : Mean Central Responses to I administration during SITTs in 
Patients
0-iniiinle 30-iiiiniile P 60-minute P* p * *
LH(IU/L) 8.75 ± 5.59 8.45 + 4.66 NS 8.45*6.12 NS NS
FSH(IU/L) 4.97+1.32 5.09+1.34 NS 4.99 * 1.47 NS NS
GH (ng/niL) 1.69*3.77 3.81+6.74 0.0018 2.69*4.06 0.05 NS
PRL(IU/L) 303 + 278 313 ±433 NS 292*294 NS NS
Groups were compared using Student's t-test. (P*) compares 30-min with 60-min, wliile (P**) compares 0-min 
with 60-min. P > 0.05 is NS.
C o n t r o l s
Similarly, in controls there were no significant changes in Gn and PRL responses to I injection (Table 5- 
XlVb). Growtli hormone showed, however; a different pattern with a rise at 30-minutes which was 
insignificant (due to wide variations between subjects), and then decreased significantly at 60-minutes.
Table 5-XIVb ; Mean Central Responses to I administration during SITTs in Controls
0-minute 30-minute P 60-minute P * p * *
LH (lU/L) 4 .1 3 * 3 .9 0 3 .8 4 * 3 .8 3 NS 3 .6 6 * 3 .4 2 NS 0.058
FSH (lU/L) 4 .0 5 * 1 .9 0 4 .0 6 * 1 .9 3 NS 3 .9 9 * 1 .9 6 NS NS
GH (ng/niL) 2 .3 4 * 2 .9 8 4 .0 7 * 5 .4 3 NS 2 .1 1 * 2 .0 4 0.039 NS
PRL(1U/L) 3 4 0 * 3 9 8 3 6 1 * 4 1 2 NS 3 2 0 * 3 2 6 NS NS
witli 60-min. P k 0.05 is NS.
5.6,2 A D R E N A L  R E S P O N S E
Cortisol and DHEA-S responses to I injection in patients at 0-minute, 30-minutes and 60-minutes, are 
demonstrated in Table 5-XV. Cortisol, another regulatory hormone to the action of I, showed a late, 
tliough significant response at 60-minutes. Dehydroepiandiosterone-sulphate was measmed at 60- 
minutes and was not significantly different from the basal value. The controls showed similar patterns in 
cortisol and DHEA-S responses.
Table 5-XV : Mean Adrenal Responses to I administration during SITTs in Patients
0-minute 30-minute P 60-minute P* p **
Cortisol (ug/mL) 13.3*6.4 13.4*6.4 NS 15,89*6.54 0.021 0.005
DHEA-S (umol/L) 1805*1187 1732*1158 NS
Groups were compared using Student's t-test. (P*) compares 30-min with 60-min, wliile (P**) compares O-min 
witli 60-min. P > 0.05 is NS,
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5.6.3 O V A R IA N  R E S P O N S E  . A L L  T E S T S
P a t i e n t s
The patients' main ovarian endocrine responses following exogenous I injection are shown in Table 5- 
XVIa. Oestradiol showed a dramatic decrease at 30-minutes following the I injection and continued to 
decline at 60-minutes, accounting for about a 17% decrease from the basal (t^  = 60.28 pg/mL) values.
Testosterone followed the same pattern, although to a lesser degree, and was significantly decreased at 
60-minutes compared to 0-minute (11% decline at 60-minutes).
Tabic 5-XVIa : Mean Ovarian Responses to I administration during SITTs in Patients
0-minute 30-minute P 60-minute P* p **
(pg/mL) 60.28 +  23.19 54 .85*21 .25 0.0002 49.85 *  17.99 <0.0001 <0.0001
T (nnioi/L) 2 .1 9 * 1 .3 6 2 .0 5 * 1 .3 4 NS 1.93*1 .18 NS 0.006
SHBG(iuiiol/L) 46 .55*25 .24 5 4 .32*26 .9 NS 47 .99*26 .54 NS NS
FAI 6 .1 0 * 4 .6 7 3 .9 4 * 2 .8 4 NS 5 .68*4 .14 NS NS
IGF-I (nniol/L) 12 .58*5 .5 12.97*5.43 NS
Groups were compared using Student's paired data t-test. (P*) compares 30-min witii 60-min, wliile (?**) compares O-min 
witli 60-min. F k 0.05 is NS.
C o n t r o l s
Similar observations were noted in the control group as in the patients (Table 5-XVIb). No significant 
change in SHBG or IGF-I levels was observed but E2 and T concentrations and FAI were significantly 
decreased across the test.
Table 5-XVlb ; Mean Ovarian Responses to I administration during SITTs in Controls
0-minute 30-minute P 60-minute P* p **
Ej (pg/iiîL) 77 .27*39 .09 68 .14*34 .60 <0.0001 63 .29*30 .20 0.0124 0.0011
T (nmoI/L) 1 .37*0 .74 1.29*0 .71 NS 1.15 +  0.56 0.057 0.061
SHBG(iuiiol/L) 66 .11*30 .54 67 .50*31.85 NS
FAI 2.48 *  1.69 2 .01*1 .29 0.0386
IGF-I (mnol/L) 3 1 .64*12 .83 31.59*12 .15 NS
Groups were compared using Student's paired data t-test. (?*) compares 30-min witli 60-min, while (?**) compares O-min 
witli 60-min. P > 0.05 is NS.
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Role of BMI
Growtli liomione response after I administration was more pronounced in lean patients than obese 
patients (Table 5-XVII), although the responses in tlie control group were less remarkable.
Table 5-XVH : Role of BMI in the Metabolic Responses to I Administration
Patients (P-value) Controls (P-value)
< 29 > 2 9 < 29 > 2 9
0-30 30-60 0-60 0-30 30-60 0-60 0-30 30-60 0-60 0-30 30-60 0-60
GH (iig/mL) 0.027 0.0011 NS NS 0.05 0.025 NS 0.071 NS NS NS NS
Cortisol (ug/mL) NS NS NS NS NS NS NS NS NS NS NS NS
IGF-I (mnol/L) NS NS NS NS
R e s p o n s e s  t o  I  a d m i n i s t r a t i o n  i n  O v u l a t o r y  C y c l e s  
F o l l i c u l a r  P h a s e
The responses to I were analyzed, separating follicular and luteal phase tests. These are illustrated in 
Table 5-XVIIIa. They show a similar trend to those described for tlie whole group but the decrease in T 
is not significant (P = 0.083).
Table 5-XVnia ; Mean Ovarian Responses to I administration in the Follicular Phase of
0- minute 30-ininute P 60- minute p>i= P**
\  (pg/mL) 59 .60*34 .28 53 .40*31 .16 0.0072 48 .80*27 .84 0.0009 <0.0001
T (nmol/L) 2 .1 9 * 0 .8 8 1 .98*  1.03 0.083 1 .95*  1.01 NS 0.0924
SHBG(mnol/L) 45 .22*22 .40 44 .02*25 .85 NS
FAI 6 .0 2 * 4 .2 5 6 .3 1 * 4 .2 7 NS
P (pg/mL) 0 .7 5 * 0 .5 2 0 .6 3 * 0 .3 8 NS 0 .7 6 * 0 .5 2 NS NS
IGF-I (nmol/L) 13.24*5.51 12.56*3.69 NS
Groups were compared using Student's pair ed data t-test. (P*) compares 30-min witir 60-min, wliile (?**) compar es 
O-min with 60-min. P > 0.05 is NS.
L u t e a l  P h a s e  :
Ovarian T and P but not responses alter I-hr were more pronoimced when the luteal phase of 
ovulatory cycles in tlie patients were analyzed (Table 5-XVIIlb). In tlie luteal phase SHBG
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concentrations rose significantly during tlie test and as a consequence FAI values fell significantly. In 
tlie tests performed in tlie luteal phase tlie P values decreased significantly dming tlie test.
Table 5-XVinb : Mean Ovarian Responses to I  administration in the Luteal Phase of
0-minute 30-minute P 60-minute P* p**
E2 (pg/mL) 79.44 +  42.58 70 .29*36 .68 0.0169 64 .38*32 .29 0.0032 0.0009
T (iimol/L) 2,38 +  2.05 1.63*1.61 0.033 1.78*1 .46 NS 0.0225
SHBG(iimoI/L) 50.41 ±  22.22 64.06 *  26.89 0.0101
FAI 5.93 + 5.57 3 .55*3 .21 0.0279
P (pg^mL) 6.89 +  6.22 6.56 *  6.40 NS 5 .83*5 .12 0.077 0.0064
IGF-I (nmol/L) 16 .33*5 .32 13.33*4.93 NS
Groups were compared using Student’s t-test. (P*) compares 30-min with 60-min, while (P**) compares O-min 
witli 60-min. P > 0.05 is NS.
5.7 DISCUSSION
T h e  S I T T  a n d  F I  a n d  F I R I
In tliis study, the SITT test was the dynamic test chosen to measure IR. The fall in plasma glucose 
concentration in the test depends on both the inliibition of endogenous glucose production (principally 
from the liver), and the stimulation of glucose uptake by tissues (principally the muscles); the faster the 
decline in plasma glucose concentration, the more sensitive the individual is to I. The dose of I used, 
(0.1 lU/Kg), is supraphysiological, causing suppression of hepatic glucose production/release. Hence, the 
rate of glucose disappearance from the circulation is a measure of glucose uptake by the tissues. 
However, hypoglycaemia often results when blood glucose reaches its nadir, by about 20-minutes, and 
tliis will trigger a pronoimced counter-regulatory response which in turn reverses tlie decline in plasma 
glucose concentration. The glucose disappearance rate in the first 1 5 - 2 0  minutes should therefore 
measure only the action of the injected I (Akinmokun et al 1992). The rate of fall of blood glucose 
(KITT-value) was calculated from values in samples collected at 2-minute intervals between 3 and 15 
minutes. The rate of fall in percent per minute was calculated using tlie least squares analysis and this 
was taken as an index of IS (Rajkliowa et al 1994) (Appendix V).
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The KITT-values found in tliis study are similar to those reported by other observers (Harrison et al 
1976; Akimnokun et al 1992; Hirst et al 1993). The mean KITT-value in nonnal weight, non-diabetic 
adults reported was 3.0 %/min (range 0.59-4.84) (Harrison et al 1976), higher than that expected in 
diabetic individuals. In tliis study, tlie mean KITT-value for patients was 4.20 ± 1.99 %/min (range 
0.005 - 8.48). However, tlie mean KITT-values showed no difference between patients and their weight- 
matched contiols. Rajkliowa et al. (1994) showed tliat the KITT-value, used as an index of IS, correlated 
inversely witli BMI, and obese patients witli PCOD had significantly lower KITT-values than did obese 
contiols, but lean PCO women were similar to lean controls. The data reported in tliis thesis do not 
agree with these observations either witliiii the obese or lean groups.
The correlations between KITT-1 and KITT-2 in botli patients and controls (r = 0.60, 0.63, respectively), 
indicated the poor reproducibility of the test within the subjects. These coiTelations were poorer than the 
correlations of FI witliin subjects of this study (r = 0.86, 0.78; respectively), and tlie correlations reported 
for SITT and the euglycaemic clamp (r = 0. 86 for normal and 0.81 for diabetic subjects) (Akimnokun et 
al 1992). Analysis of tlie profiles of I concentrations during tlie SITT showed considerable 
inconsistency. Tins may be related to the poor correlation between the 2 SITTs in each subject. 
Furthermore, the KITT-values failed to confirm the well-established relationships witli anthropometric 
variables. The reliability of the SITT must therefore be doubted; the FI or FIRI appeared to be more 
reliable tests for estimating IR with regard to intra-subject consistency and also relationship with 
antluopometric criteria.
Altliough a weak correlation was foimd in tliis study between the mean FI and the mean KITT-values 
and between the mean FIRI and the mean KITT-values in patients; tlie FI and FIRI were found to be 
more reliable within subjects and also showed the expected relationship with antliropometric criteria. 
Evidence fi'om EUdnd-Hirsch et a l (1993) showed that in patients with PCOD, FI correlated well with 
IR measmed by intravenous GTT (r = 0.66, P < 0.02), suggesting tliat FI levels are predictive of IR. The 
mean FIRI recorded by Cleland et al. (1996) suggested that it may be an alternative method with the 
benefit of including patients with raised glucose and I.
I N S U L I N  a n d  G L U C O S E
All the individuals in the study had normal fasting glucose concentrations and the mean value of glucose 
for tlie patients was similar to that of the control group. This agreed with the findings of other observers 
(Buyalos et al 1993; Holte et al 1994a). Basal fasting glucose did not correlate with any of the endocrine
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or metabolic variables and tlie glucose response to the injected I (0.1 lU/Kg ) was similar in both groups 
of women.
The cut-off accepted value for nonnal FI concentration in tins study, derived from the control group data 
(mean ± SD), was 13.0 mlU/L. Similar values have been employed in otlier studies (Dunaif et al 1989; 
Buyalos et al 1991; Nestler et al 1991; Akinmokun et al 1992; Dale et al 1992b). Significantly higher 
mean FI concentrations were observed in patients with PCOD irrespective of BMI (Shoupe et al 1983; 
Chang et al 1983; Bruno et al 1985; Lanzone et al 1990a; Buyalos et al 1993; Conway et al 1993; 
Filicoii et al 1996). In tliis study 41.2% of tlie patients and 26.3% of tlie control group were found to 
have a higher FI tlian the cut-off normal value, tliis resulting in only a borderline significant increase in 
FI when comparing tlie patients to tlie controls (P = 0.057). A significant linear correlation between FI 
and fasting glucose values was found in the patients only (r = 0.47, P = 0.0048), suggesting a resistance 
to I in tlie patient group, but not in tlie controls.
C -  P E P T I D E
In tliis study, fasting C-peptide levels were found to be similar in the patients and tlie control group. 
These data contrast witli tlie observation of Filicori et a l (1996) who reported lower levels in patients 
with PCOD, while Holte et a l  (1994a) showed higher levels in controls; tliese levels were increased in 
patients witli PCOD over tlie whole range of BMI. The increased C-peptide concentrations in these other 
studies were presumably a byproduct of the increased I production. It is clear that the data concerning C- 
peptide are confused, and the results from this study with weight-matched cases of oligo/amenorrhoea 
and normal menstrual rhytlun suggest that it has no pathophysiological role in the disturbances of 
ovarian function measured under tliese circumstances.
I N S U L I N  R E S I S T A N C E  a n d  A N D R O G E N S
None of the parameters used in tliis study to estimate IS showed any significant relationships witli total 
circulating T or A in the study group. Similar findings have been reported in tlie literature (Ciaraldi et 
al 1992; Buyalos et al 1993; Rajkhowa et al 1994), with no significant correlation of hyperinsulinaemia 
witli raised T and A concentrations in obese and non-obese PCO women. These authors suggested that 
hyperandrogenaemia and IR were independent features of PCO and tliat obesity exacerbates tlie clinical
171
expression of hj'perandrogenaemia. Others (Chang et al 1983; Bruno et al 1985; Geffiier et al 1986) 
have concluded tliat T concentrations, in patients witli PCOD and their contr ols, were lüghly correlated 
to fasting hyperinsulinaemia and IR which may be partially responsible for the observed imbalance in 
glucose/insulin homeostasis. The data presented in tliis study support tlie former hypotliesis that IR and 
hyperandrogenism are independent features.
In this study, FI was significantly correlated witli SHBG (negatively) and FAI in both patients and the 
control group. The correlation between IR and FAI in tlie oligo/amenorrhoea group appears to be 
secondary to the inverse correlation of SHBG to senim I. Altliough I has been shown to have direct 
effects on ovarian theca cells, in viti o^, the effects of I on androgen metabolism are also likely to be by 
modification of synthesis and secretion of SHBG, which in turn, may lead to profound changes in 
androgen clearance and production (Sharp et al 1991). Insulin, rather than sex steroids, appears to be 
tlie primary regulator of circulating SHBG concentrations (Dunaif, 1992a). Insulin is thought to lower 
serum SHBG levels by acting directly to reduce hepatic SHBG synthesis (Buyalos et al 1993; Rajkhowa 
et al 1994) such an effect of I was not seen in healthy non-obese women in tlie present study. There 
were significant inverse correlations of SHBG witli BMI in botli patients and controls indicating that 
hyperinsulinaemia in obese patients lowered tire SHBG levels. Tliis was subsequently reflected in the 
FAI in botli tlie patients and in the control group, and hence enliances the manifestation of 
hyperandrogenaemia. Hyperandrogenized patients, with high FAI, showed IR as expressed by 
significant hyperinsulinaemia (P = 0.0006) and liigher FIRI values (P = 0.0021) than patients with 
normal FAIs. Similar observations have shown weak but significant positive conelations between FI and 
FAI (Lanzone et al 1990a; Dale et al 1992b).
The cause and effect relationship between I and androgens in PCOD is still controversial. Insulin has 
been implicated in the increased ovarian production of androgens (Nagamani & Stuart, 1990; Buyalos et 
al 1993; Elkind-Hisch et al 1993; Rajkhowa et al 1994), while it has also been suggested that androgens 
modulate IS in PCOD (Bruno et al 1985). Studies have indicated that chronic hyperinsulinaemia may be 
responsible for hyperandrogenism in PCO by acting directly or indirectly to enhance LH-mediated 
androgen synthesis by the ovary (Shoupe et al 1983; Buyalos et al 1993; Elkind-Hisch et al 1993; 
Rajkliowa et al 1994), By testing women known to be hyperandrogénie due to increased BMI, it was 
possible to show that hyperandrogenism may be tlie trigger to the cycle of androgen-insulin excess. 
Wliether this is a direct effect of androgen or is mediated by secondary factors, such as elements of the 
GH-IGF axis, is unclear (Speiser et al 1992). The bulk of the evidence in the literature indicate that the 
role of androgens in IR is questionable. Men aie not more IR than women and oophorectomy or 
suppression of circulating androgens have failed to improve IS in women (Dunaif, 1992a). Reversal of
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hyperandrogenisin did not normalise IS (Geffiier et al 1986; Dunaif et al 1990; Lanzone et al 1990a; 
Speiscr et al 1992). The data presented here confirm that endogenous andiogens do not play a role in 
sustaining IR. Therefore, there is an association of elevated androgens and changes in IS but tlie 
mechanisms by which hyperinsulinaemia induces hyperandiogenaemia are still miiesolved.
Hyperinsulinaemia may exert its steroidogenic action on the ovaiy tluough IGF-I and its receptors. 
Insulin and IGF-I are closely related peptides and both have been shown to potentiate LH-induced 
ovarian androgen synthesis. The human ovaiy contains I and IGF-I receptors, and both I and IGF-I 
stimulate human ovarian androgen production (Dunaif, 1992a; EUdnd-Hisch et al 1993). Insulin 
suppression of locally produced IGF-I binding proteins might be one of the factors in tlie pathogenesis of 
I-induced hyperandrogenaemia by increasing IGF-I receptor binding in tlie ovary and enhancing 
androgen production by theca-interstitial and stromal cells (EUdnd-Hisch et al 1993). It has been 
suggested tliat if I is to produce ovarian hyperandrogenism, I concentiations must be increased into the 
range that can activate the IGF-I receptors, and polycystic ovarian changes must be present tliat 
predispose tlie ovaries to secrete excess androgens (Dunaif, 1992a). Andiogens may produce ineversible 
changes in target tissue sensitivity to I action. Therefore, suppression of hyperandrogenaemia would not 
alter such effects and may not be a clinically effective modality to improve I action and subsequently 
decrease the risk of NIDDM in patients witli PCOD (Diuiaif et al 1990; Dunaif, 1992a).
A D R E N A L  A N D R O G E N
In the present study, no significant relationship was found between the concentrations of DHEA-S and 
IR. Conflicting information concerning the acute effect of hyperinsulinaemia on circulating adrenal 
androgens, specifically DHEA-S has been reported. In women with PCOD, Pasquali el al. (1983) 
demonstrated a negative correlation between DHEA-S and fasting GLU/INS ratio, and Falcone et al. 
(1990) showed that FI concentrations were significantly associated witli the basal DHEA levels. 
Suppression of DHEA concentrations normally caused by I is impaired in women with PCO and IR and 
this impairment may be another manifestation of a peripheral reduction in I action. This disturbance 
may contribute to adrenal androgen excess in some women with PCOD and may reflect changes in 
adienal responsiveness or peripheral clearance (Falcone et al 1990). However, this mechanism was not 
apparent in the groups of women observed in tliis study.
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G R O W T H  H O R M O N E  /  R E G U L A T O R Y  H O R M O N E S
Baseline GH concentiations were low in both patients and tlie control group. Wliile PCO patients in the 
study by Kazer et a l ( 1990) showed lower GH levels, normal GH levels have been reported by otliers in 
patients described as PCO (Chang et al 1983; Geffiier et al 1986; Slowinska-Srzednika et al 1992). Low 
GH levels could be due to decreased secretion from the anterior pituitary, increased clearance from the 
circulation, or an abnormality of the GH. Kazer et a l (1990) suggested tliat GH levels may be low due to 
impaired GH secretion, since I can reduce GH production. In the present study, no correlation was 
established between GH and FI, supporting the concept tliat tliere was no abnormality in GH secretion 
related to hyperinsulinaemia.
The study patients were weight-matched witli tlieir control counterpar ts, and no correlations were found 
between body mass and either GH or IGF-I in the study groups. However, lean individuals had higher 
(tliough not significant perhaps due to tlie limited sensitivity of the assay) mean fasting serum GH 
concentrations than obese subjects. This may support a relationship between GH and body mass in the 
form of obesity, altliough the timing of blood sampling might have masked this relationship as GH 
exliibits a diurnal variation (Hatasaka et al 1994). It is also known that tlie nutritional status alters GH, 
as acute fasting or chronic malnutrition raises GH and obesity lowers it (Oerter et al 1992).
No significant difference in fasting serum cortisol and/or PRL levels were found between the patients and 
the controls, similar to previous reports (Chang et al 1983; Geffiier et al 1986). The patients and 
controls showed similar rates of fall of glucose during the SITT, and the control group’s GH responses 
showed a similar pattern to that of the patients. However; these responses were not significantly different 
in lean or obese individuals compared to the patients. The regulatory responses of GH, cortisol, glucagon 
and catecholamines vary from individual to individual and according to the rate of fall of glucose, hence 
interpretation of the results is difficult (Pochner et al 1984).
I N S U L I N - L H C E  G R O W T H  F A C T O R - !  ( I G F - I )  a n d  I G F B P s
Basal serum IGF-I concentrations were significantly lower in oligo/amenorrhoeic patients tlian in the 
controls (P < 0.0001) in spite of normal levels of GH; tliis observation was confinned at tlie repeat SITT 
effected 5 weeks later. These findings support tlie obsei-vations of Barreca et a l (1996) who found lower 
IGF-I levels in follicular fluids from patients mth PCOD than in follicular fluid from normally ovulating 
women. However, normal (Kazer et al 1990; Sharp et al 1991; Slowinska-Srzednika et al 1992; Holte et
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al 1994a) and elevated (Laatikainen et al 1990) IGF-I concentrations have also been reported by others. 
These marked differences could be due to the metliods used for IGF-I assays, which depend upon 
extraction of IGF-I from its binding proteins, although simple explanation of the conflicting observations 
are not obvious.
Growth factors are polypeptides tliat regulate the replication and differentiated function of cells. Growth 
factors are present in tlie systemic circulation and are syntliesized by a variety of cell systems and tissues; 
therefore, they may act as systemic or local regulators of cell metabolism. In the circulation, giowtli 
factors are present, free or bound to specific binding proteins as they may also act at a local level. The 
synthesis and effects of the locally produced factor can be modified by systemic hormones in tissues 
expressing tlie hormonal receptor(s). Whereas GH is one of the most important regulators of IGF-I 
synthesis, other hormones such as oestrogens, parathormone and glucocorticoids affect the synthesis of 
IGF-I (Canalis, 1992). Cells tliat secrete IGF-I also secrete one or more IGFBPs. So fai, at least six 
structurally related IGFBPs have been identified and are termed IGFBP-1 through 6. The IGFBPs like 
IGFs are hormonally controlled. The IGFBP-3, the predominant form of IGFBP present in human 
serum, is GH dependent, whereas serum concentrations of IGFBP-1 are suppressed by I. The function of 
the var ious IGFBPs is not exactly known; tliey could be important in increasing tire half-life of IGFs, 
presenting IGFs to their receptors, or modulating tire activity of IGFs by binding tlie biologically active 
free IGF. IGFs have biochemical and functional properties resembling those of I. Insulin-like growtlr 
factor-I induces hypoglycaernia when infused to rats or humans because, like I, it increases intracellular 
glucose transport. Furtliermore, IGF-I decreases I degradation. It is important to note that IGFs are 
expressed by a variety of tissues, and changes in local production are not likely to be detected by serum 
measurements. IGF-I tends to be low and IGFBP-I is elevated in rmfreated DM patients because its 
production is inliibited by I. Insulin-like growth factor-I production is regulated through different 
intracellular mechanisms in liver and peripheral tissues (Tiitinen et a! 1990).
The synthesis and secretion of IGFBPs may play a major role in the regulation of IGF hormonal action at 
the target cell. The role of IGFBPs in ovarian physiology remains unknown. FSH decreases tire release 
of IGFBPs, by an rmcertain mechanism, and tliis may enliance the cellular action of endogenously 
generated and also circulating IGFs at the gramrlosa cells (Adashi et al 1988; Adashi et al 1991; San 
Roman & Magoffin, 1992). The ability of FSH to inlribit the release of IGFBPs from granulosa cells is 
dose- and time-dependent. Low-dose exposure for a relatively short period of time may be compatible 
with the needs of the granulosa cell in the earlier phases of follicular development. Therefore, tlie 
diminished IGFs would be compatible witli the relatively slow early follicular development. More 
prolonged exposure to high doses of FSH and the consequent increase in IGFs may be sufficient to
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maintain and enliance tlie terminal phases of follicular development. FSH-insensitive follicles 
imdergoing atresia may be compromised by decreased IGFs (Adashi et al 1991).
The changes in tissue IGF-I concentiations and thereby activities may be influenced by changes in 
specific IGF-I binding proteins wliich were not evaluated in tlie present study. It has been reported tliat 
IGFBP levels are inversely correlated witli I, resulting in more bioactive unbound IGF-I activity in 
hyperinsulinaemia which may contribute to increased androgen production (Franks, 1989) even in the 
presence of normal or reduced total IGF-I concentrations. In this sbidy, basal IGF-I demonstrated no 
relationsliip witli T or SHBG but a weak positive correlation witli FAI (r = 0.46, P < 0.05) was observed 
in the patient group only.
Circulating levels of seirnn IGF-I, which do not vaiy diuing tlie day and are not influenced by meals 
(Kazer et al 1990), did not correlate with basal GH concentrations. No correlation was found between 
IGF-I and obesity. However; lean controls showed significantly liigher IGF-I levels than obese controls, 
and both lean and obese patients. Nutritional status can alter GH and lGF-1 in normal subjects in 
opposite directions and IGF-I levels change significantly witli age and sex. In cliildren, acute lasting or 
chronic malnutrition lowers IGF-I and ovemutrition raises IGF-I (Oerter et al 1992). It seems tliat tlie 
relationship between IGF-I and obesity may not be a simple linear correlation. Thus it is important to 
weight match controls in any study of PCO and/or disturbed ovarian activity.
The human ovary has both I and IGF-I receptors. Receptors for IGF-I have been identified in rat 
interstitial and granulosa cells, however; specific binding sites for I (Poretsky et al 1984; Nagamani & 
Stuart, 1990) and for IGF-I (Nagamani & Stuart, 1990) have been identified in human ovarian stroma. 
In the normal ovaiy under physiological conditions, I may exert its effect on ovarian steroidogenesis 
mainly tluough its own receptors. However, in PCO, when I is present in higher concentrations, I might 
mediate its action tluough IGF-I receptors (Nagamani & Stuart, 1990), particularly when IGF-I 
concentrations are reduced.
In vitro studies vith granulosa cells of polycystic ovaries indicate that physiological concentrations of 
IGF-I are as effective as FSH in stimulating synthesis and it has been shown that follicular fluid
contains IGF-I. The in vitro studies with Inmian granulosa cells showed that IGF-I and FSH may act 
synergistically to contiol the level of E^  production (Erickson et al 1990). Whetlier a dysfunction in IGF-
I activity is involved in the failure of follicular maturation and reduction in E^  secretion, observed in
PCOs may be questioned or follicular fluid of PCOs may contain inliibitors of IGF-I action such as 
binding proteins. Insulin and IGF-I are closely related peptides and both I and IGF-I receptors have been
176
found in human ovarian tissue (EUdnd-Hisch et al 1993). Ciraldi and coworkers (1992) showed 
functionally intact I receptor binding in adipocytes taken from women with PCOD and a post-receptor 
defect may be involved. There is tlie possibility of hyperinsulinaemia as a consequence of IR and an 
increase in circulating bioavailable IGF-I collectively exerting their actions on the ovaiy tlirough the 
IGF-I receptors (EUdnd-Hisch et al 1993).
Measurements of IGF-ÏI have been less usehil than IGF-I as markers of endocrine disorders (Canalis, 
1992). The granulosa cell IGF-I receptor may constitute one of several variables responsible for 
follicular selection (Adaslii et al 1988).
Follicles of women with PCOs were reported to contain high concentrations of A but reduced E^  and
significant amounts of aromatase activity. However, FSH is unable to stimulate normal amounts of E^
production and release in vivo due to a reduction in tlie number of the granulosa cells and there may also 
be a defect in tlie granulosa cells due to tlie presence of one or more substances in tliese follicles which 
modify the action of FSH. Recently, it has been shown that in the presence of physiological 
concentiations of IGF-I the same amoimt of FSH is capable of stimulating maximal E^  biosynthesis
suggesting that IGF-I may be important for sensitizing tlie granulosa cells to FSH (Adashi et al 1988; 
Mason et al 1993; Barreca et al 1996). Decreased IGF-I concentiations or activity in oligo/amenorrhoeic 
patients may be related to ovulation (Chapter Six). Growth hormone administration, by increasing IGF-I 
levels in follicular fluid, may correct the IGF imbalance and overcome the defect in granulosa cells in 
PCO patients and tlius improve ovarian follicular maturation (Barreca et al 1996).
R E S P O N S E S  T O  E X O G E N O U S  I N S U L I N  A D M I N I S T R A T I O N
Growth hormone, one of the central regulatoiy hormones for I, showed a significant increase at 30- 
minutes after I administration, probably tlie expected response to hypoglycaernia induced by tlie 
exogenous I injection. Tliis increase was statistically significant in the patients but not so in the contiol 
group. Lean patients showed a more significant rise in GH at 30-minutes than in obese patients and in 
lean and in obese controls. This difference cannot be attributed to obesity as obese contiols showed 
similar responses to their lean counterparts. Other cential hormones, such as Gn and PRL, did not show 
a change during the SITT in either patients or controls. Although I stimulated Gn secretion in isolated 
rat pituitaiy cells, human studies indicated that I iiiftision failed to alter Gn release in normal or in
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PCOD patients (Dunaif & Graf, 1989; Dunaif, 1992a). Cortisol, another regulatory honnone for insulin, 
showed a delayed rise at 60-ininutes after I administration..
Dehydroepiandrosterone-sulphate was measured 60-minutes following the I injection and was not 
significantly different from its basal levels. The effect of physiological increases in circulating I 
concentrations on DHEA-S is not well established. Circulating DHEA-S levels during endogenous I 
release in response to OGTT did not change either in patients with PCOD or in controls (Buyalos et a! 
1991). Tliis is not surprising because of the extensive volume of distribution, the prolonged half life, and 
the slow MCR of DHEA-S which would make acute changes in circulating levels of this steroid unlikely. 
Minimal diurnal variability is observed in circulating DHEA-S levels, despite the well established 
pulsatile and circadian fluctuations of cortisol and DHEA. It is luilikely that an acute increase in I within 
the physiological range would be important in the regulation of chculating DHEA-S levels in either PCO 
or euandrogeiiic women (Buyalos et aî 1991). However, rapid changes in circulating DHEA-S in 
response to supraphysiological 1 levels have been reported (Nestler et al. 1987).
A dramatic change was noted in circulating E^  and T concentrations following I administration. 
Supraphysiological hyperinsulinaemia resulted in a significant decline in the levels of E^  at 30-minutes 
and tliis decrease continued at 60-minutes and accounted for a drop of about 17% from tlie basal levels in 
both tlie patients and the control group. Testosterone showed a similar pattern, although to a lesser 
extent (11% decrease from the basal values). Sex hormone binding globulin, FAI and IGF-I did not 
show any significant changes during tlie period of monitoring (60-minutes). However, when the luteal 
phases of tlie ovulatoiy cycles in the patients were analyzed separately, E^ , T, FAI and P showed
significant decreases; while SHBG showed a significant increase during the period of monitoring. 
Significant reductions in E^  and FAI were shown in both the follicular and the luteal phases of the
control group, and other hormonal changes were not significant. A reduction in circulating androgen 
concentrations has been recorded after administration of exogenous I to women with PCO (Dunaif & 
Graf, 1989; Speiser et al 1992). The change in androgen levels following I administration camiot be 
explained on the basis of the physiological diurnal variation because the control group did not show a 
significant decrease although the diurnal variation of androgens was reported to be similar in healthy 
women and in PCO patients (Baird et al 1977). The significant reduction in ovarian steroid 
concentrations was sustained at 60-minutes and a possible effect of acute I administration on ovarian 
steroid secretion must be proposed. This suppression of ovarian androgens in oligo/amenorrhoeic 
women argues against a simple, direct relationsliip between hyperinsulinaemia and hyperandrogenaemia
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(Dunaif & Graf, 1989). The decrease in concentrations was more than the decrease in androgen, 
suggesting that tlie effect on E^  is probably not due to inhibition of supply of androgen precursor alone.
Dunaif & Graf (1989) reported that 1 infusion to achieve supraphysiological levels decreased tlie levels of 
potent androgens (T, DHT and FAI) and acutely increased A and E^  levels in patients witli PCOD. In 
normal women, tlie only significant change in steroid levels dining I infusion was an increase in E^
levels but no change in androgen levels were noted. The relationship between I and androgens is 
complex. Wliile chronic hyperinsulinaemia is associated with hyperandrogenaemia, acute 
supraphysiological I administration was found to decrease the circulating androgen concentrations. 
Insulin-like giowtli factor-I and/or I appears to play a physiological role in tlie regulation of gonadal 
steroidogenesis, but supraphysiological I concentrations can act through the IGF-I receptor. 
Hyperinsulinaemia could act synergistically with other honnonal disturbance(s) such as LH 
hypersecretion, to enhance abnormal gonadal steroidogenesis by increasing ovarian sensitivity to IGF-I 
via regulation of the latter’s receptors (Dunaif & Graf, 1989). However, the same autliors claimed that in 
extreme IR, profound long-standing hyperinsulinaemia alone may be sufficient to produce 
hyperandrogenaemia. The study of the kinetics of these responses to I may reveal changes in ovarian 
steroid output which relate to tlie problems of failure of follicular maturation seen in PCO patients.
O B E S I T Y
Significantly lower mean GH levels were found in obese individuals compared with lean controls, 
indicating that the difference is attributable to obesity. However, BMI was correlated negatively with 
mean serum concentiations of GH in tlie control group, but not the patients. Low GH levels could be due 
to decreased secretion from tlie anterior pituitary, increased clearance from tlie circulation, or an 
abnormality of the GH molecule resulting in misleading immunoassay results. Obesity and IR contribute 
to an increased GH clearance. Lean patients and controls showed a more rapid increase in GH 
concentrations in response to I administration (30-minutes) than obese indhuduals, who showed a rather 
delayed increase of GH (significant at 60-minutes).
Insulin sensitivity and anthiopometric variables have a well-recognized relationship (Sharp et al 1991; 
Dale et al 1992b; Rajkhowa et al 1994). In tliis study, the mean KITT- values failed to show any 
relationship with BMI or WHR in either patients or controls. On the other hand; FI, GLU/INS ratio and 
FIRI proved to be more reliable tlian the KITT values witli the expected relationsliips being shown witli
179
anthropometric variables, including BMI, WHR and waist measurements. Body mass index, WHR and 
waist measurements showed almost identical relationships with FI and FIRI in tlie patients. In tlie 
contiol group, stronger correlations were obsen ed between FI and FIRI with waist measurement than 
witli WHR. Furtliermore, comparison of lean and obese individuals showed a more prominent influence 
of obesity. Fasting I and FIRI were significantly higher in obese than in lean women. In addition obese 
patients showed levels of FI and FIRI similar to obese controls which strengthens tlie apparent role of 
obesity on IR.
Although no single entity is diagnostic of PCOD, obesity is encomitered in 35-80% of cases (Dale et al 
1992b). It has been suggested that obesity is a pathogenic factor in PCOD by contributing to increased 
extraglandular aromatization of androgens into oestrogens. Obesity is also associated witli IR and 
hyperinsulinaemia (Sharp et al 1991; Dale et al 1992b; Rajkliowa ct al 1994).
It is generally accepted that the increased I secretion in obesity seives as a mechanism to compensate for 
IR. However, the processes that trigger hyperinsulinaemia in human obesity and the possible 
patliophysiological consequences of hyperinsulinaemia are not fidly identified. Insulin resistance has 
been observed in lean patients with PCO, so the combination of PCOD and obesity may have a 
synergistic impact on glucose tolerance (Dunaif, 1992a). Current imderstanding of tlie IR and obesity is 
fragmented and inconclusive. Furthemiore, much less is known about the IR in non-obese subjects. It 
has been postulated that tliose individuals with IR and normal BMI will have increased body fat mass in 
comparison to individuals matched for age and BMI. Therefore, individuals witli an identical BMI may 
have differing amounts of fat that correlate with tlie degree of IR. The implication is tliat normal-weight, 
I-resistant subjects must have a complementaiy decrease in lean body mass. In fact, tlie normal-weight, 
I-resistant subjects may show increased body fat when compared with I-sensitive weight-matched subjects 
(Caro, 1991). Women witli PCOD may have significant IR tliat is independent of obesity (Chang et al 
1983).
Although IR and otlier obesity-related metabolic abnormafities are frequently associated witli overall 
accumulation of fat in the body, there is growing evidence tliat tlie distribution of fat may have an 
important additional role. Little is known about the relationsliips between generalized and regional 
deposition of fat in obesity. Fat deposition in tlie subcutaneous region of the trunk was foimd to be 
significantly and independently associated witli peripheral and hepatic IR (Abate, 1996). WHR 
measurements and waist girtli were significantly related to IR (Ferrannini et al 1996).
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Young I-sensitive lean women may have enlianced likelihood of developing IR associated witli both age 
and weight gain (Ferrannini et al 1996). The ability of I to stimulate glucose uptake can vaiy 
substantially in non-obese persons with no apparent disease. The degiee of obesity and level of physical 
activity can also modulate I action. The compensatoiy response to a decrease in I-stimulated glucose 
uptake is an increase in plasma I concentration, and a significant direct relationsliip between magnitude 
of IR and the degree of associated hyperinsulinaemia in non-diabetic individuals has been documented. 
Insulin resistance was much more clearly associated with upper body fat tlian with androgens (Holte et al 
1994a), but hyperinsulinaemia and IR may not be due entirely to obesity, and may be related to the 
degree of hyperandrogenaemia, mainly of adrenal somces (Pasquali et al 1983). However, no significant 
role of adrenal androgens has been obseived in the present study.
O V U L A T I O N
When assessment of tlie controls of the present study, were compared in the follicular and the luteal 
phase, no significant differences were obseived in FI, fasting glucose, C-peptide, GH, IGF-I or PRL 
concentrations. The follicular phase mean KITT-value was similar to that of the luteal phase in both the 
control group and in patients who ovulated (n = 17). The cycle phase had no significant influence on 
FIRI (P > 0.05). However, significant differences in IS were obseived between patients with 
oligo/amenorrhoea and tlieir weight-matched control gi'oup. Anovulatoiy patients were more IR, with 
significantly higher FI and lower GLU/INS ratio, tlian the controls (P = 0.022, 0.039; respectively); these 
differences were not significant when compared with patients witli oligo/amenorrhoea who ovulated 
spontaneously (P = 0.31, 0.08; respectively). This effect was diluted when FIRI was applied (Chapter 
Six).
Blood glucose levels have been reported to be increased in anovulatoiy patients witli PCOD and to be 
greater tlian those in ovulatoiy patients (Filicori et al 1996). The groups reported in tliis study showed 
no difference. The GLU/INS ratio was reduced in both ovulatory and anovulatoiy patients compared to 
the control group.
Filicori et al. (1996) have suggested that obesity and impaired GTT are negative prognostic factors when 
oiTilation is induced witli pulsatile GnRH in PCOD patients. Higher I concentrations in ano\Tilatory 
compaied with ovulatory women with hyperandrogenaemia may indicate tliat IR in the ovaiy contributes 
to tlie mechanism of anovulation in PCOD, but it is important to use weight-matched controls in such 
studies. The fact that I levels were not significantly raised in the groups as a whole but were elevated in
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anovulatory compared with ovulatory women, despite similar androgen levels, suggests that I is not 
directly involved in the increased andiogen production in these women (Shaip et al 1991). The 
obseivations of the present study support tliis statement.
C O N C L U S I O N
Insulin secretion is regulated by numerous metabolic, hormonal, and nemal signals, and tliis hormone 
also feeds back on the pancreatic p-cell to regulate its own receptors. Total body IS can be assessed by 
different techniques, altliough the simpler methods should be implemented for routine clinical practice.
This study showed that the SITT was mueliable for Üie measurement of IR in oligo/amenorrhoeic 
patients because tlie KITT-values were similar in patients and their weight-matched control group, and 
more importantly; tlie test failed to show any correlation witli antliropometiic variables. In addition, the 
correlation witliin patients between the 2 SlTTs, expressed as KITT-values, was poor and disappointing 
compared to other parameters such as FI and logio FIRI. Simpler methods, FI and FIRI, were more 
convenient, easy to measure and showed the ejqiected relationsliips with tlie anthropometric variables - 
comparable ivith the standar d methods of IR measurement.
The baseline IGF-I concentrations were significantly lower in the patients than the controls on botli test 
occasions despite normal circulating GH concentrations.
Fasting glucose and FI were not significantly different between the patients and the controls. However, 
significantly liigher FI and FIRI were observed when obese and lean subgroups were compared. Thus the 
importance of weight-matched controls in any study of PCOD and/or disturbed ovarian activity must be 
emphasized.
The cause and effect relationship between 1 and androgens is controversial. None of the methods used to 
estimate IS showed a significant relationsliip witli androgens in this study. The inverse correlation 
between IS and FAI in tlie oligo/amenorrhoeic group appeared to be secondary to tlie inverse correlation 
of SHBG to sertini I. These powerful relationships between SHBG and FI and logio FIRI were 
demonstrable in both patient and control groups. Insulin is tliouglit to regulate the circulating SHBG 
concentrations (Franks, 1989) by acting directly on hepatic syritliesis of SHBG (Buyalos et al 1993; 
Rajkliowa et al 1994). Hyperandrogenized patients, with high FAI, showed significant 
hyperinsulinaemia and higher FIRI values than patients witli normal FAI.
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The prevalence of impaired glucose tolerance or frank diabetes in obese women ivitli PCOD was shown 
to be 20 % (Dimaif, 1992a), tlierefore; a measmement of GTT is important in these women (Harrington 
& Balen, 1996).
Although IR was independent of obesity, tlie combination of PCOD and obesity had a synergistic impact 
on glucose tolerance. The presence of hyperinsulinaemia may be important since long-term follow-up of 
patients with PCOD indicates tliat tliey are at increased risk of developing DM and CHD. Research on 
the mechanisms of anovulation in PCOD, tlie role of obesity and the clinical significance of the 
relationship between IR and hyperandiogenism are on-going.
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CHAPTER SIX : LONGITUDINAL OBSERVATIONS IN 
INFERTILE WOMEN WITH OLIGO/AMENORRHOEA
6.1 INTRODUCTION
It has been shown that infertile women with oligomenoiThoea are often capable of undergoing 
spontaneous episodes of follicular development, maturation and ovulation. This phenomenon was 
investigated in depth in order to study the endocrine aspects, ovarian morphological development, and 
antliropometiic criteria associated with tliese events.
All patients were investigated longitudinally for a period of 5 weeks. They were monitored for ovarian 
activity twice weekly by measuring plasma levels and once a week by a pelvic US examination. These 
observations were started a miiiimmn of 14 days following a menstrual bleed. Ovarian volume, the 
presence of microcysts and stromal thickness were assessed dming tlie US scan. If Eg concentrations 
and/or US scan indicated signs of follicular maturation at any stage during tlie 5-week period, tlien blood 
sampling was changed to daily and the frequency of US examinations, was increased. Follicular 
maturation and ovulation, were assessed over tlie following two weeks. Cases witli evidence of folbcular 
matmation and ovulation were assayed for P in the luteal phase. If concentiations of E^  and/or tlie US 
scan indicated no ovarian activity, the E^  sampling was terminated after tlie 5* week.
Results aie presented as mean values for each individual patient dming each week of observation. By 
design this was a minimum of 2 samples/week for endocrine estimations and 1 observation per week for 
US scans. Wliere follicular growth was noted tlie nmiiber of observations was increased. In sections 6.2 
and 6.3 “mean values during tlie 5-weeks period” the mean represents individual means of all samples 
analyzed dming that week.
There were 3 main sections to the observations : - I) Changes in the reproductive hormone 
concentiations dming tlie 5-week ivindow will be discussed in section 6.2. The occurrence of 
spontaneous ovulation in oligo/amenonhoeic patients and assessment of tlie luteal phases are recorded. 
Relationsliip of antluopometric variables, LH and hyperandrogenization with tlie incidence of 
spontaneous ovulation are examined and discussed, as is tlie role of IR. 2) Changes in the ovarian US 
picture dming tlie 5-weeks of observation aie recorded in section 6.3. The dynamic changes in TOV,
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follicular distribution and the presence of stromal density are examined. 3) Section 6.4 covers tlie 
variations in tlie endocrine parameters and in ovaiian volmne within patients and correlates this witli the 
clinical presentation of the patients.
Unfortunately tliere were no ultrasonographic examinations for tlie control group because of their 
reluctance to undergo the examination. The upper limit of ovarian volume for normal subjects was taken 
as 9.0 cm  ^(Chapter Foiu) and the ovary was considered enlarged in patients when the volume was > 9.0 
cm^ .
6.2 CHANGES IN ENDOCRINE VARIABLES DURING THE 
WINDOW (5-WEEKS) OF OBSERVATIONS
6.2.1 VARIATIONS IN  ENDOCRINE OBSERVATIONS
There was a wide range of variations in concentrations witliin the whole group of patients and also 
witliin individual patients. There was no biological point of reference in such analyses, as not all 
subjects showed a LH surge, and the occurrence of spontaneous follicular maturation and omlation at 
any time rendered comparison of different weeks inappropriate. However, Figme 6.1 shows the 
considerable range of values seen during the period of observations vaiying from menopausal levels
(< 30 pg/mL) to normal mid-cycle peak values (approximately 300 pg/mL). Figme 6.2 shows the 
variations seen witliin patients dming tlie same time (Table 6-1), indicating that ovarian follicular 
function is not static in these patients.
185
Figure 6.1
Figure 6.2
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Similar variations were also observ ed for the other reproductiv e hormones monitored during the window 
of observation - LH, T, SHBG and consequently FAI. Figures 6.3 to 6.10 demonstrate the wide 
variations confirming that these hormones are not static and serve to indicate how unrepresentative a 
single hormone value can be.
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The profiles of LH showed large variations within the group during the 5-week window (Figure 6.3) 
(range 1.5 - 39.5 ÎU/L), and Figme 6.4 shows tliat tlie vaiiations witliin patients were also large. If tlie 
upper limit of normal is taken as 10.0 lU/L then 24 patients (57.1%) showed botli normal and 
supranormal values, while 18 patients (42.9%) showed all samples witliin tlie normal or supranormal 
ranges.
Figure 6.3 :
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Similarly, T concentrations showed wide variations within the group (Figure 6.5), and also within 
patients (Figure 6.6) during the 5-week period of monitoring. Testosterone concentrations were 
consistently normal (< 2.5 nmol/L) in 12 patients wliile always elevated in only 6 patients. Figure 6.6 
and Table 6-1 demonstrate the wide variation mtliin patients.
Figure 6.5 ;
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As with E2 , LH and T, the profiles of SHBG showed large variations within the group, ranging between 
11 and 295 ninoLL (Figure 6.7). However, Figure 6.8 shows tliat SHBG concentiations were relatively 
stable within individuals during tlie 5-week window of observation, and showed tlie most consistent 
values witliin patients of all of the parameters measured (Table 6-1).
Figure 6.7 :
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Consequent to the relatively stable SlIBG concentrations, FAI variations within the group and within the 
patients (Figures 6.9 and 6.10) showed similar patterns to those of T.
Figure 6.9 :
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Table 6-1 : Variations in the Endocrine Hormones within Patients
Homione Average Coetficient of Variation range (%)
Ez (pg/mL) 30.1 % 4.0 - 78.7
LH(IU/L) 26.0 % 10.2-75 .4
T (mnol/I,) 31.5% 8.7 - 64.5
SHBG (mnol/L) 25.4% 5.0 - 72.6
FAI 36.4 % 6.0 -110 .0
These wide variations in the reproductive homione concentrations during the 5-week window of 
obseivations indicate that ovarian fimction is not static in oligo/amenorrhoeic patients. This emphasizes 
the limited value of single sample honnone assays when used as diagnostic criteria or as means to 
investigate tlie patliophysiology of tlie disorder.
6,Z2 RELATIONSHIP BETWEEN ANTHROPOMETRIC VARIABLES AND 
FOLLICULAR PHASE ENDOCRINE PROFILES
The relationsliips between antluopometric variables and follicular endocrine profiles in tlie patients were 
explored with reference to spontaneous ovulation.
The conelations between mean follicular endocrine profiles and BMI and WHR are demonstrated in 
Table 6-II. Significant relationships were only observed between the mean follicular hormones 
representing tlie androgenic state in the patients, and aiitliropometric variables (Figures 6.11 -6.14).
The clearest link between endocrine and anthropometric variables was seen in tlie SHBG data which was 
also tlie most consistent element.
Table 6-H : Correlations betiveen Mean Follicular Endocrine
BMT W H R
r P r P
^2 (pg/inL) 0.01 NS 0.09 NS
LH (lU/L) 0.03 NS 0.08 NS
FSH (lU/L) 0.05 NS 0.01 NS
LH/FSH Ratio 0.06 NS 0.002 NS
T (mnol/L) 0.38 0.013 0.14 NS
SHBG (nmol/L) -0 .39 0.0097 -0.43 0.0042
FAI 0.42 0.0057 0.23 NS
A (mnol/L) 0.06 NS 0.15 NS
P* (ng/niL) 0.32 NS 0.39 NS
17a-OHP (ng/mL) 0.18 NS 0.11 NS
DHEA-S (mnol/L) 0.18 NS 0.06 NS
PRL(IU/L) 0.23 NS 0.29 0.062
P» represents tlie mean values o f luteal phases o f ovulatory cycles only. P> 0.05 is NS
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Figure 6.11
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Figure 6.13
Figure 6.14
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The mean follicular phase T, SHBG and FAI concentrations showed more powerful relationships with 
anthropometric variables than did tlie basal levels of the same hoimones (Chapter Fom). While tlie basal 
levels of T showed no significant relationsliip with BMI or WHR, the mean follicular phase T correlated 
significantly with tlie body mass. On the other hand, tlie relationships between antliropometiic variables
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and the basal as well as the mean follicular phase SHBG concentration, and subsequently FAI were 
consistent (Chapter Four). These relationships were even stronger with tlie mean follicular phase SHBG 
and FAI than tlie single basal concentrations. These obseivations emphasize the importance of repeated 
sampling of such hormones, and tliat a single assay is not an accurate representation of tlie hormone 
concentrations. Furthermore, the consistent and powerful relationships between SHBG and 
antliropometiic variables (BMI and WHR) suggest tliat SHBG may be a better niaiker of tlie disorder 
than E2 , LH or T.
6.13 SPONTANEOUS OVULATION
Spontaneous ovulation was defined by the occurrence of a LH surge followed by a significant rise in P 
above 1.5 ng/iuL. The LH surge was diagnosed by the presence of at least doubling of the preceding LH 
values from one sample to the next to a concentration > 10.0 lU/L. Evidence of adequate iuteinization 
was confirmed if a single P concentration of > 4 ng/mL was detected, at least 48 hours after the LH 
surge. The mean luteal phase serum P concentration was estimated to assess luteal function. Tliis 
required a sample to be taken between days LH peak + 4 and LH peak + 9 inclusive.
All samples taken outside the luteal phase were designated as "folliculai’" phase. The mean of the 
samples at tlie follicular phase represent the mean of all the samples of tlie observation period for those 
who did not ovulate, and the mean of all the samples of the follicular phase taken at least 2 days before 
tlie day of the LH peak for those who ovulated.
Follicular development and o\mlation was documented in 18 patients (43.9%) during tlie period of 
obseivation. All the patients who ovulated exhibited a demonstrable LH siuge and Iuteinization with 
circulating P concentrations > 4 ng/mL. The mean concentration of the mid-luteal phase P secretion 
(day LH peak + 7) for tlie patients who ovulated spontaneously was 13.2+4.58 ng/mL (range 5 -2 5 .5  
ng/mL).
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6.2.4 ASSESSMENT OF LUTEAL FUNCTION-PROGESTERONE INDEX ( P I )
The mid-luteal phase (day LH peak + 7) P secretion for the patients who ovulated spontaneously, was 
similar to the mean P value of the mid-luteal phase in the control group of tliis study (13,2 ± 4.58 ng/mL 
and 12.20 ± 7.16 ng/niL; respectively).
The mean luteal P value (LH peak + 4 to + 9 inclusive) was 11.60 ± 2.30 ng/mL (range 7.11 - 13.30 
ng/mL). The luteal phase profile of P was quantified using a PI which describes tlie area imder the curve 
of tlie patient's plasma P concentrations on days LH peak + 4 to + 9 inclusive, relative to that described 
by the mean of the laboratory normal range. The formula used was :
sum [P] (LH + 4 to LH + 9) (PT) x 100 / sum [P] (LH + 4 to LH + 9) (Laboratory normal mean) 
(Fleming et al 1995).
The laboratory normal mean data was derived from daily samples taken from 18 fertile volunteers with 
normal menstinal rhythm, and from 12 spontaneous conception cycles. The laboratoiy normal mean 
AUC value of P (LH +4 to +9 inclusive) was 73.4 ng/mL. A normal profile yielded a PI of 100, and the 
lower limit of the normal range was 70 (Fleming et a! 1995). The mean PI of the study patients was 
subnormal (57.75 ± 29.56) with a range of 13.6 - 112.4. Almost half of the group had a Pis of < 70 (10 
out of 18 patients); altliough normal P concentiations were established in all patients by mid-luteal phase 
(LHpeak + 7 days).
Body Mass and Ovulation
There was no significant difference in BMI between patients who showed spontaneous folliculai 
maturation and ovulation, and tliose who failed to ovulate, or the control group (Figure 6.15). However, 
WHR was higher in patients who did not ovulate compared to tliose patients with spontaneous ovulation 
and also the controls (P = 0.075, 0.0004; respectively) (Figure 6.16). When the waist measurements 
were compared between the gioups, these relationships were less significant than when WHR 
measurements were used (Figure 6.17). These impoitant observations suggest that the ratio of body fat 
distiibution, rather than total body mass, may be related to tlie capacity to undergo follicular matmation 
and ovulation.
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6.2.5 RELATIONSHIPS BETWEEN ENDOCRINE & METABOLIC VARIABLES 
AND SPONTANEOUS OVULATION
6.2.5.1 Reproductive Endocrinology and Ovulation
Analyses of the mean follicular phase concentrations of the reproductive hormones in patients who 
ovulated spontaneously (n =18) were compared with those who did not ovulate and also with the control 
group (Table 6-III).
Patients who ovulated and tliose who did not ovulate showed similar follicular phase values of LH, FSH, 
LH:FSH ratio, A and 17a-0HP. Significantly lower concentrations of E^ , SHBG, FAI and PRL were
determined in the anovulatory patients compared with tlie ovulators, while differences in T and DHEA-S 
were not significant.
Compared with tlie control group, LH, LH:FSH ratio and FAI were raised in botli groups of patients; 
tliose who ovulated and tliose who did not.
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Table 6-n i : Comparison of the Me:m Follicular Phase Endocrine Variables in relation to
Patients Controls
Ovulation No Ovulation P P* p * »
n 18 23 19
E2 (pg/mL) 67.35 ±  19.9 48.11 ±25.98 0.013 65.00 ±34 .20 NS 0.0765
LH (lU/L) 9.67 ±  2.76 9.98 ± 0 .7 4 NS 5.25 ± 4 .39 0.0009 <0.0001
FSH (lU/L) 4.41 ±1.51 5.09 ±0.45 NS 5.15 ± 1 .73 0.018 NS
LH:FSH Ratio 2.11 ±  0.66 2.04 ± 1.43 NS 1.07 ± 0 .80 0.0001 0.0001
T (nmol/L) 1.97 ±  0.78 2.59 ± 0.31 0.09 1.53 ± 0 .93 0.40 <0.0001
SHBG (nmol/L) 56.66 ±  11.52 48.17 ±9.13 0.012 62.53 ±25.77 NS 0.017
FAI 4.52 ± 3 .29 6.81 ± 0 .48 0.047 2.62 ± 1.78 0.036 <0.0001
A (nmol/L) 7.89 ± 4 .15 6.31 ±3.33 NS 6.13 ±2.85 NS NS
P (ng/niL) 13.20 ± 4 .5 8 12.20 ± 7 .16 NS
17a-OHP (ng/mL) 1.56 ± 0 .32 1.70 ± 0 .4 7 NS 1.48 ± 1 .14 NS NS
DHEA-S (nmol/L) 2762 ± 1 7 5 0 2097 ±272 .0 0.079 2126 ± 1788 NS NS
PRL(IU/L) 226.0 ±  138.6 349.9 ±29 .18 0.0002 424.3 ±519.6 NS NS
Groups were compared using Student's t-test. 
(P*); whereas the differences between patient'
The differences between patients who ovulated and controls were expressed as 
's who did not ovulate and controls were expressed as (P**). P > 0.05 is NS.
Figure 6.18 shows tlie distributions of the mean follicular phase E2 concentrations amongst tire patients 
who failed to ovulate, those who ovulated and the controls.
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The mean follicular phase LH concentration in tlrose patients who ovulated was similar to those who did 
not ovulate (9.67 ± 2.76 vs 9.98 ± 0.74 lU/L, respectively) (Figme 6.19). The basal LH concentiation 
showed a similar observation.
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Consistently elevated follicular LH concentration was obseived in 11 oligo/anienorrhoeic patients 
(26.8%), and 4 of these showed spontaneous o\mlation with a mean PI of 33.3 ± 20.82. Six of 14 
(42.9%) women with nonnal levels of LH were observed to ovulate. When they did ovulate, Figure 6.20 
shows tliat tlie range of PI values seen in tlie two gi oups was similar, indicating that elevated LH was not 
directly related to the incidence of follicular maturation, luteinization, occurrence of spontaneous 
ovulation or tlie deficient luteal fimction obseived in tliese patients.
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Figure 6.21 shows the distributions of the mean follicular phase T concentrations amongst tlie patients 
who failed to ovulate, those who ovulated and the controls. The data show the raised values of T in the 
no oiulation group compared witli the controls, but the difference between them and the patients who 
ovulated was not significant. The differences in tlie distribution of SHBG in patients who ovulated, 
failed to ovulate and the controls are illustrated in Figure 6.22, and show broad overlaps in tlie data 
despite the statistical significance. Similarly, Figure 6.23 illustiates tlie significant differences in FAI 
among the subgroups. These observations strongly emphasize the influence of follicular SHBG 
concentrations, ratlier than LH or TT, on the occurrence of follicular maturation and spontaneous 
ovulation in patients witli oligo/anienonhoea.
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There was no significant difference in the mean follicular phase T concentrations seen in patients who 
ovulated or those who did not (Table 6-1V). In addition, there was no significant difference in the 
proportion of patients witli elevated T concentrations (mean ± SD of contiols = 2.5 nmol/L) who show ed 
spontaneous ovulation (4 out of 10), and those with normal T concentrations (14 out of 30, P > 0.05). 
However, tlie mean follicular T concentrations were significantly higher in the patients with elevated LH 
values (1.78 ± 0.74 (normal LH), 2.57 ± 1.16 (high LH); P = 0.0105) and the correlation between 
follicular phase LH and T concentrations was r = 0.29 (P = 0.061).
Examination of the incidence of spontaneous ovulation among patients, with respect to FAI, showed that 
tlie proportion of patients witli elevated mean follicular phase FAI (mean ± SD of controls > 4.5) who 
had spontaneous ovulation (7 out of 24) was lower tliaii for those with normal FAI (11 out of 16, P = 
0.053). This observation suggests that the more hyperandrogenized (as an effect of SHBG rather than 
TT) the patient is, tlie less likely she is to have spontaneous ovulation. Similar relationships were 
obsen'ed when basal concentrations of T and FAI were applied.
Table 6-lV : Relationship between T and FAI and Spontaneous Ovulation in Patients
Spontaneous Ovulation No Ovulation P
Normal (n) High (n) Normal (n) Higli (n)
T (imioI/L) 1.72 ± 0 .59  (14) 2.78 ± 0 .83  (4) 2.18 ± 0 .85  (16) 4 .0 4 ± 1 .7 4 (6 ) NS
FAI 2.38 ± 1 .15  (11) 7.58 ± 2 .8 9  (7) 2 .6 4 ± 1 .1 9 (5 ) 8.48 ±  3.44 (17) NS
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6.2.S.2 Metabolic Variables and Ovulation
Mean basal cortisol» GH, FI, fasting glucose, C-peptide and KITT- values were similar in patients who 
had spontaneous ovulation or patients who did not ovulate and in tlie control group (Table 6-V). A 
significantly higher mean basal IGF-I concentration was found in tlie controls than in botli subgroups of 
patients, and in addition tlie values of IGF-I were also significantly higher in patients who ovulated than 
ill those who did not (Table 6-V) (Figure 6.24).
Table 6-V : Comparison of the Mean Follicular Phase Metabolic Variables in relation to
Patients Controls
Ovulation No Ovulation P P* p »*
n IS 22 19
Cortisol (ug/dL) 13.03 ± 5 .94 15.31 ±7.21 NS 13.89 ± 3 .99 NS NS
GH (ng/mL) 3.09 ± 5.85 1.68 ± 3 .02 NS 2.39 ± 2 .3 8 NS NS
IGF-I (mnol/L) 16.29 ±4.35 11.1 ±5.38 0.010 29.07 ± 12 .48 0.007 < 0.0001
FI (inlU/L) 10.67 ±6 .98 13.78 +  12.08 NS 8.09 ±  5.53 NS 0.066
Fasting glucose (mniol/I^) 5.16 ± 0 .5 7 5.11 ±0.45 NS 5.09 ± 0 .46 NS NS
C - Peptide (ng/mL) 1.03 ± 0 .6 4 1.32 ±0.66 NS 1,05 ± 0 .59 NS NS
KITT - value (% / min) 4.94 ±  1.52 3.61 ± 2 .42 NS 4.73 ± 1 .9 2 NS NS
Groups were compared using Student's t-test.Tlie differences between patients who ovulated and controls were expressed as (P*); 
whereas the differences between patient's who did not ovulate and controls were expressed as (P**).P > 0.05 is NS.
Figure 6,24 :
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There was no relatioiisliip between IGF-I and E2, LH, FSH, T or SHBG. However, IGF-I was 
significantly related to mean follicular FAT (r = 0.48, P = 0.041). It may be that IGF-I stimulates tlie 
accumulation of free circulating androgens ratlier tlian the production of androgens.
6 , 2 . 5 , 3  I n s u l i n  S e n s i t i v i t y  a n d  S p o n t a n e o u s  O v u l a t i o n
Fasting insulin concentrations, GLU/INS ratio and FIRI, as simple metliods to estimate insulin 
sensitivity, showed variable relationsliips with tlie incidence of spontaneous follicular growth and 
ovulation in the patient group (Table 6-VI). There was a tendency towards increasing FI and FIRI with 
the degree of disturbance of ovarian function, but the differences were not significant except when 
patients who failed to owlate were compared with controls. The difference in FI between patients who 
ovulated and those who did not may be masked by a single high reading in the o\mlatory group (FI = 34 
mlU/L) (Figure 6.25). However, this indicates that I may not have a direct influence on tlie occurrence 
of spontaneous oWation in these patients.
Table 6 - V I :  Relationships between Spontaneous Ovulation and Insulin Resistance
Patients Controls
Ovulation No Ovulation P P* p **
n 17 17 19
FI(mIU/L) 10.26 ± 6 .9 7 14.15 ±9.01 NS 8.09± 5.53 NS 0.022
Glucose/Insulin Ratio 0.61 ±  0.26 0.62 ± 0.49 NS 0.95±0.49 0.08 0.039
FIRI 2.21 ±1.73 2.95 ± 2 .34 NS 1.70± 1.44 NS 0.054
Groups were compared using Student's t-test. The differences between patients who ovulated and controls were expressed 
as (P=*=); whereas the differences between patients who did not ovulate and controls were expressed as (P**). P > 0.05 is NS.
Altliough FI was significantly higher in patients who did not ovulate tlian in tlie control group; this effect 
was diluted when logio FIRI was applied (Figures 6.25 and 6.26).
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Figure 6.25
Mean Fasting Insulin and Spontaneous
Ovulation in Patients and Controls
P = 0.31
P = 0.17
P = 0.0223 0 -
B
Ea
1 0 -
CTRL
Figure 6.26
Mean Logio FIRI and Si>ontaaeous Ovulation 
in Patients and Controls
2 .0-1
P = 0.131 .5 -
P =  0.48
P = 0.0541.0 -
0 .5 -
oo
0.0 - oq
-0.5 No Oviüaüon CTRLOvulation
Ô . 2 . 5 . 4  L e p t i n  a n d  S p o n t a n e o u s  O v u l a t i o n
The mean plasma concentrations of leptin were similar in patients and controls (Table 6-VII). The mean 
leptin concentration in patients who ovulated was lower than patients who did not ovulate but the
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dififërence did not reach statistical significance (18.75 ± 13.28 vs 27.54 ± 16.66 ng/mL, P = 0.075). No 
correlation was found between leptin and E2 , LH, FSH, T, SHBG or FAI.
The strong coiTelations between leptin concentrations and antliropometiic variables in patients and 
controls, are demonstrated in Table 6-VII and Figures 6.27 - 6.30. The serum leptin levels were higher 
in obese individuals, patients and controls. Leptin concentrations were significantly higher in lean 
patients than lean controls (P < 0.05), but there was no such difference between obese patients and their 
counterpart obese controls.
Table 6-VII : Mean Leptin Concentrations and BMl in Patients and Controls
Patients Controls P
n 40 19
All 23 .6 9 + 1 5 .5 3 (3 .8 5 -6 6 .0 1 ) 21.77 ±16.79  (3 .68-56 .14) NS
BMI < 29 kg/nf 15.97+ 9.90(3.85-40.28) 9.46 ± 4.28(3.68-18.17) 0.0448
BMI > 29 kg/iiF 35.03 ± 15 .52  (10.0-66.01) 37.89 ± 12 .2  (25.37-56.14) NS
WHR <0.8 9.25 ± 4 .8 7  (3.85-17.77) 11.05 ± 7 .64  (3.68-29.33) NS
WHR > 0.8 27.08 ±15.23 (5.52-66.01) 33.70 ±16.28  (8.34-56.14) NS
Although the relationsMp between sermn leptin concentrations and fat distribution, expressed as WHR, 
was more pronoimced in patients tlian the controls, it is apparent tliat tlie association of leptin witli 
obesity was similar in the two groups, tliere being no difference between the correlation criteria (slope, r, 
and intercept) (Figure 6.27).
Waist measurements were conelated with leptin concentrations (Figure 6.29) and confrrnied tlie strong 
correlations shown with tlie other antliropometric variables. This emphasizes tliat leptin is influenced by 
body fat, especially truncal obesity.
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Figure 6.29 :
Correlation : Waist and Leptin in Patients
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The relationship between Leptin, BMI and the occurrence of spontaneous oiuilation in patients are shoim 
in Table 6-VIII and Figures 6.30 - 6.31. Leptin levels were significantly higher in obese patients 
whetlier they ovulated or not. However, in lean anovulatory patients the range of leptin concentration 
was markedly Mgher tlian tlie range in ovulatory patients. Therefore, the difference in the mean leptin 
concentration between the lean subgroups could be masked by the wide variation between patients as 
demonstrated by a high SD.
Tabic 6-VIII : Relationship between Leptin and Spontaneous Oiiilation in BMI-matched 
Patients
Spontaneous Ovulation No Ovulation
Leptin (ng/mL) Lean (n=12) Obese (n=6) P Lean (n=ll) Obese (n~ll) P
mean+ SD 12.92 +  4.81 32.32 ±  14.73 0.0006 17.00+11.22 34 .92+ 18.48 0.0098
range 3.85-19 .01 10.00-47.92 4.44-39.71 6.46 - 66.01
Groups were compared using Student’s t-test. Tlie differences were expressed as P-value witli P 5:0.05 is NS.
The effect of leptin on the occunence of spontaneous ovulation was masked in tlie obese individuals. 
However, when lean individuals were examined, a borderline significance was found between lean 
patients and lean controls (Table 6-IX).
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Table 6-IX : Relationship between Leptin and Spontaneous O'viilation in Lean patients
Lean Patients Lean Controls
Leptin (ng/mL) Ovulatory Anovulatory P P»
n 12 11 11
mean + SD 12.92 ±4.81 17.00 ±11.22 0.075 9.46 ±  4.28 0.0837 0.050
range 3.85-19 .01 4.44 - 39.71 3 .68 -18 .17
Groups were compared using Student's t-test. The differences between patients who ovulated and controls were expressed 
as (P*); whereas tlie differences between patients who did not ovulate and controls were expressed as (P**). P > 0.05 is NS.
Figure 6.30 :
Relationship between Leptin, BMI and 
Spontaneous Ovulation in Patients
80-1
7 0 - P =  0.0098
6 0 - □
1 5 0 - P =  0.0006 □a
4 0 - o □■ □
3 0 - 0
m □
2 0 - o• • • " , DO• • • • ■■
1 0 - o ■_
;
0 - < 2 9  > 2 9
O vu lation
(BMI) < 2 9  > 2 9
No O vulation
Figure 6.31 :
Relationship between Leptin, WHR and 
S]K)ntaneous Ovulation in Patients
7 0 -
6 0 -
P = 0 .01!5 0 -
oo
Dn,
oo □□10- oo
< 0.8 (WHR)> 0.8 < 0.8 > 0.8
O vu lation No O vulation
209
It is apparent that the occurrence of ovulation was not directly related to leptin concentrations when 
compared in BMI-matched or WHR-matched patients (Figme 6.32 and 6.33). Similar observations were 
found when patierrts were compared to their weight-matched controls (Figure 6.34).
Figure 6.32
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Figure 6,34 :
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Figures 6.35 - 6.37 show tliat tliere were similar relationships between seiimi leptin concentrations and 
antlu'oponietric variables in tlie two groups of patients : ovulators and non-ovulators. Figure 6.35 shows 
tliat the relationship between leptin and BMI was similar in tlie ovulatory patients and the controls, and 
tliat the patients showed parallel but slightly offset relationship (i. e. for a given BMI, leptin was higher 
in tlie anovulatoiy patients but the difference was not significant). It is milikely that the occurrence of 
spontaneous ovulation in oligo/ainenorrhoeic patients is directly influenced by leptin levels.
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Figure 6.35
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Figure 6.36
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Figure 6.37 :
Correlation : W aist, Leptin and Siwntaneous
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6.2.6 CORRELATION BETWEEN LEPTIN AND INSULIN RESISTANCE
Highly significant relationships were obsen^ed between serum leptin concentrations and the indices of m, 
expressed as FI and logio FIRI, and fasting glucose (Figures 6.38 - 6.40). More significant relationships 
were obseived between FI and leptin and logio FIRI and leptin concentrations in o\mlatory than 
anovulatoiy patients (Figme 6.41 and 6.42). Patients with IR (high FI and FIRI) showed significantly 
higher leptin concentiations. This may indicate that spontaneous ovulation is indirectly influenced by 
tlie strong relationship between leptin and IR. There were no relationship between leptin and IGF-I 
concentrations.
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Figure 6.38
Figure 6.39
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Figure 6.40 :
Figure 6.41 :
Correlation : Logio FIRI Leptin in Patients
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Figure 6.42 :
Correlation : Logio FIRI, Leptin and
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6.3 CHANGES IN OVARIAN ULTRASOUND VARIABLES 
DURING THE WINDOW OF OBSERVATIONS
63,1 VARIATIONS OF TOTAL OVARIAN VOLUME (  TOV)
There was a wide range of vaiiations in TOV witliin the whole group of patients during tlie 5-week 
window of observation (Figure 6.43). These variations were even more pronounced witliin individual 
patients (Figure 6.44). The range of TOV was wide, varying from < 5 cnf to 65 cm ,^ (the average 
coefficient of variation was 23%, range 2.16 - 56.8%).
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Figure 6.43
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6.3,2 DYNAMIC CHANGES IN TOV
The dynamic changes in ovarian volimie were correlated to tlie changes in the reproductive hormones, tlie 
changes in the metabolic variables and the occurrence of spontaneous ovulation during the 5-week 
window of observations.
6 . 3 . 2 . 1  R e l a t i o n s h i p  w i t h  R e p r o d u c t i v e  H o r m o n e s
There was no relatioiisliip between the TOV and any of the reproductive hormones. In addition, the 
levels of Ez, LH, FSH, T, SHBG and FAI assayed on tlie day of the ultrasoiuid scan at the smallest and 
the largest TOV are demonstrated in Table 6-X and Figures 6.45 - 6.47. It is apparent that there was no 
influence of ovaiian volume on tlie concentrations of the reproductive hormones.
T a b le  6 -X  : T h e  C o n cen tra tio n s o f  R ep ro d u ctiv e  H orm o n es a t th e  S m a llest
S m a lle s t  T O V L a r g est  T O V P
E2 (pg/mL) 59.9 ±  33.2 72.4 +  52.4 NS
LH (lU/L) 9.6 ±  4.9 10.6 ±  5.0 NS
FSH (lU/L) 5 .3 +  2.7 5.6 ±  5.8 NS
T (nmol/L 2.7 ± 1 .7 2 .6 +  1.5 NS
SHBG (nmol/L) 55.9 +  33.3 63.9 ±  32.9 NS
FAI 5.8 ±  4.5 5.1 ±  3.8 NS
The data was compared using paired t-test, P > 0.05 is NS
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Figure 6.47 :
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The patients’ 5-weeks TOV mean (mean of each patient’s 5-week mean TGV) was 19.33 ± 7.45 cm^ .
There were wide dynamic changes in TOV during the period of observation, ivith 68.3% of patients 
showing > 60% change in their TOV and 41.5% had > 100% change in TOV during the same period. 
However, tliere was no difference in endocrine profiles or antluopometiic variables between patients who 
showed these changes in TOV and those who did not.
The mean difference between maximum and minimum TOV for tlie patients was 11.23 ± 9.62 cn f. 
About half of the patients showed a variation in their TOV more than tlie group mean difference between 
minimum and maximum volume.
6 . 3 . 2 . 2  R e l a t i o n s h i p  w i t h  A n t h r o p o m e t r i c  V a r i a b l e s
The mean values of TOV of the patients did not corr elate with BMI or WHR during the 5-week window 
of obseivations. In addition, when the patients were subgrouped to BMI < or > 29 Kg/m ,^ TOV 
measurements were similar in obese and lean patients (Figure 6.48). Similarly, TOV was not 
significantly different in patients witli WHR > 0.8 and those with WHR < 0.8 (Figure 6.49).
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Figure 6, 48 :
Figure 6.49 :
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There was no relationship between tlie anthropometric variables and tlie number of follicles or the 
presence of thick stroma.
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6 . 3 . 2 . 3  R e l a t i o n s h i p  w i t h  I n s u l i n  R e s i s t a n c e  a n d  M e t a b o l i c  V a r i a b l e s
Tliere was no relationship between mean TOV and FI, logio FIRI, GH or cortisol. Also none of the 
metabolic variables was correlated with the number of follicles or follicular distribution.
6.3.3 F O L L IC U L A R  D IS T R IB U T IO N  (P E R IP H E R A L  /  C E N T R A L )
There were 407 ultrasonographic ovarian obseivations for follicular distributions. On 234 occasions 
(57.5%) a peripheral follicular distribution was observed. Only 6 patients showed a central follicular 
distribution throughout tlie period of monitoring, 12 patients always showed a peripheral follicular 
distribution and the rest of the patients had a mixed picture.
Interestingly, a cliange from peripheral to central follicular distribution or the reverse was noticed in one 
or both ovaries in 63.4% of patients, with a total number of 72 changes, seen equally in the right and left 
ovaries.
The mean ovarian volume was similar when follicles were peripherally (10.3 + 7.0 cm )^ or centrally (9.8 
± 6.4 cnf) distributed (Figme 6.50).
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However, when patients with only centrally distributed follicles (6 patients) were compared witli those 
patients with only peripheral (12 patients) or witli mixed (peripheral and central) pictures (24 patients), 
tlie following was observed : the mean TOV for centrally distributed follicles (13.47 ± 1.54 cm )^ was 
significantly smaller than tire mean TOV for peripherally distributed follicles (18.40 ± 1.05 cnf) and that 
of the mixed picture (21.0 ± 0.94 cm )^ (P = 0.0004, < 0.0001; respectively). In addition, patients with 
centrally distributed follicles had significantly lower mean follicular phase T concentrations and FAX 
than patients witli peripheral or mixed follicular distribution. The mean follicular phase SHBG 
concentrations were similar in patients who had centrally or peripherally distributed follicles but 
significantly higher than patients with a mixed picture. The mean follicular phase E2 , LH and FSH were 
similar in the three groups.
The mean number of follicles per ovary during the 5-week window of observations was 12.5 ± 2.9 (range 
5-24). There was no difference in the number of ovarian follicles between patients or witliin patients. 
The mean number of follicles was similar when peripherally or centrally distributed. The number of 
follicles was significantly correlated with TOV (r = 0.53, P = 0.0051) dining tlie 5-week period of 
observation.
It is apparent from the data, tliat the larger tlie ovarian volume the greater the number of follicles pushed 
peripherally by the thickened ovarian stroma due to hyperandrogenization. However, tlie number of 
follicles does not influence their distribution (Figure 6.51).
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6,3,4 STROMAL DENSITY
Thick stroma was demonstrable in bolh ovaries by US scanning in 31 patients (75.6%), while only 8 
patients (19.5%) had a unilateral thick stroma. The TOV measurements were significantly larger in 
patients who showed bilaterally thickened stioma compared with a unilateral observation during the 
period of monitoring (Table 6-Xl). However, tliere was no difference in BMl, WHR, Ez, LH, FSH, T, 
SHBG, FAl and A between these two group of patients.
Table 6-XI : The TOV in Bilateral versus Unilateral Ovarian 
Thickened Stroma in Patients
Bilateral Unilateral P
11 31 8
Week -1 20 .20+  8.10 12.53 ±  10.68 0.0238
Week-2 20.42 ±  7.90 12.78 ±  9.71 0.0188
Week-3 21.67 ±  9.90 13.84 ±  8.43 0.0365
Week-4 20.66 ±  6.40 15.26 ±  11.84 0.073
Week-5 20.78 ± 10 .58 13.15 ±  5.75 0.045
6,3,5 ULTRASOUND OBSERVATIONS IN PATIENTS WITH SPONTANEOUS 
OVULATION
The total number of patients who showed spontaneous ovulation was 18. Suiprisingly, during the 5- 
week window of observations, the mean TOV of patients who ovulated was similar to that of patients 
who failed to ovulate. The variability in tlie TOV (difference between minimum and maximum TOV) 
was no different in this group compared with those who did not ovulate. These obseivations indicate that 
in the event of or absence of spontaneous ovulation tliere is still a large variation in ovarian volume. 
These changes may also weaken the significance of ovarian volume as a criterion to diagnose PCO as 
48.8% of patients showed both “ normal ” and “ supranomal ” values.
An equal proportion of patients with a luiilaterally (3 out of 8) or bilaterally thickened stroma (15 out of 
31) showed spontaneous ovulation.
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6.3,6 CORRELATION BETWEEN ULTRASONOGRAPHIC OBSERVATIONS 
AND CLINICAL PRESENTATION
The TOV or follicular distribution were not related to the length of oligo/amenoiThoea or years of 
infertility. However, a negative relationship was found between tlie nmnber of ovarian follicles and the 
duration of oligo/amenorrhoea (r = -0.35, P = 0.0478). This means less E2 and T, indicating less ovarian 
activity, dierefbre, fewer oestrogen witlidiawal or ovulatory bleeds in these patients.
Patients who had a unilaterally thickened stroma had a significantly longer duration of 
oligo/amenorrhoea (18.0 ± 14.2 weeks) tlian those with bilateral (11.73 ± 5.13 weeks) (P = 0.0395) 
changes. No relationship was found between the presence of a unilateral or bilateral thickened stroma 
and the occurrence of andi'ogeiiization or lirilization.
6.4 DISCUSSION
Tliis study presents data from longitudinal endocrine assessment in patients with oligo/amenorrhoea, and 
relates ultrasonic evaluation and antluopometric variables to each otlier.
E N D O C R I N E  V A R I A B L E S
In tills study, the wide range of variations in the profiles of E2 , LH, FSH and T concentrations within tlie 
whole group of patients as well as within individual patients duiing the 5-week window of observations, 
clearly confinn tliat ovarian function is dynamic in these patients in spite of oligo/amenorrhoea and the 
rarity in tlie occuirence of follicular growtli and spontaneous ovulation. This emphasizes the importance 
of sequential studies, and reveals the limitation of single assessments.
Yen et al. (1970b) foimd tliat tlie variation in tlie fluctuation of daily seiuin LH concentiations was rather 
high between patients as well as within patients, altlioiigh the daily serum FSH concentrations were 
constant. In patients with PCOs, the cyclic pattern of LH and FSH is typically absent and there is a 
dispropoitionately liigh secretion of LH with constant low FSH secretion resulting in anovulation (Yen et 
al 1970b). It was reported that the high LH concentrations foimd in PCO patients appeared to be tlie 
result of greater amplitude or increased frequency of pulsatile LH release or both (Yen, 1980), and that in
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about 10% of PCO patients, basal levels and the pulsatile pattern of LH release are indistinguishable 
from those of normal cycles in women, which may simply reflect day-to-day variation in LH release or 
the time at which the sample is taken. More tlian half (57.1%) of the patients in the present study 
showed both normal and supra-normal LH concentrations.
Amongst the study patients, SHBG showed tlie least variation during the period of observation in 
comparison to tlie otlier endocrine variables measured. This obseivation indicates that SHBG (and 
subsequently FAI) may be the most suitable endocrine variable for diagnosing or investigating the 
pathophysiology of the disorder in patients witli oligo/amenorrhoea.
S P O N T A N E O U S  O V U L A T I O N  
D o c u m e n t a t i o n  o f  S p o n t a n e o u s  O v u l a t i o n
The elevated LH levels, seen in patients with PCOD, are not caused by an inability of the hypothalamic- 
pituitary system to respond to the negative or positive feedback effects of oestrogen (Yen, 1980) because 
following an increase in endogenous Ez from an induced or spontaneous follicular maturation, an LH 
surge witli subsequent ovulation does occur (Yen, 1980).
About 42% of tlie study patients showed follicular development and ovulation was documented in all 
these cases. All tlie study patients who ovulated spontaneously exhibited a demonstrable LH surge and 
luteinization witli circulating P concentiations > 4 ng/mL. These findings confirms Yen’s observation.
Fleming et a l (1995) reported a similar' occurrence of follicular development in tlieir patients witli 
oligomenorrhoea and that a LH surge and luteinization were confirmed in most of their cases.
A lower incidence (25%) of spontaneous ovulation in patients witli PCOD was reported by Baird et al. 
(1977) who used 6-weeks period of observation and urinary products to assess ovarian function. Tliis 
observation was interpreted as that occasional ovulatory cycles may occur spontaneously in patients with 
PCOD presenting with oligo/amenorrhoea (Baird et al 1977). The finding of a corpus luteurn as an 
evidence of ovulation was demonstrable in 22% of tlie cases with PCOD (Pache et al 1990).
In normal menstrual cycles, tlie LH peak was observed between cycle day 13 and 18, reflecting a 
considerable variation in ovulation time (Pache et al 1990), which is exaggerated in patients with 
menstrual disturbances, especially oligo/amenorrhoea. Altliough the window of observation was
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extended to 5-weeks, and also blood sampling started > 2 weeks after last menstrual period, it is probable 
that the incidence of spontaneous ovulation was underestimated.
The discrepancy in the incidence of spontaneous ovulation in patients with PCOD in the literature could 
be due to the diagnostic criteria of the patients, the wide variation in tlie presentation, tlie selection of 
patients and period of observation, and when the observations were started. Most methods lead to 
underestimation of the phenomenon because of the variability seen.
The mean concentrations of tlie mid-luteal phase P secretion for patients of this study who had 
spontaneous ovulation was 13.2 ± 4.58 ng/mL (range 5 - 25.5 ng/mL) and was similar to the mean P 
value of the mid-luteal phase in the control group. In addition, the mean of the mid-luteal phase P 
secretion was almost equal to tlie mean P (LH peak + 4 to + 9 inclusive) value. These findings indicate 
that the study patients generally showed adequate luteal ftmction.
The key featme of anovulation in PCOD is failure of normal follicular maturation. Poor follicular 
maturation is associated with subnormal or absent P secretion and therefore, unopposed oestrogen 
production by the ovary or by peripheral tissues. The normal negative feedback control of the pituitary is 
disturbed and the rise of FSH, which occurs in the late luteal phase of normal cycles and is responsible 
for normal development of the next crop of follicles, fails to occur (Franks et al 1985). Perhaps the low 
FSH levels during the follicular phase induce abnormal follicular maturation or require longer periods of 
stimulation to initiate follicular maturation (Wu & Mikhail, 1979). Elevated LH and/or androgen levels, 
hyperinsulinaemia and IR, are believed to be crucial factors involved in maturation arrest of follicles in 
PCO (Anderson, 1974). However, tliere is no suggestion from the present study tliat LH or T have any 
relationsliip with the incidence of ovulation. These factors are discussed separately below.
P r o g e s t e r o n e  I n d e x
In this study, in order to assess the luteal function more accurately, the luteal phase P profile was 
quantified by the PI. Although normal P concentrations were established in all of the study patients by 
mid-luteal phase assessment, the mean PI was sub-nonnal with almost half of the group having a PI of < 
70 (lower limit of normal). This indicates that a single measurement of mid-luteal sermii P 
concentration may be inadequate for evaluation of luteal fimction and ovulation.
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A sub-normal PI (< 70) was demonstrated in the majority of tlie ovulatory cycles, and tlie mean values of 
PI for tlie patients with nonnal and with elevated LH were similar. This confirms tliat the occurrence of 
spontaneous ovulation and tlie inadequacy of the luteal phase P profiles were independent of follicular 
phase LH concentrations.
Sherman and Korenman (1974) were first to describe the subnormal P concentration profiles in infertile 
oligomenorrhoeic patients, indicating an inadequate luteal phase due to tlieir long cycles. Wu & MiMiail 
(1979) in a small series showed that in oligomenorrhoeic patients oWatron may fail to occur, despite an 
adequate LH surge, and if ovulation occurs, it tends to be abnormal leading to a deficient luteal phase.
Sub-normal mean plasma P profiles in the early luteal phase in 53% of tlieir oligomenorrhoeic patients 
who demonstrated LH surges, were reported by Fleming et a l (1995) altliough normal P concentrations 
were established by tlie mid-luteal phase. The same autliors also found that the proportion of patients 
with elevated LH was no different fi-om that of the whole group witli oligomenorrhoea and that tlie mean 
follicular phase LH concentration of those patients showing a normal PI was similar to tlie mean LH 
concentration of patients demonstr ating follicular growtli and a sub-normal PI.
F o l l i c u l a r  L H
A significantly higher mean follicular phase LH concentration was found in tlie study patients in 
comparison to the control group as has been reported by others (Eden et al 1989a; Fleming et al 1995). 
Persistently liigh follicular LH concentrations were observed in 26.8% of tlie oligo/amenorrhoeic patients 
of tlüs study, while 34.1% of tlie patients showed normal follicular LH concentrations. The mean 
follicular phase LH concentrations of patients with oligomenorrhoea was reported to be mildly elevated 
but with a considerable range of values (Fleming et al 1995), and about 60% of patients showed 
consistently elevated LH concentrations duiing the period of observation.
In the present study, almost similar proportion of patients with normal or liigh follicular phase LH 
showed spontaneous ovulation. However, tlie PI range was not different, indicating that high LH was not 
a major determinant of the incidence of follicular maturation or the quality of the luteal function in such 
patients. This agrees with the findings reported by other investigators (Fleming et al 1995), where there 
was no relationsliip between LH and PI, and the distribution of Pis was similar in tlie nonnal LH and 
elevated LH groups.
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In contrast, Sagle et a l (1988) reported that LH concentrations are usually normal in women with PCOs 
who ovulate and Baird et a l (1977) have shown that urinary LH concentrations were higher in 
oligomenorrhoeic patients who did not ovulate than in those who ovulated. Although tlie mean basal LH 
value was foimd to be nearly double in patients than in controls during the eaily follicular phase, the 
concentration was variable from patient to patient and also within the same patient from day to day 
(Baird et a! 1977). The elevated LH levels have been linked witli abnomial ovarian function, although 
the mechanism is not fully understood. Yen (1980) suggested that the elevated LH concentrations, 
observed in women with oligomenorrhoea, play a major role in tlie aetiology of PCOD and can result in 
failure of follicular maturation and ovulation. However, the results of the present study clearly disagree 
with such conclusions.
Minakami et al (1988a) showed that the basal LH level, as well as tlie LH response to LHRH, were 
dependent on tlie time since tlie last menstrual cycle and tliat LH elevation above normal in PCO patients 
may be related to their long-standing follicular phases. They also noted that the elevated LH 
concentiations declined after oWation to normal or near-normal range at the end of the luteal phase and 
in tlie early follicular phase. The declined LH level gradually increased again with the increasing days 
from the beginning of menstrual flow and remained at a liigh level until the next ovulation. In the 
present study, most patients with oligomenorrhoea were sampled at similar time in relation to tlieir 
menstrual cycle and continued for a period of 5-weeks; a similar proportion of oWatoiy cycles was 
observed in both tlie Ingh LH gioup and the normal LH group. This is in addition to wide variations 
seen within patients at any stage. If LH is to be used as a diagnostic criterion, tlien tlie timing of the 
blood sampling is important, since concentrations in tlie luteal phase and the early follicular phase may 
be lower than at otlier times.
Abnormal secretion of LH and androgens were claimed to contribute to the subfertility of women with 
PCO (Eden et al 1989a), and liigh follicular phase levels of LH may also impair feitilization (Stanger & 
Yovich, 1985). A raised serum LH concentrations during tlie follicular phase of unstimulated (Regan et 
al 1990) or stimulated (Hombuig et al 1988) ovulatory cycles resulted in a substantial risk of infertility 
and pregnancy loss (up to 65%).
Homburg et a l (1988) reported tliat exposure of the ovaries to liigh concentrations of LH during the 
follicular phase in women with PCOs have a harmful effect on rates of conception and may cause early 
pregnancy loss. The mean basal serum LH concentrations of oligomenorrhoeic patients who ovulated 
after pulsatile LHRH therapy was found (by the same authors) not to differ fiom those patients who failed 
to ovulate, and tliere was no difference in LH concentrations between those who did not ovulate and those
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who ovulated but failed to conceive. However, the LH concentrations were significantly lower in those 
who ovulated and did conceive and in tliose whose pregnancy progressed beyond the first 4 weeks 
compared with those who suffered early pregnancy loss (Homburg et ai 1988). In addition, oocytes 
obtained from tlie pre-ovulatory follicles during stimulated cycles of women witli elevated LH levels were 
found to have impaired in-vW'o fertilization ability and the embryos wliich formed were less likely to 
implant successfiilly (Stanger & Yovich, 1985). It would be of interest to study the cunent group of 
patients during stimulated cycles.
A study of ovarian tissue taken by wedge resection from patients with PCOD showed tliat the binding of 
LH to the membrane receptor, did not basically deviate from normal in PCOD. However, when 
compared with normally developing follicles, the nimiber of follicle receptors for LH was decreased. It 
was suggested that abnormal follicular development and function in PCOD may be due to tonic excessive 
LH stimulation of the follicles too early in development, leading to a decreased number of receptors for 
LH (Rajaniemi et al 1980). However, the observation of apparently normal follicular development in 
some patients in tlie present study does not support tliis hypothesis.
A n d r o g e n s
Mean follicular T concentrations were not different in patients who did not ovulate compared to those 
patients who ovulated, but both were liigher than the levels in tlie control group. A similar observation 
was found by Eden et a l (1989a) who examined single samples. Similar proportions of patients in the 
current study, who had normal mean follicular phase T concentiations and tliose who had elevated T 
concentrations showed spontaneous ovulation. The mean follicular T concentrations were significantly 
higher in patients with elevated LH values (P = 0.0105), and there was a weak correlation between LH 
and T (r = 0.29, P = 0.061). Tliis indicates tliat TT was not directly implicated in tlie incidence or 
inliibition of spontaneous follicular growtli supporting the obseivations in the literature (Fleming et al 
1995), A liigher (3.7 nmol/L) upper limit of the normal range for TT was reported by Fleming et a l 
(1995) tlian in the present study, however, there was no difference in the mean follicular phase T 
concentrations seen in their patients who showed follicular growth and those who did not. Testosterone 
concentrations were found by tlie same autliors to be positively correlated with LH (r = 0.47, P = 0.008) 
but there was no link with the incidence of spontaneous follicular growth. There was no significant 
difference in the incidence of spontaneous ovulation in patients witli elevated or with normal mean
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follicular phase T concentrations. However, the T concentiations were significant^ higher in patients 
with elevated LH values (P < 0.001). The data of tlie present study supports tliese findings.
Eden et al. ( 1989a) suggested that abnormal secretion of TT concentrations and subsequently high FT 
may contribute to the subfertility of women with PCO, and it was proposed that high follicular phase 
levels of androgens could impair intrafolHcular control mechanisms (Yen, 1980). In tliis study, a 
relationship between hyperandrogenism and spontaneous ovulation was only detected through differences 
in SHBG and consequently FAI, rather than total androgen levels. The differences in the mean follicular 
FAI values were significant between patients who failed to ovulate and patients who ovulated and the 
controls, mainly through tlie effect of SHBG. More patients with normal FAI experienced a spontaneous 
ovulation than did those with liigh FAI.
O t h e r  R e p r o d u c t i v e  H o r m o n e s  a n d  S p o n t a n e o u s  O v u l a t i o n
The study patients who ovulated showed similar mean follicular phase FSH, LH:FSH ratio, A and 17a- 
OHP concentrations, higher E^  and SHBG concentrations, and significantly lower FAI and PRL values 
compared to those patients who failed to ovulate.
Although the study patients who ovulated spontaneously showed significantly Mglier LH concentrations 
than the contiol gioup, the mean follicular E^  concentrations were similar, indicating the similarity in Ez 
secretion during follicular matiuation. The concentrations of FSH were significantly lower in patients 
who ovulated than in tlie controls. Similar observations of normal E2  and a low FSH have been reported 
by others (Sherman & Korenman, 1974).
The E2 profiles in patients showing follicular growth were reported to be normal when compared with 
normal controls and there was no difference in the E2 profiles of patients with elevated LH or normal LH 
values (Fleming et al 1995). Surprisingly, significantly lower follicular phase E2  concentrations were 
estimated in urine of patients with PCO who had spontaneous ovulation than in patients with anovulation 
(Baird et al 1977).
It may be suggested that low FSH concentrations, observed in tlie study patients during the follicular 
phase, induce abnormal follicular maturation or require longer periods of stimulation to effect follicular 
maturation as proposed by Wu & Michail (1979). In contrast, ovulatory women with PCO were reported 
to have larger follicles and higher levels of FSH despite similar concentrations of En , when compared
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with tlie controls (Eden et al 1989a). However, modem more specific immunoassays may more reliably 
detect real differences, and if tlie observations recorded here represent biological activity tlien low FSH 
caimot be the cause of blocked follicular giowtli. The old hypothesis that low FSH in patients witli 
oligomenorrhoea and PCOD leads to anovulation is wrong as lower FSH concentrations were observed in 
ovulators than in non-ovulators. Therefore, a new explanation for anovulation in such patients is needed.
M e t a b o l i c  V a r i a b l e s  a n d  I R
Despite similar GH concenti ations between the groups of this study, a significantly lower mean follicular 
phase IGF-I concentration was observed in patients who failed to ovulate spontaneously in comparison to 
tliose patients who ovulated and the controls. However, in spite of significantly low IGF-I levels in 
comparison to the control group, spontaneous ovulation was still obsei-ved in patients. This indicates that 
IGF-I may influence the adequacy of luteal function rather than the occurrence of ovulation.
Barreca et al. (1996) found significantly lower IGF-I in follicular fluid from patients with PCOD than in 
follicular fluid from nomial subjects. The human ovaiy has botli I and IGF-I receptors. Specific binding 
sites for I (Poretsky et al 1984; Nagamani & Stuart, 1990) and for IGF-I (Nagamani & Stuart, 1990) 
have been identified in human ovarian stroma. In presence of hyperinsulinaemia, I might mediate its 
action through IGF-I receptors (Nagamani & Stuart, 1990), particularly when IGF-I concentrations are 
reduced. Follicle stimulating homione inhibits tlie release of IGFBP’s from granulosa cells. Therefore 
the decreased IGFs would be compatible witli tlie relatively slow early follicular development. FSH- 
insensitive follicles undergoing atresia may be compromised by decreased IGFs (Adashi et al 1991). 
Increasing IGF-I levels in follicular fluid may correct the IGF-I imbalance and overcome the defect in 
granulosa cells in PCO patients and improve ovarian follicular matiuation (Baneca et al 1996).
There was a tendency towards an increase in the indices of IR, assessed by FI, GLU/INS ratio and FIRI, 
with tlie degree of distiubance of ovarian function which was more pronoimced between tlie study 
patients who did not ovulate and the control group. Tliis indicates that IR may have an influence on 
ovarian function and the occurrence of spontaneous ovulation, possibly through effects of IGF-I.
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Anthropometric Variables
In this study, significant relationships were observed between anthropometric variables and the mean 
follicular hormones representing the androgenic state of tlie patients; the clearest links were seen in the 
SHBG data.
It was apparent in this study, tliat tlie ratio of body fat distribution (WHR) rather than BMI influences the 
capacity to undergo spontaneous follicular maturation and ovulation. Weight loss seems an effective 
form of tlierapy, resulting in improvement in menstrual cyclicity, return of ovulation (Harlass et al 1984; 
Holte et al 1995)and restoration of IS in such patients (Holte et al 1995).
L e p t i n
In this study, tlie mean values and ranges of plasma leptin concentiations were similar in patients and 
controls. Leptin concentrations were strongly correlated to BMI, WHR and waist in both study groups. 
Similar relationships have been found by others (Considine et al 1996; Klein et al 1996). Obese patients 
and controls had significantly higher mean leptin concentrations than tlieir lean counterparts (P < 
0.0001). The concentrations of leptin in obese and lean individuals fell in the same ranges reported by 
other authors (Considine et al 1996; Hafiflier et al 1996). However, when the study patients were 
compared with weight-matched controls, lean patients had higher leptin concentrations than lean 
controls but the difference was lost between obese patients and controls. The finding of increased serum 
leptin concentrations in obese subjects may suggest increased resistance to leptin, although tlie detection 
of leptin by immunologic methods does not prove that it is biologically active (Considine et al 1996). 
Considine et al. (1996)reported that the fluctuation of serum leptin concentrations was large in the 
presence of relatively small changes in body weight. These observations may indicate that although tlie 
rate of leptin production is directly related to obesity and it is increased per unit body fat (Considine et al 
1996; Klein et al 1996), tliere are otlier factors wliich may regulate its production such as chronically 
elevated levels of I (Bonora et al 1989; Considine et al 1996) and IR, sympathetic neivous system 
activity and corticosteroids (Caro et al 1996; Klein et al 1996). In tliis study, a higlily significant 
relationsliip was found between mean serum leptin concentrations and indices of IR (FI, GLU/INS ratio, 
logio FIRI).
No relationship was observed between leptin concentrations and E^ , LH, FSH, T, SHBG or FAI. The 
relationship between leptin concentrations and TOV was weak (r = 0.28, P = 0.075). Mean leptin levels
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were lower in patients who ovulated tlian those who did not ovulate but the difference did not reach 
statistical significance (P = 0.075). The relationship between leptin and tlie occunence of spontaneous 
ovulation was masked in the obese individuals. However, leptin concentrations in lean controls were 
similar to their levels in oroilatoiy patients but were lower tlian in lean anovulatoiy patients (P = 0.05). 
However, for a given BMI, leptin concentrations were not significantly different in patients who failed to 
orulate, compared with those who did. It is unlikely tliat the occmrence of spontaneous ovulation in 
oligo/amenorrhoeic patients is influenced by leptin levels. The relationships between leptin and indices 
of IR were stronger in patients who ovulated tlian anoWatoiy patients. This may indicate tliat the 
occurrence of spontaneous ovulation was indirectly influenced by the stiong positive correlation between 
leptin and I.
It has been reported that animals with mutations in the obese gene are obese and lose weight when given 
leptin, but little is known about the physiologic actions of leptin in humans (Considine et ai 1996). In 
mice, leptin receptors were identified in tlie ovary and leptin administration was found to stimulate 
gonadal function, causing a significant increase in LH, sex steroid production and increased ovarian and 
uterine weights, indicating greater amounts of follicular development wliich were confirmed 
histologically. In normal animals leptin seives as a metabolic signal to tlie reproductive system (Barash 
et al 1996). However, similar studies on humans have not yet been carried out.
U L T R A S O N O G R A P H I C  O B S E R V A T I O N S
The accurate assessment of follicular growth and development is important in the investigation and 
treatment of the infertile woman. Assessment of follicular growth by US scan is important in evaluating 
and treating all infertile women and in particular oligo/amenoiTlioeic patients. Ultrasonic assessment of 
follicular growth is a useful addition to hormonal measurements (Hackeloer et al 1979).
In the present study ovaiian stmctiual changes were recorded in women suffering fiom cycle 
disturbances and infertility. The observed changes were correlated with clinical and biochemical 
featiues. Repeated sonography examinations were performed to assess possible dynamic changes in the 
ovaries.
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T O V
Significant variations in the TOV wme observed between and within the patients, regardless of the 
occurrence of spontaneous ovulation. However, there was no influence of ovarian volume on the mean 
follicular phase concentrations of LH, and T. Pache et a i  (1991), however, showed that there was no 
statistically significant difference between serial examinations of the same ovary.
In addition comparison between the hormonal concentrations at tlie lowest and at tlie largest TOV during 
the period of observation showed no influence of ovarian volume on the concentrations of any of the 
reproductive hormones. However, significant correlations have been reported in tlie literature between 
ovarian volume and LH and T (Pache et al 1993).
In this study, no significant difference in tlie mean ovarian volume was observ'ed between the right and 
left ovaiy. Similar observation have been reported by others (Pache et al 1991; Takahaslii et al 1994b).
The patients’ 5-weeks TOV mean was 19.33 ± 7.45 cnf, and almost half of tlie patients had mean TOV 
greater than tlie group mean. More than half of tlie patients showed > 60% change in tlieir TOV while 
41.5% had doubled their ovarian volume duiing the period of monitoring. This significant change in 
TOV was not accompanied by any significant difference in the endocrine hormones, IR or other 
metabolic variables. Furtliermore, tlie wide variations in TOV were not influenced by BMI or WHR. 
The mean ovarian volume has been reported to be significantly larger in patients than in controls (Pache 
et al 1991; Pache et al 1992b), with 9.8 niL in patients and 5.9 niL in controls (Pache et al 1992b) but 
there was a wide overlap in size, suggesting that tlie discriminative power of the ovarian volume as a 
diagnostic US parameter of PCOs is poor.
Marked asymmetry between tlie two ovaries, i. e., one is smaller than 75% of the other, has been reported 
in 28.5 - 64.4% in some series (Yeh et al 1987; Takaliashi et al 1994b), however, tliere was not such a 
marked asymmetry between the ovaries of controls.
In the present study, no relationsliip was found between TOV and metabolic variables, including IR. In 
contrast, I and IR were significantly correlated with ovarian volume in the study of Pache et al. (1993).
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Follicular Number and Distribution
In this study, the mean number of follicles diuing the 5-week period of observation was higher tlian 
reported in the literature for patients with PCOD and almost twice the number of follicles found in 
controls (Pache et al 1991; Pache et al 1992b; Takaliaslii et al 1994b). A significantly higher number of 
follicles than in the current study was reported (Takahaslii et al 1994a). However, a considerable overlap 
existed between control subjects and patients with PCOD in follicular number and size (Pache et al 
1992b), In their study, a maximum number of 11 follicles could be detected in normal ovaries. On the 
other hand, a considerable nimiber of ovaries in patients with PCOD contained fewer tlian 11 follicles. 
Therefore, the specificity of a cut-off value of 12 or more follicles per ovary may be high, whereas the 
sensitivity of this level is too low to rule out the diagnosis of PCO. This indicates that follicular number 
as well as ovarian volume may not be used separately as a single reference to discriminate between 
normal and PCOs and the question of what should be tlie threshold follicle number for the ovary to be 
considered as polycystic should be addressed further.
In tlie present study, there was no significant difference in tlie number of small follicles between the right 
and left ovary wliich was similar to reports in the literature (Takaliashi et al 1994b) and the mean 
number of follicles showed a variation during tlie period of monitoring which was significantly correlated 
to TOV. However, otliers (Pache et al 1990; Pache et al 1991) showed a slight variation in the follicular 
number throughout tlie menstrual cycle, although a considerable inter-individual variation existed.
More tlian half of the study patients showed a mixed picture of peripheral and central follicular 
distribution in relation to the stroma in their ovaries. Interestingly, the distribution of follicles in one 
ovary was not static and a change from peripheral to central or the reverse was observed in > 60% of 
ovaries. The mean TOV tended to be smaller if tlie follicles were consistently centrally distributed tlian 
if they were peripherally distributed. Larger ovarian volume favoms tlie peripheral distribution of the 
follicles and was associated witli a significantly greater number of follicles than the small ovary. 
Therefore, tlie larger tlie ovarian volume tlie greater tlie number of follicles pushed peripherally by tlie 
tliickened ovarian stroma caused by hyperandrogenization. However, the number of follicles does not 
influence tlieir distiibution. A strong relationship between ovarian vohmie and follicle nmnber has also 
been reported in tlie literature (Pache et al 1991).
In tliis study, no relationship was denionstiated between follicular number and endocrine, metabolic or 
antluopometric variables. No correlation between follicular number and BMI was found by others 
(Pache et al 1993). However, a correlation has been reported between tlie follicle number and LHtFSH
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and FAI (Pache et al 1991), between follicle number and androgens (Pache et al 1993; Takaliashi et al 
1994a), and between follicle nimiber and IR (Pache et al 1993).
Mean follicle size was not related to mean follicle number, indicating that the extent to which individual 
follicles glow is not related to tlie number of matming or atretic follicles present (Pache e/ a/ 1991). It 
has been reported that tliere was a significant correlation between the number of small cysts on 
transvaginal US and the nimiber of atretic follicles with hypertrophied and luteinized inner theca cells, 
and tliickened ovarian capsules demonstiated liistologically in ovarian tissues from patients with PCOD 
(Takahaslii et al 1994a). All stages of folliculogenesis were increased in tlie PCO and atretic follicles 
fonned about 76% of small cysts on histological examination. When > 10 small cysts in each ovary are 
observed by transvaginal US, the patient can be liistopatiiologically diagnosed as a PCOD patient with 
numerous atretic follicles (Takahaslii et al 1994a). Therefore, the assessment of ovarian morphology by 
transvaginal US in these patients provides an insight to the pathological state and possibly the degiee of 
progression of the disease (Takaliashi et al 1994a). Interestingly, significantly more small follicles were 
associated mth a lack of response to ovulation induction with clomiphene citrate, therefore, the US 
features could be clinically usefid for distinguishing tlie non-responders from the responders to 
clomiphene citrate (Takahashi et al 1994b).
S t r o m a l  D e n s i t y
In this study, tliick stroma was tlie most sensitive US criterion to diagnose PCOs. The majority of cases 
had bilateral tliick stroma while only 21.4% had unilateral thick stroma. Bilateral rather tlian miilateral 
tliick stroma was associated significantly with larger TOV. A significant correlation has also been 
reported by others (Robert et al 1995). Tliis may be explained by the clarity of visualization when TOV 
is large. However, there was no influence of LH, androgen concentrations or antliropometric variables 
on the presence of unilateral or bilateral thick stroma. However, significant relationships have been 
reported between tliickened stroma and LH, T and IR (Pache et al 1993).
Total follicle number in both ovaries was found to be well conelated ivith ovarian stroma echogenicity 
(Pache et al 1991). The echogenicity of ovaiian stroma was reported to be increased in 10 - 16% of 
controls and was normal in 6 - 26% of PCOD patients (Pache et al 1992b; Robert et al 1995). Increased 
echogenicity was reported to be the most sensitive and specific sonographic sign of PCOs (Pache et al 
1992b; Robert et al 1995). Increased stroma is considered to be a classical morphological criterion for 
the diagnosis of PCOs (Pache et al 1991). However, assessment of the echogenicity of ovarian stroma is
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subjective, with the risk of overestimating tlie hypertrophy. The inter-obseiver variation was minimized 
when all US assessments were carried out by a single operator.
Ovarian capsular tliickness was observed in 63% of PCOD patients but no correlation has been found 
between the thickness of tlie capsule and tlie morphology of ovaiian structures (Takahaslii et al 1994a). 
The same authors found that androgen concentrations and that ovarian capsular tliickness were 
significantly correlated with the number of atretic follicles, witli tlie latter found to be significantly 
liigher in PCOD patients with thickened ovarian stroma than in tliose without. Therefore, the ovarian 
capsular thickness might be related not only to hyperandrogenism, but also to the morphology of ovarian 
structures (Takahashi et al 1994a).
Stromal hypertrophy is a frequent and specific US finding in hyperandrogénie and/or oligomenorrhoeic 
women. Robert et al. (1995) demonstiated similar accuracy between visual and computerized analyses 
for stromal assessment, ivitli the main advantage being avoiding false-positive results in normal patients 
using the computerized analyses, especially in doubtftil cases.
S p o n t a n e o u s  O v u l a t i o n
In this study, there was no influence of ovarian volume or the presence of unilateral or bilateral thickened 
stroma on the occurrence of spontaneous ovulation. The changes in the mean TOV were not restricted to 
tliose patients who ovulated spontaneously but significant enlargement of tlie TOV was attained despite 
tlie absence of ovulation. This may even weaken the significance of ovarian volume as a criterion to 
diagnose PCO.
All patients (43.9%) who had spontaneous ovulation showed a mature follicle by US scan (>18 mm). 
However, maturing follicles on US scans (1.5 - 2.9 cm) have been reported to be much lower in PCOD 
patients (13.5%) tlian in healthy women (36%) (Yeh et al 1987). Wlien ovulation occurs in patients with 
PCOD, it does not usually exliibit regular inteivals wliich makes the detection of a mature follicle 
difficult.
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C l i n i c a l  P r e s e n t a t i o n
In the study patients, TOV or follicular distribution were not related to the period of infertility and the 
presence of oligomenorrhoea or amenonhoea. However, the longer tlie period of menstmal disturbance, 
tlie lesser tlie number of ovarian follicles observed. This may indicate less ovarian activity, therefore, 
lower E2  concentrations and subsequently less withdrawal or ovulatory bleeds. Therefore, a solid variant 
of US PCO picture reported by Orsini et al. (1985) may indicate more severe disease.
The presence of bilateral tliick ovarian stroma does not indicate that the disease is more severe than the 
presence of unilateral thick stroma. On the contraiy, tlie presence of unilaterally thickened stroma was 
significantly associated with prolonged durations of menstrual disturbance but not with the 
presence/absence of hyperandrogenism.
There was no significant difference in median follicular number, follicular size, ovarian volume, or 
ovarian stroma estimates between patients witli oligomenorrhoea and patients with amenonhoea (Pache 
et al 1992b). Hirsutism was positively correlated in previous studies with the number of follicles, ovarian 
volume, and stroma echogenicity (Pache et al 1993; Takahashi et al 1994a).
C O N C L U S I O N
There is a tendency to consider oligo/amenorrhoea and PCOD as static conditions, and diagnosis with a 
single blood sample for hormone assay and/or US assessment has been the practice. However, it is 
evident from the longitudinal studies tliat more biological variability exists tlian strict criteria would 
allow and a cut-off level for any of the quantitative parameters which would have provided both a 
satisfactory sensitivity and specificity for diagnosis was not found.
The levels of SHBG showed the least variation witliin and between patients and was the most consistent 
of tlie endocrine variables. In addition, the mean basal as well as mean follicular phase SHBG 
concentrations showed the most significant relationsliips witli the anthropometric variables, tlie 
occurrence of spontaneous follicular growth and ovulation in comparison to tlie other reproductive 
hormones. Therefore, SHBG is a better predictor of ovar ian function tlian LH and T.
A significantly lower mean IGF-I concentration was found in the patients who failed to ovulate than in 
tlie patients who had spontaneous ovulation and in the controls. Furthermore, the IGF-I concentrations
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were significantly lower in the group of patients who ovulated than in the control group. Insulin-like 
growtli factor-I may influence tlie adequacy of luteal fimction ratlier tlian tlie occmrence of ovulation.
Insulin and IR did not demonstrate any direct effect on tlie occurrence of spontaneous ovulation or on the 
ovarian gross morphology monitored by US. However, there was a tendency towards an increase in FI 
and FIRI with tlie degree of disturbance of ovarian function but tliese differences were not significant. 
The obseiTed cycles might not represent the entire menstrual history of such patients. It is expected tliat 
if IR plays a major role in the pathogenesis of PCOD, it should also correlate with ovulation and 
polycystic changes of the ovaries. Insulin may influence ovarian activity indirectly tluough its 
relationships with IGF-I and leptin. These interactions need further exploration.
It was apparent tliat WHR, rather than BMI, influences the occurrence of spontaneous follicular growth 
and ovulation.
The mean values and ranges of plasma leptin concentrations were similar in patients and controls and 
were strongly related to BMI, WHR and waist in both study groups. However, in the absence of obesity, 
leptin concentrations were liigher in lean patients than lean controls. Altliough the rate of leptin 
production is directly related to obesity, there are other factors which may regulate its production such as 
chronically elevated levels of IR. A highly significant relationship was found between mean serum leptin 
concentr ations and indices of IR, No relationsliip was observed between leptin concentrations and any of 
tlie endocrine variables or TOV, The mean leptin levels were lower in patients who o\ailated than those 
who did not ovulate but tliis difference was not significant. It is unlikely that the occurrence of 
spontaneous ovulation is directly influenced by leptin levels. However, studies on the physiologic actions 
of leptin and its relationship to the reproductive system in humans are needed.
The most sensitive and specific US scan criteria, for the diagnosis of PCOD, shown in this study was the 
combination of thick stroma and follicular number.
The mean TOV of tlie study patients was significantly larger than tlie TOV of the controls. No 
relationship was found between any of the US indices and endocrine, metabolic or anthropometric 
variables. Asynmietiy of ovaries was quite a conmion finding and about half of tlie patients at least 
doubled tlieir ovarian volume, even in tlie absence of ovulation. The dynamic state of the ovaries was 
demonstiable by changes in TOV and the number and distiibution of follicles, regardless of tlie 
occurrence of spontaneous ovulation, and these changes were not related to hormone concentration 
changes. Interestingly, a change fiom a peripheral to a central distribution of ovaiian follicles or the
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reverse, was obseived in > 60% of US occasions. Larger TOV favoured a greater number of follicles 
witli a tendency towards peripheral distribution as well as the presence of a bilateral thick stroma.
Assessment of ovarian morphology by means of US is currently employed as a substitute for liistologic 
examination in the diagnosis of PCOs. However, because of tlie heterogeneity of the PCOD, US cannot 
be used alone for diagnosis (Anderson, 1974). One-third of patients witli biochemically documented 
PCOD ivill have normal-appearing ovaries by US (Takahaslii et al 1994a). Transvaginal US enables 
reliable diagnosis of PCOs and cliaracterization of limits for normal number and size of follicles will 
allow more accurate differentiation between normal and abnormal ovarian function.
Since PCOD represents a wide variation of presentation, ovarian enlargement and follicle formation may 
vary according to the duration and degree of hormonal disturbance (Hann et al 1984). Differences in 
methods applied (equipment used for US examination, assays applied for hormone measurements, timing 
of investigations, accuracy in measuring ovarian diameters, etc.), and in the criteria for selection of 
subjects might account for tlie conflicting data in tlie literature regarding this disorder.
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CHAPTER SEVEN : LEPOFROTEINS, POST-HEPARIN 
HEPATIC LIPASE ACTIVITY AND THE RISK OF 
CORONARY HEART DISEASE IN WOMEN WITH PCOD
7.1 INTRODUCTION
The gender difference in CHD rates in younger adults (20-50 years) and tlie increased risk following the 
menopause in women help in understanding the basis of the CHD pathogenesis.
The LDL is associated with a high risk of CHD (Laing et al 1993). The main influences on the LDL 
subfraction profiles are the TG, the activities of hepatic and lipoprotein lipases and the presence of IR 
(Knopp et al 1994; Tan et al 1995).
The small, dense LDL (LDL-lII) is widely considered to be the most atlierogenic form of LDL. When it 
is present at a concentration in excess of 100 mg/dL tliere is a 7-fold increased risk of CHD regardless of 
the plasma cholesterol level. In men with increased waist size, LDL-llI was shown to be significantly 
raised, with a plasma TG in excess of 1.5 nmiol/L, higher FI and an elevated content of the large, TG- 
rich VLDL subfraction.
Males on average demonstiated twice the HL activity of females (Tan et al 1995). This enzyme is 
thought to be responsible for the conversion of LDL-11 to LDL-111 and it is considered to be under sex 
hormone control. It is possible tliat the lipoprotein associated risk in women is due in part to an altered 
androgen/oestrogen balance which stimulates HL, and in so doing promotes the redistribution of 
circulating LDL into LDL-lIl. Women with central obesity, indicated by increased BMI and WHR, and 
high FI levels were reported to have raised plasma TG and VLDL but accumulation of LDL-II (a more 
benign LDL subfraction) rather than tlie LDL-111 (Tan et al 1995). This was attributed to the 50% 
reduction in HL in women compared to men. However, the precise effects of changes in antliropometric 
indices on plasma lipoprotein subfraction distributions are unknown (Tan e ta l 1995).
Early menopause has been shown to be a feature of women who get early CHD. In addition, studies of 
hormone replacement therapy with unopposed oestrogen have shown about 50% reduction in the risk of 
CHD. Therefore, it is clear that the hormonal status in females is a potentially important determinant of
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risk. Tliis includes oestrogen/androgen status and also the presence of IR, as diabetic women lose their 
gender associated protection from CHD. Insulin and sex hormones influence a large number of 
metabolic pathways including those involved in lipid transport.
A review of the known risk factors in women witli CHD reveals tliat die same risk factors are operative 
as in men but tlie importance of elevated plasma TG, low HDL-C and an increased WHR has been 
emphasized (Talbott et al 1995).
It is presumed that lipid-associated risk in women is due to the combination of : i) central obesity/ER. 
leading to increased levels of large VLDL and total LDL and ii) an increased andiogen/oestrogen ratio 
which stimulates HL and redistributes circulating LDL into a small, dense, atherogenic LDL-111.
The pmpose of tliis study was to investigate whetlier HL activity was similar to normal women or men in 
women witli oligomenorrhoea. The majority of such cases demonstrate hyperandrogenism. In tlie study, 
HL activity was assayed in post-heparin plasma in 11 women witli oligomenorrhoea and PCO.
The objectives were to correlate the LDL subfraction distiibution and concentrations with anthropometric 
indices, plasma lipid and lipoprotein concentrations, the activity of post-heparin HL, the degree of IR and 
androgen/oestrogen status in women with PCOD. The data were compared with published laboratory 
normal frgmes.
7.2 RESULTS
The patients \rith PCOD (n = 11) had significantly larger BMls tlian those of nonnal females (n = 67) 
and normal males (n = 71), established from previous studies (Tan et al 1995) (Table 7-1). The WHR 
was significantly liigher in patients than in normal female volunteers (P = 0.01) but was similar to that of 
male volunteers (P > 0.05), indicating tlie difference in body fat distribution of these patients.
Table 7-1 shows that tlie patients had significantly liigher plasma FI and TG, and a significantly lower 
total HDL-C than the normal volunteers (females and males).
The mean post-heparin HL activity was twice as high in the patients compared to normal females (22.38 
± 8.85 vs 11.4 ± 5.40 umolFA/niL/h; P < 0.0001), and indeed fell ivithin the male range (19.5 ±8.1  
imiolFA/mL/li; P > 0.05) (Figure 7.1).
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Only one patient had an LDL-III > 100 mg lipoprotein/dL plasma (the level above which significant 
CHD risk occurs) (Tan et al 1995), and showed the highest TG (9.7 nmioI/L) concentrations and the 
lowest LDL% (7.3%). However, tliis patient exhibited tlie lowest HL activity (16.61 uniolFA/niL/h) of 
the patient group.
Table 7-1 ; Anthropometric indices. Plasma Lipids, HL and Lipoproteins in the study groups
Patients Female Controls Male Controls p* P**
Ï1. 11 67 71
Age 28.4 ± 3 .6 37.0 ±  11.0 35 .6+ 11 .2 0.0113 0.0349
BMI 31 .18± 6 .6 24.6 ± 3 .9 24.9 ±  3.0 <0.0001 <0.0001
WHR 0.88 ± 0 .08 0.80 ±  0.1 0.90 ±0.1 O.OIOI NS
FI(mIU/I4 12.82 ± 7 .8 7 7.65 ± 4 .1 7 8.55 ±  4.3 0.0007 0.0063
F.Glucose(mmoI/L) 4.75±0.37 4.63 ±  0.51 4.93 ±  0.51 NS NS
Cholesterol (nunol/L) 4.51 ±  0.69 5.20 ±  1.0 5.30 ± 1 .1 0.0570 0.0477
TG (nmiol/L) 1.56 ±  0.78 1.0 ±  0.5 1 .2+  0.6 0.0066 NS
HDL-C (nunol/L) I .I 5 ±  0.22 1.50 ± 0 .3 1.20 ±  0.3 < 0.005 0.0061
LDL-C (nunol/L) 2.84 ±  0.64 3.20 ± 0 .9 3.50 ±  1.0 NS 0.0670
VLDL-C (mmol/L) 0.53 ±  0.32 0.50 ±  0.3 0.60 + 0.3 NS NS
Chol/HDL ratio 4.11 ±  1.23 3 .7 0 + 1 .2 4.60 ±  1.4 NS NS
HL (umolFA/mL/li) 22.38 ± 8.85 11.40±  5.4 19.50 ±  8.1 <0.0001 NS
LDL (mg/dL) 181.0 ±  63.6 304.0 ±  97.0 294.0 ±  89.0 0.0007 0.0007
LDL-I (mg/dL) 40.71+ 31.5 81.0 ± 41 .0 59.0 ±  35.0 <0.0001 NS
LDL-II (mg/dL) 94.7 ±  41.47 175.0 ±  73.0 172.0 ± 67 .0 0.0024 0.0016
LDL-III (mg/dL) 45,3 ±  40.01 44.0 ±37.0 88.0 ±  81.0 NS NS
patients with normal males. P > 0.05 is NS.
; Student’s t-test. (P*) compares patients witli nonnal females, while (P**) compares
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Variations in plasma TG levels in tlie patients coiTelated positively with LDL-III (r = 0.80, P = 0,0168) 
(Figmes 7.2), VLDL (r = 0.96, P = 0.0001) (Figure 7.3), total cholesterol concentration (r = 0.68, P = 
0.0626), and negatively with HDL (r = -0.72, P = 0.0421).
The LDL-C was positively conelated with total semm cholesterol (r = 0.92, P = 0.0013), T (r = 0.73, P = 
0.04) and negatively correlated with HDL-2 (r = -0.74, P = 0.0344). Similar observations have been 
reported by Holte et al. ( 1994b). There was no correlation witli SHBG.
On tlie other hand, LDL-I showed significant positive relationships with SHBG (r = 0.79, P = 0.0208), 
LDL-mass (r = 0,64, P = 0.0848) and total cholesterol (r = 0.86, P = 0.0056). There was also a negative 
relationsliip with logioFIRI (r = - 0.70, P = 0.0515)
Significant correlations were established between LDL-II and E2  (r = 0.67, P = 0.067), LDL-mass (r = 
0.71, P = 0.0498), and cholesterol (r = 0.79, P = 0.0185). The LDL-III was significantly correlated with 
VLDL-C (r -  0.87, P -  0.0046) (Figure 7.4).
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Figure 7.3
Figure 7.4
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Total HDL-C levels were negatively correlated with FAI (r = -0.68, P = 0.064), and also with total LDL- 
C (r = -0.65, P = 0.0815). These relationsliips showed borderline significance.
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Post-heparin HL activity had significant associations with total LDL mass (r = 0,77, P = 0.0256) (Figure 
7.5), cholesterol (r = 0.71, P = 0.047), LDL-II (r = 0.91, P = 0.0018) (Figure 7.6), and LDL/HDL ratio (r 
= 0.74, P = 0.0361).
Figure 7.5
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7.3 DISCUSSION
Due to the recruitment process, the patients with PCOD were younger tlian tlie normal volimteers. It 
was notable that while the BMI was significantly higher in tlie patients than in tire normal vohmteers 
(females and male) the WHRs of the patients and the normal male volunteers were identical, indicating a 
similarity in the central or tnmcal fat distribution in the patients with PCOD compared with that of 
normal males.
In this study, tlie patients with oligomenorrhoea showed a male CHD risk-factor profile : they showed 
significantly increased risk factors compared with laboratory normal control women. These included 
increases in BMI, WHR, PI and TG levels and decreased total HDL. These findings are supported by the 
results of Talbott et al (1995); significantly lower HDL-C was observed in patients who developed CHD 
(P < 0.05) (Hargreaves et al 1992), and LDL-C correlated highly witli total serum cholesterol (Holte et al 
1994b), indicating tliat women with PCOD should be monitored for early detection of these risk factors. 
It remains to be determined whether the mere existence of oligomenorrhoea may be a marker for 
increased risk factors irrespective of PCOs.
The IR has been linked to the raised plasma TG, lower HDL-C and tlie presence of small LDL. Insulin 
resistance and the presence of central obesity can lead to changes in androgen/oestrogen balance (Tan et 
al 1995). However, in tliis study, no correlation was demonstrated between FI and cholesterol or TG. 
Similar observations were reported by Laing et al. (1993). In addition, FI did not correlate with HDL or 
LDL subfraction concentrations, failing to identify I as a direct risk factor for CHD. Similar observations 
have been reported by otliers (Hargreaves et al 1992). Tliis is in contrast to the findings of Laing et al. 
(1993).
However, when logio FERl was applied as a measure of IR, a significant negative correlation was foimd 
with the LDL-1. Therefore tlie more 1 resistant the patient is, tlie lower tlie concentration of LDL-Ï (tlie 
least dense species of the lipoprotein) is. Tliis finding may suggest that logio FERl is a more relevant 
marker of IR than FI, witli respect to lipid metabolism.
The LDL-C showed a highly significant relationship with T, while the subfraction LDL-1 showed a 
significant positive correlation witli SHBG. The protective lipoprotein HDL-C was negatively correlated 
with FAI, probably through the effect on SHBG. These data suggest tliat hyperandrogenaemia may be a 
stronger determinant of seitmi lipids in PCOD tlian IR.
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One of the most important observations reported by Talbott et al. (1995) was that the differences in risk 
factors between patients witli PCOD and control subjects were generally stronger at eailier ages. This 
was probably due to an early onset of hormonal changes and obesity and possibly to the distribution of 
body fat among patients witli PCOD. The risk factors in the PCOD women are probably elevated at an 
earlier age tlian in non-PCOD women. If tlie central obesity, hyperinsulinaemia, and low HDL-C and 
high TG levels noted in tlie PCOD cases are really a miique profile of risk factors of atlierosclerosis and 
subsequent CHD, then women with PCOD should have a liigher incidence of atherosclerosis than control 
subjects, especially at younger ages. If the risk of atlierosclerosis is primarily related to elevated LDL-C, 
then there is an alternative reason for a higher prevalence of atherosclerosis in PCOD patients. The 
patients witli PCOD present risk-factor characteristics foimd in yoimger men and older obese 
postmenopausal women (Talbott et al 1995).
Hepatic lipase plays an important role in determining tlie relative concentrations of LDL-11 and LDL-111 
in plasma. The HL acts on LDL-11 to hydrolyze the TG enriched particles and generate LDL-llI. If the 
enzyme activity is low then LDL-11 remains the major species in plasma and is relatively TG enriched. 
The finding of significantly higher mean HL activity in patients with PCOD than in the normal female 
volunteers, (P < 0.0001), and activity identical to that of normal male subjects, adds weight to the 
increasing body of evidence that the sex hormone status of PCOD women plays a role in disturbance of 
tlie lipoprotein subfractions.
Hepatic lipase is decreased by oestrogen treatment, which is also thought to play a role in the removal of 
the remnant lipoprotein (Knopp et al 1994). The lipoprotein effects of sex hormones are of practical 
importance. The lipoprotein effects of progestins and androgens on lipoprotein metabolism oppose those 
of oestrogens. Gestrogens raise plasma TG concentrations but lower LDL and raise HDL levels wliile 
progestins and androgens lower TG concentrations. Oestrogen appears to explain tlie lower LDL levels 
experienced by women prenienopausally. The physiologic effects of oestrogens and progestins are the 
basis of tlie male/female difference in lipoprotein levels and cardiovasculai' disease risk. Reductions in 
HDL-cholesterol with androgen or androgenic progestin administration are well described. Reductions 
in HDL are associated with increases in HL activity presimiably via increased HDL phospholipid 
hydrolysis and hepatic uptake. Hyperinsulinaemia and obesity can produce the same lipoprotein picture. 
These effects raises the risk of CHD in the postmenopausal women and they provide an approach to its 
prevention. Understanding sex steroid effects on lipoprotein physiology is essential because CHD 
accounts for 50% of tlie mortality in women; actually exceeding tliat in men. While the greater liability 
of cardiovascular disease in women compared with men may have a number of explanations, whatever
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the cause, prevention of cardiovascular disease in women as well as in men is now a very high priority 
(Knopp et al 1994).
IR, hyperinsulinaemia, hypertension, hj-pertriglyceridemia, and low plasma HDL-C concentrations are 
closely related variables and tend to occur in the same persons (Hargreaves et al 1992). This cluster of 
metabolic abnormalities might usefully be referred to as syndrome X. In addition to being closely related 
and present in tlie same person, the abnormalities associated witli resistance to I action, namely, glucose 
intolerance, hyperinsulinaemia, and a low plasma HDL-C concentration, have been identified as 
increasing the risk of CHD.
In general, consideration of metabolic risk factors for CHD has focused on the role of LDL-C. Howe\ e^r, 
it is becoming increasingly apparent tliat CHD can occur in the absence of elevated LDL. Insulin 
resistance, and tlie degree to wliich tlie endocrine pancreas responds to this defect play important roles in 
the pathogenesis and clinical course of high blood pressme, dyslipidemia, and CHD (Hargreaves et al 
1992).
7.4 CONCLUSION
In keeping with otlier studies, patients with PCOD demonstrated higher WHR and fasting plasma TG 
concentrations and lower HDL-C concentrations. A significantly liigher post-heparin HL activity was 
demonstrated in patients with PCOD. This enzyme is stimulated by androgens, and it is presumed that 
tlie hyperandrogenaemia in tliis group of women is responsible for stimulating HL activity into the male 
range. These findings add weight to the increasing body of evidence that tlie sex hormone status of 
women plays a major role in the disturbance of lipoproteins in an atherogenic direction.
Women with PCOD demonstrate male type HL activity. Further studies are needed to establish the 
differential roles of obesity, IR, and sex hormones.
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CHAPTER EIGHT : GENERAL CONCLUSIONS, 
RECOMMENDATIONS & PROPOSALS FOR FUTURE 
WORK
S.1 INTRODUCTION
The studies described in tliis tliesis were performed to attempt to address the objectives described in 
Chapter One (Section L4). The section below summarises the conclusions which can be dratvn from 
these studies with regard to the various headings.
8.2 DIAGNOSIS OF PCOD
During tlie literature survey performed as a prelude to carrying out the research described in tliis study it 
was obvious that tlie disease reported in the literature as PCO, PCOD and PCOS was not a homogeneous 
entity but consisted of a heterogeneous mixture of related conditions. Polycystic ovarian disease is a 
common cause of female infertility in women witli menstrual dysfunction. In one series (Franks et al 
1988) PCO was diagnosed in 87% of women with oligomenorrhoea and in 26% of those who complained 
of amenorrhoea. Very few of tlie patients reported ftdfilled the original criteria described by S-L. 
Furthermore in more recent times the diagnosis of PCOD has become more complicated witli the advent 
of ovarian US scanning. Whilst US has been shown to be of extreme value in assessing the structure and 
function of ovaries its use as the sole criterion for diagnosing PCOD is obviously suspect particularly in 
light of the published data (Adams et al 1986b) tliat up to 22% of normally cycling women show PCOs 
on US examination. It was therefore decided that as part of tlie investigations performed in tliis study the 
usefulness of the various criteria used in PCOD diagnosis would be addressed and an attempt made to 
decide what would constitute the ideal diagnosis.
All patients recruited had menstrual disturbance (oligo/amenorrlioea with or without DUB) and 
infertility. About half of the patients were hyperandrogenized.
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Women with oligo/amenoiThoea and PCOD showed significantly higher semm basal concentrations of 
LH, LH:FSH ratio, T and FAI and lower SHBG tlran did the control group whilst basal E^ , FSH, DHEA-
S and PRL concentrations were similar in the study patients and the controls.
The mean follicular phase endocrine profile in patients who ovulated showed significantly higher LH, 
LHFSH ratio and FAI, and a significantly lower FSH than the controls wliile concentrations were
similar. In comparison to patients who failed to ovulate, higher E^ , and lower SHBG and FAI were
found in patients who o\ulated. Luteinizing hormone and FSH were similar.
In evaluating the sensitivity and the specificity of the biochemical diagnosis of PCOD : liigh LH levels, 
raised LH:FSH ratio or elevated TT concentration were not diagnostic of tlie disorder because less tlian 
half of the study patients satisfied any of tliese biochemical criteria. However, FAI of > 4.5 was the most 
sensitive endocrine index. The acciuacy of the diagnosis was increased when more than one criterion 
was applied. Only one quarter of the whole group of patients satisfied all of the classical biochemical 
diagnostic criteria. It is important to remember that these differences may be due to a nmnber of factors : 
the wide variation in the presentation of patients and their selection criteria; the number and timing of 
blood sampling in relation to the patient’s last menstrual period; liomional assay metliodology as well as 
the period of observation.
There is a tendency to consider oligo/anienorrhoea and PCOD as static conditions, and diagnosis with a 
single blood sample for hormone assay and/or US assessment is a common practice. However, it is 
evident from the longitudinal observations that more biological variability exists than strict criteria would 
allow and a cut-off level for any of the quantitative parameters wliich would have provided both 
satisfactory sensitivity and specificity was not available.
The PI was a better predictor of luteal phase fimction than a single mid-luteal phase serum P 
concentration - showing deficient luteal phases in many.
The mean TOV of the study patients was significantly larger tlian the TOV of controls (using published 
data). No relationship was found between any of the US indices and endocrine, metabolic or 
anthropometric variables.
Asymmetry of ovaries was a common finding and about half of tlie patients at least doubled tlieir ovarian 
volume, even in the absence of ovulation. The dynamic state of the ovarian structure was demonstrable 
by changes in TOV and the number and distribution of follicles during the period of observation. 
Interestingly, a change from a peripheral to a central distribution of ovarian follicles or the reverse, was
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observed in > 60% of ovaries. Larger TOV favoured a greater number of follicles with a tendency 
towards peripheral distribution as well as the presence of bilaterally thickened stroma compared to the 
smaller ovaries.
Assessment of ov arian morphology by means of US is currently employed as a substitute for Mstological 
examination in tire diagnosis of PCOs. However, because of tlie heterogeneity of the PCOD, US alone 
caimot be used alone for diagnosis. Repeated assessment will give more information than a single scan. 
A unilateral PCO was diagnosed in 20% of patients. There was no indication that unilateral PCO, 
diagnosed by US scan, was less severe tlian bilateral PCOs. However, it would be interesting to follow 
these patients with unilateral PCO for any progression of tlie disease.
Tliick stroma, the most sensitive single US criterion, was found in at least one ovary in 95.2% of the 
patients. Enlarged ovarian volume, tlie least sensitive US parameter, was observed in 55% of patients. 
Increased Follicle number (> 10) was found in 85.7% of patients. However, combination of more than 
one US criterion increased the diagnostic accuracy. The most sensitive and specific US scan criteria for 
tlie diagnosis of PCOD, shown in tliis study, was tlie combination of thick stroma and tlie number of 
follicles.
Transvaginal US enables reliable diagnosis of PCOs and characterization of limits for normal numbers 
and sizes of follicles will allow more accurate differentiation between normal and abnormal ovarian 
function. Results may also serve as a reference for US monitoring of ovulation induction by exogenous 
Gn in PCOD patients.
Since the disease represents a wide spectrum of presentation, ovarian enlargement and follicle fonnation 
may vary according to the duration and degiee of hormonal disturbance (Haiui et al 1984). Differences 
in methods applied (equipment used for US examination, assays applied for honnone measurements, 
accuracy in measuring ovarian diameters, sampling regimens, etc.), and in tlie criteria for selection of 
subjects with PCO might account for much of the conflicting data in tlie literature.
It can be concluded ftom the data collected in this study, that the combination of at least two endocrine 
(including SHBG) and two US (including thick stroma) indices, assessed repeatedly, is the most sensitive 
criteria for the diagnosis of PCOD.
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8 3  ASSESSMENT OF IR - COMPARISON OF SITT WITH FI, FIRI & 
GLU/INS RATIO
Despite the potential advantages of and the reproducibility of the SITT in measuiing IR wliich have been 
reported in tlie literature, tliis study showed that tlie SITT was unreliable in oligo/anienorrhoeic patients 
because tlie KITT-values were similar in patients and their weight-matched control group, and more 
importantly; the test failed to show any correlation with anthropometric variables. In addition, the 
correlation witliiii patients between tlie 2 SITTs, expressed as KITT-value, was poor and disappointing in 
comparison to FI and logio FIRI.
Otlier methods for assessment of IR were also assessed. The FI, FIRI and GLU/INS ratio, were more 
convenient, easy to measure and showed tlie expected relationships with the antluoponietric variables - 
comparable witli the standard method of IR measurement (euglycaemic clamp). For the purposes of 
assessing IR in this study tlie simplest and most reliable assessment was tlie FI.
8.4 EFFECTS OF OBESITY & HYPERANDROGENAEMIA ON I  LEVELS
Obesity was a conmion featme in the study patients (40.5%). Tins may indicate that obesity is conmion 
in patients with menstrual disturbance and PCOD and that the prevalence of PCOD in obese women can 
be expected to be high, given diat PCO is common in tlie general female population (Poison et al 1988). 
The combination of PCOD and obesity may have an additive adverse effect on glucose tolerance. The 
prevalence of impaired glucose tolerance or frank diabetes in obese women witli PCOD has been shown 
to be significant (20%) in other studies (Franks, 1989). The presence of hyperinsulinaemia may be 
important as well, since long-term follow-up of patients ivith PCOD indicates tliat tliey are at increased 
risk of developing DM and CHD. Therefore, measurement of GTT in such patients is important.
The cause and effect relationship between I and androgens is contr oversial. None of tlie methods used to 
estimate IR showed a significant relationship with androgen concentrations in this study. The 
correlation between IR and FAI in the oligo/amenorrhoeic group appeared to be secondary to the inverse 
correlation of SHBG to serum I. These powerful relationships between SHBG and FI and logio FIRI 
were demonstrable in botli patient and control groups.
Supraphysiological hyperinsulinaemia following I administration (during the SITTs), resulted in a 
significant decline in and T concentrations at 30- and 60 minutes, demonstrating a possible effect of
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acute I administration on ovarian steroid secretion. Tliis suppression of ovarian androgens argues 
against a simple, direct relationship between hyperandiogenaemia and hyperinsulinaemia.
Research on the mechanisms of anovulation in PCOD, tlie role of obesity and the clinical significance of 
the relationsliip between IR and hyperandrogenaemia are on-going.
8.5 EFFECTS OF ANTHROPOMETRIC PARAMETERS ON ENDOCRINE & 
METABOLIC VARIABLES
Sex hormone binding globulin showed the most significant and consistent relationships witli the 
antlu'opometric parameters in patients and controls, compared with the other endocrine variables. 
Fasting glucose and FI were not significantly different between the patients and the controls. However; 
IR increased in parallel with increasing BMI in both groups. Thus the importance of weight-matched 
controls in any study of PCOD and/or disturbed ovarian activity must be emphasized.
8.6 THE GH STATUS OF PCOD PATIENTS VS NORMAL
Growth hormone concentrations were similar and normal in patient and control groups despite 
significant differences in IGF-I levels. Results could be affected by timing of blood sampling and/or 
limitations of the assay sensitivity. There was no relationship between GH and FI.
8.7 OVARIAN ACTIVITY - EFFECTS OF LH, SHBG, IR, GH & IGF-I : 
OVULATION VS ANOVUI^TION
Follicular growth and spontaneous ovulation occurred in 47% of patients with oligo/amenorrhoea during 
the observation period. Luteinizing honnone, androgens and 1 levels had no direct influence on tlie 
occurrence of spontaneous ovulation.
The levels of SHBG showed tlie least variation witliin and betiveen patients and was the most consistent 
of all of the endocrine variables. In addition, the mean basal as well as mean follicular phase SHBG
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concentrations showed the most significant relationsliips with the anthropométrie variables, and the 
occurrence of spontaneous follicular growtli and o\aiIation when compared to the otlier reproductive 
homiones. Therefore, SHBG was a better predictor of ovarian function than LH and/or T.
Waist ; hip ratio ratlier than BMI, influenced the occmrence of spontaneous follicular growth and 
ovulation.
Insulin and IR did not demonstrate any direct effect on the occunence of spontaneous ovulation or on tlie 
ovarian gross morphology as monitored by the US scan. There was a tendency towards an increase in FI 
and FIRI with increased degree of disturbance of ovarian function but tlie differences were not 
significant. The observed cycles might not represent the entire menstrual liistoiy of the patients. It may 
be expected that if IR plays a major role in tlie pathogenesis of PCOD, it should also correlate mth 
ovulation and polycystic changes in the ovaries. Insulin may influence ovarian activity indirectly 
tlirough its relationships with IGF-I and leptin. These interactions need further exploration.
Significantly lower mean basal IGF-I concentrations were found in patients with oligo/amenorrhoea than 
in the control group, despite similar mean GH concentrations. Furthermore, similar mean IGF-I 
concentrations were found in patients who failed to ovulate as in patients who had spontaneous ovulation 
and in controls. The concentrations of IGF-I were also significantly lower in the group of patients who 
ovulated than in tlie control group. Insulin-like growth factor-I may influence the adequacy of luteal 
fimction rather tlian the occurrence of ovulation.
Insulin and/or IGF-I appear to play a physiological role in the regulation of gonadal steroidogenesis. 
Insulin is thought to regulate the circulating SHBG concentration (Franks, 1989) by acting directly on 
the hepatic synthesis of SHBG (Buyalos et al 1993; Rajkhowa et al 1994). Hyperandrogenized patients 
ivith high FAI showed significant hyperinsulinaemia, higher FIRI values and less occmrence of 
spontaneous ovulation than patients ivith nonnal FAI. Insulin can act through the IGF-I receptors 
especially when the IGF-I levels are low.
It is apparent from the findings of this study that anovulation in patients with PCOD was not caused by 
liigh LH, high androgens or low FSH concentrations. Tlierefore, a new hypothesis to explain 
anovulation in such patients is proposed.
The finding of significantly low circulating IGF-I concentrations may be a clue. An IGF-I threshold at 
the level of tlie ovaiy may be critical for the occuiTence of ovulation, especially since low IGF-I levels 
have been reported in follicular fluid of patients witli PCOD than in normal women. Low circulating
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IGF-I concentrations may indicate dysfunctionally low IGF-I concentrations at the ovarian level. It is 
known that I can act through the IGF-I receptor and the presence of low IGF-I concentrations favoius 
this action especially in the group of patients with liigh I,
Significantly low SHBG concentrations were found in PCOD patients and I exaggerates tliis effect by a 
direct action on SHBG synthesis in the liver. Tlüs results in lugli circulating levels of free androgens 
(high FAI).
Although a direct relationship between I and androgens could not be established in this study, it can still 
be postulated tliat an interaction between I and ff ee androgens will result in anovulation which is 
exacerbated by the presence of low IGF-I and low SHBG concentrations and in turn result in increased I 
activity and hyperandrogenaemia.
The observation in these studies in preliminary data that IGF-I levels were significantly lower in the 
patient gioup are exhemely interesting but need to be confirmed when all of the results are available. 
This finding may be of extreme importance since it is well established tliat by some, as yet unclear, 
mechanism IGF-I effects ovarian function. Previous reports have described contradictory results witli 
IGF-I levels the same as those in controls (Kazer et aï 1990; Sharp et al 1991; Slowinska-Srzednika et al 
1992; Holte et al 1994a) or greater than those in controls (Laatikainen et al 1990). It is possible that the 
differences in IGF-I levels could be a function of different assay methodology being used in the different 
studies.
If the findings of low IGF-I concentrations in the PCOD patients is confirmed tliis may be an important 
clue with respect to these patients “ ovai ian dysfiuiction ”.
8,8 LIPID METABOLISM IN  PCOD  -  EFFECTS OF ANTHROPOMETRIC, 
ENDOCRINE AND METABOLIC VARIABLES
The mean values and ranges of plasma leptin concentrations were similar in patients and controls and 
were strongly related to BMI, WHR and waist in both groups. However, in the absence of obesity, leptin 
concentrations were higher in lean patients tlian lean controls. Although the rate of leptin production is 
directly related to obesity, other factors may regulate its production - such as a chronic state of IR. A 
highly significant relationship was found between mean serum leptin concentrations and indices of IR. 
No relationsliip was observed between leptin concentrations and any of tlie endocrine variables or TOV.
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Leptin concentrations were not significantly different in patients who failed to ovulate, compared with 
those who did. It is unlikely that tlie occmrence of spontaneous ovulation in patients with 
oligo/amenoiTlioea is directly influenced by leptin levels.
Patients witli PCOD demonstrated liigher WHR and fasting plasma TG concentrations and lower HDL-C 
concentrations. Significantly higher post-heparin HL activity was demonstrated in patients with PCOD 
than in nonnal female volunteers. Women with PCOD demonstiated male type HL activity. Hepatic 
lipase is stimulated by androgens, and it is presumed that the hyperandrogenaemia in this group of 
women was responsible for stimulating HL activity into the male range. These findings add weight to 
the increasing body of evidence that tlie sex hormone status of women plays a major role in tlie 
distmbance of lipoproteins in an atlierogenic direction.
8,9 FUTURE WORK
The importance of weight-matched contr ols in any study of PCOD and/or distmbed ovarian activity must 
be emphasized.
Total body IS can be assessed by different techniques, although simpler methods should be implemented 
if possible for routine clinical practice. The results presented in this thesis suggest tliat FI alone might be 
as good as any technique.
Further research on the mechanisms of anovulation in PCOD needs to be perfonned in order to establish 
the differential roles of obesity, IR, hyperandrogenaemia, IGF-I and leptin on tlie reproductive system. 
Particularly the roles of the significant differences in IGF-I and SHBG need further investigation to 
establish any functional effects.
Because of the heterogeneity of the PCOD and the dynamic state of the ovary, repeated endocrine and US 
assessments are recommended in any fiiture studies.
The US features could be clinically usefiil to distinguish between responders and non-responders to the 
treatment of ovulation induction.
It will be of interest to follow-up tlie patients with unilateral PCO to observe any progression of the 
disease.
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APPENDICES
APPENDIX I : PATIENT INFERTILITY SHEET
Date of Consultation ;
Patient’s Name :
Date of Birth : Contact Phone Number (Home) :
(Work) :
Referred by ; Occupation :
Husband’s Name : 
Date of Birtli : 
G.P.
Occupation ;
Years since marriage : Parity :
Period of Infertility :
Frequency of Intercourse : Dyspareunia (Y/N) : Type :
Other Sexual Dvslvmction (Y/N) :
- Impotence - Premature Ejaculation - Vaginal Soreness - Others
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Previous Mamage(s) / Relationship(s) :
Husband :
Wife :
Gvnaecoloeical History :
Outcome : 
Outcome ;
Age at Mcnarche ; LMP : Cycle (K) :
Regular / Irregular : Duration of Irregularity :
Description of Irregularity ;
Blood Loss : DUB : Dysmenorrhoea (Y/N) : Type : Duration :
M B  (Y/N) ; PCB (Y/N) : Vaginal Discharge (Y/N) :
Change in Weight :
Excessive Hair Growth (Y/N) : Duration : Location :
Acne (Y/N) : Greasy Skin : Change of Voice
Frequency of Removal 
Breast Discharge :
Current or Previous illness
Wife
Operation : 
Wife
Husband
Husband
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History of Medications / Drues (including smoking and alcohol ) :
Wife Husband
Family History :
General Exainination : Appearance :
Height : Weight ; BMI : WHR:
Pulse : Blood Pressure :
Thyroid : Breast Examination -Tamier’s Stage (I - V)
- Galactorrlioea :
- Lumps :
Chest Examination Heart Examination :
Abdominal Examination :
Pelvic Examination :
Hair Distribution (Normal / Abnormal) Description of Hair Distribution
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APPENDIX II : PATIENT INFORMATION SHEETS
AN EXPLANATION & INSTRUCTIONS FOR PATIENTS 
UNDERGOING POLYCYSTIC OVARY 
STUDY
INTRODUCTION
In women with normal ovarian function, an egg is released from tlie ovary each month; it eitlier meets a 
sperm and fertilization takes place resulting in a pregnancy, or bleeding will occur (the period). A 
prolonged menstiual cycle of more than 41 days, called " Oligomenorrhoea ".
“Oligomenorrhoea ” can be caused by many endocrine disorders” which might prevent tlie ovaries from 
producing an egg every month; this will result in delaying the period and reducing the chances of 
pregnancy as well.
“ Oligo/amenorrhoea ” study will involve studying the hormone changes involved in tlie irregular ity of 
your cycles and this should help in design of best tr eatment as well.
The blood tests and tlie scans, which will be carried out as explained below, are named “ Oligo screen
INSTRUCTIONS FOR PATIENTS
To commence an “ Oligo screen ”, please contact the nursing staff at tlie Assisted Conception Services 
“ACS ” Unit witlriri tlie first 2 weeks of your period starting, udtli a note of first day of its start.
Make sme tliat you are not on any treatment tlrat stimulates the ovaries, or hormonal contraceptive for a 
period of at least 2 months before you start tire investigations. A date will be given to you then to start 
your investigations, which may be between day 15 and 20 after a period, or as convenient if yom period 
was too long ago.
Investigation of your hormone levels involves having approximately 10 ruL blood sample taken twice 
every week for a maximum of 5 weeks. The hormones will be monitored and if ovarian activity is
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detected you will need to give a blood sample every day for a maximum of 2 weeks or till your next 
menstrual period whichever occms first.
On tlie day of your first blood samples, you should come fasting overnight, and be at tlie ACS Unit at 
8:30 am. Your weight will be recorded and 10 niLs of blood sample will be taken for basal levels of yom' 
hormones, then a specific test called Short Insulin Tolerance Test,“SITT”, will be carried out. This is 
explained simply as follows :
[After a 12-h overnight fast, the first group of blood samples will be collected from you after 5 and 15 
minute of the start. This is followed by a single insulin injection into a vein in yom arm and a carmula 
will be kept in your vein order to collect blood samples during the test easily. The second group of blood 
samples will be collected 5,10,15,20,30 and 60 minutes after the injection. At 15-20 minutes following 
the insulin injection, you will be given a sweaty diink,(a cup of tea or coffee with sugar for example). 
Although it rarely happens, you might feel dizzy and sweaty because of the drop in yom blood sugar 
level. This can be easily treated, if necessary, with a drip of glucose coimected to your vein tluough the 
same camrula previously mentioned ].
The first ultrasound scan (us scan) will be performed during the day of your first blood tests, fiirther 
scans will be assigned as needed.
If the analysis fiom the laboratory indicates that ovulation may occur, you will be asked to change to 
daily blood tests for a maximmn of two weeks to assess tlie quality of tlie ovulation.
A repeat of the "SITT" test will be carried out once more during week 5 after the start of sampling, or 7- 
10 days after ovulation.
1 .  B l o o d  S a m p l e s
These may be taken either at tlie hospital or at your G.P.'s Surgery.
Hospital : blood samples are taken at the "ACS" Unit. Times for blood tests are between 9:00am and 
9:30am eveiy day, including Satmday and Simday.
G.P, ; If yom G.P. is willing to take blood samples for you, bottles, labels, envelopes and containers will 
be supplied by the hospital. Please label the bottles cleaily with your Name and Date of sampling and
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ensure their delivery or postage (First Class) to the University Laboratory in the Royal Infirmary 
Hospital. 10 mLs of blood ar e required for each sample. You can keep tlie bottles in the fridge till time of 
postage.
N.B. The "SITT" test will be done at tlie hospital and while your are fasted.
2. Ultrasound Scans
Scans are necessary to assess ovaiian function; tliey can detect growing follicles and/or polycystic 
ovaiies. These scans are carried out in tlie ultrasound room, at the ACS Unit. Vaginal scanning is the 
metliod used wMch does NOT require a fi.ill bladder. It is similar to an "internal examination". This is 
not painfiil and it gives more accurate information about ovarian activity than other methods. You will 
need a number of scans during the "Oligo screen" and will be inhumed after scanning of the date of your 
next scan.
3. Results ;
A clinic appointment will be made after the last blood sample where the results will be discussed and 
treatment ivill be assigned for you. Please make sure that you have this appointment on completion of 
your "Oligo screen" scan.
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EXPLANATION & INSTRUCTIONS FOR PATIENTS UNDERGOING 
THE STUDY OF THE REGULATION OF BLOOD 
FAT LEVELS BY HORMONES
I understand that a team of researchers at the GRI are investigating the key hormonal factors which 
control blood fat levels in women.
The studies involve the following :
Taking an initial 5 inL blood sample for a full blood count,
Filling in a questioimaire which will allow tlie doctor to assess yom- suitability to receive heparin. The 
reason for asking you these questions is that heparin is used to thin the blood and in rare circumstances 
can cause you to bleed. This is much more likely, however, if individuals have had certain medical 
problems in the past.
Taking a 40 mL fasted blood sample.
On the same occasion as (3) above, the administration of heparin followed by a 10 riiL blood sample, 
after you have been assessed by a doctor as to yom' suitabilify for receiving heparin.
Giving a blood sample may be associated with minor discomfort.
I understand that my involvement in this study is entirely voluntary and that I may witlidraw at any time.
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APPENDIX III : CONSENT FORMS
Consent Form (1) :
Full Name of Patient : 
Addiess of Patient :....
I consent to participate in the “ Study of Oligo/amenorrhoea ” and agree to take the tests involved in tlie 
study including the “ Short Insulin Tolerance Test - SITT ”. The procedme has been explained to me in 
detail by the staff and an information sheet given by :
and I am aware that I am free to withdraw from the study without prejudice to my future treatment.
Patient’s Signature Date
Doctor’s Signature Date
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Consent Form (2)
I, (Name) ; 
of (Addiess) :
agree to take part in tlie Study of “ Regulation of blood fat by hormones ” described in “ Patient’s 
Summary
Dr  has explained to me what I have to do, how it might
affect me and the pmpose of tlie Research Project / Study Programme.
Patient’s Signatiue Date
Doctor’s Signatiue Date
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Heparin Administration Medical Questionnaire :
Patient’s Name ; ...........................................................................................
Date of Birtli ; ...........................................................................................
Dear Patient ;
Tliank you for participating in our study. You ivill be given an injection of heparin to enable us to 
measure the activity of key factors involved in fat metabolism. In order for us to be certain that it is safe 
to give you tlie heparin, would you please answer tlie questions and sign the sheet when you have 
finished. If you have any further questions or sometliing is unclear, please ask.
1. Are you quite fit at the moment ? YES / NO
2. Are you receiving any medical treatment ? YES / NO
3. If so, please specify : .......................................................................
4. Have you taken aspirin recently ? YES / NO
5. As far as you know, are you sensitive to heparin ? YES / NO
6. Do you have haemopliilia or any other diagnosed bleeding disease ? YES / NO
7. Have you ever suffered firom a stroke ? YES / NO
8. Have you had rheumatic fever ? YES / NO
9. Have you had a recent surgery ? YES / NO
10. Have you had a recent head injmy or trauma requiring hospital admission ? YES / NO
Height : ..................................  Weight......... :..... Blood Pressure.;.......................
Signature ;   Date : .......................................
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APPENDIX IV : THE BETWEEN- AND WITHIN-ASSAY
COEFFICIENTS OF VARIATION OF THE ENDOCRINE 
METHODS
H o r m o n e s B e t w e e n - a s s a y  
C. V . ( % )
W i t h i i i - a s s a y  
C .V . ( % )
( pg/niL ) 4.8 2.5
LH ( lU/L ) 6.4 5.3
FSH ( lU/L ) 5.9 1.7
T ( iimol/L ) 7.9 1.4
SHBG ( nmol/L ) 3.5 3.2
P ( ng/mL ) 5.6 3.8
A ( miiol/L ) 6.9 3.4
170C-OHP ( mnol/L ) 9.6 3.1
DHEA-S ( umol/L ) 8.0 5.7
PRL ( mU/L ) 5.7 8.9
T4 ( nmol/L ) 6.3 1.3
T3 ( nmol/L ) 6.4 3.8
FT4 8.3 6.2
FI ( mlU/L ) 5.4 3.6
Glucose (lumol/L) 3.4 2.2
C-peptide (ng/mL) 7.9 3.6
GH ( ng/mL) 6.5 3.7
IGF-I ( nmol/L ) 10.5 4.0
Cortisol (ug/dL) 8.3 4.9
Leptin (ng/mL) <10 0.7
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APPENDIX V : US SCAN DATA
T h e  M e a n  a n d  C o e f f i c i e n t s  o f  V a r i a t i o n  o f  T O V  i n  P a t i e n t s
Patients Mean TOV 
(cm^)
Within-Patient 
C.V. (%)
Patient 1 8.7 1.8
Patient 2 31.2 5.1
Patient 3 21.6 5.7
Patient 4 24.9 8.0
Patient 5 26.7 3.3
Patient 6 19.3 1.7
Patient 7 10.7 1.9
Patient 8 19.2 7.3
Patient 9 40.5 4.7
Patient 10 20.1 7.4
Patient 11 11.6 9.0
Patient 12 20.2 0.2
Patient 13 16.7 7.3
Patient 14 26.9 6.5
Patient 15 18.0 4.0
Patient 16 11.3 6.8
Patient 17 27.7 1.2
Patient 18 9.7 7.5
Patient 19 14.5 1.9
Patient 20 15.8 8.7
Patient 21 18.7 2.4
Patient 22 17.6 5.9
Patient 23 6.5 3.8
Patient 24 13.8 4.0
Patient 25 15.7 4.0
Patient 26 18.2 1.1
Patient 27 19.2 4.8
Patient 28 11.2 10.1
Patient 29 17.2 3.5
Patient 30 16.3 9.1
Patient 31 8.1 9.5
Patient 32 10.4 10.2
Patient 33 2.9 6.7
Patient 34 17.7 6.5
Patient 35 23.5 2.3
Patient 36 35.3 3.0
Patient 37 14.1 10.4
Patient 38 24.5 6.8
Patient 39 19.5 4.1
Patient 40 10.6 4.5
Patient 41 15.1 5.5
Patient 42 8.5 4.3
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APPENDIX IV : US SCAN DATA
TRANSVAGINAL US IMAGES OF THE OVARY
Figure (1) ; A picture of an ovary in one of tlie study patient with oligo/amenorrhoea. 
showing a “ PCO ” picture with a large number of follicles centrally 
distributed with minimal, thick stroma left behind.
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Figure (2) : Another oligo/amenorrhoeic patient with an enlarged “ PCO ” picture, 
where the small follicles are multiple and distributed peripherally.
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APPENDIX VI : METHOD OF CALCULATION OF THE KITT 
VALUES IN THE “ SITT ”
PROGRAM FOR KITT VALUATION 
data in hudasitt to calculate KITT from glucose decay 
USE HUDASITT
set frit to KITT = 0 .AND.G3>0.AND.G5>0 .AND. G7>0 .AND. G9>0 □
.AND. G11>0 .AND. GI3>0 .AND. G15>0 
GOTO?
DO WHILE .NOT. EOF()
SX=63
SY=LOG(G3)+LOG(G5)+LOG(G7)+LOG(G9)+LOG(Gll)+LOG(G13)+LOG(G15) 
SXY=(L0G(G3)*3)+(L0G(G5)*5)+(L0G(G7)*7)+ (L0G(G9)*9)+ □
(L0G(G11)*1I)+ (L0G(G13)*13)+ (L0G(G15)=*=15)
SSXY=SXY-((SX*SY)/7)
SXS= 679
SXX=679-((SX*SX)/7)
MKITT=(SSXY/SXX)*-100
REPL KITT WITH MKITT
REPL THALF WITH 69.3/MKITT
SKIP
LOOP
enddo
set frit to KITT30 = 0 .AND.G3>0.AND.G5>0 .AND. G7>0 .AND. G9>0 □
.AND. G11>0 .AND. G13>0 .AND. G15>0 .AND. G20>0 AND. G25>0 .AND. G30>0 
GO TOP
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DO WHILE .NOT. EOFQ 
SX=138
SY-LOG(G3)+LOG(G5)+LOG(G7)+LOG(G9)+LOG(G11)+LOG(G13)+LOG(G15)+LOG(G20)+LOG(
G25)+LOG(G30)
SXY=(L0G(G3)'!=3)+(L0G(G5)^5)+(L0G(G7)*7)+ (LOG(G9)*9)+ (LO G (G U )ni) + (LOG(G13)^13)+ 
(LOG(G15)*15)-t- (LOG(G20)*20)+ (LOG(G25)*25) + (LOG(G30)*30)
SSXY=SXY-((SX*SY)/10)
SXS= 2597
SXX=2597-((SX*SX)/10)
MKITT=(SSXY/SXX)^-100
REPL KITT30 WITH MKITT
REPL THALF30 WITH 69.3/MKITT
SKIP
LOOP
ENDDO
USE
CANCEL
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APPENDIX VII : ABSTRACTS SENT FOR PUBLICATION
A B S T R A C T  -  1  :  V a r i a t i o n s  i n  P a r a m e t e r s  o f  O v a r i a n  F u n c t i o n  a n d  I n s u l i n  
T o l e r a n c e  i n  I n f e r t i l e  W o m e n  w i t h  O l i g o / a m e n o r r h e o a
Al-Naser, H., Fleming, R , Yates, R  W. S, Coutts, J. R  T.
University Department of Obstetrics & Gynaecology,
Royal Infirmaiy, Glasgow, UK
Introduction : Infertile women (n = 23) with oligo/amenorrhoea (K > 41 days) are frequently obsen^ed to 
have polycystic ovaries (PCO) and demonstrate evidence of hyperandrogenism and elevated serum LH 
concentrations, and also insulin resistance. They may also ovirlate spontaneously. The aim of tliis study 
was use the the short insulin tolerance test (SITT) to estimate tire insulin resistance in such patients, to 
determine its within-patient variability, and to explore its relationship with other parameters in those 
patients showing evidence of follicular maturation and ovulation, compared with those witlr no follicular 
development.
Methods : Blood sampling was initiated > 14 days after a menstrual period at a frequency of 2 samples 
per week for 5 weeks. When the plasma oestradiol (E2 ) indicated tlrat follicular groutli was established 
daily samples were taken to estimate follicular maturation and the luteal phase progesterone profile. The 
initial SITT was effected at tire shut of the blood sampling and a second was effected eitlrer at the end of 
sampling or in the luteal phase of those who ovulated.
Results : Forty five SITT tests were effected in 23 patients. The initial results indicate that there was 
considerable variation in the KITT, both within and between patients. The KITT-value was uirrelated to 
tire circulating E2 concentration or tire ovarian volrrme, which also showed high intra-patient variability. 
The KITT was also unrelated to the body mass index. Eight of tire 23 patients showed evidence of 
follicirlar maturation and ovulation dming the period of observation. The KITT was no different in those 
who ovulated compared with those who did not. Patieirts demonstrating supranormal LH at the SITT (ir 
= 12) showed higher circulating testosterone and lower E2 concentrations, and also higher KITT-values 
thair those with nomral LH.
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Discussion : The data indicate tliat the SITT yielded reliable within patient results. However, there was 
no association of the SITT data witli any of the physiological or endocrine measurements studied. Tliis 
implies that IR is only loosely associated with specific parameters of PCOD.
The abstract was published'm Journal o f Endocrinology (1995), 144 (3), Suppl., P339.
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A B S T R A C T  -  2  :  F e m a l e  H y p e r a n d r o g e n i s m  S t i m u l a t e s  H e p a t i c  L i p a s e  A c t i v i t y  
i n t o  t h e  M a l e  r a n g e
Sattar, N., Al-Naser, H., Lindsay, G., Fleming, R , Coiitfs, J. R  T., Wallace, A. M., Fackhard, C  J,
Departments of Clinical Biochemistry and Obstetrics & Gynaecology,
Glasgow Royal Infirmary University NHS Trust, Glasgow, UK
Abstract : Recent epidemiological studies have highlighted tire importance of low densit^  ^ lipoprotein 
(LDL) subtype as a risk marker for coronary heart disease. LDL wliich is small and dense is associated 
with liigh risk, independent of total LDL concentration. In a previous population study we demonstrated 
tlrat in women, the development of a liigh concentration of small, dense LDL is dependent upon botli 
plasma triglyceride and hepatic lipase levels. Tlris enzyme is regulated strongly by sex hormones levels. 
On the basis of these findings we fomurlated tire hypothesis tlrat lipoprotein associated risk in women is 
due in part to an altered androgeir/oestrogen balance which stimulated hepatic lipase and in so doing 
promotes the redistribution of circulating LDL into small, dense, atherogenic LDL.
Methods : To test the relationsliip between sex hormone status and hepatic lipase activity we measured 
the activity of this enzyme in eight women with oligomenorrhoea and polycystic ovaries (demonstrated 
by ultrasound). The majority of such cases demonstrate hyperandrogenism.
Results : The mean hepatic lipase activity for tliis group of women was significantly greater than tire 
mean activity for normal females (n = 67), established from previous studies (20.55(4.74) vs 11.30(5.68) 
uM/FFA/mL/lu-, P = 0.0007), and indeed fell into tire male range.
Discussion : This finding adds weight to the increasing body of evidence that sex hormone status of 
women plays a major role in perturbing lipoprotein in an atherogenic direction.
The abstract was published in Scottish MedicalJoumal (1995), 40, p.p. 126.
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ABSTRACT - 3 : Oligo/Amenorrhoea - Relationship between Leptin and
S p o n t a n e o u s  O v u l a t i o n
Al“Naser Al-Zekii, H. M. I., Fleming, R,, Yates, R. W, S., Coutts, J. R. T.
University Department of Obstetrics & Gynaecology,
Royal Infirmary, Glasgow, UK.
Introduction : It is known tlrat tire main cause of infertility in women with oligo/amenoiThoea is 
anovulation. The key feature of anovulation in such patients is failure of normal follicular maturation, 
and obesity is commonly associated witlr tliis condition. Leptin, a recently discovered hormonal product 
of the obesity gene, is expressed by adipocytes and thought to play a role in tire regulation of food intake 
and metabolism. There is a strong positive correlation between serum leptin concentration and body fat. 
Leptin receptors are widely distributed in the body, however, it is not known yet where the site(s) of 
leptin action are located; even in tlie hypothalamic-pituitaiy-gonadal axis. In mice, leptin receptors were 
identified in the ovary and leptin administration was found to stimulate gonadal fimction, causing 
significant increases in LH, sex steroid production and increased ovarian and uterine weights, indicating 
greater amounts of follicular development which were confirmed liistologically. Little is known about 
the physiologic action of leptin in humans. The aim of tliis study was to determine a relationship 
between circulating leptin concentrations and tlie occurrence of spontaneous ovulation in 
oligo/amenorrhoeic human females.
Methods : Forty one infertile women with oligo/amenorrhoea and PCOD (menstrual cycle >41 days) 
and age of < 38 years were recruited for the study. The group of patients were compared with normal 
and regularly menstruating, age and weight-matched volunteers (n = 19). The investigations were 
started at least 14 days after tlie last menstrual period in oligomenorrhoeic cases and between days 508 
for the controls.
Results : During the period of observation, 18 patients ovulated spontaneously. The mean leptin 
concentrations were similar in patients and controls. However, lean patients had higher leptin 
concentrations tlian lean controls (P = 0.0449) but tliere was no such difference between obese patients 
and controls. No relationship was found between leptin concentrations and E2 , LH, FSH, T or SHBG. 
The relationsliip between leptin and the occurrence of spontaneous ovulation was masked in the obese
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individuals. However, leptin concentrations in lean controls were similar to its levels in oxailatory 
patients but were lower than in lean anovulatory patients (P = 0.05). However, for a given BMl, leptin 
concentrations were not significantly different in patients who failed to ovulate, compared with those 
who did.
Discussion : It is imlikely that tire occmrence of spontaneous ovulation in oligo/amenorrhoeic patients is 
influenced by leptin levels.
The abstract was accepted for the “European Society of Human Reproduction & Embryology Congress” 
Meeting, (ESHRE), 22-25 June, 1997.
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A B S T R A C T  -  4  :  D y n a m i c  C h a n g e s  O f  O v a r i a n  V o l u m e  i n  P a t i e n t s  w i t h  
O l i g o / A m e n o i T h o e a  -  A b s e n c e  o f  R e l a t i o n s h i p  w i t h  H o r m o n e  P a r a m e t e r s
Al-Naser Al-Zekri, H. M. L, Fleming, R , Yates, R. W. S. Coutts, J. R  T.
University Department of Obstetrics & Gynaecology,
Royal Infirmary, Glasgow, UK.
Introduction : There is a tendency to consider oligo/amenorrhoea and PCOD as static conditions, and 
diagnosis with a single ultrasound assessment has been a cormnon practice. However, it is evident from 
the longitudinal stirdies that much biological variability exists.
Methods : A group of patients (ri = 41) witlr infertility and oligo/amenorrhoea and PCOD were recruited. 
The assessmerrt of ovarian morphology, by means of transvaginal ultrasound scaiming, was carried out at 
least twice weekly for a period of 5 weeks. The investigations were started > 14 days after tire last 
menstrual period. Blood samples were collected for Ez, LH, FSH, T and SHBG assays at tire time of each 
scan.
Results : Follicular growth and spoirtaireous owilation was observed in 18 patients. Sigrrificarrt 
variations in the total ovarian volume (TOV) were observed both between and within patients during the 
5-week observation period, regardless of tire occurrence of spontaneous ovulation. The TOV was not 
related to tire length of oligo/anrenorrhoea or years of infertility. In addition, tliere was no influence of 
ovarian volume on the rrrean follicirlar phase concentrations of the reproductive honnorres. Marked 
asynrmetry between the two ovaries on the basal scan, i. e., one being less tiran 75% of the contralateral 
was observed in 39% of patients. The patients’ 5-weeks TOV was 19.33 ± 7.45 cm ,^ and more than half 
of tire patients showed > 60% change in their TOV, wlrile 41.5% had doubled their ovarian volume 
during the period of monitoriirg. These significant changes in TOV were not accompanied by any 
significant difierence in the endocrine hormones. Furthermore, the wide variations in TOV were not 
related to BME or WHR. Surprisiirgly, during the 5-week window of observations, tire mean TOV of 
patients who ovulated was similar to that of patients who failed to ovulate. The variability in tire TOV 
(difference between minimum and maximum TOV) was no different in patients who ovulated compared 
with those who did not ovulate.
281
Discussion : This study clearly showed that assessment of ovarian morphology by means of ultrasound 
demonstrated the dynamic state of the ovaries as marked changes in TOV, regardless of the occurrence of 
spontaneous ovulation, and the changes were not related to hornrone concentration changes.
The abstract was accepted for tlie “Eru'opean Society of Himian Reproduction & Embryology Congress’ 
Meeting, (ESHRE), 22-25 Jime, 1997.
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